Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs.

Global Burden of Colorectal Cancer (CRC)

Incidence and Mortality Trends Associated with CRC

Colorectal cancer (CRC) is among the most lethal and prevalent cancers globally, ranking third in incidence and second in overall mortality, with similar incidences and mortality rates in both genders ( Table ). CRC accounted for 1.9 million new cases in 2020, and is projected to exceed 3 million cases by 2040. CRC incidence and mortality vary considerably among different countries. Generally, cases have increased in tandem with socioeconomic development, particularly in countries with an increasing human development index (HDI), due to growing risk factors such as a more westernized diet, population aging, smoking and physical inactivity. Consequently, in Asia, the incidence and mortality of CRC have also been increasing steadily and were the highest globally in 2018. Of note, the incidence of CRC is significantly higher in Chinese populations compared to other ethnicities in multiracial countries within Southeast Asia, suggesting genetic factors might predispose Chinese to CRC more than other ethnicities. However, no specific genetic markers have been found exclusively or significantly more expressed in Chinese CRC patients. Other factors contributing to this higher incidence of CRC in Chinese population (i.e., host, environmental, and endogenous factors) are currently under investigation.

Clinical Guidelines on the Treatment of CRC

CRC slowly develops from an abnormal growth, often referred to as a polyp, on the inner lining of the rectum or colon. Polyps can form a tumor and expand into blood vessels, facilitating cancer metastasis. CRC cases can be subdivided based on the location of the developed tumor such as colon and rectal cancer or left-sided and right-sided tumors ( Figure ). These classifications help to systematically guide diagnosis, identify suitable treatment options, and provide estimated prognosis based on comprehensive clinical practice guidelines issued by leading oncology networks, such as the National Comprehensive Cancer Network (NCCN). Right-sided tumors, for instance, are more common in females whereas left-sided tumors are more predominant in male patients.

The standard of care for detection and treatment of CRC in early stages (i.e., stage I–III) is surgical resection with curative intent ( Table , section ) for the removal of polyps (i.e., polypectomy) and tumors (i.e., colectomy). − These surgeries are often supplemented with neoadjuvant, adjuvant, or perioperative systemic therapies in order to reduce recurrence risk and improve patient survival by up to 90% ( Table ). Advanced CRC cases that are diagnosed at late stages (i.e., stage IV), when the disease is symptomatic and has metastasized to other tissues and organs, , are associated with poorer prognosis ( Table ). , For advanced metastatic CRC (mCRC), systemic therapies such as chemotherapy (ca., 66–67%, section ) and immunotherapy ( section ) are the cornerstones of treatment, aiming for outcomes ranging from potential cure to palliation and life prolongation. − Platinum (Pt)-based chemotherapeutics ( section ), particularly oxaliplatin ( OXP )­( section ), play a crucial role in current clinical regimens owing to their unique mechanisms of action ( section ). On the other hand, immunotherapies using immune checkpoint inhibitors (ICIs) offer an effective alternative for specific advanced CRC patient subsets (i.e., deficient DNA mismatch repair (dMMR)/ microsatellite instability (MSI)-high) ( section – ).

In addition, EGFR inhibitors (such as cetuximab and panitumumab) are best used in metastatic colorectal cancer patients whose tumors are KRAS and NRAS wild-type and located on the left side of the colon, as these patients benefit most; they are ineffective in tumors with KRAS or NRAS mutations and less effective for right-sided tumors. VEGF and VEGFR inhibitors (such as bevacizumab, ramucirumab, and aflibercept) can be used in metastatic colorectal cancer regardless of RAS or BRAF mutation status or tumor location, and are typically given in combination with chemotherapy, provided there are no contraindications such as bleeding risk or uncontrolled hypertension.

Despite these advances, significant challenges remain ( section ). The efficacy of current CRC chemotherapeutics (e.g., OXP ) for mCRC is often diminished by major dose-limiting toxicities (e.g., OXP -induced peripheral neuropathy) and the emergence of drug resistance ( section – ), which restrict therapeutic options and impact patients’ quality of life. Additionally, the differences in the tumor microenvironment (TME) between primary and metastasized tumors affect tumor sensitivity toward systemic treatments such as chemotherapies and immunotherapies. , As a result, the majority of the advanced CRC patients do not benefit from ICI therapies due to low response rates, resistance development as well as immune-related adverse events ( section ). Consequently, treatment decisions are increasingly reliant on patient-specific molecular profiling for optimal treatment regimens ( section – ). These limitations underscore the critical need for innovative therapeutic strategies that can enhance efficacy, overcome resistance mechanisms, reduce systemic toxicities, and potentially offer novel combination approaches. Emerging strategies include targeted Pt-based chemotherapeutics ( section ), Pt-based chemoimmunotherapeutics ( section ), and innovative drug delivery strategies ( section ) which could represent promising alternatives to overcome these challenges. Furthermore, the development and application of suitable experimental models are crucial for optimizing the evaluation and accelerating the discovery of novel Pt-based drug candidates with clinical potential ( section ).

Chemotherapy

Chemotherapy is often provided either before (neoadjuvant therapy) or after (adjuvant therapy) surgery to reduce the risk of recurrence and improve patients’ survival ( Table ). In stage IV CRC (i.e., mCRC) and in patients with unresectable tumors, chemotherapy becomes the primary treatment, essential for increasing overall survival (OS) rates. , Chemotherapeutic drugs typically suppress tumor growth by interfering with cellular function, which eventually induces apoptosis in cancer cells. Patients abstaining from chemotherapy typically observe a short median survival, ranging from 0 to 5 months. The main classes of chemotherapeutics approved for treating CRC include fluoropyrimidines, folic acid derivative, deoxyribonucleic acid (DNA) topoisomerase I inhibitors, angiogenesis inhibitors and platins ( Table and Figure ).

Other classes of drugs including nucleosides, antibiotics, anthracyclines, and mitogen-activated protein kinase (MAPK) signaling pathway inhibitors, while approved for other cancers, are still under clinical evaluation for treating CRC patients ( Table ). Recently, drugs that target specific cancer-associated gut microbiota have been proposed as a new approach to treating CRC. The Fusobacterium nucleatum ( F. nucleatum ) bacteria in tumor tissue, for instance, have been linked to increased chemoresistance, reduced T-cell infiltration, and poor patient survival. Consequently, targeting F. nucleatum using an antibiotic like metronidazole can reduce cancer cell proliferation and tumor growth. However, this approach is still preliminary and has yet to reach clinical trials.

For the clinical management of CRC, various chemotherapy drugs that target different cellular pathways are available ( Figure ), such as 5-fluorouracil (5-FU), irinotecan (Camptosar), oxaliplatin ( OXP , Eloxatin), trifluoridine–tipiracil (Lonsurf), and capecitabine (Xeloda). However, single-agent chemotherapy regimen is not commonly used for advanced CRC management. Instead, combination therapies such as FOLFOX (leucovorin calcium + 5-FU + OXP ), , FOLFIRI (leucovorin calcium + 5-FU + irinotecan), − FOLFOXIRI (leucovorin calcium + 5-FU + OXP + irinotecan), , and CAPOX (capecitabine + OXP ) , are more routinely used as first-line treatment for advanced CRC to improve their overall efficacy by working synergistically or additively according to their mechanisms of action ( Table ). , ,

One example is the combination of 5-FU, a commonly used chemotherapeutic agent for CRC treatment, with leucovorin (LV) (i.e., a reduced folate compound). 5-FU is a fluoropyrimidine that interferes with ribonucleic acid (RNA) synthesis as well as DNA synthesis and repair. , However, the reported response rate of 5-FU is less than 20%, with median survival time of less than 9 months. As a result, LV is added on top of 5-FU to enhance its cytotoxicity by acting as an external source to increase the intracellular levels of reduced foliate cofactors, which can stabilize the binding of 5-FU metabolite (i.e., 5-fluorodeoxyuridine monophosphate) to thymidylate synthase, resulting in pronounced and prolonged inhibition of DNA synthesis. , Indeed, a meta-analysis of 3300 patients from 19 randomized trials found that a combined treatment of 5-FU and LV was more likely to induce at least a 50% reduction in tumors and statistically improve the OS rate when compared to 5-FU alone in CRC patients. The addition of the Pt­(II) drug OXP further improved the mean survival from 17.4 (FOLFIRI) to 21.9 months (FOLFOXIRI) ( Table ). Complementary to chemotherapy, targeted therapies are available in CRC such as antibodies targeting Epidermal Growth Factor (EGF) or the vascular endothelial growth factor (VEGF) ( Table ).

Pt­(II) Chemotherapeutics for CRC

Since their discovery in the 1960s–1970s, , cis -Pt­(II) drugs, in which at least 2 identical ligands are on the same side of the molecule, have been highly effective in treating various solid tumors ( Figure , Table ). Cisplatin ( CDP ), carboplatin ( CBP ), and oxaliplatin ( OXP ) are first-line chemotherapeutic agents for various cancers. Nearly half of all chemotherapeutic regimens involve the use of these Pt­(II) drugs.

Cisplatin (CDP)

CDP is a first-generation Pt compound with a simple cis -square planar structure consisting of two chlorido and two ammine ligands ( Figure ). It is used to treat several cancers through intravenous (IV) administration ( Table ). However, the lack of specificity for cancer cells also makes CDP highly toxic, being associated with severe side-effects (e.g., chronic nephrotoxicity, ototoxicity, gastrointestinal toxicity and neuropathy) that can persist long after chemotherapy ends (please refer to section for more details).

Carboplatin (CBP)

CBP is a second-generation cis -Pt compound that replaces the chlorido ligands in CDP with a cyclobutane-1,1-dicarboxylate leaving group ( Figure ). , This makes CBP less reactive than CDP , resulting in milder toxicity mainly in the form of myelosuppression in patients and higher maximum tolerated dose (MTD) by the patients ( Table ). CBP treatment is comparable to CDP treatment both as a single agent and in combination chemotherapy for lung and ovarian cancers. − However, CDP treatment has been shown to remain superior to CBP for germ cell tumor, bladder, head and neck cancers despite its poorer toxicity profile. , CBP is typically used in treating ovarian cancer with combination chemotherapy and is selected over CDP in palliative care to maximize the patients’ quality of life. −

Oxaliplatin (OXP)

OXP is a cis -Pt compound containing trans -(1 R ,2 R )-diaminocyclohexane (DACH) ( Figure ) and oxalate ligands. The oxalate ligand reduces the reactivity of OXP compared to CDP , resulting in much fewer associated toxicities than CDP ( Table ). However, acute chemotherapy-induced peripheral neuropathy (CIPN), a persistent pain sensation from peripheral neurons, is a key challenge to the therapeutic use of OXP (please refer to section for more details). OXP has been more effective for treating CRC compared to other Pt­(II) drugs, but the molecular mechanisms behind the higher CRC-specificity is not well-understood. , Several studies suggest that OXP is more efficiently transported into CRC cells due to its higher affinity for the organic cation transporters. , Additionally, OXP forms bulkier and more hydrophobic Pt-DNA adducts via its DACH ligand, enhancing its ability to inhibit DNA synthesis and cellular proliferation as well as reducing its cross-resistance with CDP and CBP . − Consequently, OXP has demonstrated to be more effective than CDP and CBP in inhibiting cellular proliferation in 6 out of 8 CRC cell lines (i.e., DLD-1, HCT116, HCT-15, HT-29, KM20L2, SW620) taken from the National Cancer Institute (Bethesda, Maryland, USA) automated screening panel. Currently, chemotherapy regimens for treating mCRC include FOLFOX, the systemic administration of OXP , 5-FU, and LV ( Table ). The addition of OXP to the cocktail improved the average response rate and OS rate of patients. , OXP alone demonstrated low responses rates of around 20% in clinical trials, but in combination with LV and 5-FU (i.e., FOLFOX), the responses rates increased up to ca. 60%, with an increased progression-free survival (PFS) and OS. OXP can be used both as first-line and adjuvant therapy in CRC. The combination regimen depends on factors such as tumor type, stage, and burden. Unlike FOLFIRI ( Table ) treatment, FOLFOX is effective in an adjuvant setting, leading to its use in postoperative therapy. FOLFOX and CAPOX ( Table ) regimens are the most frequently used in metastatic conditions. In addition, OXP is also being evaluated in clinical trials for the treatment of gastric, pancreatic, breast and non-small cell lung cancers, though no official outcome has been made available yet. The detailed mechanisms and advantages of OXP for CRC treatments have been extensively discussed by O’Dowd et al.

Other Clinically Relevant Pt­(II) Drugs

Other Pt­(II) drugs that have been approved for use in other countries include nedaplatin in Japan (for esophageal, ovarian, cervical, bladder, lung, head and neck cancers) ( Table and Figure ), lobaplatin in China (for chronic myelogenous leukemia and inoperable, metastatic breast and small cell lung cancer) and heptaplatin in Korea (for advanced gastric cancer). picoplatin is another promising Pt­(II) drug candidate designed to circumvent glutathione-mediated cellular resistance mechanism. Picoplatin demonstrated promising preclinical efficacy in CDP - and OXP -resistant ovarian and colorectal cell lines (i.e., A2780, CH1, 41M, HCT116, HT-29), respectively, and can be administered orally, which is attractive for improving patient compliance. , While picoplatin has undergone various phase I–II clinical trials (e.g., NCT00465725 and NCT00478946 ) for the treatment of CRC, it has yet to demonstrate significant improvement to warrant clinical approval.

Mechanisms of Action of Pt­(II) Drugs in CRC

Uptake and Efflux Mechanisms

Passive diffusion across the cell membrane was initially proposed as the main mode of internalizing Pt­(II) drugs in cells. However, physical characterizations of Pt­(II) drugs (e.g., CDP , CBP , and OXP ) indicated that they are hydrophilic, which disfavors their diffusion across the lipophilic cell membrane. Membrane transporters have been implicated as key players in the cellular accumulation of Pt drugs, directly influencing the anticancer efficacy of Pt­(II) drugs. , Several membrane transporters, in particular, have been recognized as common transporters for all Pt­(II) compounds.

The copper transporter 1 (CTR1) is the most well-known substrate transporter for CDP , OXP and CBP in mammalian cells. , The genetic knockout and reduced expression of the SLC31A1 gene that encodes for CTR1 are associated with decreased cellular accumulation of and sensitivity to CDP , OXP , and CBP in cancer cell lines. − Clinically, the efficacy of Pt chemotherapy correlates well with the expression level of CTR1, suggesting that the CTR1 expression can be used as a prognostic marker of patient response to Pt chemotherapy. For example, CDP treatment was more effective, extending PFS by 20 months, in ovarian cancer patients with a 2-fold increased of CTR1 messenger RNA (mRNA) expression in tumor tissue.

Other copper transporters involved in cellular uptake of Pt­(II) drugs include the copper transporter 2 (CTR2) and the P-type ATPase copper transporters (e.g., ATP7A and ATP7B), which utilize energy from adenosine triphosphate (ATP) hydrolysis to transport copper­(I) across cellular membranes by conductance. Pt agents bind to the N -terminus of the methionine-rich motifs of CTR1/2 and are transported into cells via endocytosis. In vitro , in vivo , and clinical studies found that decreased CTR2 expression correlated to increased intracellular Pt and greater efficacy of Pt chemotherapy. , , Conversely, overexpression of ATP7A and ATP7B on the cell surface is associated with increased Pt resistance in ovarian cancer cell lines (e.g., 2008/EV and 2008/MNK) and patients with ovarian cancer. , These findings suggest that the overexpression of ATP7A and ATP7B represent a cellular response when developing resistance mechanisms to Pt. As transporters, CTR2, ATP7A and ATP7B are likely responsible for the efflux of Pt out of the cell, thereby reducing the sensitivity of the cells to Pt.

The volume-regulated anion channels (VRACs), a membrane transporter family that facilitates the exchange of osmolytes, such as chloride, to maintain cellular homeostasis, , have recently been found to play a major role in the cellular uptake of CDP and CBP . The VRACs are formed by at least 2 different leucine-rich repeat containing 8 (LRRC8) subunits, one of which is LRRC8A. Specific combinations of LRRC8 augment the permeability of the resulting pore, thereby modifying the regulated osmolyte for which the channel is responsible. Planells-Cases and co-workers found that up to 50% of cellular CDP and CBP entered cells via the VRACs, and the cellular Pt content was significantly reduced in cells with malformed VRACs. Consequently, increased LRRC8A and LRRC8D expression correlated with increased survival in ovarian cancer patients undergoing Pt-based chemotherapy. While the importance of the VRACs for cellular uptake of OXP was not evaluated, the authors postulated that VRACs could accommodate any molecular compound small enough to fit through the 12–14 Å channel diameter.

Organic cation transporters 1–3 (OCTs 1–3), which facilitate the transport of a broad spectrum of organic cations of 60–350 kDa, represent another class of transporters for Pt­(II) drugs. Although the OCTs are not as well-investigated as the copper transporters, current studies suggest that each Pt­(II) drug has a preferred OCT for transport into the cell. For example, CDP relies on OCT1 for cellular transport. Studies by Yonezawa et al. and Zhang et al. showed improved intracellular accumulation of CDP and CBP in human embryonic kidney (HEK-293) cells overexpressing human (h) OCT1 but no change was observed upon overexpression of hOCT3. , Interestingly, Yonezawa et al. found that overexpression of hOCT2 improved the cellular accumulation of CDP , whereas Zhang et al. found no significant influence of the same channel on CDP accumulation. Critically, Yonezawa et al. performed Pt accumulation studies using much higher concentrations (i.e., 100–1000 μM) than Zhang et al. (i.e., 6 μM). These differences account for the distinct kinetics of transport via the OCTs. OXP is a good substrate for all OCTs, displaying improved accumulation in the cells overexpressing OCT1, OCT2, and OCT3, which have been reported to be overexpressed in CRC tumors, contributing to the greater efficacy of OXP in treating CRC compared to the other Pt compounds. ,

Pt-DNA Adduct Formation

After cell entry, Pt compounds undergo aquation to form electrophilic Pt­(II) aqua species that preferentially react at nucleophilic N7 positions of purine residues ( Figure ). Reactivity with guanine is preferred due to H-bonding interactions between the ammine ligands and the exocyclic guanine-O6, giving rise to a majority of 1,2-d­(GpG) and 1,2-d­(ApG) intrastrand Pt-DNA adducts (ca., 80–90%) in the major groove, with the remaining Pt-DNA adducts constituted by 1,3-intrastrand and interstrand cross-links (ca., 10%). − These adducts distort DNA through local unwinding and interfere with cell function by inhibiting RNA transcription and DNA replication. ,

While nuclear DNA has long been regarded as the primary target of Pt drugs, mitochondrial DNA (mtDNA) has been recently implicated in the mechanism of action of CDP . Unlike nuclear DNA, mtDNA lacks histones, making the structure more vulnerable to oxidative damage. Additionally, absence of the nucleotide excision repair (NER) pathway in mtDNA makes it more sensitive to damage induced by Pt drugs. LeDoux and co-workers observed that, while nearly 70% of Pt-DNA adducts were removed from nuclear DNA within 24 h, there was comparatively minimal repair of the same damage in mtDNA of Chinese hamster ovary cells. The distortion of the mtDNA compromises mitochondrial function (e.g., hydrolysis of ATP), thereby activating apoptotic pathways.

Nucleolar Stress Induction

Certain Pt­(II)-based drugs have recently been found to cause cell death by triggering nucleolar stress. Nucleoli are the largest subnuclear structures in eukaryotic cells. Their primary role is the biosynthesis of ribosomes, the intricate cellular machines pivotal for translating mRNA into proteins. This complex process involves the coordination of approximately 200 proteins to synthesize ribosomal RNA (rRNA) and assembles it with ribosomal proteins. However, the homeostasis of ribosome biogenesis can be impaired by morphological alterations in nucleoli, such as segmentation or disruption, a condition recently termed “nucleolar or ribosomal stress”. These changes can ultimately trigger the activation of the p53 signaling pathway, leading to cell cycle arrest and apoptosis. , Pt­(II) drugs containing a cyclic diamino bidentate ligand, like OXP and other Pt­(II)-DACH derivatives, have been observed to induce nucleolar stress by inhibiting rRNA transcription. On the other hand, Pt­(II) complexes with monodentate or alkyl-based bidentate amino ligands, such as CDP or CBP , have been predominantly seen to operate by DNA-adduct formation.

Oxidative Stress Induction

A third axis to comprehend the cellular activity of Pt­(II) complexes is oxidative stress, characterized by an imbalance between the production and accumulation of reactive oxygen species (ROS) such as hydroxyl radical (•OH), superoxide anion (O 2 • – ) or hydrogen peroxide (H 2 O 2 ), and the ability to detoxify these byproducts by antioxidant defenses. , ROS are known to have a two-edged sword-like behavior in cancer: malignant cells usually display higher ROS levels than healthy cells, and the homeostasis of these species, regulated by generally overexpressed antioxidant defenses, can promote proliferation and tumor growth. However, a sharp increase in the intracellular levels of ROS can easily overwhelm the inefficient antioxidant arsenal of cancer cells and induce oxidative stress-mediated apoptosis.

After aquation, the formed Pt­(II) center is a soft Lewis acid, providing a highly electrophilic species prone to react with several nucleophilic biological targets, especially sulfur-containing moieties. For example, glutathione (GSH), an important metabolite for maintaining intracellular redox potential and nonenzymatic ROS scavenger, can be depleted through Pt-GSH binding, resulting in oxidative stress induction. Oxidative stress can also be generated due to the formation of adducts with mtDNA. Due to the lack of repair mechanisms, OXP -DNA adducts formed within mitochondria cannot be repaired. This ultimately leads to mitochondrial dysfunction and the generation of ROS.

Immunogenic Cell Death (ICD)

Immunogenic cell death (ICD) is a form of regulated cell death (RCD) that induces the activation of both innate and adaptive immune responses. It involves the release of damage-associated molecular patterns (DAMPs) from dying cells and their subsequent recognition by pattern-recognition receptors (PRRs) on immune cells, generating specific antitumor immune responses. Doxorubicin was the first ICD inducer found to regress tumor in immunocompetent mice through ICD-mediated immune responses. Since then, extensive research has been done to elucidate the molecular and cellular mechanisms of ICD. One of the key factors that initiates ICD is organelle and cellular stress. In particular, ROS overgeneration by various means, such as photogeneration or redox reactions, is strongly associated with the onset of endoplasmic reticulum (ER) stress, which in turn triggers ICD. − Once initiated, ICD leads to the orderly exposure and release of DAMPs or alarmins from dying cancer cells, in a time- and space-dependent manner. Some of the key DAMPs and biological hallmarks found to be responsible for ICD include the exposure of calreticulin (CRT) on the cell membrane, − heat-shock proteins (HSPs) on the cell membrane or released passively, , the passive release of high-mobility group box 1 (HMGB1), − surface exposure of annexin A1 (ANXA1), − and the active or passive release of ATP. , , These DAMPs interact with their respective PRRs on antigen-presenting cells such as dendritic cells (DCs), which ultimately leads to the activation of both the innate and adaptive immune systems through a network of cytokines and chemokines. − This can lead to the activation and recruitment of immune cells to the site of the cancer, which helps in tumor elimination. For example, the main “eat me” signal is represented by the cell surface exposure of CRT, which interacts with low-density lipoprotein receptor-related protein 1 (LRP1) on DCs. ICD inducers can be broadly divided into two groups: (a) Type I inducers, which primarily target intracellular organelles excluding the ER, initiating DAMP-related signaling via subsequent ER stress responses; and (b) type II inducers, which involve ER as the primary target organelle. As it was observed that Type II ICD inducers generally display higher levels of DAMPs and require simpler DAMPs trafficking, they are presumed to be more efficient ICD inducers than their type I counterparts. ,

OXP is the first metal-based chemotherapeutic shown to elicit ICD-mediated immune response in CRC and has been classified as a type I ICD inducer. Besides DNA-adduct formation, it is widely accepted that the other determinant for OXP ’s anticancer efficacy is ICD induction. , In contrast, CDP does not induce preapoptotic CALR exposure via the PKR-like endoplasmic reticulum kinase (PERK)/eukaryotic initiation factor 2 alpha (eIF2α)/caspase 8/ B-cell receptor-associated protein 31 (Bap31) that is required for ICD induction. , OXP treatment has also shown to have longer lasting antitumor protection in CRC in vivo as compared to CDP , consistent with the ICD-inducing ability of OXP . − CDP only induces extracellular release of HMGB1 protein, which is similar to OXP , but it does not cause ICD unless combined with ER stress inducers such as thapsigargin. OXP treatment has been found to reverse immunosuppressive TME by (a) enriching TME with infiltration of innate and adaptive immune cells such as CD8 + T cells, − natural killer (NK) cells, , and DCs, and (b) depleting immunosuppressive cells such as tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs). ,

The importance of trans -(1 R ,2 R )-DACH ligand structure on OXP immunomodulatory activity has been explored by substituting it with different cis -1,3-diaminocycloalkanes. The results show that Pt­( cis -1,3-diaminocyclobutane)­Cl 2 displays comparable cytotoxicity and ICD features with OXP in microsatellite stable (MSS) CT26 cell line. Macrophage-mediated antigen presentation to effector cells such as helper T cells (Th) is a key factor in tumor immunity. While OXP can effectively induce ICD DAMPs, it has been shown in various in vitro phagocytosis assays that OXP does not induce macrophage phagocytosis. , Interestingly, Pt­( cis -1,3-diaminocyclobutane)­Cl 2 increased J774 macrophage phagocytosis markedly, implying that it could be a better ICD inducer than OXP , since macrophage-mediated antigen presentation to effector cells such as Th cells is a key factor in tumor immunity.

In addition to the favorable immunostimulatory effect associated with the structural change of trans -(1 R ,2 R )-DACH ligand, substitution using other isomers such as cis -1,4-DACH and trans -1,2-diamino-4-cyclohexene (DACHEX) has also demonstrated comparable or superior cytotoxicity against a range of cancer cell lines, including OXP -resistant CRC cells, relative to CDP and OXP . These improvements, particularly in overcoming OXP resistance, are likely driven by altered mechanisms of action resulted from ligand substitution. These include the formation of distinct DNA adducts that are less efficiently recognized and repaired by cellular DNA repair pathways, enhanced inhibition of DNA polymerases, and induction of metabolic stress. Moreover, Pt­(IV) complexes incorporating DACHEX-based ligands demonstrate that axial ligands modifications can further enhance cellular uptake and activation, through modulation of lipophilicity and reduction potential, ultimately leading to an increased in vitro potency against both OXP -sensitive and OXP -resistant CRC cell lines. Notably, the chirality of these DACH ligands has also been found to have significant impact on their anticancer efficacy, depending on the final structure of the Pt­(II) or Pt­(IV) complexes.

Immunotherapy

Immunoediting and Immune Escape Process of CRC

Immunotherapy for CRC has shown promise, yet its effectiveness can be significantly influenced by the immune escape process, which highlights the complexity of the interplay between tumor cells and the immune system within the cancer-immunity cycle. The theory of cancer immunosurveillance, which was first formalized by Sir Frank MacFarlane Burnet in 1970, proposes that the host’s immune system has the capacity to identify and eliminate emerging tumor cells. However, subsequent evidence demonstrated that tumors can still develop in immunocompetent hosts. More recently, evading immune destruction has been identified as one of the main hallmarks of cancer. This phenomenon arises because the immune system functions as a double-edged sword. On one hand, it protects the host by eradicating tumors through immunogenic mechanisms. On the other hand, it exerts immune pressure on genetically unstable tumor cells, leading to the emergence of immunosuppressive variants through a process called immunoediting. Immunoediting results in tumor cells capable of thriving and progressing by avoiding immune recognition (i.e., low immunogenicity), increasing immunity resistance, or suppressing immune responses (i.e., immunosuppressive TME). The dynamic process of immune escape unfolds in five phases: (1) homeostasis, (2) elimination; (3) equilibrium, (4) immunoediting, and (5) immune escape ( Figure ).

Unsurprisingly, the tumorigenesis of CRC also involves different phases of the immune escape process. In the elimination phase, tumor cells express stress-induced molecules such as surface CRT, peptide-major histocompatibility class I (MHC-I), and NK group 2 member D (NKG2D) ligands that can attract immune cells to undergo cytotoxic activities. Tumor cells that survive the elimination phase then progress into the equilibrium phase, marked by a delicate balance between cancer cells and the immune system. These surviving cancer cells eventually transition from equilibrium phase into the escape phase, driven by the immunoediting process under constant immune pressure. For instance, it has been found that MSI-High CRC with intact antigen presentation machinery can survive immune selection by producing immunogenic frameshift peptides that are less detectable by the immune system. Furthermore, highly immunogenic MSI CRC has also been reported to overcome the innate and adaptive immune systems by overexpressing immune checkpoints such as programmed cell death protein 1 (PD-1), programmed cell death ligand 1 (PD-L1), cytotoxic T-lymphocyte associated protein 4 (CTLA-4), lymphocyte-activation gene 3 (LAG-3), and indoleamine 2,3-dioxygenase (IDO), compared to CRC with higher microsatellite stability. As a result, the high immune cells infiltration in CRC with MSI is counteracted by the overexpression of immunosuppressive immune checkpoints, resulting in “exhausted” immune cell populations, and consequently the depletion of antitumor immunity.

Other studies also revealed that CRC subpopulations associated with more favorable prognosis exhibit elevated expression levels of chemokines such as chemokine (C–C motif) ligand (CCL) 5, chemokine (C–X–C motif) ligand (CXCL) 9, and CXCL10 as well as cytokines such as interleukin (IL)-7, IL-8, IL-15, IL-18, and IL-1β that promote the immune inflammatory profile as compared to other CRC subpopulations. Therefore, it is evident that the immunoediting process generates tumor cells that are poorly immunogenic, rendering them more “invisible” to the immune system and facilitating their immune escape.

CRC Consensus Molecular Subtypes and Their Immune Landscape

The prognosis and treatment outcome of CRC immunotherapy are strongly linked with its phenotype and immune status. Therefore, stratifying CRC into distinct subpopulations based on their variations in genetic and immune landscape would greatly enhance the clinical decision-making process ( Figure ). The CRC consensus molecular subtypes (CMSs) represent one such approach in classifying CRC subpopulations. In CMSs, CRC is divided into four major subtypes that remain the current best transcriptome-based descriptor for CRC.

CMS1 “MSI Immune” phenotype, which accounts for about 14% of early stage CRC cases, has a faulty DNA mismatch repair (MMR) system due to the loss of function of genes such as MLH1 , MLH3 , MSH2 , MSH3 , MSH6 or PMS2 , similar to other dMMR/MSI-High tumors. This results in hypermutation and hypermethylation of CpG islands. CMS1 CRC also has significant mutations in ring finger protein 43 ( RNF43 ), R-spondin and BRAF V600E genes. CMS1 CRC is considered to be immunologically ‘hot’ as it exhibits strong activated immune cell infiltration in the TME, especially by CD8 + T cells, CD4 + Th1 cells, NK cells, and CD68 + macrophages.

Other CRC subtypes are categorized into CMS2 to CMS4, which originate from chromosomal instability (CIN) and have a MSS status. They follow the classical model of CRC progression, involving “driver” mutations in APC , KRAS , TP53 , SMAD4 , and PIK3CA genes. − The highest proportion (ca., 37%) of CRC patients falls into the category of CMS2 “canonical”. While CMS2 is indistinguishable from CMS4 in terms of CIN and MSS, CMS2 is differentiated from CMS4 due to the aberrant activation of WNT and MYC pathway (i.e., canonical pathway) as well as overexpression of oncogenes (e.g., EGFR , HER2 , IGF2 , IRS2 , HN4FA ). CMS2 is also known as an immune desert subtype due to its reduced immune cell activation and low number of infiltrating lymphocytes and monocytes, explained by minimal transcription of leukocyte chemotaxis and activation genes. , Only a few memory B and Th cells and naive CD4 + cells were found in these tumors, albeit without the ability to mount an antitumor response. Moreover, low-level expression of PD-1 and PD-L1, which are common traits among immunodeficient tumors, also characterizes the CMS2 molecular phenotype.

CMS3 “metabolic” subtype contributes to about 13% of CRC cases and is identified by prominent metabolic dysregulation and KRAS -activating mutations. These mutations and alterations are thought to occur early in CRC tumorigenesis, with a unique combination of KRAS mutations and copy number events resulting in distinct metabolic deregulation profile. Like CMS2, CMS3 possesses a quiescent tumor immune microenvironment (TIME). Th17 and resting T cell infiltrations reinforce the immunological dormancy of this subtype and mark it as “immune excluded”. Unlike CMS2, intratumoral cells of CMS3 tumors reveal PD-1 upregulation. , CMS4 “mesenchymal” tumors, which represents about 23% of CRC, are driven by the unusual activation of the transforming growth factor-β (TGF-β) signaling pathway, which induces angiogenesis, tissue remodeling, and epithelial–mesenchymal transition. , CMS4 tumors have a high stromal content and a complex immune landscape, with a predominance of immunosuppressive cells (e.g., MDSCs, Treg, Th17), cytokines (e.g., TGF-β, CXCL12), and chemokines (e.g., IL-23, IL-17). , As a result, despite high levels of immune infiltration, CMS4 tumors are considered as immunologically “cold” and have low sensitivity toward mono-ICI therapy. Finally, 13% of early stage CRC have no clear subtype classification and show mixed features from the other subtypes, suggesting that they are either transitional or heterogeneous tumors.

Tumor Immune Microenvironment (TIME) in CRC Development and Progression

One of the key strategies that tumor cells use to evade immune surveillance is to modify the TME to achieve suppression of antitumor immunity. The CRC TME, as with many other solid tumors, comprises of both cellular and noncellular components, each with distinct functions that also interact to make the TME a dynamically evolving entity throughout different stages of cancer progression. As our comprehension of the TME in CRC progression and metastasis advances, the significance of each constituent within this complex system is increasingly recognized. Therefore, studying of the roles and mechanisms governing the interplay between TME remodeling and CRC evolution has received substantial attention over the past decade, as it holds promise for enhancing current anticancer strategies, particularly in the development of novel immunotherapies.

The TME comprises key elements like the extracellular matrix (ECM) and cellular components including stromal cells (e.g., cancer-associated fibroblasts, pericytes), immune cells, endothelial cells (e.g., blood vessels), and lymphatic vascular networks. In addition, these cellular components also secrete noncellular soluble products to the extracellular environment such as chemokines, cytokines, growth factors, and extracellular vesicles to communicate immunostimulatory or immunosuppressive signals. Notably, CRC cells interface with the gut microbiota, consisting of trillions of microorganisms, and are considered essential for understanding CRC development and treatment response. Indeed, some microbial species and microbial metabolites, such as Enterotoxigenic Bacteroides fragilis , Escherichia coli , and Fusobacterium nucleatum have been implicated in promoting colorectal carcinogenesis and therapy resistance. −

Immune cells, fibroblasts, and endothelial cells play pivotal roles within the CRC TME. Tumor-infiltrating lymphocytes, comprising CD4 + T cells, CD8 + T cells, B cells, and NK cells, contribute to both immune evasion and tumor elimination. Notably, the Immunoscore, developed for routine clinical assessment, enables a prognosis by characterizing cytotoxic and memory T cell infiltration into TME of individual CRC patients. , Additional studies have also shown the roles played by a specific subtype of T cells in the prognostic outcome of CRC patients. − For example, in addition to the traditional lymphoid cells, another subset known as group 3 innate lymphoid cells (ILC3) has been shown to regulate the balance between the immune system and gut microbes to prevent CRC progression and resistance to immunotherapy. Unlike CD8 + T cells, naïve CD4 + T cells require priming by antigen-presenting cells displaying peptide-major histocompatability class II (MHC-II) complexes before they can expand and differentiate into various CD4 + Th cell subsets. The main Th cell subsets identified in the TME of CRC are Th1, Th2, Th17, Th22, follicular helper T (Tfh) cells, and regulatory T (Treg) cells, which can be either immunostimulatory or immunosuppressive. For example, Th1 cells and their cytokines can infiltrate CRC and suppress cancer cell proliferation through mechanisms such as CD8 + T cells recruitment, apoptosis induction, angiogenesis reduction, and senescence induction. − Moreover, tumor necrosis factor alpha (TNF-α) and IL-6 can promote the differentiation of naïve CD4 + T cells into Th22 cells, which are correlated with better outcome in human CRC. High Tfh cells abundance has also been associated with positive CRC prognosis. Another study in mice demonstrated that IL-21, produced by Tfh cells, can regulate CD8 + T cell responses and enhance interferon gamma (IFN-γ) and granzyme B production.

TAMs are another key cellular component of the CRC TIME that communicates with tumor cells through exosomes or cytokines to influence tumor immunity. − Based on their phenotype and function, TAMs are divided into two major distinct subsets, namely, M1- and M2-like macrophages. Depending on the immunomodulatory signal received from the tumor, the TME, and external treatments such as chemotherapy and radiation, macrophages rapidly polarize between M1 and M2 phenotypes. In contrast to other tumors, the contribution of TAMs to CRC outcome is controversial. TAMs have been shown to support CRC progression through interactions with cancer cells, supporting cancer cell stemness and modulation of the immune response. − However, TAM density and their prognostic role change with tumor stage. Despite the documentation of phospholipase D4 (PLD4) from TAMs and protein kinase C alpha (PKCα) from CRC in promoting M1-like macrophage polarization and CRC regression, , most solid tumors, including CRC, have a TME that favors the M2-like polarization of TAMs, which facilitates tumor growth. For instance, EGF secreted by CRC can induce M2 polarization of TAMs via the epidermal growth factor receptor (EGFR)/Phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT)/ mammalian target of rapamycin (mTOR) pathway. Likewise, paxillin can activate the PI3K/AKT pathway and increase the proliferation and invasion of CRC cells by modulating M2 polarization. Moreover, the “Warburg effect” in proliferating tumor cells can trigger the expression of VEGF and arginase 1 (ARG1) in TAMs, resulting in macrophage recruitment and M2 polarization. In addition, TAMs can secrete CCL2 to attract Treg cells, which inhibit antitumor function of T cells and NK cells, − and interfere with immune cell interactions, creating an immunosuppressive TME in CRC. −

A crucial component of the innate immune system is represented by the NK cells, which are cytotoxic lymphocytes that can recognize and eliminate foreign cells, similar to the cytotoxic T cells of the adaptive immune system. NK cells are divided into two main subsets: (a) immature CD56 + CD16 – cells that secrete cytokines such as IFN-γ and TNF-α, and (b) mature CD56 – CD16 + cells that perform cytotoxic functions. , The cytotoxic function of NK cells is a well-established prognostic factor in reduced cancer risk and CRC recurrence. Several studies have also demonstrated that a high infiltration of NK cells within the tumor was associated with a favorable prognosis in CRC. , , However, some CRC patients show modified NK cell phenotypes in the tumor and peripheral blood, with reduced expression of activating receptors and increased expression of inhibitory receptors, which compromise their cytotoxic functions. − These receptors, such as killer cell immunoglobulin-like receptors, and their ligands, are part of the complex network that regulates NK cells activities. − If this network is disrupted, the tumor cells may evade the immune system more easily.

MDSCs control antitumor immunity by restricting T cell growth and promoting Treg differentiation. MDSCs found in the blood of CRC patients can restrain T cells proliferation in vitro , , and neutralizing MDSCs activity restored IFN-γ secretion by T cells. This is because T cell proliferation and activity is negatively affected by the depletion of l -arginine in the TME, which is being consumed by high levels of ARG1 expressed on MDSCs. , Similarly, MDSCs have also been found to affect T cell activation through regulation of O 2 production and inducible nitric oxide synthase (iNOS) activities. , ,

Cancer-associated fibroblasts (CAFs) in CRC are plastic cells that respond to cytokines and are influencing matrix remodeling and supporting cancer stemness through Wnt signaling. , Interleukin-1 receptor type 1 (IL1R1) + CAFs in CRC contribute to an immunosuppressive environment and T cell exclusion. Tumor-associated endothelial cells (TECs) produce factors, significantly contributing to angiogenesis in the TME and influencing CRC stemness, metastasis, and chemoresistance.

Noncellular components within the ECM, consisting of proteins like collagen and fibronectin, shape the TME stiffness and cellular functions, ultimately influencing CRC progression. Within the TME there are many signaling molecules that modulate tumor progression, such as the cytokine TGF-β that is released by various cells including macrophages and fibroblasts with immunoregulatory activity in CRC. Exosomal microRNAs (miRNAs) also mediate cellular communication within the TME, affecting CRC development, antitumor immunity and serving as potential biomarkers. ,

Current Immunotherapy Landscape for CRC

The first clinical success of immunotherapy ( NCT00094653 ) with ipilimumab (anti-CTLA-4) for metastatic melanoma in 2010 marked the rise of ICIs as a promising immunotherapeutic strategy, compared to other methods such as IL-2 or α-interferon-based cancer vaccines, or chimeric antigen receptor (CAR) T-cell therapies that have shown limited effectiveness along with high toxicities. − Unlike the conventional approval of other anticancer regimens, the fast-track approval granted by US FDA for ICIs to treat advanced solid tumor such as mCRC is based on tumor-agnostic, dMMR/MSI-high biomarker-driven approach, irrespective of the tumor origin or type ( Table ).

The efficacy of pembrolizumab (anti-PD-1), nivolumab (anti-PD-1) plus ipilimumab (anti-CTLA-4), and dostarlimab (anti-PD-1), in dMMR/MSI-high advanced CRC were substantiated by positive data from several clinical trials including KEYNOTE-016 ( NCT01876511 ), , KEYNOTE-028 ( NCT02054806 ), KEYNOTE-164 ( NCT02460198 ), , KEYNOTE-177 ( NCT02563002 ), Checkmate 142 ( NCT02060188 ), − GARNET ( NCT02715284 ), and NICHE ( NCT03026140 ), which demonstrated that these ICIs could induce lasting responses in patients with dMMR/MSI-high advanced CRC. Furthermore, ICIs treatments have also shown promising results in addressing dMMR/MSI-high tumors of other types, as evidenced by the findings from KEYNOTE-012 ( NCT01848834 ), KEYNOTE-158 ( NCT02628067 ), and GARNET ( NCT02715284 ). Beyond therapeutic benefits, pembrolizumab exhibited low immunogenicity and favorable safety profile for advanced solid tumor patients. Notably, the increased tumor mutational burden (TMB) and T-cell inflamed gene-expression profile have been associated with clinically significant improvement in the efficacy of pembrolizumab monotherapy. The compelling efficacy demonstrated across various clinical trials unequivocally establishes the capability of ICIs in inducing durable and safe responses in patients with dMMR/MSI-high CRC.

It is unfortunate that the majority of CRC patients (ca., 85%) that are characterized by proficient MMR (pMMR), MSS, or MSI-low tumors have poor responses to ICI treatments. , , , − MSS CRCs are usually considered to be immunologically “cold” tumors, with lower TMB than MSI CRCs, posing a major challenge for ICI therapy. However, some studies have suggested otherwise: some MSS tumors are reported to have intermediate (75% MSS vs 83% MSI) and high (21% MSS vs 45% MSI) immunoscore, , albeit lower than MSI tumors. Moreover, some patients with large immune infiltrates have shown a pathological response to ICI therapy. , , , Additionally, POLE mutations affecting DNA polymerase ε, which facilitate lead strand DNA replication, have been found in MSS mCRC patients who respond to pembrolizumab treatment. The tumor regression observed in CRC patients with POLE mutation may be due to greater CD8 + T cell infiltration and enhanced expression of effector cytokines and cytotoxic T-cell markers. However, clinical efficacy of ICI therapy is still limited in MSS tumors, with only up to 25% patients responding positively, potentially due to low immunogenicity. , , , Immunologically “hot” MSI CRC also suffers from moderate outcomes from treatment with ICIs with about 50% patients responding positively. MSI CRC could develop resistance to immunotherapy via various mechanisms, such as low neoantigen presentation, expression of multiple immune checkpoints, neutrophil and Treg immunosuppression, and inflammation and immunosuppression. , , To address these challenges, efforts have been made toward developing combinatorial therapies and identifying predictive biomarkers to maximize the benefits of ICI therapies. Currently, suitable patients to receive ICI therapy are selected based on three FDA-approved predictive biomarkers, namely dMMR/MSI status, TMB, and immune checkpoint PD-L1 expression, as well as emerging biomarkers such as the immunoscore and the hematology index, to achieve optimal therapeutic efficacy.

Combination Therapy to Enhance CRC Immunotherapy Efficacy

Due to the limited eligibility of CRC patients for immunotherapy, current research mainly focuses on investigating the combination of immunotherapy with other treatments such as chemotherapy, radiotherapy, targeted therapy, and vaccines. This strategy seeks to address treatment resistance and broaden the scope of potential benefits to a more extensive CRC patient population, ultimately improving overall treatment outcomes.

The synergy between chemotherapy and immunotherapy is based on the observation that chemotherapeutic drugs can lead to the overexpression of tumor-associated antigens and stimulate tumor antigen-specific T-cell responses. Clinical trials combining chemotherapy with immunotherapy, such as the GOLFIG regimen (i.e., granulocyte macrophage colony-stimulating factor and low-dose interleukin-2, following gemcitabine + FOLFOX-4), have shown promising results in terms of response rates, disease control, and PFS. − These studies reported the effect of chemotherapy on immune cells, specifically the reduction in Treg, and enhanced tumor-specific T-cell responses. However, conflicting results have emerged regarding the impact of chemotherapy on intratumoral T-cell densities, emphasizing the necessity for further clinical trials to elucidate the precise mechanisms involved.

The integration of radiation therapy with ICI therapy has shown potential in overcoming immune resistance of pMMR mCRC. Studies have also demonstrated improved survival rates for CRC patients undergoing complete liver metastasis resection when treated with radiotherapy combined with monoclonal antibodies against carcinoembryonic antigens.

Recent advancements in targeted therapies, particularly antiangiogenic drugs, are being integrated into the clinical treatment of various tumors, including CRC. These therapies have demonstrated immune-enhancing effects offering a potential improvement in clinical outcomes in combination with immunotherapy for resistant MSS tumors. For example, studies have shown increased immune cell infiltration in CRC patients responding to bevacizumab (VEGF inhibitor) or chemotherapy with cetuximab (EGFR inhibitor), both of which are antibodies rather than small molecules. , In contrast, results from trials involving MAPK/extracellular signal-regulated kinase (ERK) (MEK) inhibitors and PD-L1 inhibitors have failed to achieve improved outcomes, , emphasizing the need for further investigation and optimization of the combination strategies for low immunoscore tumors. Cetuximab, in combination with NK cells, has also demonstrated antitumor effects by inducing antibody-dependent cell-mediated cytotoxicity (ADCC), representing another promising combination approach for CRC patients. ,

Promising outcomes from human clinical trials of therapeutic cancer vaccines are prompting investigations into whether combining ICI therapy with vaccination could enhance efficacy beyond ICI monotherapy in dMMR/MSI-high CRC and potentially induce responses in pMMR/MSS CRCs, which are typically unresponsive to ICI therapy alone.

Combining CRC Immunotherapy with Clinical Pt Drugs

A variety of combination strategies have been investigated to enhance the efficacy of ICI therapy in MSS CRC patients who have low response rates, and in MSI CRC patients who could develop resistance to ICI therapy. These strategies include combining ICI therapy with another ICI, chemotherapy, anti-VEGF therapy, anti-EGFR therapy, antiangiogenic therapy, radiotherapy, oncogenic pathway inhibitors, bispecific antibodies, and cancer vaccines. Many of the clinical trials for these combinations have been thoroughly discussed in previous reviews, − hence we will focus on the attempts in combining ICI therapy with Pt-based chemotherapy to enhance the response rate of CRC patients to ICI immunotherapy, especially for pMMR/MSS phenotype.

As previously mentioned in section , the primary clinical treatment for advanced CRC typically involves combinatorial chemotherapies ( Table ). These cocktail regimens aim to enhance overall chemotherapy efficacy through synergistic or additive effects. Another reason for the combination of chemotherapeutics of different classes is that their combination can enhance immunomodulation in various ways, on top of their cytotoxic effects. For instance, the combination of 5-FU and OXP in FOLFOX regimen can improve tumor immunity by selectively inhibiting MDSCs , and inducing tumor cells ICD, respectively. In a CT26 murine CRC model, FOLFOX treatment increased CD8 + T cell infiltration and decreased exhausted CD8 + T cell population. FOLFOX therapy also reversed the immunosuppressive TME by reducing the expression of inhibitory receptor such as PD-1 and T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) to enhance the cytotoxic IFN-γ and TNF-α secretion. At the same time, an in vivo CT26 model exposed to FOLFOX showed upregulation of PD-L1 induced by high levels of IFN-γ and TNF-α, indicating that FOLFOX treatment could trigger tumor adaptive immune resistance.

Therefore, it is conceivable that these immunostimulatory effects induced by OXP combination chemotherapy regimens may expand the potential beneficiaries of ICI therapy among CRC patients, including those with pMMR/MSS CRC or dMMR/MSI-high CRC that do not respond to ICI immunotherapy. In particular, CT26 cell line, representative of pMMR/MSS tumors, has been extensively studied for its immunological response to chemotherapy and demonstrated encouraging antitumor effects when combined with ICIs. Recently, it was found that immune checkpoints CD47 and PD-L1 were upregulated in CT26 cells post-treatment with either FOLFOX or OXP alone, both in vitro and in vivo . Remarkably, the combination of anti-CD47, anti-PD-L1, and FOLFOX in vivo demonstrated a significant improvement in mice survival and tumor regression. This combination also promoted immunoinflammatory TME through reduction in Tregs and MDSCs, as well as elevation in CD8 + INF-γ + lymphocytes and M1/M2 macrophage ratio. Similar positive outcomes were also observed in the studies combining OXP with anti-PD-L1 antibodies in the CT26 mice model, showing an increase in survival, inhibition of tumor growth, and a favorable TME for antitumor immune responses. , Furthermore, a synergistic effect was noted when FOLFOX was combined with anti-PD-1 treatment, leading to a complete tumor regression in both CT26 and MC38 CRC mouse models that were resistant to monoanti-PD-1 therapy. The synergism observed was associated with enhanced tumor infiltration by activated PD-1 + CD8 + T-cells and increased IFN-γ induced PD-L1 expression on tumor cells. Notably, CRC patients in the same study also displayed induced PD-L1 expression and high CD8 + T-cell infiltration in the TME. In another MC38 in vivo mice model that is resistant to ICI therapy, the combination of ICI therapy (i.e., anti-CTLA-4 plus anti-PD-1) with OXP treatment successfully invoked an antitumor response. Moreover, trifluridine/tipiracil with OXP demonstrated the ability to induce ICD in a panel of murine and human pMMR/MSS CRC cell models, namely CT26, SW620, Caco-2, and Colo-320, both in vitro and in vivo . This combination resulted in improved CD8 + T-cell infiltration and activation through M2 TAMs elimination. The adaptive immune resistance involving PD-L1 expression on tumor cells and PD-1 induction on CD8 + T cells was overcome when anti-PD-1 was coadministered with trifluridine/tipiracil and OXP , resulting in enhanced antitumor efficacy. These preclinical findings provide compelling evidence that the synergy between Pt-based chemotherapeutics and ICIs can offer significant benefits to cancer patients currently unresponsive to ICI therapy, not only in CRC but also in other cancers such as lung cancer , as well as head and neck cancer.

To comprehend and investigate the safety and efficacy of employing Pt-chemotherapeutics for sensitizing pMMR/MSS mCRC patients toward ICI therapy, numerous clinical trials have been initiated, exploring diverse combinatorial treatment regimens involving both Pt-based chemotherapeutics and ICIs ( Table ).

As a start, METIMMOX ( NCT03388190 ) assessed the efficacy of FLOX (5-FU + leucovorin + OXP ) with or without nivolumab (anti-PD-1) in pMMR/MSS mCRC patients. Preliminary results revealed a modest improvement in median PFS (i.e., 5.6 months vs 6.6 months) between control arm and experimental arm, suggesting that short-course OXP -based chemotherapy could indeed sensitize pMMR/MSS mCRC patients to ICI therapy. Another study, COLUMBIA-1 ( NCT04068610 ) investigated the combination of FOLFOX and bevacizumab (anti-VEGF) with or without durvalumab (anti-PD-L1) and oleclumab (anti-CD73) in pMMR/MSS mCRC patients. Although the addition of durvalumab and oleclumab to FOLFOX plus bevacizumab in the experimental arm significantly increased the objective response rate (ORR) (44.0% vs 61.5%), median PFS remained unaffected (11.1 months vs 10.9 months) compared to the control arm. Additionally, cohorts B and D in KEYNOTE-651 ( NCT03374254 ), which received the combination of mFOLFOX7 and pembrolizumab with or without beinimetinib, reported median PFS of 8.6 months and median OS of 28.6 months with no new safety concerns emerged for using this regimen in pMMR/MSS mCRC patients.

AVETRIC ( NCT04513951 ) examined the combination of mFOLFOXIRI, cetuximab (EGFR inhibitor), and avelumab (anti-PD-L1) in pMMR/MSS mCRC patients with wild-type RAS, and met its primary end point with median PFS of 14.1 months, a ORR of 82%, a disease control rate (DCR) of 98%, and a R0 recession rate of 21%. AVETUX ( NCT03174405 ) trialed the combination of mFOLFOX6, cetuximab, and avelumab as a novel strategy to increase the immunogenicity of pMMR/MSS tumors in mCRC patients with wild-type rat sarcoma viral oncogene homologue (RAS)/B-Raf proto-oncogene, serine/threonine kinase (BRAF), and achieved a final median PFS of 11.1 months, median OS of 32.9 months, ORR of 79.5%, and DCR of 92.3%.

Notably, follow up analysis of AVETUX found that tumor clonality and diversity could serve as potential biomarkers for predicting the response to chemo-immunotherapy combination in pMMR/MSS mCRC treatment.

Several clinical trials have investigated the efficacy and safety of combining immunotherapy with chemotherapy and/or targeted therapy in patients with mutant variants of pMMR/MSS mCRC. For example, the triple combination of durvalumab (anti-PD-L1), tremelimumab (anti-CTLA-4), and mFOLFOX6 for RAS mutant pMMR/MSI-Low mCRC patients in MEDITREME ( NCT03202758 ) demonstrated favorable PFS of 90.7% and 60% for 3 months and 6 months, respectively. , MEDITREME also reported higher median PFS (6 months vs 8.2 months) and ORR (63%) in the treatment group compared to historical FOLFOX control group. Immunological analysis also demonstrated that this triple combination regimen could enhance the tumor-specific neoantigen immune response in both tumor and peripheral tissues. BBCAPX ( NCT05171660 ) assessed the combination of sintilimab (anti-PD-1), CAPOX, and bevacizumab in RAS/BRAF mutant pMMR/MSS mCRC patients, reporting an impressive ORR of 84%, disease control rate of 100%, and median PFS of 18.2 months with a tolerable safety profile. − Biomarker assessment analysis indicated that some patients transitioned to an immunologically “hot” subtype after receiving the combination therapy. Furthermore, heavily pretreated chemorefractory patients with pMMR/MSS mCRC were treated with combinatorial therapy of pembrolizumab and pemetrexed with or without OXP in NSABP FC-10 ( NCT03626922 ) and achieved clinical benefit rate (CBR) of 50% and ORR of 12.5%, comparable to those reported in KEYNOTE-016 ( NCT01876511 ). ,

HCRN GI14-186 ( NCT02375672 ) evaluated the efficacy and safety of mFOLFOX6 and pembrolizumab in mCRC patients. , The trial reported median PFS of 8.8 months, median OS of 19.9 months, and ORR of 56.7%, which are similar to the historical data of FOLFOX alone (i.e., median PFS = 9.0 months, median OS = 16.2 months). This suggests that the combination is well tolerated and does not compromise the activity of FOLFOX. CheckMate 9 × 8 ( NCT03414983 ) compared mFOLFOX6 plus bevacizumab with or without nivolumab in mCRC patients. The trial did not meet its primary end point of median PFS (11.9 months vs 11.9 months), but it revealed that the addition of nivolumab causes improvements for PFS, median OS (i.e., 29.2 months), ORR (i.e., 46% vs 60%), and DCR (i.e., 84% vs 91%) after 12 months, when compared to the control arm. AtezoTRIBE ( NCT03721653 ) tested FOLFOXIRI plus bevacizumab with or without atezolizumab in mCRC patients. − The trial demonstrated that the combination of atezolizumab was safe and increased both ORR (i.e., 59.0% vs 64.0%) and median PFS (i.e., 11.5 months vs 13.1 months) against the control arm. Moreover, the trial identified potential responders for this combination from the patient pool based on high immunoscore or high TMB. NIVACOR ( NCT04072198 ) investigated the combination of FOLFOXIRI, bevacizumab, and nivolumab in RAS/BRAF-mutated mCRC patients regardless of their MSI status, and achieved a high ORR of 76.7%, median PFS of 10.1 months, DCR of 97.3% and median duration of response (DOR) of 8.4 months. ,

Efforts to enhance therapeutic efficacy and overcome resistance to ICI therapy among CRC patients persist with ongoing clinical trials, such as METIMMOX-2 ( NCT05504252 , FLOX + nivolumab), APHRODITE ( NCT04653480 , OXP /irinotecan + surufatinib + toripalimab), POCHI ( NCT04262687 , XELOX + bevacizumab + pembrolizumab), COBP ( NCT05585814 , CAPOX + pembrolizumab + bevacizumab), BASKETII ( NCT04895137 , mFOLFOX6 + bevacizumab + sintilimab), NCT05588297 (CAPOX + nivolumab + bevacizumab), ATOMIC ( NCT02912559 , FOLFOX ± atezolizumab), and COMMIT ( NCT02997228 , atezolizumab ± (mFOLFOX6 + bevacizumab)). Even though the combination between immunotherapy and chemotherapy is still not a standard treatment option in patients who are MSS or TMB-low, as well as many trials have yet to report their results, the synergistic potential of combining Pt-based chemotherapeutics with ICIs seems to be promising in addressing challenges associated with ICI therapy.

Other CRC Treatment Modalities

Surgery

Surgery is the primary treatment for localized and regional CRC cases ( Tables and ). Most patients with early stage (stage I–II) CRC can be treated with polypectomy (ca. 3%) or colectomy (ca. 84%), surgical removal of polyps and diseased part of the colon, respectively ( Table ). Surgical resection of primary tumors and affected tissues can achieve complete remission in approximately 50% of CRC patients. However, the benefit and effectiveness of surgery decrease as the disease progresses, with the 5-year survival rate dropping to as low as 30% at stage III. At stage IV, surgical resection of the primary tumor is typically reserved for treating symptoms such as bowel obstruction, although this palliative benefit is offset by the increased mortality and risk of postoperative complications in mCRC patients with weakened immune systems. As this review focuses on discussing Pt drugs for treating CRC, please refer to reviews by Shinji et al. for recent advances in surgical techniques for CRC patients.

Radiotherapy

Various radiotherapy techniques, such as stereotactic ablative radiotherapy and selective internal radiotherapy, are commonly employed for CRC patients to achieve local control of inoperable liver and lung colorectal metastases, respectively. − In addition, neoadjuvant radiotherapy, either in a short course (SC-RT, 5 × 5 Gy) or long course with concurrent chemotherapy (LC-CRT, 45–50.4 Gy, 25–28 fractions), are the current standard-of-care for locally advanced rectal cancer (LARC, stage II–III), which carries a higher risk of local recurrence and a poorer overall prognosis. − SC-RT has demonstrated a significant reduction in local recurrence rates (LRR) from 26% to 9% ( p < 0.001) and an increased OS from 30% to 38%. Furthermore, preoperative SC-RT has been shown to improve the quality of total mesorectal excision surgery by substantially reducing LRR as compared to just surgery alone. , Similarly, long-course chemoradiotherapy, often followed by total mesorectal excision surgery, is associated with improved curative surgery and reduced LRR. Typically, patients receive chemoradiotherapy that utilizes fluoropyrimidine-based (e.g., 5-FU or capecitabine) chemotherapy as a radiosensitizer in combination with radiotherapy, followed by total mesorectal excision surgery. ,

Despite the evident benefits of providing preoperative chemoradiotherapy in conjunction with total mesorectal excision surgery for rectal cancers, this combination does not completely eliminate local recurrences and distant metastasis in patients. Furthermore, radiotherapy can result in unwanted side effects, including radiation injury and hematological toxicity. Moreover, the application of Stereotactic ablative body radiotherapy in CRC liver metastasis is constrained due to its suboptimal efficacy and potential harm to healthy liver cells. For greater insights into the advances and efficacy of radiotherapy for CRC patients, please refer to a review by Tam et al.

Experimental Models for CRC Drug Screening and Development

3D in Vitro Cancer Models

Currently, conventional chemotherapeutic drug development strategies follow progressive evaluations of lead compounds in vitro , then preclinical in vivo models and, finally, clinical trials. However, this lengthy process has a low 6.7% success rate of developing a clinically approved drug from phase I. This is largely attributed to the inadequate recapitulation of true pathological conditions in preclinical two-dimensional (2D) in vitro models, causing poor predictions of the patient outcomes. 2D cell cultures present an oversimplified scenario, where cells are uniformly exposed to nutrients or drugs due to a high surface area-to-volume ratios. This neglects the complex reality of solid tumors, where drugs must navigate through tumor vasculature and penetrate tissue to reach all cancer cells. These processes delay drug exposure, significantly impairing the anticancer efficacy of short half-lives therapeutics. Furthermore, 2D cell culture lacks key characteristics of the TME that can be mimicked in 3D culture ( Table ), such as 3D spatial arrangements within the ECM of different cell types and the presence of an hypoxic environment, which influence drug sensitivity.

Local inflammation is a significant promoter of CRC tumorigenesis, attracting stromal cell populations which, along with immune cells, tumor-associated vasculature and the ECM ( Figure , Table ), form the CRC TME. , In turn, interactions between tumor, stromal and immune cells further promote CRC progression. − For example, CAFs adjacent to CRC cells overexpress IL-6 and serine protease inhibitor Kazal type 3 (SPINK3), which promote tumor angiogenesis and cancer cell growth while suppress tumor inhibition. , The inability of 2D cell cultures to recapitulate these critical TME elements represents a significant limitation, contributing to discrepancies between in vitro drug efficacies and clinical outcome with inevitable failures of clinical trials. Therefore, 3D in vitro CRC models were developed to better mimic the complex tumor TME. , −

These 3D models, such as spheroids and organoids, offer improved recapitulation of cell-cell and cell-matrix interactions, as well as spatial organization of tumors. Further, they allow for the incorporation of multiple cell types, including stromal and immune cells, to more accurately represent the heterogeneous nature of tumors. To further bridge the gap between in vitro models and in vivo conditions, organ-on-a-chip or microphysiological systems (MPS) have emerged as advanced platforms that integrate microfluidics with 3D cell culture techniques. − CRC tumor MPS provides additional human-relevant complexity to the TME, ultimately aiming at improving the rate of success in translation of preclinical findings to clinics. − Moreover, advancements in bioprinting technologies, in which tissues or organs are manufactured additively layer by layer, enable greater customization over biological characteristics in 3D cultures. , For more extensive reviews on 3D models for CRC, please refer to the following reviews by Vitale et al. and others for 3D models to better emulate the complexity of the tumor tissues; , and reviews by Reidy et al. and others for 3D models for screening novel therapeutics. , ,

Why Murine as an Experiment Model for CRC?

Despite the fact that extensive research has been done on CRC in the past decades, there are still substantial issues that need to be addressed, like difficulties in early detection of micrometastases and resistance to treatment. The animal models are therefore crucial assets to address these challenges. Since the rodent models enable researchers to concurrently assess and measure a complicated disease including CRC, they provide a valuable contribution to knowledge advancement. The affordability, ease of management, short gestation period, anatomical similarities, and accessibility of genetic modification, as well as their classification as mammals are among the benefits when utilizing murine models. The current understanding of tumor biology, carcinogenesis, and the effects of specific molecular processes on colon biology might all be enhanced by the use of murine models. These murine models make it possible to comprehend and track the disease progression, as well as to find and create novel preventive measures that could potentially be implemented in clinical trials in the future. An ideal murine model of a human disease should be easy to understand, inexpensive, and able to replicate the disease’s pathology, the biological behaviors and the biochemical changes. Although animal research cannot take the place of human clinical trials, it can be employed as a prescreening approach in order to make human trials more targeted in view of their key recapitulative features.

The development, structure, and functions of the murine and human intestinal tracts are almost identical ( Figure A). The rectum, anus, colon, and cecum are components of the large intestine, which is in charge of absorbing salt and water from digested food before preparing the faecal matter. A curled blind bag called the cecum discharges into the proximal colon, supporting bacterial fermentation. Compared to murine, the cecum in humans is significantly smaller and forms a continuous portion of the proximal colon located distal to the ileocecal valve. Histologically, the murine mucosal folds vary by region; the cecum and proximal colon mucosa are transverse, distal colon and rectum mucosa are longitudinal, and midcolon mucosa has no folds and is flat. Also, the human mucosal fold is transverse in all regions. The murine anal canal is bordered by a keratinized, stratified squamous epithelium, while the human anal canal is bordered by a stratified squamous epithelium and nonkeratinized lines. Despite the comparable histology between rodents and humans, rats and mice lack adipose tissue in their submucosa, in contrast to humans.

The first model that successfully used carcinogens to induce CRC was the APC (Adenomatous polyposis coli) Min/+ model, where chemical mutagenesis was used to create the diseased animal. These models are useful in recapitulating the early phases of tumor carcinogenesis, due to their low rate of developing tumors. However, only a small percentage of the mice under such circumstances develop tumors, and even if they do, their location, dissemination, and differentiation vary greatly.

Diet Induced Models (DIMs)

Compelling epidemiological data associate obesity resulting from diet, excess body and abdominal fat with a higher incidence of colon cancer and a lower prognosis following diagnosis. The relationship between eating a high-fat diet and obesity and the incidence and spread of colon cancer has been studied in murine models in an effort to simulate the human condition. The intake of a high-fat diet leads to obesity, which is associated with elevated tumorigenesis, reduced apoptosis and rapid proliferation of tumor cells. The main advantage of this model is the development of carcinoma in the proximal colon, cecum, and small intestine. Nonetheless, the time required for tumor development is long, and there is a high risk of failure to develop tumors. Also, there is currently no description of dietary mutations, and few animals acquire neoplastic cancers.

Chemical Induced Models (CIMs)

The first mouse intestinal tumor model was successfully established by feeding mice with methylcholanthrene. Later, colon carcinoma was induced in rats by feeding them with radioactive yttrium (Y). , A decade after these models, hydrazines were found to be colon carcinogenic agents and adenocarcinoma was induced to rats upon treatment with excessive amount of cycad flour, which contains a form of methylazoxymethanol (MAM), often referred as cycasin. In general, chemically induced models (CIMs) are noninvasive and do not metastasize; tumors formed in this way represent the transition of adenoma to adenocarcinoma from aberrant crypt foci. They have an advantage of enabling different routes of administration, including oral gavage, intraperitoneal (IP), intramuscular (IM), and subcutaneous (SC) injections. Even though the CIMs are easy and good models of CRC, they are not thought to be relevant for recapitulating the immune response and the TME. The chemically induced tumors in rodents randomly exhibit pathological and genetical similarities with human CRC. Since the tumor progression must occur from normal cells to adenocarcinoma or carcinoma in this model, establishing a successful model requires a significant amount of time. Apart from this, the development of adenocarcinoma or carcinoma is highly influenced by the rodent’s age, gender and genetic background. Furthermore, the effective local concentration of carcinogenic substances might result in interference with their metabolism caused by the gut flora, diet, and immune status of rodents. The different chemicals used to induce the CRC model, their doses and/or concentrations, routes of administration to murine and the strain/species used are reported in Table .

Limitations of Induced Models

Various risk factors, such as poor eating habits, the environment, exposure to carcinogenic substances, and other variables, are associated with higher incidence of CRC. Even though the chemically induced rodent models of CRC are useful for exploring new therapy strategies and for the identification of diagnostic and prognostic markers, generating these models requires longer experimental cycles and duration. These models have a low carcinogenic efficiency, a low modeling rate, and a variable molding time. Also, CIMs cannot be used alone as they have low carcinogenic effect and require multiple administrations. Since the quantification of treatment volume is challenging, they usually cannot be utilized to analyze CRC metastases, and the induced mutations are random.

Metastasis Models

Understanding the etiology of CRC and the roles that various genetic and genomic alterations play in its onset and progression is necessary for target authentication ( Table ).

To comprehend how mutations behave in the natural environment, most of the research has focused on developing genetically engineered mice models (GEMMs) that precisely represent late-stage diseases. Researchers are now able to identify a gene’s pathophysiological significance by creating genetically engineered autochthonous mouse models (GEAMMs) using clustered regularly interspaced short palindromic repeats (CRISPR)-associated Protein 9 (CRISPR-Cas9) technology, in which a tumor develops from healthy cells.

Despite these advances, the lack of a mouse model that accurately mimics the course of human disease, from adenoma and adenocarcinoma to metastasis or changes in the microenvironment remains a common issue. The most widely employed models of GEMMs and GEAMMs include adenomatous polyposis mouse models (APMM) and hereditary nonpolyposis colon cancer mouse models (HNPCC). While HNPCC is the consequence of genetic changes to the MMR genes, APMM is mainly caused by germline mutations of the APC gene, a tumor suppressor gene. When it comes to comprehending the molecular pathways and therapeutic targets involved in the onset and evolution of CRC, APMM has proven to be particularly valuable. Hereditary nonpolyposis CRC, or Lynch syndrome (LS), is a prevalent syndrome predisposing to cancer that is caused by germline pathogenic mutations in MMR genes. HNPCC models provide a platform for researching the processes underlying drug resistance and for testing novel combinations of immunotherapies and targeted therapies. However, the creation of these models is costly and time-consuming, and environmental influences may cause variations in the mice’s phenotypes. In these APMM and HNPCC models, various genes such as oncogenes like C- myc , SRC , Kras , etc., tumor suppressor genes like DCC, MDD, p53 , Apc , etc., and DNA repair genes like hMsh1, hMsh2, hMlh6, hPms1, and hPms2 are used to create a successful CRC model. Each of the genes plays a distinct role in the development of CRC, and mutations in two or more of those genes are commonly linked to the malignant phenotype of CRC. The most prevalent model, which accounts for 86% of human CRC cases, is a mouse with a mutant Kras gene. This model is used to explore the onset, course, and efficacy of possible therapies for CRC. Mice with mutations in the Apc gene, which is present in 90% of human CRC and mice with mutations in the p53 gene, which is present in 60% of human CRC, are the other common GEMMs that are used in CRC research. The advantages and disadvantages of modifying the different genes to induce CRC model in murine species are summarized in Table .

Taking into account all the genes involved in the development of the genetic model, these GEMMS and GEAMMs aid in the growth of in situ tumors and replicate the early phases of oncogenesis including stage I and II. Since gene alterations occur at the biological level, these models depict the clinical circumstances of cancer in terms of the natural immune system. This is because of a well-known genetic event, and the cancer cells and stroma are from the same species. However, the creation of these models is costly and time-consuming, and metastases are seldom created. The complete replication of human cancer differs from that of the animal model due to secondary mutations, even though the immune system remains untouched. Since the imaging of disease assessment in these models requires costly and user-dependent (i.e., high skill required) techniques like magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), endoscopy and so on, one of the primary limitations of these models is their limited noninvasive imaging options.

Xenograft Models

Human tumor cells or tumor fragments are grafted into immunocompromised animals to create xenograft models. Xenograft refers to the transplantation of tissue including fresh human tumor, intact or single cell from one species into another. SC, intrasplenic, and orthotopic transplantation are the three types of transplantation routes. Orthotopic transplantation involves delivering cancer cells to the same tissue or anatomic site where a tumor type originated. To create syngeneic models, animal tumor cell lines like CT26 or any commercially available immortalized cells are transplanted into animals that share the same genetic heritage as the cell line. It is also feasible to distinguish between orthotopic and heterotopic models in this context.

Cell Derived Xenograft Model (CDX)

Owing to its ease, accessibility, and high tumor growth, SC injection (i.e., heterotopic model) is one of the most popular techniques; however, the TME differs from that of the colon, and metastases do not form. Considering its low level of technical requirements, ease of seeing tumor growth, low cost of maintaining colonies, high yield generation, and tolerable tumor latency, CDX model is widely used at the injection site. Commonly used mice are typically naked (i.e., athymic) mice strains and the severe combined immunodeficient (SCID) mice, which are devoid of either T cells or both B and T lymphocytes, respectively. Moreover, NOD/SCID animals lack NK cells in comparison to SCID mice. However, this model cannot replicate the genetic heterogeneity of the original tumor because of the loss of original inheritance and the absence of relevant TME components during in vitro passage. Additionally, modifications at the genomic and epigenetic levels may arise from repeated passaging with enrichment for specific subclones. There are advantages of injecting cells into the intestinal serosa of immune-deficient animals for orthotopic xenografts of CRC cell lines. The advantages of this approach are comparable to those of the SC model; however, certain cell lines metastasise to the liver, and the CRC cells are housed in a more natural milieu. Nonetheless, a significant limitation of these models for immuno-oncology investigations is their inability to support studies on checkpoint blockade treatments, cytotoxic T cells, or adaptive immunity.

Patient Derived Xenograft Model (PDX)

To address the weaknesses of the CDX model, PDX models have been established to deepen the understanding of tumor biology and to develop novel medicines for the treatment of cancer. PDX models are developed by grafting human tumors or tumor cells onto murine species. The outcomes of drug evaluation using PDX model is the most similar to clinical settings, and the kind of immunodeficient mice employed and the mode of administration influence the engraftment rate. Evidence has shown that in CRC, PDX models maintain the heterogeneity of the underlying tumor and the most popular method for promoting engraftment is to monitor and treat the tumor after SC implantation. The most frequently employed original source is surgical specimens since the quantity of initial tumor material greatly influences the outcome of PDX engraftment. The highest percentage of engraftment (ca., 60–100%) in CRC is observed in PDX models with 89% of the hosts being Balb/c nude mice with orthotopic implantation; however, nonobese diabetic (NOD)/SCID and NOD/SCID/IL2rγ null (NSG) mice are used as hosts in the PDX model with 76% with subcutaneous injection. − Compared to 2D cultured cancer cell lines, the PDX model has a higher stromal component, which could be useful for studying the interactions between cancer cells and TME. Studies have shown that PDX preserves the human donor tumor’s global gene-expression patterns, mutational status, metastatic potential, histological differentiation, and histopathological subtypes. The CRC humanized PDX model has been utilized in numerous studies to evaluate the efficacy of immunotherapy medications and other systemic chemotherapeutic medicines. It has also been used to identify drugs and biomarkers, generate cell lines, construct colospheric structures, and gain additional insights into the biology of tumor. A strong foundation for examining the biology of metastases and the response to treatment in CRC is offered by PDX orthotopic models. However, orthotopic implantation requires a high level of technical skills, and this model’s capacity and reproducibility are limited. Recently, fluid from malignant ascites or pleural effusions, circulating tumor cells (CTCs), or both have been used to construct PDXs that maintain tumorigenicity in mice. Therefore, it is possible to analyze the genetic evolution of tumors and evaluate how new therapies are responding to tumors using CTC-derived PDX models. The PDX model has some drawbacks, such as high costs, longer tumor production time and poor engraftment rate. Establishing a viable PDX model is challenging, and the possibility of gene mutations further complicates the process.

Patient Derived Organoid Xenograft Model (PDOX)

Since the PDX model is known to be a tedious and expensive process, patient-derived organoid xenograft (PDOX) may be able to help with these problems. Patient derived organoids (PDOs) are created from patients’ stem cell collections or isolated organ progenitor cells, which result in clusters of three-dimensionally cultured multicellular aggregates. Investigations have demonstrated that PDOX model preserves the original matrix’s characteristics as well as the functions of the tissues. Also, PDOs perfectly replicate the in vivo tissues in both the healthy and diseased conditions, including CRC. This model can be genetically edited and is easy to maintain. It has been shown that PDOs preserve the parental tumors’ histological, transcriptomic, and genetic characteristics. In other words, the PDOX model preserves the essential cell signaling pathways to sustain the growth of the tumor cells while removing any chance of the tumor cells being rejected because it lacks an adaptive immune system. The PDOX model’s capacity to precisely mimic the tumor biology and histology in patients, as well as preserve driver mutations from the original tumor, represent key advantages. As a result, pharmacological efficacy and toxicities can be realistically evaluated in an in vivo model that closely mimics the clinical setting. Since PDOX implantation has a tumor formation rate of 60% in the colon wall and 100% in the cecum, respectively, it offers a strong basis for more accurate CRC murine models. Since the concept is still in its infancy, PDOX technology validation and standardization processes are still lacking. These models might not be appropriate for producing results that can be applied to other patient populations because they are based on individual patients. Nonetheless, it is still less costly to establish a PDOX setup compared to PDX models.

Inferences and Implications on Murine Models

Animal models play a critical role in biomedical research, particularly in understanding disease mechanisms and evaluating therapeutic interventions. Their performance depends on how well they mimic the pathophysiology, progression, and treatment responses of human diseases. The overview of the performance of various models has been discussed in ( Table ).

Understanding the advantages and disadvantages of CRC models, as well as how to apply them most effectively for medication development and studies into the origins and evolution of tumors, is essential for CRC researchers. Even though there are a few animal models available for the study of CRC, none can be considered as a perfect model; rather, they are all valuable resources for understanding the etiology of colon cancer in humans and other animals as well. Nonetheless, the selection of the model should take into account the objectives of the study, the costs, and the benefits and drawbacks of each model, animal strain, and gender.

Over the past few decades, human cell lines and xenograft models have been widely used because they are inexpensive and simple to use. However, the heterogeneity of CRC tumors cannot be replicated by these models used individually. Every animal model has benefits and drawbacks. While certain models are effective at inducing carcinogenesis on their own, in other situations combining two induction methods yields the most representative results for human carcinogenesis. By combining two induction methods, researchers can create models that more accurately represent human diseases, improving the predictive value of preclinical studies. An example is the combination of genetic mutation plus carcinogen exposure. Such a combination can be achieved through the use of an APC gene mutation model, such as the Apc Min/+ mouse, which predisposes animals to develop tumors and Administration of a chemical carcinogen like azoxymethane (AOM), which induces DNA damage and accelerates tumor formation. As discussed, certain individual animal models are considered particularly suitable for research on CRC because they closely replicate the pathophysiology of the disease in humans. These models provide valuable insights into tumor initiation, progression, and metastasis, as well as responses to various therapeutic strategies. It should be highlighted, nonetheless, that the majority of models necessitate the combination of at least two CRC strategies. This is because CRC is a complex condition, meaning that a number of variables, including hereditary and environmental factors, can contribute to its development. To summarize, a model that fully captures the pathophysiology of CRC is still needed. Murine CRC models remain a valuable resource for advancing our knowledge and management of this disease.

Other in Vivo CRC Models

Fruit Fly Model ( Drosophila melanogaster )

Drosophila melanogaster , a common fruit fly, has evolved into a useful tool for research on cancer ( Figure ). WNT, HIPPO, JAK/STAT, RAS, NOTCH, HEDGEHOG, BMP, and TGF-β are just a few of the important elements in cancer-related pathways that have been successfully identified using Drosophila as a pathway discovery platform. About 75% of the genes associated with human diseases are reported to have functional homologues in Drosophila. The fruit fly contains important genes related to the cell cycle, differentiation, migration, polarity, adhesion, and apoptosis in the setting of cancer. It is important to note that, compared to mammals, Drosophila exhibits less genetic redundancy, which results in a lower frequency of these genes. Therefore, compared to conventional 2D in vitro cell culture systems, fruit flies can more precisely reflect the cancer state. The organism can produce a lot of offspring and has a quick life cycle (ca.,10 days). It is also reasonably priced and simple to care for. Furthermore, 96-well microtiter plates can accommodate both larvae and mature adults because of their small size and also the organism may be used to screen wide pharmacological libraries at high throughput screening. Despite lacking a colon, Drosophila can be used as a model to study the cellular and genetic processes that contribute to CRC. By altering APC , Ras , and other genes linked to cancer, gene-editing techniques can shed light on the origin of epithelial tumors. Owing to their short life cycles and low cost, Drosophila models are especially useful for high-throughput screening and fundamental mechanistic research.

Platy Fish Model (Xiphophorus Fish)

Classically, Xiphophorus fish were used to successfully develop melanoma models ( Figure ). Xiphophorus hybrids have been used in a number of attempts to model cancer development following exposure to toxins. Utilizing well-known carcinogens with potent mutagenesis properties, the tests successfully induced a wide range of distinct cancer histotypes, which replicated numerous known human tumor entities. Even in the absence of carcinogens, certain strains of Xiphophorus produce other forms of neoplasia, such as thyroid and ocular tumors, although these results were not investigated further. Smaller models of xiphophorus fish that display both naturally occurring and environmental-induced tumors are helpful in comprehending the genetics of CRC and the biology of malignancies. Understanding how genetic and environmental factors combine to generate CRC is made possible by the ease with which species with different susceptibilities to the disease can be crossbred.

Zebrafish Model ( Danio rerio )

The zebrafish, or Danio rerio , is an animal model that was first employed in studies of developmental biology in the early 1980s ( Figure ). As early as 1982, it was also used in studies on cancer. Numerous factors, including high fecundity and external fertilization, rapid growth, and optical clarity throughout the larval stage, made zebrafish one of the most widely used animal models in study. Furthermore, the genomes of zebrafish and humans have 70% of similarities, including the preservation of even some epigenetic markers. Zebrafish provides numerous opportunities for the research of invasion and dissemination by enabling in vivo imaging to track the interactions among the implanted cancer cells. Furthermore, the interaction between endothelium and cancer cells can be studied in vivo using angiographic zebrafish models, such as the Tg­(fli:eGFP) zebrafish line, a transgenic animal containing GFP-labeled blood vessels. Because of their transparent embryos, which enable real time viewing of tumor growth, zebrafish are being used more and more in CRC research. Research into gene functions, metastasis, and treatment responses is made possible by genetic modification and xenografts, particularly PDXs. Zebrafish models are perfect for high-throughput drug screening because of their quick reproduction and genetic resemblance to humans.

Dog Model

One of the most significant animal models of human cancer is spontaneous cancer in dogs ( Figure ). Unlike most genetically modified or xenograft mouse models, they capture the essence of human cancer since they are naturally occurring, diverse, and their immune system is intact. Additionally, dogs are more biologically similar to humans than mice, with similar telomere and telomerase activity and a higher incidence of spontaneous malignancies of epithelial origin. In an effort to support the dog-human molecular similarity, researchers identified copy number aberrations (CNAs) in the genomes of canine CRC. Furthermore, they have successfully developed a novel dog–human comparison technique for cancer driver and passenger amplified/deleted gene discrimination. The significance of canine models in promoting drug discovery for personalized oncology is shown by the fact that a number of targeted medicines created for humans are linked to a favorable prognosis when applied to canine tumors with certain genomic abnormalities. Given that some dog breeds are more naturally prone to spontaneous CRC, researchers can examine CRC pathology in a setting more similar to human diseases, particularly with relation to spontaneous tumor growth. Dogs with CRC are a good model to investigate tumor growth and treatment responses because they share genetic and environmental risk factors with humans.

Pig Model

Considering the numerous similarities to humans in terms of longevity, size, organ anatomy, physiology, drug metabolism, genetics, and immunology, the pig is a promising alternative model organism ( Figure ). Pigs and humans have comparable small intestinal structure, but the pig’s large intestine differs slightly because of its bigger cecum, absence of an appendix, and spiral colon. Crucially, since pigs are larger than rodents, there are more options for longitudinal sampling and, consequently, for tracking the progression of tumors throughout therapy. The onco-pig model is an intriguing disease model for intestinal types of cancer, since it provides a variety of opportunities for long-term research on intestinal cancer development, metastatic conditions, and treatment response. Pigs are valuable in CRC research for their anatomical and physiological similarities to humans, especially in the digestive system. These models help study CRC carcinogenesis and chemoprevention. CRISPR-Cas9 has enabled the creation of genetically engineered pigs with mutations in APC and other CRC-related genes, providing a unique approach to understanding tumor progression and drug effects.

Nonhuman Primates Model

The heterogeneous environment of cancer requires a validated and reliable preclinical model for the successful clinical translation of the research. Rhesus and cynomolgus macaques are examples of nonhuman primates (NHPs), which are similar to humans in many ways, including physiology, genetics and, most importantly, immune cell populations, immune regulatory systems, and protein targets ( Figure ). NHPs have been a vital tool for analyzing pathogenic pathways and evaluating the effectiveness of vaccines against a variety of human infections, highlighting significant parallels between the immune systems of humans and NHPs. In rhesus macaques, palpable abdominal mass, intermittent diarrhea, weight loss, hypoproteinemia, microcytic anemia, and fecal occult blood are typical clinical indications of CRC. Since tumor targeting, tumor regression, PKPD biodistribution, intratumoral metabolic activity, and immunogenicity can all be similarly examined in tumor bearing monkeys, the evaluation of drug candidates in these preclinical models is similar to that done clinically in patients. Nonhuman primates offer a high degree of genetic, physiological, and immunological similarity to humans, providing a unique model for studying CRC’s pathology and immune response. Though ethical and logistical limitations reduce their frequent use, NHPs are valuable for preclinical validation of therapies where translational fidelity is critical. Monkeys with tumors could help close the experimental gap between clinical patients and preclinical models.

Challenges for Current Treatment Modalities in CRC

Toxicities and Side Effects of Pt­(II) Drugs

Apart from the emergence of acquired resistance, particularly notable for CDP , Pt­(II)-based chemotherapy is associated with severe dose-limiting systemic side effects, that can persist long after chemotherapy ends. This results from the lack of specificity of Pt­(II) drugs for cancer cells. Pt­(II) complexes are highly reactive toward both cancerous and healthy cells, and interact with biomolecules beyond DNA, such as proteins (e.g., metallothioneins (MTs), albumin) or small molecules (e.g., GSH). It has been shown that less than 10% of the Pt administered intravenously, whether through bolus IV injection or slow IV infusion, attaches to nuclear DNA.

While various toxicity profiles are associated with different Pt­(II) complexes ( Table ), they arise from the aforementioned mechanisms of action within healthy cells. An illustration can be given with CDP -induced nephrotoxicity. Nephrotoxicity can manifest in various ways, with the most critical and prevalent form being acute kidney injury (AKI), affecting roughly 20–30% of all patients. Pt accumulation in kidneys, stemming from variations in the expression of OCT2 or CTR1 transporters, is a factor contributing to CDP -induced nephrotoxicity by facilitating CDP -transport to renal tubular cells after filtration at the glomerulus. − Subsequently, CDP can disrupt cellular function by interfering with the cell cycle through Pt-DNA adduct formation, and/or by inducing the production of ROS. This activates MAPK, inducing apoptosis, and stimulates inflammation and fibrogenesis, causing nephrotoxicity. Mitochondrial dysfunction has been identified as a contributor to nephrotoxicity, given the high mitochondrial density in kidney cells. Notably, a correlation has been established between intracellular Pt levels and mitochondrial content in ovarian cancer cells. Other factors, including inflammation and interactions with components of the immune system, may also contribute to the development of AKI. Apart from renal cells, CDP can disrupt similar processes in other healthy cells that give rise to ototoxicity, gastrointestinal toxicity and so on. Consequently, the tubular damage and tubular dysfunction with Na + , K + , and Mg 2+ wasting can progress from acute to chronic even after the suspension of treatment. However, in the context of CRC, a focus will be given to OXP -induced peripheral neuropathy (OIPN), a major challenge in the treatment of CRC, in section .

Drug Resistance Mechanisms in CRC against Pt­(II) Drugs

Although significant progresses have been made in systemic combination of chemotherapy and targeted therapy, resistance to chemotherapy and tumor recurrence remain the main issues and challenges in CRC treatment and management. The resistance phenomena in tumors can be intrinsic or acquired. Intrinsic resistance is associated with factors such as tumor heterogeneity, drug inactivation, and genetic mutations. Acquired resistance occurs in a large majority (ca., 90%) of patients with metastatic cancer. The associated mechanisms can differ depending on the chemotherapy, but acquired resistance to one cytotoxic agent can confer resistance to other drugs, leading to multidrug resistance. An increase in the tumor size typically leads to an increase in the occurrence of metastases and resistance. The constant evolution of cancer cells drives heterogeneity in tumors, with cell populations showing differences in metabolism, proliferation or morphology. It is accompanied by various modifications at molecular levels, driving the acquisition of resistance. In the context of this review, CRC is characterized by a high intratumor and intertumor heterogeneity.

Resistance to Pt-based chemotherapy is a multifactorial process and can be acquired through general mechanisms such as a decrease in the cell uptake, an increase in the drug efflux, changes in metabolic enzymes, or reduced sensitivity to the drug(s) caused by genetic or epigenetic modifications ( Figure ). Acquired resistance is also associated with changes in the TME (please refer to section . for more details). The cellular uptake of Pt drugs is mediated/regulated by ATP-binding cassette (ABC) transporters and P-type ATPase copper transporters such as ATP7A and ATP7B. Additionally, Pt drugs are substrates of the copper transporter CTR1 and of the organic cation transporters OCT1–3, members of the solute carrier family 22 (SLC22) transmembrane transporters family, that contribute to Pt cellular uptake. OCT1–3 transporters and their expression levels are involved in Pt accumulation in CRC cells, and thus they have a role in acquired resistance mechanisms.

Additionally, Pt drugs form covalent conjugates with GSH, which contributes to the inactivation of the drug. Enhanced GSH levels are often encountered in resistant cells. It has been shown that upon conjugation of OXP with GSH, the expression level of multidrug resistance-associated protein 2 (MRP2) increases, contributing to enhanced drug efflux. ,

The NER mechanism relies on proteins such as excision repair cross-complementation group 1 (ERCC1) and excision repair cross-complementation group 2 (ERCC2) for DNA-adducts recognition and base excision. ERCC1 has been shown to be upregulated in OXP -resistant tumors. High levels of ERCC1 mRNA is observed in 5-FU resistant tumors with poor response to FOLFOX. This supports the notion that enhanced DNA repair diminishes sensitivity to Pt drugs and may be an acquired resistance mechanism. The NER system can therefore be considered a predictive factor in the treatment of CRC. However, the resistance mechanisms of OXP slightly differ compared to those of CDP and CBP . For example, inactivation or mutation of p53 alters CDP ’s cytotoxic activity, but such an effect is observed to a lesser extent for OXP -treated CRC lines.

Deregulation of signaling pathways, such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), is another mechanism leading to resistance. This transcription factor regulates the expression of genes involved in numerous pathways involved in CRC progression, such as apoptosis, proliferation, inflammation, angiogenesis, invasion, and metastasis. NF-κB is constitutively activated in CRC and other tumors, leading to antiapoptotic genes upregulation. Consequently, NF-κB and its associated survival pathway have been considered as therapeutic targets for resistance reversion. For a more in-depth discussion on the cellular mechanisms of resistance to Pt­(II) chemotherapeutics, please refer to the review by O’Dowd et al.

Resistance and TME

Apart from cancer cells, the TME comprises multiple other types of cells such as stromal cells such as CAFs, epithelial, immune cells such as TAMs and MDSCs, and blood vessels ( Table ). CAFs have been linked to the development of resistance. The activation of the TGF-β pathway in these stromal cells is a hallmark of poor prognosis in CRC. In addition, the secretion of soluble factors such as IL-6, associated with an increase in CAFs, activates pathways (e.g., PI3K/AKT and JAK/STAT) that cause apoptosis inhibition. Accumulation of Pt in CAFs upon long-term exposure to Pt drugs was proposed to facilitate drug resistance. The TME also contains other elements such as ECM and growth factors. The components of the TME enable the development of the tumor and their response to anticancer drugs significantly impacts the development of resistance. These contributing components include a hypoxic environment, pH, levels of growth factors, inflammatory factors, and angiogenic factors.

Resistance and Epigenetic Modifications

Besides alterations in genes expression, epigenetic changes have been shown to be involved in the development of resistance (i.e., intrinsic and acquired), in CRC and other types of tumors ( Table ). For example, DNA methylation of cytosine, which is one of the epigenetic regulations, catalyzed by DNA methyltransferases in CpG dinucleotides, is known to induce resistance to 5-FU in CRC. DNA hypermethylation is another hallmark in CRC and considered as a predictive biomarker. In the context of resistance, epigenetic modifications affect drug efflux and the ability of the cells to evade chemotherapy-induced cell death (e.g., apoptosis, autophagy and ferroptosis). For example, the inactivation of the BRCA1 interactor SRBC gene by DNA methylation is associated with OXP -resistance and shorter PFS in CRC.

Epigenetic changes can occur in other TME-associated cells (e.g., CAFs, TAMs, and MDSCs), leading to TME reprogramming and contributing to immune evasion, survival, and resistance. In the context of tumor heterogeneity, epigenetic modifications can promote the development of drug-tolerant cells that are able to survive chemotherapies. Epigenetic modulations of some signaling pathways regulate the generation of cancer stem cells (CSCs) that are described as an important factor in chemotherapy resistance. CSCs are a subpopulation of cells (ca. 5% of tumor cells) with the ability of self-renewal and differentiation. Epigenetic processes facilitating the epithelial-mesenchymal transition (EMT) such as epigenetic regulation of EMT markers (e.g., E-cadherin) or EMT-inducing transcription factors (EMT-TFs), contribute to resistance mechanisms and to the formation of cells with a mesenchymal phenotype generally more resistant to chemotherapy in CRC.

Resistance Reversion

Numerous compounds and formulations were evaluated in the reversion of OXP -acquired resistance. Curcumin, for example, was shown to enable reversion in CRC cell lines mediated by CXC-chemokine/NF-κB signaling pathway. Epigenetic drugs have also been evaluated in CRC treatment, in preclinical and clinical trials, with some success. 5-Aza-2′-deoxycytidine (decitabine) and 5-azacytidine are FDA-approved inhibitors of DNA methyltransferases (DNMTs) to treat myelodysplastic syndrome (MDS). Decitabine was shown to improve the activity of OXP on CRC cells in an in vitro study. , Some clinical activity of azacytidine along with CAPOX was also described in mCRC patients ( NCT01193517 ).

Histone deacetylase inhibitors (HDACi) were also explored in CRC treatments. Histone deacetylases (HDACs) are often overexpressed in CRC, and are one of the main mechanisms of resistance to OXP in CRC cells. The combination of the HDACi suberoylanilide hydroxamic acid (SAHA or Vorinostat) with OXP reduced HDAC2 levels and induced mitotic cell death, suggesting that HDACi could potentially be used to revert chemotherapy resistance. Other targets for epigenetic drugs to potentially reverse chemotherapy resistance in CRC include histone methyltransferases (HMTs) and histone demethylases (HDMs), as deregulated histone methylation in CRC has been linked to tumor recurrence and poor survival rates. Consequently, proliferation of OXP -resistant CRC cells was significantly reduced upon treatment with a combination of OXP with the KDM6A/6B histone demethylase inhibitor GSK-J4. Targeting dysregulated miRNAs is also explored as a therapeutic strategy to overcome resistance. As an example, dichloroacetate (DCA) inhibits the miR-543/PTEN/Akt/mTOR pathway and improves OXP sensitivity in CRC cells. , Mimicking the downregulated tumor-suppressive miRNAs, such as miR-483-3p, is also another interesting approach to revert OXP resistance in CRC.

Prediction of Response to OXP Resistance

Predicting the response to OXP -based therapy in CRC is challenging due to the complex molecular and genetic heterogeneity of tumors. Generally, variations in DNA repair pathways such as MMR and NER influence OXP sensitivity, while factors like immune infiltration and EMT further complicate prediction ( Table ).

Advancements in multiomics have led to the identification of various biomarkers in CRC, including genomic, epigenetic, transcriptomic, proteomic markers, and those related to the gut microbiome (e.g., metagenomics) and metabolomics. Liquid biopsies, which detect CTCs and nucleic acids, have emerged as promising noninvasive tools for early detection and predicting treatment outcomes. However, translating these biomarkers into clinical practice remains difficult. Despite the discovery of numerous biomarkers, only a few have been FDA-approved for clinical use. Comprehensive overviews of established, promising, and potential biomarkers, along with omics technologies used in CRC, are provided in recent reviews. − This discussion focuses on biomarkers related to OXP -based therapy in CRC.

While FOLFOX regimen is a standard first-line therapy for mCRC, many advanced CRC patients develop chemoresistance, reducing the 5-year survival rate to 14%. Understanding the mechanisms behind OXP -resistance is crucial for improving treatment outcomes. Guinney et al. identified four CMSs for colon cancer, which are useful for predicting patient prognosis. Cancers classified as CMS4 (i.e., mesenchymal tumor) are linked to the poorest OS and relapse-free survival (RFS). , Although standard adjuvant therapies (e.g., FOLFOX) for stage III are recommended, CMS4 cancers do not benefit from systemic adjuvant treatments.

Few studies have developed gene signatures to predict OXP -resistance. Lin et al. identified 495 resistance-related genes by analyzing data from resistant and nonresistant cell lines in the Gene Expression Omnibus (GEO) database and developed a four-gene (i.e., ALCAM , CD22 , CASP1 , and CISH ) signature that predicted OS. High-risk patients showed poorer outcomes, with a 5-year OS prediction area under the receiver operating characteristic (ROC) curve of 0.72. Using a similar systems biology approach, Cheraghi-shavi et al. analyzed differentially expressed genes (DEGs) between sensitive and OXP -resistant CRC cells, identifying upregulation of transglutaminase 2 (TGM2) and high-mobility group AT-hook 2 (HMGA2) and downregulation of FXYD domain containing ion transport regulator 3 (FXYD3) and Galectin 4 (GALS4), which may serve as novel therapeutic targets. A recent study by Zhang et al. in 2024 integrated data from a microarray data set of CRC patients, an OXP -resistant CRC cell data set from GEO, and RNA-sequencing (RNA-seq) data from The Cancer Genome Atlas Program (TCGA) to establish a prognostic model for OXP -resistant CRC. This model evaluated both the immune landscape and prognostic risk. Notably, prostate transmembrane protein androgen induced 1 (PMEPA1), CD8 + T cells, and M0 macrophages emerged as key biomarkers, suggesting potential therapeutic targets for overcoming OXP resistance and reducing disease progression in CRC patients.

OXP -resistance is associated with DNA repair mechanisms, particularly NER and MMR pathways. High expression levels of ERCC1, X-ray cross-complementing group 1 (XRCC1) and xeroderma pigmentosum group D (XDP) correlate with OXP resistance and can serve as drug sensitivity indicators. Studies suggest that patients with dMMR or MSI-high in colon cancer have better survival rates than those with pMMR or MSI-Low. , Additionally, activation of the Wnt/β-catenin signaling pathway and TGF-β1-induced EMT contribute to FOLFOX resistance. − KIAA1199 promotes resistance by inhibiting apoptosis through poly­(ADP-ribose) polymerase 1 (PARP-1) upregulation and reducing endoplasmic reticulum stress. Other biomarkers, such as pyruvate kinase M2 (PKM2) and Williams–Beuren syndrome chromosomal region 22 (WBSCR22) protein, further predict resistance and outcomes. ,

miRNAs, long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs) have gained significant attention as predictive factors for CRC due to their roles in gene regulation. − For instance, miR-128-3p is a key regulator in tumorigenesis and a potential marker for OXP -based chemotherapy, as it decreases B cell-specific Moloney murine leukemia virus integration site 1 (BMI1) and MRP5, enhancing chemosensitivity in CRC. Li et al. reported that miR-34a is significantly downregulated in OXP -resistant CRC patients and multidrug-resistant cells. Similarly, Ning et al. found that exosomal miR-208b promotes Treg expansion by targeting programmed cell death 4 (PDCD4), contributing to tumor growth and OXP resistance. Circulating miR-208b is a promising noninvasive biomarker for predicting FOLFOX sensitivity and a potential immunotherapy target. Zhuang et al. also identified miR-5000-3p as upregulated in CRC and OXP -resistant cells, modulating drug resistance by targeting ubiquitin-specific peptidase 49 (USP49).

Several oncogenic lncRNAs, including lncRNA GIHCG and lncRNA ARSR, regulate OXP resistance in CRC. , Another lncRNA, lnc-RP11-536 K7.3, is associated with OXP resistance and poor prognosis by recruiting SRY-box (SOX) 2 to activate ubiquitin-specific protease 7 (USP7) expression and stabilize hypoxia-inducible factor 1-alpha (HIF-1α). Knockdown of lnc-RP11-536 K7.3 improves chemosensitivity and reduces tumor proliferation, making it a potential therapeutic target for reversing OXP resistance. Moreover, lncRNA cancer susceptibility candidate 15 ( CACS15 ), which promotes the expression of ATP-binding cassette, subfamily C, member 1 ( ABCC1 ) involved in Pt drug efflux, was shown to be upregulated in OXP -resistant CRC cells and associated with poorer prognosis in patients. Furthermore, lncRNA taurine upregulated gene 1 ( TUG1 ) induces OXP resistance in CRC stem cells and inhibits apoptosis by interacting with GATA-binding factor 6 (GATA6). Colorectal cancer-associated lncRNA (CCAL) and lncRNA H19, found enriched in exosomes generated from CAFs, play a role in the regulation of the extracellular matrix and contribute to OXP -resistance in CRC. The expression of circRNAs has also been linked to CRC progression and drug resistance. circHIPK3 promotes OXP resistance in CRC cells by inhibiting autophagy and activating the B-cell lymphoma (Bcl)-2/Beclin-1 signaling pathway through signal transducer and activator of transcription 3 (STAT3) expression. Lin et al. demonstrated that OXP -resistant CRC cells express higher levels of oncogenic circRNA CCDC66, and its expression is mediated by OXP -induced cellular stress via DHX9 phosphorylation. Moreover, Pan et al. showed that circATG4B is upregulated in OXP -resistant CRC cells, increasing autophagy.

Developing reliable biomarkers to predict treatment outcomes is essential for stratifying patients based on their likelihood of response, personalize treatments, and improving clinical outcomes. However, the clinical relevance of many emerging biomarkers is still under investigation, requiring further research and validation in larger patient cohorts.

Chemotherapy-Induced Peripheral Neuropathy (CIPN)

CIPN is one of the main off-target toxicities of systemic chemotherapies, affecting the peripheral nervous system (PNS). Generally speaking, the peripheral neuropathy leads to numerous highly debilitating symptoms that may differ with the type of affected nerve fibres. Damages of small nerve fibres, either unmyelinated such as C-fibres (related to the perception of heat, thermal pain) or thinly myelinated such Aδ (related to cold thermal pain), which are involved in the conduction of information associated with mechanical and thermal pain, are associated with burn sensations, tingling, hyperalgesia or allodynia. Damages of myelinated fibres of larger diameters (e.g., Aβ fibres) are associated with sensory dysfunctions such as numbness and loss of balance or motor impairments. CIPN patients show paraesthesia and dysesthesia with a typical “sock-and-glove” distribution.

The PNS targets of CIPN are the dorsal root ganglia (DRG), the nerve fibers, and their components, until the distal nerve terminations. The main targets, the neurotoxicity mechanisms and the symptoms vary according to the chemotherapeutic agent ( Figure ).

The prevalence of CIPN depends on factors such as age, environmental/habit factors or genetic conditions/factors. The severity of the symptoms depends on the administered chemotherapeutic drug, the injection schedule and the cumulative dose. In general, the higher the dose and the frequency of the administered neurotoxic agent, the higher the incidence of CIPN.

Its evaluation also varies with the clinical assessment method. Due to the variety of symptoms, diagnoses and evaluations are still difficult and a matter of debate. The clinical evaluations include sensory and motor clinical examinations and neurophysiology studies of sensible nerve conduction velocity (NCV), where a reduction of sensible nerve action potential amplitude (SNAP) reflects axonal damage. Different grading scales are used in clinical diagnosis of CIPN, such as the European Organization for Research and Treatment of Cancer (EORTC) QLQ-CIPN20, among others. ,

Around 68% of cancer patients receiving chemotherapy develop CIPN in the first month of treatment. CIPN severely affects the patients’ quality of life and often leads to the reduction of administered doses or even to treatment discontinuation, jeopardizing the treatment outcome. Managing and reducing CIPN through treatment or prevention is therefore a major public health issue. Despite intense efforts to decipher the multifactorial mechanisms of CIPN and identify molecular strategies toward their reduction, no preventive or therapeutic clinically approved solution is currently available, although clinical practice guidelines are available. ,

OXP-Induced Peripheral Neuropathy (OIPN)

Among the Pt-based anticancer agents, OXP shows the highest neurotoxicity, associated with an acute form of OIPN possibly evolving in a chronic OIPN. The OXP -specific acute, transient peripheral neuropathy appears during or a few hours after administration, and typically disappears 48–72 h post treatment but it recurs with subsequent administrations. Acute OIPN affects around 85–95% of all patients. Its main symptoms are cold allodynia along with paresthesia and dysesthesia in both hands and feet. Although not dose-limiting, the degree of acute peripheral neuropathy has been thought to correlate with the development of chronic peripheral neuropathy. , This observation is important since it may lead to dose limitation or arrest. Continuous administration of OXP and subsequent bioaccumulation can lead to the development of chronic peripheral neuropathy, in approximately 40–93% of patients (at cumulative doses superior to 780–850 mg/m 3 ), its incidence and severity depending on the cumulated OXP dose. Comparable to CDP -induced peripheral neuropathy but occurring in a more prominent and larger extent, as described by Joseph et al. in a rat model, its main symptoms include numbness, tingling in hands and feet, and motor dysfunctions (e.g., loss in proprioception) leading, in some cases, to disability. The reversibility of these symptoms is rare, and they can persist years after the cessation of the treatment, severely impacting the patients’ quality of life. In chronic OIPN, a “coasting” phenomenon (i.e., a worsening of the symptoms after the cessation of treatment) is also often observed. Different mechanisms are believed to be involved in acute or chronic OIPN.

OIPN Mechanisms

The neurotoxicity of OXP derives from its lack of specificity for cancer cells and a preferential accumulation in the DRG sensory neurons, facilitated by the absence of blood–nerve barrier in the DRG. Different transporters have been involved in the accumulation of OXP in DRG neurons ( Figure ). OCT transporters, particularly OCT2, expressed in DRG neuronal cells, were shown to play a role in the uptake. Huang et al. reported that, after a single injection of OXP (10 mg/kg), wild-type mice (C57BL/6, FVB, or DBA strains) reported acute OIPN-like symptoms, while the mice deficient in OCT1/2 transporters did not display such symptoms. This was not the case for OCT3-deficient mice, suggesting that this transporter is less implicated in the accumulation of OXP in DRG. The same results were obtained in a model of chronic OIPN, supporting the hypothesis that OCT1/2 transporters could be a valuable therapeutic target. CTR1 and multidrug and toxin extrusion protein 1, efflux (MATE1) were also shown to be involved in OXP ’s cellular accumulation in vitro . Organic cation transporter novel types 1 and 2 (OCTN1/2) were recently suggested as key mediators for the preferential accumulation of OXP in PNS components, particularly in DRG. In vitro , both OCTN1 and OCTN2 impacted OXP ’s uptake in cells, and their knockout led to reduced toxicity in neurite PC12 and primary cultured DRG cells. In vivo , only OCTN1 levels seemed to affect OXP ’s accumulation in rats’ DRG, its inhibition reducing Pt accumulation in DRG and improving OXP -induced mechanical hypersensitivity.

Once internalized in the neuronal cells, mechanisms of action similar to those in cancer cells occur. Having less efficient DNA repair systems, DRG sensory neurons display a strong sensitivity to the generation of DNA adducts. Targeting of mitochondrial DNA and subsequent events including mitochondrial swelling, dysfunction and damage, eventually leads to caspase activated apoptosis. OXP also provokes the generation of elevated ROS levels in neurons. Additionally, Calls et al. reported, in 2022, an increase in the levels of pro-inflammatory cytokines and NF-κB p65 protein (implicated in cellular responses to stress, among others) in DRG neurons upon treatment with OXP , suggesting that a transient inflammatory response is involved in OIPN. Through activation of glial cells, OXP induces the activation of immune cells and an increase in the levels of pro-inflammatory markers and cytokines such as IL-6 and IL-1β or TNF-α. Oxidative stress and neuroinflammation are therefore widely accepted mechanisms in the case of chronic OIPN as a result of Pt accumulation in peripheral nerves and dorsal root ganglia. ,

OXP also targets sensory axons, where it leads to a disruption of ion channels activation. Acute OIPN would arise from axonal hyperexcitability leading to the described symptoms of acute neurotoxicity. Acute OIPN has been reported to directly depend on Na v voltage-gated sodium channel activation impairments, that were suggested to be induced by oxalate, a byproduct resulting from the nonenzymatic degradation of OXP , , which acts as a well-known calcium chelator. Disrupting calcium levels homeostasis alters the function and kinetics of voltage-gated sodium channels, leading to increased sodic currents and both neuronal and peripheral nerve hyperexcitability. , Sodium oxalate alone was shown to induce cold allodynia (acute neuropathy) in animal models but no mechanical allodynia contrary to chronic OIPN. Other ion channels have been involved in OXP -induced neuron toxicity. Transient receptor potential (TRP) channels are nonselective cationic channels involved in the detection of mechanical, thermal and chemical signals. The overactivation of these channels leads to an axonal hyperexcitability. Members of this family such a transient receptor potential ankyrin 1 (TRPA1), transient receptor potential vanilloid 1 (TRPV1) and transient receptor potential melastatin 8 (TRPM8) were shown to be overexpressed after OXP treatment in DRG sensory neurons in rats, and thought to be associated with cold hyperesthesia.

Long-term exposure to OXP induces axonal demyelinisation and degenerescence, leading to mechanical allodynia. Chronic OIPN has often been associated with a loss in the density of intraepidermal nerve fibres (IENF), small nociceptive nonmyelinated fibres located in the extremities, in mice (from skin in hind paws). Demyelinization in sciatic nerves is also a neuropathic marker. However, the mechanisms involved are not yet fully uncovered and additional mechanisms might be involved in both acute and chronic peripheral neuropathy. A summary of the key mechanisms contributing to OIPN is depicted in Figure .

Role of CRC TME in Response and Resistance to Cancer Immunotherapy

In the CRC TME, various cell types play crucial roles in shaping the response to immunotherapy. In the context of dMMR CRCs, some sensitivity to immunotherapy is attributed to the high TMB and the generation of multiple neoantigens resulting from genomic mutations due to defective MMR genes (e.g., MLH1 , SH2 , MSH6 , PMS2 ) that fail to rectify errors in the DNA microsatellite regions during replication. CD8 + T cells have the capability to recognize these neoantigens as foreign, allowing them to selectively target and attack cancer cells while sparing healthy cells. Furthermore, T cells, macrophages, and NK cells are abundant in dMMR/MSI-high tumors, where cell surface inhibitory checkpoint molecules, such as PD-1 on lymphocytes and PD-L1 on tumor cells, are increased, enhancing the tumor response to ICI therapies. In contrast, pMMR/MSS CRCs that are found in the majority of patients, present a significant lower antitumor immune response. This is because they are unable to be recognized by cytotoxic immune cells, a consequence of the low mutational profile of these tumors, ultimately leading to resistance to ICI therapies. In addition to T cells, MDSCs enriched in pMMR/MSS CRCs also contribute to the creation of an immunosuppressive state through various mechanisms, including the release of immunosuppressive cytokines, such as TGF-β. This is consistent with in vivo data, where mice injected with MSI-high CRC experienced greater tumor regression and T-cell infiltration than MSI-low or intermediate CRC when treated with anti-PD-1 therapy. While dMMR CRCs are generally more sensitive to immunotherapy than pMMR/MSS CRCs, it is still possible for dMMR CRC patients to develop immunotherapy resistance. −

TAMs are also involved in immunosuppression by releasing cytokines, such as IL-10 and TGF-β, inducing the expression of immune checkpoint molecules, and modulating metabolism that may compromise the energy and function of antitumor T cells. These mechanisms lead to a reduction of immunotherapy effectiveness, although the prognostic significance of TAMs exhibits great variability based on both the stage and type of cancer, necessitating the evaluation of their functionality. Ongoing research focuses on reprogramming TAMs toward a pro-inflammatory phenotype or inhibiting their immunosuppressive functions to enhance the success of immunotherapy. Recent studies on tertiary lymphoid structures (TLSs) have also suggested that B cells contribute to creating an intratumor immunity cycle that increases tumor sensitivity to immunotherapies for solid tumors, including CRC, and are considered as potential prognostic markers. −

Beyond immune cells, CAFs and endothelial cells (ECs), that constitute a large part of the cancer in CRC CMS4 (“mesenchymal”) tumors, may also influence immunotherapy responses through secretion of immunosuppressive and angiogenic factors such as TGF-β, CXCL12, or VEGF. , These factors support an inflammatory environment and impact immune cell function and tumor growth. Research targeting the interaction between CAFs/ECs and immune cells aims to enhance immunotherapy responses.

The ECM and its components play a significant role in influencing sensitivity or resistance to immunotherapy in several ways within the TME. First, the ECM can act as a physical barrier, limiting the infiltration of immune cells into the tumor. The composition and stiffness of the ECM can impact immune cell function. Certain ECM components, such as collagen and fibronectin, can create a stiffer matrix, that promote CRC progression, affecting the behavior and function of immune cells and ultimately contributing to immune suppression and resistance to immunotherapy. Understanding the complex cell–cell and cell–ECM interactions within the CRC TME is crucial for overcoming potential resistance and developing comprehensive and effective immunotherapeutic strategies in CRC.

Opportunities for Emerging Treatment Modalities in CRC

Targeted Chemotherapeutic Approaches Using Pt­(IV) Prodrug Strategy

The Pt­(IV) pro-drug strategy has been propelled as a solution to address the high systemic toxicities associated with Pt­(II) drugs. Pt­(IV) complexes, containing two additional axial ligands, are relatively inert outside cells and are activated mainly intracellularly by endogenous small molecular (e.g., ascorbate, glutathione, L-methione, L-cysteins, deoxyguanosine monophosphate, metallothionein, serum albumin) or macromolecular reducing agents. Upon reduction, the Pt­(II) moiety and the two axial ligands are released ( Figure ).

The resulting active Pt­(II) species interferes with cell survival by inducing DNA damage. The two axial ligands can be utilized to improve the pharmacological properties of the prodrugs. These ligands can, for instance, enhance lipophilicity, solubility, facilitate tumor or intracellular targeting, impart imaging properties, inhibit cellular processes, or display antiproliferative properties, making them multitargeting prodrugs. − The tumor targeting strategies using Pt­(IV) scaffold is further discussed in greater details in sections .

Pt­(IV) Prodrugs in Clinical Trials

Currently, a few Pt­(IV) compounds have reached clinical trials, the most notable being ormaplatin (phase I), iproplatin (phase III), and satraplatin (phase III) ( Table , Figure ). Of the three, satraplatin has demonstrated the most promising potential, as patients displayed a decrease in Pt-associated toxicity compared to CDP in clinical trials. Moreover, satraplatin can be administered orally, significantly improving patient compliance and quality of life compared to IV administration of Pt­(II) drugs. However, satraplatin did not offer any improvement in OS compared to existing clinical treatments for prostate cancer and therefore did not receive FDA approval for clinical use. Similarly, other Pt­(IV) compounds in clinical trials did not receive approval due to the lack of longer OS compared to existing Pt drugs, despite some improvements in oral stability, , cellular uptake, and toxicity profiles. Satraplatin is also rapidly reduced in whole blood, with a half-life of about 1–2 h, largely due to efficient reduction by hemoglobin. This process converts satraplatin into its active Pt­(II) form.

One potential explanation for the limited success of the Pt­(IV) compounds reported in Table is that the Pt­(IV) compounds were easily reduced extracellularly, resulting in premature release of the bioactive Pt­(II) drug. Studies have demonstrated that the complexity of the axial groups determines the resulting reduction mechanism and half-lives of each Pt­(IV) complex: compounds carrying less electrophilic axial ligands are the most resistant to reduction. − Ormaplatin , for instance, is reduced within 1 min ( Table ), thereby releasing the active Pt­(II) species rapidly, contributing to high systemic toxicity. In comparison, satraplatin and iproplatin are less easily reduced, as evident from their comparatively longer half-lives (1.2 and 5.3 h, respectively) and consequently they are less associated with systemic toxicities ( Table ). Despite their longer half-lives, these Pt­(IV) compounds were still discontinued, indicating that there are additional contributing factors to the limited success of these Pt­(IV) compounds in clinical trials.

Another hypothesis to the observed lack of improvement in the OS stems from the simplicity of the axial ligands, with no functionality to improve the efficacy of the drugs. As such, recently developed Pt­(IV) compounds contain more complex axial ligands that confer benefits to their anticancer efficacies such as targeting to disease areas, synergistic activity to Pt, overcoming of chemoresistance, complementing photodynamic therapy (PDT) as well as expanding the molecular targets of Pt.

Dual- and Multi-Action Pt­(IV) Complexes for CRC

Pt­(IV) prodrugs represent a promising strategy to enhance therapeutic efficacy and circumvent resistance mechanisms, leveraging on improved cellular accumulation facilitated by lipophilic axial payloads as well as the capacity for synchronous targeting of multiple biological pathways offered by bioactive axial ligands. The conjugation of ancillary or “innocent” ligands such as halides, hydroxides, or carboxylate derivatives or onto Pt­(IV) scaffold results in increased cellular uptake and eventual enhancement in anticancer efficacy. − Other than “innocent” ligands, a diverse array of bioactive agents have also been conjugated onto the Pt­(IV) scaffold, including cytotoxic drugs, nonsteroidal anti-inflammatory drugs (NSAIDs), − epigenetic modulators (e.g., histone deacetylase inhibitors), − metabolic enzyme inhibitors (e.g., glutathione S-transferase inhibitor, , − pyruvate dehydrogenase kinase inhibitor, , carbonic anhydrase IX inhibitor), DNA repair inhibitor (e.g., nucleotide excision repair inhibitor), signaling pathway modulators (e.g., NF-κB inhibitor), , antimetabolites, , antimetastatic agents, − antimicrotubule agents, − vitamin analogues, and even proteolysis targeting chimeras (PROTACs). , Advancement in novel Pt­(IV) scaffold synthesis and linker technologies continues to support future expansion on repertoire of conjugatable molecules, further enhancing the versatility of the Pt­(IV) prodrug approach. , , While numerous excellent comprehensive reviews have covered multiaction Pt­(IV) complexes, − this section will specifically highlight several prominent examples that have demonstrated promising efficacy and mechanisms of action relevant to CRC models. ( Figure )

Being one of the hallmarks of cancer, chronic inflammation not only promotes the proliferation and progression of tumors, but also causes a immunosuppressive TME. As a result, NSAIDs have become a popular choice for conjugation onto Pt­(IV) scaffold with examples include aspirin, , carprofen, etodolac, diclofenac, flurbiprofen, , ibuprofen, − indomethacin, , ketoprofen, , naproxen, , − , and sulindac. These Pt­(IV)-NSAID conjugates generally exhibited comparable or enhanced antiproliferative efficacy against CRC cell lines (i.e., HCT116, SW480, CT26), as compared to their corresponding Pt­(II) precursors. − , , , While improved cellular accumulation via increased lipophilicity or nanostructure formation was initially thought to be the primary contributor to the enhanced potency, − , recent studies revealed more complex mechanisms of action. , Notably, recent in vitro and in vivo investigations using CT26 CRC model demonstrate that 1 and 2 possess reduced systemic toxicity and significant antimetastatic properties compared to their parent compounds. , The antimetastatic effect is likely attributed to the cyclooxygenase-2 (COX-2) inhibition exerted by the NSAID payload, leading to the downrefulation of matrix metalloproteinase-9 (MMP-9). ,

HDACi constitutes another prominent class of bioactive axial payloads incorporated into dual-action Pt­(IV) prodrugs, with examples including valproic acid (VPA), − octanoic acid (OA), , 2-(2-propynyl)­octanoic acid (POA), − 4-phenylbutyric acid (PhB), − and SAHA. Similar to Pt­(IV)-NSAIDs, the increased lipophilicity of these Pt­(IV)-HDACi conjugates translates to enhanced antiproliferative efficacy compared to the parent compounds across various cancer cell lines, including CRC models (i.e., HCT116, HCT-15, HT-29, SW480, LoVo). , , , , Intriguingly, Osell and Brabec found that their Pt­(IV) octanoato compound ( 3 ) can induce global DNA methylation independent of the enzymatic activity of HDAC on CRC model. This discovery is similar to what have been found on another Pt­(IV)-VPA complex on human ovarian cancer cells. Furthermore, the therapeutic potential of these Pt­(IV)-HDACi complexes extends to overcoming drug resistance, as exemplified by Pt­(IV)-POA ( 4 and 5 ) conjugates that effectively circumvented OXP resistance in OXP -resistant LoVo- OXP CRC cell line. Contrastingly, some other types of Pt­(IV)-HDACi complexes with PhB as bioactive axial payload have successfully demonstrated significant HDAC enzymatic activity inhibition.

The development of resistance to Pt-based chemotherapeutics is frequently mediated by cancer-associated metabolic enzymes, such as glutathione S-transferases (GSTs), , − pyruvate dehydrogenase kinase (PDK), , and Carbonic anhydrase IX (CAIX), among others. These enzymes employ distinct resistance mechanisms such as GST-mediated drug inactivation and efflux via glutathione conjugation, PDK-mediated metabolic reprogramming toward glycolysis influencing cellular energy production and stress responses, and CAIX-mediated modulation of the TME to promote cancer cell survival and adaptation. Therefore, incorporating inhibitors of these metabolic enzymes as bioactive axial payloads within Pt­(IV) prodrugs presents a rational strategy to enhance therapeutic efficacy and potentially circumvent Pt-drug resistance. For example, two Pt­(IV)-GSTi complexes have successfully demonstrated improved potency against CRC cell lines (i.e., HT-29 and HCT116) in antiproliferative assays using ethacrynic acid ( 6 ) and 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)­hexanol (NBDHEX) ( 7 ) as the axial payload. , Notably, 6 was observed to exhibit a faster onset of cytotoxic activity compared to its parent Pt complex.

In recent times, PROTACs has emerged as a new class of anticancer agent through targeted protein degradation (TPD) rather than conventional target inhibition. PROTACs offer advantages over traditional small molecule inhibitors including the targeting of “undruggable” molecules and the ability to overcome resistance caused by target protein overexpression or mutations. Very recently, PROTACs for two protein targets (i.e., BRD4 and PARP-1) have been attached onto the Pt­(IV) scaffold in order to improve the potency of Pt­(IV) prodrugs and overcome Pt-based chemoresistance. , In particular, CW-2 ( 8 ) has demonstrated about 4-fold increase in antiproliferative efficacy when tested in HCT116 CRC cell line. Furthermoer, CW-2 conjugated with olaparib PROTAC as PARP-1 degrader has also managed to resensitized CDP -resistant cell line to Pt-based therapy. This is likely attributed to the degradation of PARP-1 that plays a crucial role in cellular DNA repairs.

The octahedral geometry of the Pt­(IV) prodrug scaffold features two modifiable axial ligands that open up possibilities for multiaction prodrugs designs. A common approach involves the conjugation of two or more bioactive ligands with distinct mechanisms of action, in order to achieve enhanced therapeutic effects. Combinations incorporating previously discussed classes such as NSAIDs, HDACi, and metabolic enzyme inhibitors have been reported and shown improved anticancer efficacy. , , Alternatively, these axial sites can be exploited for targeted delivery, where one position is occupied by a therapeutic payload while the other incorporates a tumor-targeting moiety, such as biotin, intended to promote selective accumulation within cancer cells. , Furthermore, the versatility of the axial sites has been leveraged in more complex designs, including the development of bimetallic Pt­(IV) complexes aimed at achieving superior anticancer activity or enabling stimuli-responsive prodrug activation. ,

Photoactivatable Pt­(IV) Complexes for CRC

Enhancing the clinical effectiveness of Pt­(IV) chemotherapeutic prodrugs can be achieved by controlled activation using external physical stimuli. Light, as a stimulus, stands out due to its convenience and noninvasive nature, offering a considerable edge over other forms of stimuli for prodrug activation. Furthermore, the precise spatiotemporal control offered by photoactivation further allows for site-directed activation of Pt­(IV) prodrugs at the tumor site while maintaining high dark stability. This targeted approach not only enhances therapeutic efficacy but also minimizes adverse side effects and systemic toxicities to healthy tissues. Advancement in the field of photoactivated prodrugs has also been propelled by developments in light delivery technologies, including laser- or light emitting diodes (LEDs)-based planer, injectable, and optical-fiber devices. These technologies can cater for tumors located superficially or within internal organs, such as the colon, head, neck, esophagus, lung, bladder, and cervix.

Many photoactivatable Pt­(IV) complexes have been synthesized through modifications in their axial, leaving, and nonleaving ligands, a topic that has been extensively reviewed in many literatures. , , Here, our review is focused on photoactivatable Pt­(IV) complexes that have demonstrated effectiveness in CRC models ( Figure ). For instance, Coumaplatin ( 9 ), that is axially conjugated to a coumarin derivative and incorporates OXP as the Pt­(II) scaffold, has shown remarkable dark stability and significant photocytotoxicity in vitro when compared to OXP . This is particularly evident in CRC models such as HCT116 p53 +/+ and HT-29, where the half-maximal inhibitory concentration (IC 50 ) values are 32- and 14-fold lower, respectively, than those of OXP . Additionally, Coumaplatin displayed the ability to overcome Pt drug resistance in HCT116 p53 –/– , with an IC 50 value that is 96 times lower than that of OXP . When activated with blue light at 450 nm, Coumaplatin , which accumulates in the nucleolus, releases OXP . OXP released in the nucleolus induces cellular senescence and initiates ICD through a p53-independent mechanism involving E2F1, in addition to causing p21-mediated cell cycle arrest and apoptosis.

Another example of photoactivatable Pt­(IV) drugs was developed by conjugating rhodamine B to the axial position on CBP and OXP -derived Pt­(IV) precursors ( 10 and 11 ). The design was based on the hypothesis that the oxidation potential of photoexcited rhodamine B is sufficient to reduce the majority of traditional Pt­(IV) prodrugs. − Subsequent experiments confirmed that rhodamine B conjugation can significantly enhance the activation of both CBP - and OXP -based Rhodaplatins . This is evidenced by the marked increase in their photocytotoxicity in HCT116 CRC model under low-dose visible light irradiation (400–760 nm, 4 mW·cm –2 ), as compared to CBP and OXP . Notably, the OXP -based variant of Rhodaplatins demonstrated selective mitochondrial accumulation, which in turn induced mtDNA damage and subsequently cell apoptosis.

Incorporation of Targeting Ligands

The efficacy of Pt drugs in the treatment of CRC depends on the level of accumulation at the tumor site. The biodistribution of Pt drugs can be altered to favor tumor accumulation by taking advantage of the structural differences between normal physiological tissues and tumors. By directing the Pt drugs to their intended site of action, it is possible to reduce off-target accumulation and, consequently, their associated side effects. Moreover, the genetic differences between healthy cells and cancer cells can also be exploited to increase the uptake of Pt drugs by CRC cells.

There are several strategies to enhance the efficacy of Pt drugs: (1) incorporating targeting ligands on the chemical structure of Pt­(II) and/or Pt­(IV) compounds, (2) loading of Pt drugs into nanoparticle-based formulations (including surface engineering of these nanoparticles), and (3) administering Pt drugs through alternative routes.

The incorporation of tumor targeting ligands into anticancer Pt complexes offers a promising strategy for enhancing selectivity toward cancer cells while minimizing toxicity to healthy tissue. In the case of square-planar Pt­(II) complexes, which typically feature two nonleaving and two leaving ligands, tumor-targeting functionality can be introduced through chemical modification of the leaving groups. On the other hand, the octahedral geometry of Pt­(IV) complexes presents additional opportunities for functionalization; specifically, the axial positions offer expanded chemical space for the conjugation of tumor-targeting moieties. The targeting properties arise from the differences between normal healthy cells and cancerous cells. Some of these differences include the overexpression of membrane proteins. For instance, there are reports that glucose membrane transporters, such as GLUT1, is overexpressed in CRC. The overexpression of glucose membrane transporters can be attributed to increased glycolysis of cancer cells. As such, Pt­(II) drugs can be designed to incorporate ligands of these overexpressed proteins to improve the selectivity toward the tumor. Some of the substituents include sugars to target glucose membrane transporters ( 12 – 15 ). Specifically, 12 – 15 have shown significant improvement in in vitro antiproliferative activity against HT-29 CRC cells (ca., 4- to 6-fold lower IC 50 ). , 15 shows further efficacy in in vivo HT-29 CRC xenograft with superior therapeutic index and growth inhibitory activity. Figure shows a list of certain Pt­(II) compounds that were designed to improve selectivity toward the tumor. While some of the examples such as folate receptors targeting ( 16 and 17 ) , and biotin targeting ( 18 ) were not directly tested on CRC, it is expected that similar targeting mechanisms could make these tumor-targeting drugs accumulate in CRC tumors.

Among these examples, it is interesting to note that the conjugation of folate ligands did not give rise to an increase in anticancer efficacy. Despite the introduction of folate ligands to target the folate receptors on the cancer cells, the cytotoxicity of the folate-targeted Pt drug 16 was lower than CBP and the nontargeting Pt drug. To explain this phenomenon, Aronov et al. quantified the cellular Pt content, and the formation of Pt-DNA adducts in vitro . Despite a higher accumulation of Pt, there was less formation of Pt-DNA adducts. It was then hypothesized that the folate receptor-mediated endocytosis may inhibit the release of the drug to the cytosol and hence affect the overall efficacy of the drug. Despite the efforts to modify the structure of Pt drugs chemically to target the tumor cells, it is also important to consider the biological implications (in terms of drug uptake mechanism and intracellular release of the drug). Moreover, the pharmacokinetics of the modified drugs may also be altered depending on the hydrophobicity of the new chemical structure, which may affect the overall efficacy of the Pt drug. This may explain the difficulty encountered when designing next generation Pt-based drugs with higher efficacy and lower toxicity as well as the reasons why, despite the development of novel Pt-based compounds with tumor-targeting features, none of them has been translated into the clinics yet.

Moreover, peptides can also be introduced to increase the efficacy of Pt­(II) compounds. For instance, Singh et al. synthesized OXP conjugated with a cell-penetrating peptide (CPP) (peptide sequence: RRRRRRRR) ( 19 and 20 ). The addition of CPP drastically increased the accumulation of Pt in vitro and improved the efficacy of treatment both in vitro and in vivo . Moreover, Sepay et al. also showed that OXP conjugated with a cell-penetrating, cancer-specific peptide BR2 (peptide sequence: RAGLQF­PVGRLL­RRLLR) ( 21 ) could improve selectivity toward cancer cells over normal healthy cells. As a result of this selectivity, there was an increased accumulation in the tumor, leading to a greater tumor suppression in vivo .

Targeting ligands can be incorporated to direct the compounds to their intended site of action. Similar to Pt­(II) compounds, these ligands could target the overexpression of membrane proteins on the cancer cells ( Figures and ). For instance, sugars, such as glucose, galactose, or mannose, can be conjugated onto the Pt drugs. Interestingly, Pt­(IV) prodrugs conjugated with the unacetylated sugars can enhance cellular uptake by targeting GLUT1 transporters on cancer cell lines, unlike Pt­(IV) drugs that are conjugated with acetylated sugars ( 22 and 23 ). , The introduction of a glucoside group (targeting the overexpression of GLUT-1 on tumor cells) and a hexadecanoic chain (that could bind to human serum albumin) ( 22 ) reduced the toxicity while maintaining the efficacy of the chemotherapeutic treatment in vivo . It should be noted that GLUT1-targeting Pt­(II) complexes are not specific for CRC. They are designed to target any malignancy with high GLUT1 expression, which includes but is not limited to CRC. Their use in human patients is experimental and not limited to a particular cancer type. Besides the addition of a sugar molecule, biotin was also conjugated onto the Pt­(IV) structure ( 24 – 27 ) to target the biotin receptors on tumor cells. Similar to the Pt­(II) counterparts, the incorporation of biotin increases the cytotoxicity against tumor cells with an overexpression of biotin receptors ( 27 ). , A recent study involved the introduction of bis-organosilane groups to improve selectivity toward cancer cells and lower toxicity. With the addition of tri­(ethylene glycol) silane groups, the resultant complex is more hydrophobic, which facilitates the transport across biological membranes. The cytotoxicity of Pt­(IV)-biSi-2 ( 28 ) was higher toward HCT116 CRC cells compared to HIEC6 nontumorigenic intestinal cells. Pt­(IV)-biSi-2 was also effective in inhibiting HCT116 xenograft tumor growth while reducing renal and hepatic toxicity, which are commonly associated with CDP treatment.

Similarly, peptides can also be introduced on the axial positions to improve the accumulation and uptake of these drugs. It was discovered that tumor cells, including CRC cells, have a selective expression of HSP70. These HSP70-positive cancer cells can be targeted with a 14-mer tumor penetrating peptide (TKDNNL­LGRFEL­SG). McKeon et al. conjugated this 14-mer peptide onto a Pt­(IV) complex ( 29 ), which showed a higher cytotoxicity toward HT-29 CRC cells with a high membrane expression of HSP70.

The capacity to include additional ligands also provides the opportunity for multiple functionalized Pt­(IV) drugs. Other chemotherapeutics, such as gemcitabine, paclitaxel and estramustine, can be conjugated onto the axial positions of Pt­(IV) structures. The conjugated complex showed a higher tumor growth inhibition as compared to a coadministration of the individual drugs, implying some synergistic effects. Similarly, niflumic acid, a NSAID, conjugated onto CDP and OXP Pt­(IV) scaffold, can increase cell apoptosis, reduce cell migration and have the potential to work on metastases of HCT116 CRC cells.

Besides improving the selectivity toward tumor cells, ligands can be introduced to target other intracellular components that could further inhibit cell proliferation. These Pt­(IV) prodrugs have additional mechanism of actions and could overcome Pt resistance. As various organelle-targeting Pt complexes have been extensively discussed in previous reviews, − we will focus on new Pt complexes that have been reported recently to localize in the ER and Golgi apparatus. For instance, a Pt­(II) complex containing an aminophosphonate ester ligand was found to selectively enrich in the ER, likely due to the high affinity of this type of ligand toward the high Ca 2+ levels in the ER ( 30 ). ,

Similar to Pt-NHC and PlatinER , this complex could effectively trigger ER stress and display ICD DAMPs, likely due to its mitochondria targeting properties. The antitumor activity and vaccination effect of Pt­(II)-aminophosphonate were validated in vivo using an immunocompetent mouse bearing MB49 bladder cancer model, which also exhibited increased CD3 + CD8 + T-cells infiltration compared to OXP treatment. This example demonstrated that the rational design of Pt­(II) complex ligand is another promising way to achieve desired subcellular targeting properties. More recently, a Pt­(IV) complex that can undergo oxygen-independent activation using near-infrared (NIR) irradiation has been developed and shown to selectively accumulate in the ER ( 31 ).

The ER targeting capability of this complex synergises with its ability to act as a photooxidant, to induce severe oxidative stress and disrupt intracellular pH balance. The generation of a large amount of ROS causes the rapid oxidation of intracellular biomolecules, which subsequently triggers ER stress and initiates ICD. This has been evidenced by the detection of ICD DAMPs, and the enhancement of CD4 + and CD8 + T-cell infiltration in a 4T1 mouse xenograft model.

A novel Pt­(II) compound that selectively targets Golgi apparatus has also been recently developed and exhibits a potent anticancer activity by inducing Golgi stress and modulating the balance between autophagy and apoptosis ( 32 ). This monochlorinated Pt­(II) compound incorporated monoaza phenanthrene and N -heterocyclic carbenes (NHC) as ligands. Interestingly, the complex showed remarkable anticancer activity when encapsulated in lipid-based nanovesicles called liposomes. It completely eradicated LLC tumors in immunocompetent mice, but only inhibited A549 tumors growth in immunocompromised mice. This suggests that the complex could stimulate the host immune response and demonstrates the potential of modulating Golgi-related signaling pathways for cancer treatment, offering a novel design strategy for the development of new Pt-based drugs by working synergistically with immunotherapies.

Previously, some of us reported the development of a library of mitochondria-targeting Pt­(IV) compounds for human ovarian cancer cells (A2780). These Pt­(IV) compounds, based on either a CDP or OXP scaffold, were modified with the inclusion of a chemosensitizer which are PhB or dichloroacetic acid (DCA) and a mitochondria-targeting triphenylphosphonium (TPP) ligand ( 33 – 36 ). These modifications enhanced the sensitivity of cancer cells toward the chemotherapeutics and increased Pt-induced DNA-damage to mtDNA. Although these Pt­(IV) drugs demonstrated similar anticancer efficacy as the parent Pt­(II) drugs in vitro ( CDP and OXP , respectively), they were more efficient in inhibiting tumor development in vivo than CDP by abrogating mitochondrial function. Consequently, by enhancing mtDNA damage, these drugs could be effective in suppressing tumorigenesis in a CRC mice model, where the fidelity of mtDNA (decreased mutagenesis) is enhanced (due to the reduction of ROS in cancer cells) and is better correlated with disease progression.

Activation of CRC TME Using Immunochemotherapeutic Pt Complexes

Pt complexes are versatile compounds that can exhibit both cytotoxic and immunomodulatory effects in cancer therapy. Although classical cytotoxic Pt­(II)-based anticancer drug such as CDP or CBP were considered to impair the immune system due to their immuno- and myelosuppressive nature that negatively affect the numbers of lymphoid and myeloid cells, − growing evidence has led to the belief that anticancer Pt complexes can also exploit the host immunity to enhance their antitumor efficacy. Some of the immunomodulatory effects of CDP that have been discovered − include (1) decreased frequency of MDSCs; (2) upregulation of immune stimulatory molecules (e.g., MHC-I); (3) modulation of STAT signaling; , and (4) regulation of tumor-specific antigen (e.g., PD-L1). , Besides immunomodulatory Pt­(II) complexes, several advantages offered by the Pt­(IV) platform including better biological inertness, lower side effects, reduced systemic toxicities, and greater utilization of chemical spaces, could prove to be a silver bullet in tackling issues with conventional immunotherapy of CRC. Other than being useful for tuning chemical properties, the extra chemical spaces in the Pt­(IV) complexes can be used to integrate bioactivate molecules that can influence the antitumor immunity or alter the immunosuppressive TME. As a result, new Pt­(IV) complexes with different modes of action that target immunologically “cold” tumors have been developed. Therefore, we envision that Pt-based chemo-immunotherapeutics could be the novel way forward for improving the treatment of immunologically “cold” tumors such as pMMR/MSS CRC.

OXP- and CDP-Based Pt­(IV) Complexes

OXP can paradoxically promote immune escape by upregulating IDO expression, an enzyme that causes local immune suppression via kynurenine production. Upregulation of IDO also resulted in tryptophan depletion to trigger amino-acid sensing signal-transduction pathways such as GCN2 kinase and mTOR, which are responsible for inhibiting proliferation and differentiation of cytotoxic T cells (e.g., CD8 + and CD4 + ) and activating Treg.

Recently, an OXP -based triplet prodrug ( Figure ) ( 37 ) was designed to overcome immunosuppression induced by kynurenine biosynthesis through incorporating aspirin (i.e., COX-2 inhibitor) and 1-methyl-tryptophan (i.e., IDO inhibitor). While there are already several other publications with IDO-Pt­(IV) complexes in literature, compound 37 enhanced the anti-PD-1 immunotherapy in the CT26 mouse model by increasing the infiltration and activation of CD8 + T cells, NK cells, and effector memory CD8 + T cells, as well as the production of IFN-γ and TNF. It also reduced the number of Treg cells in the tumor. These effects were not observed when OXP and inhibitors were treated simultaneously. Similar approaches using dual-functional liposomes with OXP (IV)-conjugated phospholipid ( 38 ) and IDO inhibitor (i.e., NLG919) or metformin also achieved effective ICD induction and reversal of immunosuppressive TME in CT26 mouse models such as enhanced DC maturation, increased intratumoral CD8 + T-cells infiltration, decreased Treg, and secretion of TNF-α and IFN-γ. Met-OXP­(IV)-liposome was also found to stimulate M1-like macrophage polarization and synergise with anti-PD-1 immune checkpoint blockade therapy.

Another approach that has shown to be effective in enhancing the phagocytic clearance of OXP -treated cancer cells is compound 39 , which combines RRx-001, a nitric oxide donor, with OXP . RRx-001 modulates TAM polarization from immunosuppressive M2 to immunoinflammatory M1, and reduces the expression of CD47, a “do not eat me” signal, on cancer cells. Compound 39 significantly reduced CD47 levels and increased the ratio of CRT/CD47 on the surface of CT26 cells in vitro and in vivo . Moreover, compound 39 effectively reduced the hypoxic TME mediated by HIF-1α, increased the ratio of M1/M2 macrophages, enhanced the infiltration of CD3 + and CD8 + T cells, decreased Treg cells, and increased the production of immunostimulatory cytokines such as IL-12, TNF-α, and IFN-γ, thereby reversing the immunosuppressive hypoxic TME of CT26 in vivo .

A novel nanomedicine approach, compound 40 , was developed to overcome the immunosuppressive TME that limits the effectiveness of ICI therapy. Compound 40 is composed of polymeric all- trans -retinoic acid (ATRA) and a Pt­(IV) prodrug of OXP . The design rationale is to combine OXP with the immune activation by ATRA, which has been previously reported to stimulate inflammatory TME by promoting CD8 + T Cell proliferation and inhibiting MDSCs. , , In vitro , compound 40 delivered OXP to MC38 cells and induced all ICD hallmarks. In vivo , treatment of compound 40 in MC38 mouse model significantly reduced the immunosuppressive MDSCs and increased the pro-inflammatory M1 macrophages and CD8 + T cells. It has been found that the antitumor effect of compound 40 was mainly mediated by CD8 + T cells rather than direct cytotoxicity and was enhanced by cotreatment with anti-PD-L1 immune checkpoint blockade. Refer to section for other examples of Pt drug encapsulation in delivery systems.

An OXP -based prodrug that combines OXP with a triggering receptor expressed on myeloid cells 2 (TREM2) inhibitor (i.e., artesunate) to target and inhibit TREM2 expression on TAMs was reported ( 41 ). This concept of exploting therapeutic activation of pro-inflammatory macrophages to enhance antitumor immunity is similar to a formyl peptide receptors (FPRs) binding ligand conjugated CDP -based prodrug Pt­(IV)-WKYMVm ( 42 ) that has been previously developed by Ang and coworkers.

Compound 41 demonstrated that it can effectively inhibit TREM2 expression on macrophages both in vitro and in vivo for CRC. TAMs in human tumors express high levels of TREM2, which triggers immune reprogramming that favors tumor survival and reduces antitumor immunity. Patients with high TREM2 expression have worse outcomes and survival rates. Even though the reduction efficiency of compound 41 under chemical reductive environment is low, it can still cause significant DNA damage to HCT116 cells. Compound 41 also reshapes the immunosuppressive TME in MC38 in vivo mouse model by inducing THP-1 macrophage M1 polarization, encouraging DCs maturations, and enhancing immune infiltration of CD8 + T cells and NK cells.

In addition to IDO upregulation, OXP and CDP treatments were also found to upregulate PD-L1 and PD-L2 expression in various cancer and myeloid cells. , , , , , High PD-L1 levels can impair the T-cells cytotoxicity and antitumor immunity of tumor cells and DCs, but also sensitize tumor cells to ICI therapies. As a result, PD-L1 is currently a FDA-approved prognostic marker for ICI therapies. Flurbiprofen, a COX inhibitor and NSAID, can bind to PD-L1 and reverse immunosuppressive TME to enhance cancer treatment efficacy. A CDP -based Pt­(IV) prodrug ( 43 ) with flurbiprofen on both axial positions was developed and found to inhibit tumor growth and spread by suppressing inflammation. Other than activating the mitochondrial apoptosis pathway, this complex can also stimulate T-cell immunity by increasing CD8 + T cell infiltration and reducing PD-L1 expression in CT26 tumors in vivo .

Tranilast, a drug approved clinically for inflammatory disorders and allergies, has been reported for its efficacy in preventing human breast cancer metastasis and cytostatic activity in various cancers. Although unclear, the antiproliferative mechanism of Tranilast is suspected to be involving inflammatory pathways such as TGF-β pathway, MMP-2/9 production, or activation of NF-kB, PKC and MAPK. Compound 44 is a Pt­(IV) prodrug derived from CDP and Tranilast. Compound 44 exhibited enhanced cytotoxicity against colon and lung cancer cells in vitro compared to CDP , but reduced toxicity against immune cells. Moreover, compound 44 was evaluated ex vivo using tumor explants from CRC patients and demonstrated strong induction of intratumoral cytotoxicity and increased the infiltration of CD45 + immune cells.

Immunogenic Cell Death (ICD) Inducers

PT-112 (Imifoplatin) is a novel Pt­(II) anticancer agent that is structurally analogous to OXP , but with the oxalate ligand replaced with pyrophosphate. Despite its lower intracellular uptake, , PT-112 exhibits higher potency against CDP - and CBP -resistant cell lines due to its unique mode of action. , − Notably, PT-112 efficiently induces ICD in HCT116 human colon cancer cells in vitro by emitting ICD-associated DAMPs. The ability for PT-112 to act as an ICD inducer was further demonstrated in CT26 and MC38 in vivo , which resulted in enhanced immune infiltrations and synergism with anti-PD-1 blockade immunotherapy. , The antiproliferative and immunostimulatory effects of PT-112 is likely to be the result of nucleolar stress and ribosomal biogenesis (RiBi) interruption, which led to nucleolar protein relocalization and increase of free ribosomal proteins, respectively. Additionally, these effects can also cause ER stress and pro-apoptotic protein transportation to the mitochondria. PT-112 has been tested in clinical trials (i.e., NCT02266745 and NCT03409458 ) and has shown remarkable and durable responses in patients with advanced lung, liver, and prostate cancers who did not respond to other standard treatments. − This may be due to the fact that the pyrophosphate ligand confers greater biochemical stability, resulting in enhanced pharmacokinetic and pharmacodynamic properties, as well as accumulation in the lung, liver, and bones. , , , This could also explain the reduced side effects of PT-112 when administered to patients. Furthermore, PT-112 has shown promising results in combination with avelumab, an ICI that targets PD-L1, in clinical trials. −

The ability of a series of Pt-based anticancer drugs, both existing and emerging, to trigger ICD was screened based on CT26 in vitro assays performance such as J774A.1 macrophage phagocytosis efficacy, ICD-related DAMPs expression, and ER ROS production. Among the library, Pt-NHC , an ER targeting compound that was originally designed to cause ER stress, emerged as the most potent ICD inducer, as it significantly increased the uptake of tumor cells by cocultured J774 macrophages compared to other Pt complexes. Pt-NHC also exhibited all three biological markers of ICD induction (e.g., ecto-CRT exposure, extracellular HMGB1 and ATP release). It was then discovered that ER ROS, rather than cytotoxicity, was correlated with phagocytosis ability. Furthermore, phagocytosis activity could be modulated by coating recombinant CRT on the surface or blocking it with a CRT blocking peptide.

After successfully identifying Pt-NHC as a potent type II ICD inducer, structural optimization of Pt-NHC led to the discovery of PlatinER with superior ICD properties. By using similar in vitro testing strategies in CT26 cells, PlatinER displayed comparable performance with equipotent Pt-NHC in terms of phagocytotic ability, extracellular HMGB1 release and ecto-CRT exposure. Similar to Pt-NHC , PlatinER triggered partial ER stress response through the PERK/eIF2a pathway. However, PlatinER additionally elicited ecto-HSP90 expression as an additional “eat-me” signal, which was not observed from Pt-NHC.

Another Pt­(IV) complex that has been found to be able to induce ICD in CRC is the photoactivable trans , trans , trans -[Pt­(N 3 ) 2 (OH) 2 (py) 2 ] ( 46 ). Other than its DNA binding ability, , compound 46 can release products such as azidyl radicals, hydroxyl radicals, nitrene, and singlet oxygen that can trigger other biochemical pathways. , Furthermore, ROS and reactive nitrogen species (RNS) produced during the photoactivation of compound 46 could also contribute to the ICD induction. While the biological ICD hallmarks were confirmed on human ovarian A2780 cell line, the irradiation of 420 nm blue light on trans , trans , trans -[Pt­(N 3 ) 2 (OH) 2 (py) 2 ] treated CT26 cells significantly induced phagocytosis by cocultured J774.A1 macrophages.

Drug Delivery Strategies for CRC

Encapsulation into Drug Delivery Systems

Conventional development of chemotherapeutics, including Pt drugs, is challenged by the lack of replication of drug efficacy between in vitro and in vivo models. , , , For instance, 56MESS, a Pt­(II) scaffold of compound 24 , was significantly more potent than CDP in inhibiting cellular viability in vitro but demonstrated no significant antitumoral activity compared to CDP in vivo . Similarly, another Pt­(II) complex demonstrated nearly 8-fold improved anticancer potency compared to CDP in vitro but observed no significant improvement of the antitumor efficacy in vivo . An attributing reason to this discrepancy between in vitro and in vivo efficacy is the limited amount of active that reaches the tumor site. In order to address this limitation, alternative strategies are required to enhance the availability of the drug at the diseased area and thus the in vivo efficacy of Pt­(IV) complexes. Nanoparticles have been used clinically for the treatment of various forms of cancers. By virtue of their dimensions (i.e., 50–200 nm), intravenously injected nanoparticles are able to accumulate at the tumor tissue passively over time through the enhanced permeability and retention (EPR) effect ( Figure ). This phenomenon arises from the rapid angiogenesis of tumor tissue, creating leaky vasculature through which nanoparticles are able to extravasate from the circulatory system and reach the tumor tissue. The poor lymphatic drainage system at the tumor also reduces the clearance of the nanoparticles, allowing them to accumulate over time. Moreover, nanoparticles can impart beneficial attributes to otherwise unfavorable drugs such as increased aqueous solubility, longer circulation time, increased bioavailability, , and codelivery of several bioactive agents for combination therapy.

Several nanomedicines have been successfully developed and received FDA approval for treating various cancers ( Table ). Doxil was one of the first successful nanoparticle formulations that is used for the treatment of solid tumors from ovarian cancer, Kaposi’s sarcoma, and myeloma. Doxil is able to mitigate the cardiotoxicity of doxorubicin (DOX) through distinctively increasing the relative accumulation of DOX at the tumor compared to the heart. Likewise, other nanoparticle formulations approved by the FDA significantly reduce the toxicity as well as improve the plasma availability and circulation time of the chemotherapeutic drugs ( Table ), resulting in improved overall survival and quality of life for patients.

Interestingly, nanoformulation that includes Pt drugs as the chemotherapeutic agents have yet to be approved by the FDA. However, several CDP -encapsulated nanoparticles, such as LiPlaCis and Nanoplatin , are undergoing clinical trials for various solid tumors ( Table ). − LiPlaCis , a novel liposome for CDP , was designed to be degraded by secretory phospholipase A2 that is relatively abundant in tumor tissue. The selective and targeted release of CDP in tumor tissue enabled by this formulation was designed to significantly reduce the associated systemic toxicity from off-target Pt accumulation.

Besides those in clinical trials, further developments are being made for the loading and delivery of Pt drugs in other forms of nanoparticles ( Table ). These include lipid-based nanoparticles (e.g., nanostructured lipid carriers), polymer-based nanoparticles (e.g., polymersomes), carbon-based nanoparticles (e.g., graphene-based nanoparticles), and gold-based nanoparticles ( Figure ). For instance, Tummala et al. delivered OXP using hybrid lipid-polymer nanoparticles conjugated with anti-TRAIL antibodies. The nanoparticle formulation demonstrates strong tumor growth inhibition as compared to free OXP . Moreover, the anti-TRAIL antibodies on the surface of the nanoparticles result in a synergistic antiapoptotic effect by both targeting the HT-29 CRC cells and activating the death receptors.

Besides solely loading Pt-based drugs, multiple drugs can be coloaded into nanoformulations for synergistic effects. For instance, Li et al. coloaded CBP and paclitaxel into phosphonated calixarenes, which are a macrocycles or cyclic oligomers. Interestingly, Guo et al. formulated a nanoprecipitate of OXP and folinic acid into a PEGylated lipid nanoparticle. The lipid nanoparticles were also decorated with aminoethyl anisamide to target the CRC cells. The targeted nanoformulation with 5-FU was able to induce stronger synergistic chemo-immunotherapy without significant toxicity as compared to the free drugs mixture.

Moreover, the anticancer mechanism is not limited to the promotion of cell death of cancer cells. These loaded Pt-based nanoformulation can also suppress the growth of blood vessels within the solid tumor. Abu-Lila et al. utilized the PEGylated cationic liposomes loaded with OXP to suppress angiogenesis in dorsal air sac model. Additionally, the use of metal nanoparticles, such as gold-based nanoparticles, provides the potential for photothermal therapy. Lee et al. utilized gold nanoshells loaded with Pt­(DACH)­Cl 2 for the treatment of HT-29 xenograft tumor. The tumors were irradiated with 1W/cm 2 NIR (808 nm) for 10 min after the IV administration of the loaded gold nanoshells. The combination of chemotherapy and photothermal therapy suppressed the growth of tumor over a period of 30 days. Gold nanoparticles can also contribute to radiosensitization. In a separate study, liposomes loaded with gold nanoparticles and CBP , together with 10 Gy of radiation, significantly slowed HCT116 human CRC xenograft tumor growth progression.

Additionally, surface functionalization of nanoparticles can enhance their delivery capabilities. Targeting ligands on the nanoparticles’ surface to target cells facilitates preferential uptake of nanoparticles through diffusion and/or receptor-mediated endocytosis, potentially overcoming chemoresistance mechanisms by disfavoring cellular uptake. Some of these receptors overexpressed by CRC cells include transferrin receptors, EGFR and hyaluronic acid (HA) receptors. The incorporation of transferrin on the OXP -loaded liposomal surface reduced Colon-26 tumor growth progression in vivo . Liposomes can also be decorated with cetuximab or cetuximab-Fab′ fragments to target EGFR-overexpressing CRC cells. OXP encapsulated in cetuximab-Fab′ fragment-liposomes exhibited higher accumulation in the tumor. Moreover, the use of EGFR-targeted liposomes inhibited the growth of SW480 colorectal xenograft tumor. HA is also used as a targeting molecule to target HA-overexpressing CRC cells. HA-coupled chitosan nanoparticles loaded with OXP showed enhanced accumulation in the colon and tumor within 24 h of oral administration, effectively delaying HT-29 tumor growth in the colon.

However, surface functionalization can often be expensive and challenging to perform, depending on the specificity of the ligand chosen and its physical and chemical compatibility with the nanoparticles. In this regard, nanoparticles originated from biological sources (e.g., cells) can demonstrate intrinsic targeting toward cancer cells and could represent an attractive option in drug delivery. , These biomimetic systems include extracellular vesicles and cell-derived vesicles, where the cell membranes of natural cells are used to imbue nanoparticles with characteristics of the original cell. Erythrocyte-cloaked nanoparticles (e.g., polymeric nanoparticles, iron oxide nanoparticles, mesoporous nanoparticles, and gold nanocages), for instance, enable long circulation time by “camouflaging” the nanoparticles from the mononuclear phagocytotic system. , Extracellular vesicles isolated from milk have been used to deliver OXP to SNU-C5 colorectal tumor xenograft. Additionally, these biomimetic systems can be further engineered to enhance the accumulation within the tumor. The addition of GE11 peptide targeting EGFR has shown to improve the therapeutic efficacy of OXP -loaded milk extracellular vesicles in the treatment of SNU-C5 colorectal tumor xenograft.

Targeted Administration and Delivery

OXP , which is currently FDA-approved for the treatment of CRC, is administered by IV infusion. OXP is administered to patients over a 2 h period, often in combination with other chemotherapeutics such as 5-FU and LV. Although IV injections ensure the highest blood concentrations, patients are subjected to rounds of injections during treatment. The efficacy of the treatment is also dependent on the biodistribution of the drugs and their uptake and accumulation inside the cancerous cells. There are also associated hematological harmful effects and toxicity to healthy organs caused by off-target accumulation.

Besides the IV route, it could be advantageous to administer Pt drugs through alternative means to target the colorectal area more efficiently. The administration of Pt drugs through alternative methods has been tested in clinical trials for other forms of cancer. For instance, a sustained release lipid inhalation releasing CDP was evaluated for the treatment of lung cancer. Recent developments also demonstrate that CDP aerosol therapy can be delivered to the lymph nodes in Stage II lung cancer patients.

Instead of the parenteral route, administration through the enteral route could allow a direct targeting to the colon and rectum. Although it is not well-studied clinically, we propose that the oral administration of Pt-based chemotherapeutics may have added advantages in the treatment of CRC. The design and development of colon-targeted oral formulations for Pt-based chemotherapeutics could target the colon directly, increasing the efficacy while reducing off-target side effects. Some strategies include designing Pt compounds that could survive the gastrointestinal tract or the loading of Pt compounds into colon-targeted oral drug delivery systems. Such colon-targeted oral drug delivery systems take advantage of the physiological conditions of the colon and have a pH-triggered (e.g., Eudrajit), microbiota-triggered (e.g., polysaccharides or azo polymers) or time-controlled release (e.g., hydroxypropyl methylcellulose) of the active drug. ,

A few Pt-based chemotherapeutics have been designed and developed for oral administration. Even if it was not tested for CRC, Satraplatin was the first orally active Pt drug to be used in clinical trials. , The lipophilicity and stability of satraplatin allows for oral administration. Moreover, the efficacy of satraplatin is comparable to CDP and CBP with a reduced toxicity. Satraplatin has been tested in the treatment of various cancers in clinical trials, including prostate cancer, metastatic breast cancer, lung cancer, and brain tumors. Similarly, Ang and colleagues have developed and screened a series of asymmetric mono/bis-carboxylated Pt­(IV) complexes ( Figure ), which have shown potential in preclinical studies involving CRC, both in vitro and in vivo . The effectiveness of the Pt­(IV) complexes in the colitis-induced in vivo CRC model is likely attributed to their retention in a prodrug form postoral administration, thereby enhancing cellular uptake and thus therapeutic effectiveness.

Additionally, other clinically approved chemotherapeutics (e.g., capecitabine and trifluridine/tipiracil) have demonstrated the feasibility to use orally administered tablets for CRC treatments. Using similar approach, Pt-based drugs can also be formulated into oral dosage forms. For instance, Urbanska et al. loaded OXP into lipidoid encapsulated in alginate microcapsules. The oral delivery of OXP -loaded capsules increases the OS rate. Another study by Kim et al. demonstrated that tablets containing OXP loaded using fat employing supercritical nano system was able to further reduce HT-29 xenograft tumor growth as compared to IV route. More recently, Pangeni et al. developed a solid formulation of OXP for oral administration to treat CRC. A permeation enhancer was used to complex with OXP and then mixed with dispersing agents to form a solid amorphous oral formulation. With this oral formulation, there is a further inhibition in CT26 and HCT116 xenograft tumor growth as compared to the maximum tolerable dose by IV injection. This signifies the potential of oral administration in the treatment of CRC while reducing the adverse side effects associated to chemotherapy.

HIPEC and PIPAC for mCRC

Peritoneal metastases (PMs) are common for late-stage gastrointestinal cancers, including mCRC, and associated with poor prognosis. PMs respond poorly to systemic chemotherapy and adversely affect patients’ quality of life. Intraperitoneal chemotherapy (IPC) has been developed as an alternative delivery modality to treat PMs that could improve drug concentrations at the affected tissue and reduce systemic toxicities. In IPC, chemotherapeutic drug solutions are typically administered at high concentrations directly into the peritoneal cavity via catheters and irrigated using a perfusion machine. In the case of OXP , the drug solutions are also heated to 41–43 °C during treatment as higher temperature has been shown to improve therapeutic outcomes through increasing cytotoxicity and ensuring better tissue penetration. This modality of delivering OXP at elevated temperatures is known as hyperthermic intraperitoneal perioperative chemotherapy (HIPEC), and it is typically performed in conjunction with cytoreductive surgery (CRS). This is in part due to the need to install catheters, which would require surgical access to the patient’s abdomen. A typical HIPEC procedure ranges from 30 to 120 min and the peritoneal cavity is flushed with saline after treatment. It should be noted that there are conflicting data on the effectiveness of OXP -based HIPEC for treatment of PMs arising from mCRC following CRS vs CRS alone, despite its wide adoption. −

The invasive nature of HIPEC has led to the development of other ways of delivering OXP into the peritoneal cavity. One such technique known as pressurized intraperitoneal aerosol chemotherapy (PIPAC) involves nebulizing OXP solution into an aerosol and then introducing it into the patient’s abdomen via laparoscopy. , It is a significantly less invasive procedure since only small incisions are required for the trocar and nebuiliser injector. Several clinical trials have established the efficacy, safety and tolerance of PIPAC, with minimal systemic uptake. − At this time, PIPAC is only indicated for patients with advanced peritoneal carcinomatosis when other options such as CRS or systemic chemotherapy are not viable.

Chemoradiotherapy as an Emerging Strategy

The hypoxic TME is known to contribute significantly to the development of radioresistance for cancer radiotherapy. , Consequently, a variety of radiosensitizers have been integrated into clinical treatment regimens to enhance therapeutic efficacy of radiotherapy. For instance, 5-FU was among the first compounds recognized for its enhanced efficacy in conjunction with radiotherapy compared to radiotherapy alone for the treatment of CRC. On top of it, transition metal compounds have also been designed to be radiosensitizers for cancer radiotherapy. In addition to radiosensiting effects, chemoradiotherapeutic agents could be designed to maximize eradication of tumor cells while simultaneously minimize the negative impacts on surrounding healthy tissues.

A novel class of chemoradiotherapeutic prodrugs activated by radiotherapy has emerged in recent times. − OXP has shown promise as a chemoradiotherapeutic agent as supported by in vitro and in vivo results from preclinical studies, − although the clinical outcomes have been inconsistent. , − Recent discovery found that hydrated electrons (e – aq ) generated from radiotherapy dose of X-ray can be used as a reliable source of reductant to efficiently reduce and activate Pt­(IV) prodrugs ( 47 ). Upon X-ray irradiation, these Pt­(IV) prodrugs can readily release their active Pt­(II) precursors (e.g., CDP , OXP , CBP , nedaplatin , picoplatin , lobaplatin , transplatin ), along with their associated axial ligands such as (3-carboxypropyl) triphenyl phosphonium (CTPP), coumarin, succinic acid in physiologically related solvents. Moreover, OXP -derived Pt­(IV) compounds have demonstrated markedly enhanced anticancer activity when exposed to radiotherapy-dose X-ray (i.e., 4 Gy) on CRC models like HCT116 and HT-29 both in vitro and in vivo , outperforming the non-irradiated controls. Additionally, the hypoxic TME appears to have minimal impact on the release of active OXP from the Pt­(IV) prodrugs by radiation. These discoveries underscore the potential of radiotherapy-induced Pt­(IV) prodrugs activation as a compelling strategy for in situ prodrug activation, complementing chemotherapy’s efficacy when combined with radiotherapy.

Therapeutic Strategies Against OIPN

The onset of OIPN in patients depends on numerous factors, among which the administered dose at each cycle and the cumulative dose. In patients with acute OIPN, depending on the neurological assessment between consecutive cures and to avoid the appearance of chronic OIPN, the administered dose may be diminished, the chemotherapy protocol changed or the treatment stopped. While no clinically approved preventive or therapeutic solution exists, numerous approaches to prevent, treat, or alleviate OIPN and its symptoms have been evaluated over the last decades, including both pharmacological ( Figure ) or nonpharmacological methods, following the identification of OIPN mechanisms. , , To mitigate the systemic toxicities caused by Pt­(II) drugs, a wide range of strategies, including combination therapies, have been explored. In the context of CRC, various medications have been developed to prevent or manage OIPN, among which antioxidants, anti-inflammatory agents or ion channel modulators have been proposed. Although significantly less explored, other strategies, such as the use of Pt­(IV) prodrugs, are also being actively developed for this purpose.

Nonpharmacological Approaches against OIPN

Several nonpharmacological approaches have been evaluated against CIPN. Among those that have reached clinical evaluations, reviewed elsewhere recently, could be cited, for example, acupuncture (NCT­0588­2396, NCT­0585­0130, NCT­0450­5553), ultrasound therapy (NCT­0395­8747), physical exercise (NCT­0351­5356), or compression therapy. A short focus will be given here to cryotherapy.

Before being evaluated in the context of CIPN, cryotherapy received attention for its beneficial effect in alleviating other chemotherapy-induced side-toxicity, in particular alopecia, oral mucositis and nail toxicity. After decades of studies, scalp cooling devices received FDA approval to reduce chemotherapy-induced hair loss. Cryotherapy consists in cooling the extremities of the patients while they receive chemotherapeutic treatment. The vasoconstrictive effect of the cooling is hypothesized to limit the local delivery and accumulation of the chemotherapy and therefore its toxicity to the nerves in the extremities. Several studies and clinical trials evaluated the efficacy and the safety of different cryotherapy implementations, mostly involving taxane-based chemotherapies (e.g., paclitaxel, docetaxel). Most of the studies support the use of cryotherapy to reduce CIPN symptoms in paclitaxel-receiving patients, leading this method to progress in clinical practice and considered as a preventive approach. ,

In the context of Pt-based chemotherapies, a recent trial involving breast cancer patients that received CBP reported that patients using ice gloves and boots showed milder CIPN symptoms than patients not receiving cryotherapy.

Relative to taxanes, and because of the induced cold hypersensitivity (the patients being advised to avoid cold touch), the available data on the use of cryotherapy in the context of OXP treatment is more limited ( Table ). In a study evaluating the use of frozen gloves in OXP -treated patients, no significant beneficial effects were observed but the discontinuation rates of the patients receiving cryotherapy (one-third in total due to discomfort) was not different whether they received OXP or taxanes. A recent phase II clinical trial on OXP -receiving patients with cancers in the digestive system evaluated cryotherapy using a continuous cooling of hands and feet at a constant temperature, named hilotherapy. This approach was described to be well tolerated and to reduce acute OIPN symptoms. More work is needed to further evaluate the potential benefits of cryotherapy in the context of OIPN and to develop cryotherapy methods combining patients’ compliance and ease of implementation.

Rodent Models for OIPN Studies

This section briefly discusses the most widely used in vivo immunocompetent rodent models in the study and assessment of OIPN. , Detailed information on these models can be found in the 2020 review from Calls et al.

Different animal strains have been used in in vivo models of OIPN, among which C57BL/6 and Balb/C mice are the most frequent and Balb/C mice being the most susceptible to neurotoxicity development. Rat models, generally more prone to OXP ’s toxicity than mice, include Wistar and Sprague-Dawley strains. Intraperitoneal (IP) injections are more frequent although IV administration was also described. There is little established consensus on OIPN models and evaluation, and models differ in animals’ species, strains, age, sex, cumulated dose, and injection schedules ( Table ). Because of this variation, phenotypic outcomes obtained with behavioral tests can be contradictory for the same species. In the case of Balb/C mice, most experiments have been performed on healthy animals without a tumor xenograft, and cumulated doses typically vary from 30 to 90 mg of OXP /kg of body weight. The durations of the experiments also vary depending on injection schedules and range from 2 weeks to 3 months. Most experiments were performed on adult male individuals, even though it has been reported that female individuals are more sensitive to OIPN.

Classically performed behavioral tests comprise the Von Frey test to evaluate mechanical hypersensitivity, , and the cold plate and acetone test to measure cold hypersensitivity (acute symptoms). Contradictory results between hyperalgesia and hypoesthesia have been published and such behavioral tests only reflect some of the OIPN clinical symptoms associated with pain. Neuropathy assessment includes the quantification of the loss in IENF density in skin biopsies of hind paws (immunohistological IHC studies with PGP9.5 antibody), studies on DRG samples and sections (IHC studies), and isolated sciatic nerves to characterize axonal damage and demyelination (IHC with Luxol Blue staining, determination of G-ratio, shown to increase, confocal microscopy). Important features are nerve conduction studies, which are however not systematically carried out and if so, with significant variability across studies. The variability in the described models including variations in the injection schedules and administration route, the cumulative total doses, the animal strains/age/sex that show different sensitivities and behaviors, and the different neuropathy assessment methods (behavioral tests, molecular characterizations of OIPN) ( Table ), makes systematic comparisons between studies unrealistic.

Finally, most of the in vivo models consist of healthy animals and very few models have been used to evaluate neuropathy in rodents with tumors (CT26 xenograft in Balb/C mice). , , The presence of a solid tumor can alter the evaluated drugs’ pharmacokinetics and such a model appears more clinically relevant. The same administration schedules, duration of the experiments and therefore accessible stages of neuropathy, are however more restrained in tumor-bearing models. We believe both healthy and tumor-bearing mice models provide complementary information and the latter should be further implemented in order to determine the systemic side effects of the newly developed chemotherapeutic agents.

Combination Treatments for OIPN

The combination treatments’ approaches against OIPN include targeting molecular mechanisms and pathways, such as sodium, potassium or TRP channels, glutamate or monoamine nervous systems, oxidative stress, inflammatory responses and Pt transporters, and have been extensively reviewed. , , ,

A number of in vitro models using tumor-derived neuron-like cells of human or murine origin have been described and used for the study of the mechanisms of OXP neurotoxicity and to evaluate therapeutic approaches against OIPN. Different in vivo models for preclinical studies of OIPN have also been described, , as briefly introduced above in section .

Na + and K + have been reported to display crucial roles in the development of acute peripheral neuropathy. Na + channels have been traditionally related to the induction of acute cold hypersensitivity, and K + channels regulate sensory neuronal pain and excitability. The expression of K + channels such as TWIK-related K + channel 1 (TREK-1) and TWIK-related arachidonic acid-stimulated K + channel (TRAAK) has been shown to be altered by OXP in the DRG of rodents. , Ion channel modulators are therefore potential therapeutic options for alleviating OIPN. In this regard, several drugs known for their voltage-gated sodium or calcium channels inhibitory properties, have been reported to display neuroprotective activities in the context of CIPN. , , , Analgesics like capsaicin, lidocaine, and morphine, antidepressants such as amitriptyline, cholinesterase inhibitors such as donepezil, , renin–angiotensin system modulators such as Ramipril, among others, can reduce symptoms by acting on neurotransmission. Anticonvulsants such as carbamazepine or gabapentine reduce excitatory neurotransmitters and target voltage-gated calcium channels. However, all these drugs show secondary deleterious effects. More recently, Alberti et al. reported prevention of OXP -induced both acute and chronic peripheral neuropathy in female Wistar rats when treated in combination with topiramate, another voltage-gated sodium channel modulator. In this study, acute neuropathy was assessed through sensory nerve’s threshold observation, while chronic neuropathy was evaluated at neurophysiological, behavioral, and neuropathological levels. Since topiramate is already clinically approved for the treatment of epilepsy and migraines and shows minimal detrimental effects, it presents a promising candidate for further preclinical investigations in the context of OIPN.

As extensively covered by Stankovic et al. in 2020, exogenous antioxidants usually employed as supplementation treatments were investigated, including vitamins (e.g., C, E, or K), minerals (e.g., manganese, selenium or zinc), carotenoids, and other molecules such as lipoic acid, d -methionine, carnosine or omega-3-fatty acids. Supplementation of ROS scavengers in combination with OXP might compensate for OXP -induced glutathione depletion and re-establish redox homeostasis in healthy cells.

Antioxidants of synthetic origin have also been largely evaluated to reduce oxidative stress in neurons in rodent models, with some encouraging results. Among them, (Mn)-based complexes, mimicking superoxide dismutase (SOD) enzyme and therefore able to catalyze the dismutation of two superoxide anions (O 2 ·– ) into H 2 O 2 and dioxygen, have been widely studied in anticancer strategies , and in OIPN prevention ( 48 – 51 ). Mangafodipir , an MRI contrast agent also displaying SOD-mimicking properties, has been shown to improve the therapeutic index of OXP and prevent OIPN under both preclinical and clinical studies. , The preventive use of SOD mimics based on different scaffolds was further explored in OIPN animal models by Guillaumot et al. in 2019 and Prieux-Klotz et al. in 2022. The open-chain diamine complex Mn1 ( 49 ) was an excellent candidate due to its antioxidant and anti-inflammatory properties in various in vitro and in vivo models. , Remarkably, when combined with OXP in CT26-bearing Balb/C mice, Mn1 displayed neuroprotective activity as observed in behavioral tests and electrophysiological recordings. This Mn­(II) complex and its derivatives, all bearing a positive charge, could display improved cell penetrative properties with respect to mangafodipir and are therefore excellent candidates for further preclinical investigations. Table and Figure present selected examples of antioxidants that have shown a neuroprotective activity in preclinical models of OIPN in mice or rats.

Nuclear factor-erythroid 2-related factor 2 (Nrf2), a transcription factor that regulates the expression of antioxidant enzymes and detoxification proteins, is an interesting target in the prevention of OIPN. Dimethyl fumarate, an electrophilic Nrf2 activator approved for multiple sclerosis, was shown to protect against axonal degeneration of rats’ sciatic nerves. − Anti-inflammatory agents such as minocycline or rapamycin prevented neuronal damage in rats. Inhibitors of Pt transporters involved in Pt accumulation in DRG were also evaluated. Cimetidine and dasatinib, OCT2 inhibitors, showed some prevention of mechanical allodynia in mice, and ergothioneine, an OCTN1 inhibitor, showed a beneficial effect on mechanical allodynia in rats. Of note, inhibition of OCTN2 by L-carnithine, failed to do so. A significant number of clinical trials involving molecular approaches mentioned above were also conducted without much success, and are covered in a few recent reviews. ,

A list of pharmacological treatments evaluated in clinical trials of OXP -based chemotherapy-treated patients is proposed in Table . Among these, Duloxetine, a serotonin–norepinephrine reuptake inhibitor used to treat depressive disorders, is the only recommended drug (moderately recommended) by the American Society of Clinical Oncology, to treat neuropathic pain, although its efficacy is still debated. To counteract oxalate’s effect on sodic channels, calcium/magnesium infusions were evaluated without success. , − Goshajinkigan, a traditional Japanese medicine acting on TRP channels, gave contradictory results. −

Antioxidants such as α-lipoic acid, glutathione or vitamin E, or the anti-inflammatory minocycline failed to show any improvement in neuropathy or pain score. The Ca 2+ channel inhibitor pregabalin was studied in several clinical trials that gave differential results. Further validation of its potential efficacy is therefore needed. Calmangafodipir reached phase III trials (POLAR A and M) in CRC patients, although it gave negative results, with no OIPN reduction after 9 months. The negative charge of the complex was suspected to cause low cell penetration and possible redox reactions between the Mn­(II) and Pt­(II) centers, due to a very close in time administration, were presumably the causes of the negative effect in the last clinical trial. , Riluzole, which inhibits the accumulation of glutamate, has entered a phase II trial.

In summary, many strategies have been studied in animal models of OIPN, with some success, most of them alleviating acute OIPN symptoms and only a few showing preventive activity. These drugs must neither reduce OXP antitumoral efficacy nor generate additional side effects. There remains a gap between preclinical animal studies and clinical trials, where only a few compounds have been evaluated with very limited positive outcomes. Although efficient solutions have yet to be developed, some target candidates for neuroprotection and prevention of nerve damage have been identified. More efforts are necessary to evaluate and characterize the mode of action of potential preventive strategies and to develop assessment methods in animal models that better reflect clinical symptoms in order to bridge that gap.

Pt­(IV) Strategy in the Context of OIPN

Although vastly less explored, other strategies, such as the use of Pt­(IV) prodrugs are also under current development. The Pt­(IV) strategy can also be exploited in the context of OIPN prevention for several reasons. First, mediated uptake of Pt­(IV) prodrugs might differ from that of their Pt­(II) counterparts. The toxicity profiles of Pt­(IV) prodrugs are far from being completely deciphered and their neurotoxicity, including accumulation in DRG, has been poorly characterized so far. For instance, unlike CDP , it has been reported that dicarboxylato CDP -based Pt­(IV) prodrugs are not substrates for CTR1 transporters. However, OXP and its Pt­(IV) derivatives seem to be equally internalized via OCTs. Furthermore, the uptake of CDP -based Pt­(IV) complexes via OCT2 might be dependent on the symmetric or unsymmetric functionalization of such complexes. The role of solute and membrane transporters for Pt­(IV) complexes is, nevertheless, less explored than for their Pt­(II) analogs. Overexpression of transporters in certain tissues (e.g., OCT2 is typically expressed in neurons and is thought to play an essential role in OXP accumulation in DRG) might drastically modify the therapeutic consequences of said prodrugs. Such parameters are key for understanding Pt­(IV) complexes’ off-target effects.

On the other hand, the further functionalization achieved by the introduction of two additional axial ligands enables the introduction of neuroprotective moieties ( Figure ). In this regard, the only Pt­(IV) prodrugs described for this purpose up to date were reported by Prieux-Klotz et al. in 2022 and were bearing a Mn­(II) complex derived from SOD mimic Mn1 ( PtC1Mn x ) ( 50 and 51 ). Although poor stability upon Mn­(II) coordination was shown, PtC1Mn1 reported lower antitumoral activity mainly due to a lower effective Pt dose but an improved therapeutic index (in terms of asthenia, alopecia, diarrhea and weight loss).

The evaluation of Pt­(IV) complexes in the context of neurotoxicity and peripheral neuropathy is still in its infancy. They present a very interesting opportunity to combine optimized antitumoral activity along with a better toxicity profile with reduced neurotoxicity arising from reduced accumulation in the PNS components and protective activity in healthy cells provided by the axial ligands. This deserves active investment from Pharma companies.

Conclusion and Outlook

In this review, we have described the current approaches in treating colorectal cancer (CRC) and the drawbacks and shortcomings of the various methods, focusing on the roles that Pt anticancer agents play as first-line treatment in several malignancies. Although Pt­(II) anticancer drugs are simple cytotoxic agents that lack selectivity for cancer cells and cause severe side effects, they have been effectively used in the clinic for over four decades. Remarkably, even today, amid the era of targeted drugs, precision medicine and immunotherapy, nearly half of all chemotherapy regimens include at least one Pt drug.

Nonetheless, the primary challenges with traditional Pt drugs include the lack of selectivity, severe side effects (e.g., nephrotoxicity and neurotoxicity), and the development of drug resistance. OXP , commonly used for CRC, is particularly associated with peripheral neuropathy. The severity of the undesirable side effect is further complicated by the interplay among TME, TIME, and Pt drugs. This is because TME and TIME play significant roles in influencing the efficacy of Pt-based drugs in CRC. For instance, the dense structure and abnormal vasculature of the TME can impede drug delivery to tumor cells and the extracellular matrix (ECM) can act as a physical barrier, while hypoxia can alter cellular metabolism and promote survival pathways that counteract the effects of Pt drugs. Moreover, tumors can create an immunosuppressive TIME by recruiting Tregs, MDSCs, and producing inhibitory cytokines, which can reduce the effectiveness of chemotherapy. Recent strategies that modify the TME or TIME to enhance drug delivery and immune response are being explored. These include using agents that normalize blood vessels, modify ECM components, or modulate immune cell activity. Understanding and targeting these environments can potentially improve treatment outcomes and overcome resistance.

The discovery of immunomodulatory roles of OXP and other clinical Pt agents has led to numerous clinical trials exploring the combination of Pt chemotherapeutics with immunotherapeutics. This discovery has also broadened the potential use of immunologically active Pt compounds as small molecule chemo-immunotherapeutics. Contrary to previous beliefs that classical cytotoxic Pt­(II) anticancer drugs are detrimental to the patients’ immune system, recent evidence that have surfaced support their roles in promoting anticancer immunity. For instance, several Pt­(II) complexes (e.g., OXP , Pt-NHC , PlatinER , and PT-112 ) have been found to activate the TIME as immunogenic cell death (ICD) inducers effective against CRC.

Recent research has focused on developing Pt­(IV) prodrugs which are designed to be more stable and less toxic compared to their Pt­(II) counterparts. These prodrugs can be reduced in the cancer cell to release the active drug, potentially targeting tumors more effectively while reducing damage to healthy cells. New strategies involve designing Pt­(IV) complexes that not only deliver the cytotoxic Pt but also release additional therapeutic agents (e.g., inhibitors of specific cancer-promoting pathways) upon reduction. Researchers are also exploring new Pt complexes with modified ligands to increase efficacy, reduce toxicity, and overcome resistance. These new analogs are designed to have better pharmacokinetic properties and target specific cancer cell mechanisms. This multiaction approach aims to enhance anticancer efficacy and reduce resistance.

In addition, the Pt­(IV) platform extends the potential application of immunomodulatory Pt­(II) anticancer agents by adding pro-inflammatory payloads that can reverse the immunosuppressive TIME or compliment and enhance the immunological effects of the Pt­(II) active core. Therefore, chemo-immunotherapeutic Pt­(II) and Pt­(IV) complexes appear to be promising candidates in targeting immunologically “cold” tumors that are inherently resistant to immunotherapy, such as pMMR/MSS or dMMR/MSI-Low CRC.

Advances have also been made in developing nanoparticles and other delivery systems that encapsulate Pt drugs to improve their selectivity for cancer cells. These systems can exploit the EPR effect in tumors or utilize targeting ligands to direct the drugs specifically to cancer cells. Moreover, combining Pt-based drugs with other treatments, such as immunotherapies or targeted therapies, is being explored to overcome resistance and improve efficacy. For instance, combining OXP with immune checkpoint inhibitors (ICIs) is under investigation to enhance immune response against tumors such as lung, head and neck cancers. With regards to the latter, traditional chemotherapy works by targeting rapidly dividing cells, which include cancer cells. It generally lacks specificity, affecting both cancerous and healthy cells, which leads to side effects. Immunotherapies instead enhance the immune system to recognize and destroy cancer cells in a more targeted approach. Hence, while chemotherapy remains the standard treatment for many types of CRC, particularly in the adjuvant and metastatic settings, immunotherapy has shown to be particularly effective in dMMR/MSI-High CRCs. For these subtypes, immunotherapy can lead to durable responses and potentially better outcomes, with side effects that are no longer associated with the intrinsic toxicity of the compounds, but rather to immune activation (e.g., skin rashes, diarrhea, fatigue etc.). Nonetheless, Pt-based drugs remain suitable (and more affordable!) for a broad range of CRC patients, including those with stable disease and various molecular profiles. On the other hand, immunotherapy has the potential to lead to long-term remission in specific subsets of patients (particularly those with specific genetic markers like MSI-High or dMMR). Hence, future research should focus on expanding the use of immunotherapy to a broader range of CRC patients, including those with MSS CRC tumors. This will involve combining immunotherapy with other treatments like chemotherapy, targeted therapies, or radiation to improve efficacy.

While developing new therapeutic modalities that could address the shortcoming of Pt drugs, it is also imperative to address some of the crucial challenges of current treatments: specifically for CRC, a key priority would be to overcome oxaliplatin-induced peripheral neuropathy (OIPN). Possible approaches could include reducing the OXP dose or altering the treatment schedule to mitigate the severity of OIPN without significantly compromising efficacy, as well as coadministering neuroprotective agents such as calcium (Ca) and magnesium (Mg) infusions to reduce acute neurotoxicity. More recently, glutamate modulators like riluzole have shown a promising role by modulating neuronal excitability, and even vitamin E and glutathione proved to be beneficial by reducing the oxidative stress associated with OIPN. In addition, compounds with central effects, including antidepressants (duloxetine and venlafaxine) and antiepileptic drugs such as gabapentin seem to help alleviate neuropathic pain and improve quality of life for patients with OIPN. Emerging strategies have also been explored by our team, including SOD mimetics that reduce oxidative damage to nerves. , Alternative approaches, such as gene therapy, acupuncture and physical therapy hold some promise, too. Overall, overcoming OIPN requires a multifaceted approach involving preventive strategies, symptomatic treatments, and ongoing research to develop more effective therapies. The goal is to maintain the efficacy of Pt drugs in treating CRC while minimizing its impact on patients’ quality of life.

Very recently, several biomarkers have been studied to predict the response to Pt-based chemotherapy in CRC. These biomarkers can help tailor treatments to improve efficacy and reduce unnecessary toxicity. Among these, the DNA MMR status and MSI are of particular relevance as dMMR/MSI-High CRC tumors are known to have a better prognosis and are typically more sensitive to immunotherapy, but their response to Pt-based chemotherapy can vary. Alternatively, ERCC1 is involved in the NER pathway, which repairs Pt-induced DNA damage. High levels of ERCC1 expression may be associated with resistance to Pt-based chemotherapy, as the cells can effectively repair the DNA cross-links caused by the drugs.

Alternatively, specific miRNAs have been linked to chemotherapy resistance or sensitivity. They can modulate gene expression post-transcriptionally and have been explored as potential biomarkers for predicting response to Pt-based drugs. Lastly, tumor-infiltrating lymphocytes and immune markers, in which certain immune signatures may correlate with better responses to Pt-based treatments, represent a valuable tool to predict treatment responses. While these biomarkers show promise, it is important to note that their clinical application requires further validation through research and clinical trials. Only the successful integration of these biomarkers into clinical practice, combined with personalized treatment plans, will be able to improve the overall outcomes for CRC patients.

Taken all these aspects into consideration, the underlying question is whether we can develop a novel Pt complex that on the one hand will retain the efficacy of the current Pt drugs and on the other, will overcome their shortcomings, particularly toxicities and acquired resistance. This is quite a formidable challenge and, despite many attempts and several clinical trials of Pt­(IV) complexes, the FDA has not approved a new Pt drug for over two decades. So how should chemists go about designing such novel drugs? The structure–activity relationship (SAR) rules for developing square planar Pt­(II) anticancer drugs, described in 1973, resulted in seven Pt­(II) drugs approved for use in humans. Conversely, because no Pt­(IV) complexes were approved for use in humans, to date, there is no roadmap for the design of octahedral Pt­(IV) prodrugs. The Pt­(IV) complexes that entered the clinical trials were all unpretentious prodrugs of the Pt­(II) complexes with simple axial ligands that were devoid of any anticancer activity. They were not multitargeting prodrugs. Nevertheless, there are some important take-home lessons for the design of novel drugs that can be obtained from the clinical trials of satraplatin, which completed phase III. Satraplatin was administered orally, attesting to the stability and inertness of Pt­(IV) compared with more reactive Pt­(II) drugs that are administered intravenously. A logical starting point to treat CRC would be to design and prepare dual-action Pt­(IV) derivatives of OXP with 5-FU, irinotecan or capecitabine that are coadministered with OXP in the clinic. Designing reduction-resistant, light-activated dual-action Pt­(IV) derivatives of OXP , is another attractive approach. Photo- or radio-activable Pt complexes are designed to become activated only upon exposure to light or radiation, which can trigger the release of the Pt species directly at the tumor site. There is ongoing research to optimize these complexes in terms of their activation wavelengths, tissue penetration, and stability. Advances in this area could lead to more effective and safer chemotherapy options.

Taken together, the ability to enhance efficacy by incorporating the appropriate bioactive ligands in the axial positions of Pt­(IV) complexes, coupled with reduced side effects, makes multiaction Pt­(IV) prodrugs good candidates for treating CRC. Pt­(IV) prodrugs can also be modified to make them amenable to encapsulation in drug delivery systems, which should further enhance their efficacy and reduce toxicities. While promising, these technologies are still in the experimental stages and they are not yet ready to replace small molecule Pt agents entirely. Instead, they may complement existing therapies as part of a broader arsenal of treatment options. Hence, it is unlikely that small molecule Pt agents will be completely replaced in the near future. Instead, they may be integrated with new therapies to enhance outcomes. For instance, combining Pt drugs with immunotherapy or using them as part of a multimodal approach involving photo- or radio-activation could improve efficacy. The future likely involves a more personalized approach, where treatment is tailored based on the genetic and molecular makeup of the tumor, as well as patient-specific factors. This could mean selecting the most appropriate therapy or combination of therapies for each individual patient. Advances in personalized medicine and combination therapies are expected to shape the future landscape of CRC treatment. Until then, Pt-based chemotherapy remains a cornerstone of treatment for most CRC patients.

This work was supported by the National University of Singapore, GAP funds (GAP2002023-03-01/A-8001819-00-00 and GAP2002023-03-23/A-8002435-00-00) and the Ministry of Education (MOE), Singapore, under AcRF Tier 2 grants (T2EP30220-0039/A-0008496-00-00 and T2EP30122-0027), Tier 1 grant (A-8002936-00-00 and A-8002492-00-00) and NAMIC (M23N2K0035/A-8001601-00-00), the Sorbonne Université (Emergence EMRG-24/2023 (TOTEM)), Ecole Doctorale de Chimie Moléculaire Paris Centre (ED406), Ligue contre le Cancer (DOULEUR2024.LCC/HeB), Merlion Project, CNRS International Emerging Action, and the Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR).

Jia Xuan Kee graduated with a B.Sc. (Hons) in Chemistry from the National University of Singapore (NUS) with the Singapore National Institute of Chemistry Prize (2020). He is currently a Ph.D. candidate in Prof. Wee Han Ang’s lab at NUS under the President’s Graduate Fellowship, focusing on the development of novel Pt­(IV) prodrugs and the elucidation of their mechanisms of actions.

Jia Ning Nicolette Yau received her Ph.D. in Pharmacy in 2024 from the National University of Singapore. She is currently an internal editor of the Multidisciplinary Digital Publishing Institute.

Ram Pravin Kumar Muthuramalingam is a Ph.D. candidate at the Department of Pharmacy, National University of Singapore. His research focuses on platinum­(IV) prodrugs and biohybrid nanocarriers for targeted cancer therapy. He holds a Master’s in Pharmacology and a Bachelor’s in Pharmacy from The Tamil Nadu Dr. M.G.R. Medical University, India. With prior experience as a Research Assistant at NUS and Lecturer at PSG College of Pharmacy, his expertise spans in vivo pharmacology, extracellular vesicle-based delivery systems, and molecular techniques. He has coauthored several interdisciplinary publications in nanomedicine, oncology, and drug delivery, and is a recipient of the NUS-IRP scholarship.

Xinyi Wang graduated from Ocean University of China with a bachelor’s degree in biotechnology. Currently she is a Ph.D. student in Prof. Giorgia Pastorin’s lab, focusing on developing patient-derived immune-competent in vitro 3D models for colorectal cancer drug screening.

Wei Heng Chng received his Ph.D. from the National University of Singapore (NUS) in 2023. As a research fellow at NUS Department of Pharmacy and Pharmaceutical Sciences, he conducted research on the use of nanodrug delivery systems to deliver various drugs, including platinum-based compounds, to treat colorectal cancer. His area of research also includes the use of various nanoparticles, such as extracellular vesicles, for both therapeutic and drug delivery purposes.

Alvaro Lopez-Sanchez earned his Ph.D. in Molecular Chemistry in 2024 from Sorbonne Université, under the supervision of Dr. Hélène Bertrand. He is currently an American Cancer Society Postdoctoral Fellow in the laboratory of Prof. María Contel at Brooklyn College, The City University of New York. His research focuses on the design and biological evaluation of transition metal complexes as chemotherapeutic agents.

Dr. Kevin Kuang Wei Tay is a Senior Consultant Medical Oncologist at the Oncocare Cancer Center since 2013. He currently holds American Board certifications for the practice of Internal Medicine and Medical Oncology. Dr. Tay completed his medical oncology training in 2009 at the National Cancer Institute (NCI) in USA. Upon returning to Singapore, Dr. Tay joined the Department of Medical Oncology at National Cancer Center in Singapore from 2010 to 2013. He was part of the core translational research group at the National Cancer Center Singapore, that was awarded the prestigious center grant by the National Medical Research Council of Singapore. His main interests are in hematological cancers (lymphoma and multiple myeloma), women’s cancers (breast and gynaecological cancers), and rare cancers such as sarcomas and melanomas.

Lih-Wen Deng received her Ph.D. in Biochemistry from the University of Cambridge in 2000 and completed her postdoctoral training at Harvard University. She joined the National University of Singapore in 2004 and is currently an Associate Professor at the Yong Loo Lin School of Medicine at National University of Singapore. She also serves as Co-Research Director at the NUS Centre for Cancer Research and is an affiliated member of the National University Cancer Institute of Singapore. Her research focuses on genomic instability, therapy resistance, and targeting cancer metabolism and the tumor microenvironment for therapeutic intervention.

Dan Gibson received his Ph.D. in Chemistry in 1983 from the Hebrew University of Jerusalem (Israel). From 1983 to 1986, he was a postdoctoral fellow with Prof. S. Lippard at MIT. He joined the Department of Medicinal Chemistry in the School of Pharmacy in the Faculty of Medicine at the Hebrew University of Jerusalem in 1986. He retired as a full professor of Medicinal Chemistry in 2020. His research focuses on the development of novel multitargeting platinum based anticancer agents.

Helene C. Bertrand received her Ph.D. in Molecular Chemistry at Sorbonne University in 2008 with Dr. M.-P. Teulade Fichou and D. Fichou. She carried out her postdoctoral research at the School of Pharmacy (University College London) with G. Wells between 2009 and 2011 and at the Institut des Sciences Moléculaires in Bordeaux (2011) with S. Quideau, before joining Sorbonne University as an Assistant Professor in 2011. She is currently a Full Professor at Sorbonne University at the Laboratoire Chimie Physique et Chimie du Vivant ( https://ens-bic.fr/ ). Her research interests lie in the field of bioinorganic medicinal chemistry and include chemotherapy-induced peripheral neuropathy.

Giulia Adriani received her Ph.D. in Engineering of Machines under the Biomedical and Biomechanical Engineering program from the Polytechnic of Milan, Bari, and Turin (Italy) in 2012, with research at The Methodist Hospital Research Institute in Houston (USA). She held positions at the National University of Singapore (NUS) and the Singapore–MIT Alliance for Research and Technology. Currently, she is Principal Scientist at the Singapore Immunology Network, by the Agency for Science, Technology, and Research, with adjunct appointments at NUS and Nanyang Technological University. Her research includes advanced human-relevant microphysiological systems to model the tumor microenvironment and improve cancer therapy screening.

Wee Han Ang received his B.Sc. (Hons) from Imperial College of London (1995) and Ph.D. from Ecole Polytechnique Federale de Lausanne (2007) under the supervision of Prof. Paul Dyson. After a postdoctoral stint with Prof. Stephan Lippard at Massachusetts Institute of Technology, he joined the National University of Singapore (2009) as a principal investigator and has been there since. His current research focusses on the investigation and development of metal complexes, particularly those based on platinum group metals, for chemo- and immunotherapy.

Giorgia Pastorin received her Ph.D. in Medicinal Chemistry in 2004 from the University of Trieste (Italy). After being a research fellow at the Centre National De La Recherche Scientifique (CNRS) in Strasbourg (France), she joined the Department of Pharmacy at the National University of Singapore in 2006 as Assistant Professor. She is currently a Full Professor and Head of the Department of Pharmacy and Pharmaceutical Sciences in the same university. Her area of research includes platinum-based prodrugs and their release through innovative drug delivery systems. For the work performed by her BioNanoTechnology team, she has received both National and International awards.

J.X.K. and J.N.N.Y. contributed equally. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

The authors declare no competing financial interest.

Abbreviations

two-dimensional

5-fluorouracil

adenosine triphosphate-binding cassette

ATP-binding cassette, subfamily C, member 1

antibody-dependent cell-mediated cytotoxicity

acute kidney injury

protein kinase B

annexin A1

azoxymethane

adenomatous polyposis mouse models

adenosine triphosphate

all- trans -retinoic acid

B-cell receptor-associated protein 31

B-cell lymphoma

cancer susceptibility candidate 15

cancer-associated fibroblast

carbonic anhydroase IX

chimeric antigen receptor

carboplatin

clinical benefit rate

colorectal cancer-associated long noncoding ribonucleic acid

chemokine (C-C motif) ligand

cisplatin

cell derived xenograft model

chemical induced model

chromosomal instability

chemotherapy-induced peripheral neuropathy

circular ribonucleic acid

consensus molecular subtype

copy number aberration

cyclooxygenase-2

cell-penetrating peptide

colorectal cancer

clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9

cytoreduction surgery

calreticulin

cancer stem cell

computed tomography

circulating tumor cell

cytotoxic T-lymphocyte associated protein 4

(3-carboxypropyl)­triphenylphosphonium

copper transporter 1

copper transporter 2

chemokine (C-X-C motif) ligand

diaminocyclohexane

diamino-4-cyclohexane

damage-associated molecular pattern

dendritic cell

dichloroacetic acid

disease control rate

differentially expressed gene

diet induced model

1,3-dimethylhydrazine

deficient DNA mismatch repair

deoxyribonucleic acid

DNA methyltransferase

duration of response

doxorubicin

dorsal root ganglia

dextran sulfate sodium

endothelial cell

extracellular matrix

epidermal growth factor

epidermal growth factor receptor

eukaryotic initiation factor 2 alpha

epithelial–mesenchymal transition

European Organization for Research and Treatment of Cancer

enhanced permeability and retention

endoplasmic reticulum

excision repair cross-complementation group 1

excision repair cross-complementation group 2

extracellular signal-regulated kinase

formyl peptide receptor

FXYD domain containing ion transport regulator 3

galectin 4

GATA-binding factor 6

genetically engineered autochthonous mouse model

genetically engineered mice model

Gene Expression Omnibus

glutathione S-transferase

hyaluronic acid

histone deacetylase

histone deacetylase inhibitor

human development index

histone demethylase

hypoxia-inducible factor 1-alpha

hyperthermic intraperitoneal perioperative chemotherapy

high-mobility group AT-hook 2

high-mobility group box 1

histone methyltransferase

hereditary nonpolyposis colon cancer mouse model

heat-shock protein

intragastric

intramuscular

introperitoneal

intrarectal

intravenous

half-maximal inhibitory concentration

immunogenic cell death

immune checkpoint inhibitor

indoleamine 2,3-dioxygenase

intraepidermal nerve fiber

interferon gamma

interleukin

innate lymphoid cell

inducible nitric oxide synthase

intraperitoneal chemotherapy

lymphocyte-activation gene 3

locally advanced rectal cancer

long noncoding ribonucleic acid

low-density lipoprotein receptor-related protein 1

local recurrence rate

leucine-rich repeat containing 8

Lynch syndrome

leucovorin

methylazoxymethanol

mitogen-activated protein kinase

multidrug and toxin extrusion protein 1, efflux

metastatic colorectal cancer

myelodysplastic syndrome

myeloid-derived suppressor cell

peptide-major histocompatibility class I

peptide-major histocompatibility class II

microribonucleic acid

matrix metalloproteinase-9

DNA mismatch repair

manganese

N -methyl- N -nitro- N -nitrosoguanidine

methyl nitroso urea

microphysiological system

magnetic resonance imaging

messenger ribonucleic acid

multidrug resistance-associated protein 2

microsatellite instability

microsatellite stable

maximum tolerated dose

mitochondria DNA

mammalian target of rapamycin

National Comprehensive Cancer Network

nucleotide excision repair

nuclear factor kappa-light-chain-enhancer of activated B cell

N -heterocyclic carbene

nonhuman primate

near-infrared

natural killer

nonobese diabetic

nuclear factor-erythroid 2-related factor 2

nonsteroidal anti-inflammatory drug

oral gavage

octanoic acid

organic cation transporter

organic cation transporter novel type 1

organic cation transporter novel type 2

oxaliplatin-induced peripheral neuropathy

objective response rate

overall survival

oxaliplatin

poly­(ADP-ribose) polymerase 1

programmed cell death protein 1

programmed cell death ligand 1

programmed cell death 4

pyruvate dehydrogenase kinase

patient derived organoid

patient derived organoid xenograft model

patient derived xenograft model

PKR-like endoplasmic reticulum kinase

positron emission tomography

progression-free survival

4-phenylbutyric acid

2-amino-1-methyl-6-phenylimidazo­(4,5- b )­pyridine

phosphatidylinositol-3-kinase

pressurised intraperitoneal aerosol chemotherapy

protein kinase C alpha

pyruvate kinase M2

phospholipase D4

peritoneal metastasis

prostate transmembrane protein androgen induced 1

proficient deoxyribose nucleic acid mismatch repair

peripheral nervous system

2-(2-propynyl)­octanoic acid

proteolysis targeting chimera

rattern-recognition receptor

platinum

regulated cell death

relapse-free survival

ribosomal biogenesis

rinobucleic acid

ribonucleic acid sequencing

reactive nitrogen species

receiver operating characteristic

reactive oxygen species

ribosomal ribonucleic acid

subcetaneous

suberoylanilide hydroxamic acid

short-course radiotherapy

severe combined immunodeficient

solute carrier family 22

sensible nerve action potential amplitude

superoxide dismutase

SRY-box

serine protease inhibitor Kazal type 3

signal transducer and activator of transcription 3

tumor-associated macrophage

The Cancer Genome Atlas Program

tumor-associated endothelial cell

follicular helper T cell

transforming growth factor-β

transglutaminase 2

helper T cell

T-cell immunoglobulin and mucin domain-containing protein 3

tumor immune microenvironment

tertiary lymphoid structure

tumor mutational burden

tumor microenvironment

2,4,6-trinitrobenzenesulfonic acid

tumor necrosis factor alpha

targeted protein degradation

triphenylphosphonium

TWIK-related arachidonic acid-stimulated K + channel

regulatory T cell

TWIK-related K+ channel 1

triggering receptor expressed on myeloid cells 2

transcient receptor potential

transcient receptor potential ankyrin 1

transient receptor potential melastatin 8

transient receptor potential vanilloid 1

taurine upregulated gene 1

ubiquitin-specific peptidase 49

ubiquitin-specific protease 7

vascular endothelial growth factor

valproic acid

volume-regulated anion channel

Williams–Beuren syndrome chromosomal region 22

xeroderma pigmentosum group d

X-ray cross-complementing group 1

Deo S. V. S. Sharma J. Kumar S. GLOBOCAN 2020 Report on Global Cancer Burden: Challenges and Opportunities for Surgical Oncologists Ann Surg Oncol 2022 29 11 6497 6500 10.1245/s10434-022-12151-6 35838905

Morgan E. Arnold M. Gini A. Lorenzoni V. Cabasag C. Laversanne M. Vignat J. Ferlay J. Murphy N. Bray F. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN Gut 2023 72 2 338 344 10.1136/gutjnl-2022-327736 36604116

Fidler M. M. Soerjomataram I. Bray F. A global view on cancer incidence and national levels of the human development index International journal of cancer 2016 139 11 2436 2446 10.1002/ijc.30382 27522007

Onyoh E. F. Hsu W.-F. Chang L.-C. Lee Y.-C. Wu M.-S. Chiu H.-M. The rise of colorectal cancer in Asia: epidemiology, screening, and management Current gastroenterology reports 2019 21 36 10.1007/s11894-019-0703-8 31289917

Sung J. J. Lau J. Y. Goh K. Leung W. Increasing incidence of colorectal cancer in Asia: implications for screening The lancet oncology 2005 6 11 871 876 10.1016/S1470-2045(05)70422-8 16257795

Li L. Ma B. B. Colorectal cancer in Chinese patients: current and emerging treatment options OncoTargets and therapy 2014 1817 1828 10.2147/OTT.S48409 25336973 PMC4199792

Deng Y. Rectal cancer in Asian vs. Western countries: why the variation in incidence? Current treatment options in oncology 2017 18 64 10.1007/s11864-017-0500-2 28948490

Bray F. Laversanne M. Sung H. Ferlay J. Siegel R. L. Soerjomataram I. Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA: a cancer journal for clinicians 2024 74 3 229 263 10.3322/caac.21834 38572751

Valastyan S. Weinberg R. A. Tumor metastasis: molecular insights and evolving paradigms Cell 2011 147 2 275 292 10.1016/j.cell.2011.09.024 22000009 PMC3261217

Baran B. Ozupek N. M. Tetik N. Y. Acar E. Bekcioglu O. Baskin Y. Difference between left-sided and right-sided colorectal cancer: a focused review of literature Gastroenterology research 2018 11 4 264 10.14740/gr1062w 30116425 PMC6089587

Cardoso R. Guo F. Heisser T. Hackl M. Ihle P. De Schutter H. Van Damme N. Valerianova Z. Atanasov T. Majek O. Muzik J. Nilbert M. C. Tybjerg A. J. Innos K. Magi M. Malila N. Bouvier A.-M. Bouvier V. Launoy G. Woronoff A.-S. Cariou M. Robaszkiewicz M. Delafosse P. Poncet F. Katalinic A. Walsh P. M Senore C. Rosso S. Vincerzevskiene I. Lemmens V. E P P Elferink M. A G Johannesen T. B. Kørner H. Pfeffer F. Bento M. J. Rodrigues J. Alves da Costa F. Miranda A. Zadnik V. Zagar T. Lopez de Munain Marques A. Marcos-Gragera R. Puigdemont M. Galceran J. Carulla M. Chirlaque M.-D. Ballesta M. Sundquist K. Sundquist J. Weber M. Jordan A. Herrmann C. Mousavi M. Ryzhov A. Hoffmeister M. Brenner H. Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study The Lancet Oncology 2021 22 7 1002 1013 10.1016/S1470-2045(21)00199-6 34048685

Bryan S. Masoud H. Weir H. K. Woods R. Lockwood G. Smith L. Brierley J. Gospodarowicz M. Badets N. Cancer in Canada: Stage at diagnosis Health reports 2018 29 12 21 26 30566206

Mangone L. Mancuso P. Bisceglia I. Braghiroli B. Ferrari F. Vicentini M. Giorgi Rossi P. Five-year relative survival by stage of breast and colon cancers in Italy Tumori Journal 2021 107 4 318 324 10.1177/0300891620964565 33153410

Winawer S. J. Zauber A. G. Ho M. N. O'Brien M. J. Gottlieb L. S. Sternberg S. S. Waye J. D. Schapiro M. Bond J. H. Panish J. F. Ackroyd F. Shike M. Kurtz R. C. Hornsby-Lewis L. Gerdes H. Stewart E. T. Prevention of colorectal cancer by colonoscopic polypectomy New England Journal of Medicine 1993 329 27 1977 1981 10.1056/NEJM199312303292701 8247072

Joachim C. Macni J. Drame M. Pomier A. Escarmant P. Veronique-Baudin J. Vinh-Hung V. Overall survival of colorectal cancer by stage at diagnosis: Data from the Martinique Cancer Registry Medicine 2019 98 35 e16941 10.1097/MD.0000000000016941 31464932 PMC6736397

Májek O. Gondos A. Jansen L. Emrich K. Holleczek B. Katalinic A. Nennecke A. Eberle A. Brenner H. Survival from colorectal cancer in Germany in the early 21st century British journal of cancer 2012 106 11 1875 1880 10.1038/bjc.2012.189 22555397 PMC3364110

Miller K. D. Nogueira L. Devasia T. Mariotto A. B. Yabroff K. R. Jemal A. Kramer J. Siegel R. L. Cancer treatment and survivorship statistics, 2022 CA: a cancer journal for clinicians 2022 72 5 409 436 10.3322/caac.21731 35736631

Van den Eynde M. Mlecnik B. Bindea G. Fredriksen T. Church S. E. Lafontaine L. Haicheur N. Marliot F. Angelova M. Vasaturo A. Bruni D. Jouret-Mourin A. Baldin P. Huyghe N. Haustermans K. Debucquoy A. Van Cutsem E. Gigot J.-F. Hubert C. Kartheuser A. Remue C. Leonard D. Valge-Archer V. Pages F. Machiels J.-P. Galon J. The link between the multiverse of immune microenvironments in metastases and the survival of colorectal cancer patients Cancer cell 2018 34 6 1012 1026 10.1016/j.ccell.2018.11.003 30537506

Steeg P. S. Targeting metastasis Nature reviews cancer 2016 16 4 201 218 10.1038/nrc.2016.25 27009393 PMC7055530

Cardoso R. Guo F. Heisser T. De Schutter H. Van Damme N. Nilbert M. C. Christensen J. Bouvier A.-M. Bouvier V. Launoy G. Woronoff A.-S. Cariou M. Robaszkiewicz M. Delafosse P. Poncet F. Walsh P. M. Senore C. Rosso S. Lemmens V. E. P. P. Elferink M. A. G. Tomsic S. Zagar T. Marques A. L. d. M. Marcos-Gragera R. Puigdemont M. Galceran J. Carulla M. Sanchez-Gil A. Chirlaque M.-D. Hoffmeister M. Brenner H. Overall and stage-specific survival of patients with screen-detected colorectal cancer in European countries: A population-based study in 9 countries The Lancet Regional Health-Europe 2022 21 100458 10.1016/j.lanepe.2022.100458 35832063 PMC9272368

Benson , A. B. ; Venook , A. P. ; Adam , M. ; Chang , G. J. ; Chen , Y.-J. ; Ciombor , K. K. ; Cohen , S. ; Cooper , H. S. ; Deming , D. ; Garrido-Laguna , I. ; Colon Cancer, Version 2.2025, NCCN Clinical Practice Guidelines in Oncology . In National Comprehensive Cancer Network , 2025 . 10.6004/jnccn.2021.0012 33724754

Wolpin B. M. Mayer R. J. Systemic treatment of colorectal cancer Gastroenterology 2008 134 5 1296 1310 10.1053/j.gastro.2008.02.098 18471507 PMC2528832

Zheng J. Feng X. Hu W. Wang J. Li Y. Systematic review and meta-analysis of preoperative chemoradiotherapy with or without oxaliplatin in locally advanced rectal cancer Medicine 2017 96 13 e6487 10.1097/MD.0000000000006487 28353591 PMC5380275

Davies , J. M. ; Goldberg , R. M. Treatment of metastatic colorectal cancer . In Seminars in Oncology , Elsevier : 2011 ; Vol. 38 , pp 552 – 560 . 21810514 10.1053/j.seminoncol.2011.05.009

Chibaudel B. Tournigand C. Bonnetain F. Richa H. Benetkiewicz M. André T. de Gramont A. Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review Therapeutic advances in medical oncology 2015 7 3 153 169 10.1177/1758834015572343 26673925 PMC4406914

Bukowski K. Kciuk M. Kontek R. Mechanisms of Multidrug Resistance in Cancer Chemotherapy Int J Mol Sci 2020 21 9 3233 10.3390/ijms21093233 32370233 PMC7247559

Scheithauer W. Rosen H. Kornek G.-V. Sebesta C. Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer British Medical Journal 1993 306 6880 752 755 10.1136/bmj.306.6880.752 7683942 PMC1677246

Goldberg R. M. Sargent D. J. Morton R. F. Fuchs C. S. Ramanathan R. K. Williamson S. K. Findlay B. P. Pitot H. C. Alberts S. R. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer Journal of Clinical Oncology 2004 22 1 23 30 10.1200/JCO.2004.09.046 14665611

Douillard J.-Y. Irinotecan and high-dose fluorouracil/leucovorin for metastatic colorectal cancer Oncology (Williston Park, NY) 2000 14 51 55 11200150

Vamvakas L. Athanasiadis A. Karampeazis A. Kakolyris S. Polyzos A. Kouroussis C. Ziras N. Kalbakis K. Georgoulias V. Souglakos J. Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG) Critical reviews in oncology/hematology 2010 76 1 61 70 10.1016/j.critrevonc.2009.08.003 19729318

Porschen R. Arkenau H. T. Kubicka S. Greil R. Seufferlein T. Freier W. Kretzschmar A. Graeven U. Grothey A. Hinke A. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group J Clin Oncol 2007 25 27 4217 4223 10.1200/JCO.2006.09.2684 17548840

Zhang S. Yang Y. Weng W. Guo B. Cai G. Ma Y. Cai S. Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer Journal of Experimental & Clinical Cancer Research 2019 38 14 10.1186/s13046-018-0985-y 30630498 PMC6327560

Nosho K. Sukawa Y. Adachi Y. Ito M. Mitsuhashi K. Kurihara H. Kanno S. Yamamoto I. Ishigami K. Igarashi H. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer World J Gastroenterol 2016 22 2 557 566 10.3748/wjg.v22.i2.557 26811607 PMC4716059

Mima K. Nishihara R. Qian Z. R. Cao Y. Sukawa Y. Nowak J. A Yang J. Dou R. Masugi Y. Song M. Kostic A. D Giannakis M. Bullman S. Milner D. A Baba H. Giovannucci E. L Garraway L. A Freeman G. J Dranoff G. Garrett W. S Huttenhower C. Meyerson M. Meyerhardt J. A Chan A. T Fuchs C. S Ogino S. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis Gut 2016 65 12 1973 1980 10.1136/gutjnl-2015-310101 26311717 PMC4769120

Bullman S. Pedamallu C. S. Sicinska E. Clancy T. E. Zhang X. Cai D. Neuberg D. Huang K. Guevara F. Nelson T. Chipashvili O. Hagan T. Walker M. Ramachandran A. Diosdado B. Serna G. Mulet N. Landolfi S. Ramon y Cajal S. Fasani R. Aguirre A. J. Ng K. Elez E. Ogino S. Tabernero J. Fuchs C. S. Hahn W. C. Nuciforo P. Meyerson M. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer Science 2017 358 6369 1443 1448 10.1126/science.aal5240 29170280 PMC5823247

Grothey A. Sobrero A. F. Shields A. F. Yoshino T. Paul J. Taieb J. Souglakos J. Shi Q. Kerr R. Labianca R. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer New England Journal of Medicine 2018 378 13 1177 1188 10.1056/NEJMoa1713709 29590544 PMC6426127

Chua W. Goldstein D. Lee C. K. Dhillon H. Michael M. Mitchell P. Clarke S. J. Iacopetta B. Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer Br. J. Cancer 2009 101 6 998 1004 10.1038/sj.bjc.6605239 19672255 PMC2743363

Han S.-W. Lee H.-J. Bae J. M. Cho N.-Y. Lee K.-H. Kim T.-Y. Oh D.-Y. Im S.-A. Bang Y.-J. Jeong S.-Y. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer Int. J. Cancer 2013 132 9 2209 2216 10.1002/ijc.27888 23034738

Lyskjær I. Kronborg C. S. Rasmussen M. H. Sørensen B. S. Demuth C. Rosenkilde M. Johansen A. F. B. Knudsen M. Vang S. Krag S. R. P. Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer Scientific Reports 2019 9 1 11542 10.1038/s41598-019-47708-1 31395942 PMC6687711

Zaniboni A. Aitini E. Barni S. Ferrari D. Cascinu S. Catalano V. Valmadre G. Ferrara D. Veltri E. Codignola C. FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study Cancer Chemotherapy and Pharmacology 2012 69 6 1641 1645 10.1007/s00280-012-1875-1 22576338

Aparicio J. Fernández-Martos C. Vicent J. M. Maestu I. Llorca C. Busquier I. Campos J. M. Pérez-Enguix D. Balcells M. FOLFOX Alternated with FOLFIRI as First-Line Chemotherapy for Metastatic Colorectal Cancer Clinical Colorectal Cancer 2005 5 4 263 267 10.3816/CCC.2005.n.037 16356303

Falcone A. Ricci S. Brunetti I. Pfanner E. Allegrini G. Barbara C. Crinò L. Benedetti G. Evangelista W. Fanchini L. Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest Journal of Clinical Oncology 2007 25 13 1670 1676 10.1200/JCO.2006.09.0928 17470860

Falcone A. Masi G. Brunetti I. Benedetti G. Bertetto O. Picone V. Chiara S. Merlano M. Vitello S. Ricci S. The triplet combination of irinotecan, oxaliplatin and 5FU/LV (FOLFOXIRI) vs the doublet of irinotecan and 5FU/LV (FOLFIRI) as first-line treatment of metastatic colorectal cancer (MCRC): Results of a randomized phase III trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.) Journal of Clinical Oncology 2006 24 3513 3513 10.1200/jco.2006.24.18_suppl.3513

Nagourney R. A. Evans S. Tran P. H. Nagourney A. J. Sugarbaker P. H. Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatin European Journal of Surgical Oncology 2021 47 4 738 742 10.1016/j.ejso.2020.09.017 33004272

Degirmencioglu S. Tanrıverdi O. Demiray A. G. Senol H. Dogu G. G. Yaren A. Retrospective comparison of efficacy and safety of CAPOX and FOLFOX regimens as adjuvant treatment in patients with stage III colon cancer Journal of International Medical Research 2019 47 6 2507 2515 10.1177/0300060519848258 31099282 PMC6567718

Colucci G. Gebbia V. Paoletti G. Giuliani F. Caruso M. Gebbia N. Cartenì G. Agostara B. Pezzella G. Manzione L. Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell’Italia Meridionale Journal of Clinical Oncology 2005 23 22 4866 4875 10.1200/JCO.2005.07.113 15939922

Best L. Simmonds P. Baughan C. Buchanan R. Davis C. Fentiman I. George S. Gosney M. Northover J. Williams C. Palliative chemotherapy for advanced or metastatic colorectal cancer Cochrane Database of Systematic Reviews 2000 2000 CD001545 10.1002/14651858.CD001545 10796809 PMC7025779

Longley D. B. Harkin D. P. Johnston P. G. 5-Fluorouracil: mechanisms of action and clinical strategies Nature Reviews Cancer 2003 3 5 330 338 10.1038/nrc1074 12724731

Miura K. Kinouchi M. Ishida K. Fujibuchi W. Naitoh T. Ogawa H. Ando T. Yazaki N. Watanabe K. Haneda S. 5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs Cancers 2010 2 3 1717 1730 10.3390/cancers2031717 24281184 PMC3837334

Moran R. G. Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthase Cancer 1989 63 S6 1008 1012 10.1002/1097-0142(19890315)63:6+<1008::AID-CNCR2820631303>3.0.CO;2-Z 2521810

Rustum Y. M. Biochemical Rationale for the 5-Fluorouracil Leucovorin Combination and Update of Clinical Experience Journal of Chemotherapy 1990 2 sup1 5 11 10.1080/1120009X.1990.11738998 2195138

Thirion P. Michiels S. Pignon J. Buyse M. Braud A. Carlson R. O’Connell M. Sargent P. Piedbois P. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2004 22 18 3766 3775 10.1200/JCO.2004.03.104 15365073

Sobrero , A. ; Guglielmi , A. ; Grossi , F. ; Puglisi , F. ; Aschele , C. Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy . In Seminars in Oncology , 2000 ; WB Saunders Ltd : Vol. 27 , pp 72 – 77 . 11049035

Daher G. C. Harris B. E. Diasio R. B. Metabolism of pyrimidine analogues and their nucleosides Pharmacology & therapeutics 1990 48 2 189 222 10.1016/0163-7258(90)90080-L 2293239

Mathijssen R. H. van Alphen R. J. Verweij J. Loos W. J. Nooter K. Stoter G. Sparreboom A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11) Clinical cancer research 2001 7 8 2182 2194 11489791

Garcia-Carbonero R. Supko J. G. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins Clinical cancer research 2002 8 3 641 661 11895891

Ferrara N. Gerber H.-P. LeCouter J. The biology of VEGF and its receptors Nature medicine 2003 9 6 669 676 10.1038/nm0603-669 12778165

Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy The oncologist 2002 7 S4 2 8 10.1634/theoncologist.7-suppl_4-2 12202782

Lebwohl D. Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update Eur. J. Cancer 1998 34 10 1522 1534 10.1016/S0959-8049(98)00224-X 9893623

Ozols R. Cisplatin dose intensity Seminars in Oncology 1989 16 22 30 2669135

Barabas K. Milner R. Lurie D. Adin C. Cisplatin: a review of toxicities and therapeutic applications Veterinary and comparative oncology 2008 6 1 1 18 10.1111/j.1476-5829.2007.00142.x 19178659

Galanski M. Recent developments in the field of anticancer platinum complexes Recent patents on anti-cancer drug discovery 2006 1 2 285 295 10.2174/157489206777442287 18221042

Ree A. H. Hamre H. Kersten C. Hofsli E. Guren M. G. Sorbye H. Johansen C. Negård A. Flatmark K. Meltzer S. Repeat sequential oxaliplatin-based chemotherapy (FLOX) and nivolumab versus FLOX alone as first-line treatment of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): Initial results from the randomized METIMMOX study Journal of Clinical Oncology 2021 39 3556 3556 10.1200/JCO.2021.39.15_suppl.3556

van der Vijgh W. J. Clinical pharmacokinetics of carboplatin Clinical pharmacokinetics 1991 21 4 242 261 10.2165/00003088-199121040-00002 1760899

Dilruba S. Kalayda G. V. Platinum-based drugs: past, present and future Cancer chemotherapy and pharmacology 2016 77 1103 1124 10.1007/s00280-016-2976-z 26886018

Extra J.-M. Marty M. Brienza S. Misset J.-L. Pharmacokinetics and safety profile of oxaliplatin Seminars in oncology 1998 25 13 22 9609104

Shimada M. Itamochi H. Kigawa J. Nedaplatin: a cisplatin derivative in cancer chemotherapy Cancer management and research 2013 67 76 10.2147/CMAR.S35785 23696716 PMC3658440

Yonezawa A. Masuda S. Yokoo S. Katsura T. Inui K. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1–3 and multidrug and toxin extrusion family) J Pharmacol Exp Ther 2006 319 2 879 886 10.1124/jpet.106.110346 16914559

University, G. M. Clinical Study of Radiotherapy Combined With Nedaplatin Contrast and Cisplatin for the Treatment of Locally Advanced Head and Neck Squamous Carcinoma . In https://ClinicalTrials.gov/show/ NCT05039606 ; US National Instituetes of Health , 2021 .

Nedaplatin (Jiebaishu) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma ; Jiangsu Simcere Pharmaceutical Co. , 2013 ; https://ClinicalTrials.gov/show/NCT02088515 .

Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma ; Affiliated Cancer Hospital & Institute of Guangzhou Medical University , 2020 ; https://ClinicalTrials.gov/show/NCT04437329 .

McKeage M. J. Lobaplatin: a new antitumour platinum drug Expert opinion on investigational drugs 2001 10 1 119 128 10.1517/13543784.10.1.119 11116285

Hospital, Z. Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial ; Zhujiang Hospital , 2022 , https://ClinicalTrials.gov/show/NCT05701436 .

Clinical Analysis of HIPEC for T4 Colorectal Cancer After Surgery ; Sixth Affiliated Hospital, Sun Yat-Sen University , 2017 ; https://ClinicalTrials.gov/show/NCT03221608 .

Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy ; Wuhan Union Hospital , 2021 ; https://ClinicalTrials.gov/show/NCT04808466 .

Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy ; Wuhan Union Hospital , 2022 ; https://ClinicalTrials.gov/show/NCT04845490 .

Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer ; Zhongnan Hospital ,. 2017 ; https://ClinicalTrials.gov/show/NCT03371693 .

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer ; Chinese Academy of Medical Sciences ; 2020 ; https://ClinicalTrials.gov/show/NCT05546255 .

Lee K. H. Hyun M. S. Kim H.-K. Jin H. M. Yang J. Song H. S. Do Y. R. Ryoo H. M. Chung J. S. Zang D. Y. Lim H.-Y. Jin J. Y. Yim C. Y. Park H. S. Kim J. S. Sohn C. H. Lee S. N. Randomized, multicenter, phase III trial of heptaplatin 1-h infusion and 5-fluorouracil combination chemotherapy comparing with cisplatin and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer Cancer Research and Treatment 2009 41 12 18 10.4143/crt.2009.41.1.12 19688066 PMC2699097

Jung K. Lee D. Kim H. Han J. Jang I. Park Y. Joo S. Ro J. Lee J. Phase I clinical study of heptaplatin (H) and paclitaxel (P) in previously treated patients with advanced solid tumor Journal of Clinical Oncology 2004 22 2122 2122 10.1200/jco.2004.22.90140.2122

Kang J.-H. Kuh H.-J. Lee J.-H. Shin J.-Y. Lee K.-S. Jung J.-A. Chang D.-Y. Phase I/II clinical and pharmacokinetic trial of heptaplatin and 5-FU combination treatment in advanced head and neck cancer Journal of Clinical Oncology 2005 23 5550 5550 10.1200/jco.2005.23.16_suppl.5550

Eckardt J. R. Bentsion D. L. Lipatov O. N. Polyakov I. S. MacKintosh F. R. Karlin D. A. Baker G. S. Breitz H. B. Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer Journal of clinical oncology 2009 27 12 2046 2051 10.1200/JCO.2008.19.3235 19289620

Gelmon K.A. Stewart D. Chi K.N. Chia S. Cripps C. Huan S. Janke S. Ayers D. Fry D. Shabbits J.A. Walsh W. McIntosh L. Seymour L.K. A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131 Annals of oncology 2004 15 7 1115 1122 10.1093/annonc/mdh278 15205207

Pharmaceuticals, P. Cardiac Safety Assessment Study of Picoplatin in Solid Tumors . https://ClinicalTrials.gov/show/NCT00710697 , 2008 . (accessed.

Pharmaceuticals, P. Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer ; Poniard Pharmaceuticals , 2005 ; https://ClinicalTrials.gov/show/NCT00116610 .

A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors ; Poniard Pharmaceuticals , 2007 ; https://ClinicalTrials.gov/show/NCT00465725 .

A Study of Picoplatin and Docetaxel in Subjects With Prostate Cancer ; Poniard Pharmaceuticals , 2006 ; https://ClinicalTrials.gov/show/NCT00448734 .

Study of Picoplatin Efficacy After Relapse ; Poniard Pharmaceuticals , 2007 ; https://ClinicalTrials.gov/show/NCT00465491 .

Pharmaceuticals, P. A Study of Picoplatin in Colorectal Cancer ; Poniard Pharmaceuticals , 2006 ; https://ClinicalTrials.gov/show/NCT00478946 .

ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma ; Memorial Sloan Kettering Cancer Center , 2000 ; https://ClinicalTrials.gov/show/NCT00016172 .

ZD0473 in Treating Patients With Progressive or Relapsed Non-Small Lung Cancer ; Jonsson Comprehensive Cancer Center , 2013 ; https://ClinicalTrials.gov/show/NCT00021008 .

Rosenberg B. Vancamp L. Krigas T. Inhibition of Cell Division in Escherichia Coli by Electrolysis Products from a Platinum Electrode Nature 1965 205 698 699 10.1038/205698a0 14287410

Rosenberg B. Vancamp L. Trosko J. E. Mansour V. H. Platinum compounds: a new class of potent antitumour agents nature 1969 222 5191 385 386 10.1038/222385a0 5782119

Giaccone G. Clinical perspectives on platinum resistance Drugs 2000 59 4 9 17 10.2165/00003495-200059004-00002 10864226

Brayfield A. Martindale: The Complete Drug Reference 38th edition Pharmaeutical Press 2014 1 719 724

Wagstaff A. J. Ward A. Benfield P. Heel R. C. Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer Drugs 1989 37 2 162 190 10.2165/00003495-198937020-00005 2649354

Yarbro C. H. Carboplatin: a clinical review Semin Oncol Nurs 1989 5 63 69 10.1016/0749-2081(89)90083-1 2657932

Lokich J. Anderson N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature Annals of oncology 1998 9 1 13 21 10.1023/A:1008215213739 9541678

du Bois A. Lück H.-J. Meier W. Adams H.-P. Möbus V. Costa S. Bauknecht T. Richter B. Warm M. Schröder W. A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer JNCI: Journal of the National Cancer Institute 2003 95 17 1320 1329 10.1093/jnci/djg036 12953086

Schuette W. H. Groschel A. Sebastian M. Andreas S. Muller T. Schneller F. Guetz S. Eschbach C. Bohnet S. Leschinger M. I. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer Clin Lung Cancer 2013 14 3 215 223 10.1016/j.cllc.2012.10.001 23332288

Horwich A. Sleijfer D. T. Fossa S. D. Kaye S. B. Oliver R. T. Cullen M. H. Mead G. M. de Wit R. de Mulder P. H. Dearnaley D. P. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial J Clin Oncol 1997 15 5 1844 1852 10.1200/JCO.1997.15.5.1844 9164194

Rosvig L. H. Langkjer S. T. Knoop A. Jensen A. B. Palliative treatment with carboplatin as late line therapy to patients with metastatic breast cancer Acta Oncol 2018 57 1 156 159 10.1080/0284186X.2017.1407495 29202627

Sanborn R. E. Cisplatin versus carboplatin in NSCLC: is there one ″best″ answer? Curr Treat Options Oncol 2008 9 4–6 326 342 10.1007/s11864-009-0085-5 19225891

Tassinari D. Fochessati F. Arcangeli V. Panzini I. Ravaioli A. Sartori S. Carboplatin and gemcitabine in stage IV non small cell lung cancer: beyond cisplatin in palliative chemotherapy Lung Cancer 2003 39 1 107 108 10.1016/S0169-5002(02)00386-0 12499103

Balayssac D. Ferrier J. Pereira B. Gillet B. Petorin C. Vein J. Libert F. Eschalier A. Pezet D. Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet-NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial BMJ Open 2015 5 4 e007479 10.1136/bmjopen-2014-007479 PMC4390686 25833669

Schoch S. Gajewski S. Rothfuß J. Hartwig A. Köberle B. Comparative study of the mode of action of clinically approved platinum-based chemotherapeutics International journal of molecular sciences 2020 21 18 6928 10.3390/ijms21186928 32967255 PMC7555145

Seetharam R. Sood A. Goel S. Oxaliplatin: pre-clinical perspectives on the mechanisms of action, response and resistance ecancer 2009 3 153 10.3332/ecancer.2009.153 PMC3224005 22276017

Tenzer S. Docter D. Kuharev J. Musyanovych A. Fetz V. Hecht R. Schlenk F. Fischer D. Kiouptsi K. Reinhardt C. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology Nat Nanotechnol 2013 8 10 772 781 10.1038/nnano.2013.181 24056901

Yokoo S. Masuda S. Yonezawa A. Terada T. Katsura T. Inui K. Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer Drug Metab. Dispos. 2008 36 11 2299 2306 10.1124/dmd.108.023168 18710896

Zhang S. Lovejoy K. S. Shima J. E. Lagpacan L. L. Shu Y. Lapuk A. Chen Y. Komori T. Gray J. W. Chen X. Organic cation transporters are determinants of oxaliplatin cytotoxicity Cancer Res. 2006 66 17 8847 8857 10.1158/0008-5472.CAN-06-0769 16951202 PMC2775093

Rixe O. Ortuzar W. Alvarez M. Parker R. Reed E. Paull K. Fojo T. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute’s Anticancer Drug Screen panel Biochemical pharmacology 1996 52 12 1855 1865 10.1016/S0006-2952(97)81490-6 8951344

Schmidt W. Chaney S. G. Role of carrier ligand in platinum resistance of human carcinoma cell lines Cancer Research 1993 53 4 799 805 8428361

Voland C. Bord A. Peleraux A. Penarier G. Carriere D. Galiegue S. Cvitkovic E. Jbilo O. Casellas P. Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells Molecular cancer therapeutics 2006 5 9 2149 2157 10.1158/1535-7163.MCT-05-0212 16985047

de Gramont A. Figer A. Seymour M. Homerin M. Hmissi A. Cassidy J. Boni C. Cortes-Funes H. Cervantes A. Freyer G. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 2000 18 16 2938 2947 10.1200/JCO.2000.18.16.2938 10944126

Wheate N. J. Walker S. Craig G. E. Oun R. The status of platinum anticancer drugs in the clinic and in clinical trials Dalton transactions 2010 39 35 8113 8127 10.1039/c0dt00292e 20593091

O’Dowd P. D. Sutcliffe D. F. Griffith D. M. Oxaliplatin and its derivatives - An overview Coord. Chem. Rev. 2023 497 215439 10.1016/j.ccr.2023.215439

Holford J. Raynaud F. Murrer B. Grimaldi K. Hartley J. Abrams M. Kelland L. Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis -[Amminedichloro (2-methylpyridine)] platinum (II)­(AMD473) Anti-Cancer Drug Design 1998 13 1 1 18 9474239

Sharp S. O’Neill C. Rogers P. Boxall F. Kelland L. Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin Eur. J. Cancer 2002 38 17 2309 2315 10.1016/S0959-8049(02)00244-7 12441268

Holford J. Sharp S. Murrer B. Abrams M. Kelland L. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473 British journal of cancer 1998 77 3 366 373 10.1038/bjc.1998.59 9472630 PMC2151285

Hall M. D. Okabe M. Shen D. W. Liang X. J. Gottesman M. M. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy Annu Rev Pharmacol Toxicol 2008 48 495 535 10.1146/annurev.pharmtox.48.080907.180426 17937596

Loh S. Y. Mistry P. Kelland L. R. Abel G. Harrap K. R. Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes Br. J. Cancer 1992 66 6 1109 1115 10.1038/bjc.1992.419 1457352 PMC1978040

Liu J. J. Lu J. McKeage M. J. Membrane transporters as determinants of the pharmacology of platinum anticancer drugs Curr Cancer Drug Targets 2012 12 8 962 986 10.2174/156800912803251199 22794121

Ishida S. Lee J. Thiele D. J. Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals Proc Natl Acad Sci U S A 2002 99 22 14298 14302 10.1073/pnas.162491399 12370430 PMC137878

Larson C. A. Blair B. G. Safaei R. Howell S. B. The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs Mol. Pharmacol. 2009 75 2 324 330 10.1124/mol.108.052381 18996970 PMC2684896

Holzer A. K. Manorek G. H. Howell S. B. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin Mol. Pharmacol. 2006 70 4 1390 1394 10.1124/mol.106.022624 16847145

Lin X. Okuda T. Holzer A. Howell S. B. The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae Mol. Pharmacol. 2002 62 5 1154 1159 10.1124/mol.62.5.1154 12391279

Song I. S. Savaraj N. Siddik Z. H. Liu P. Wei Y. Wu C. J. Kuo M. T. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells Mol Cancer Ther 2004 3 12 1543 1549 10.1158/1535-7163.1543.3.12 15634647

Lee Y. Y. Choi C. H. Do I. G. Song S. Y. Lee W. Park H. S. Song T. J. Kim M. K. Kim T. J. Lee J. W. Prognostic value of the copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum-based chemotherapy Gynecol Oncol 2011 122 2 361 365 10.1016/j.ygyno.2011.04.025 21570711

Howell S. B. Safaei R. CTR1 as a determinant of platinum drug transport Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy: Molecular Mechanisms and Clinical Applications 2009 89 94 10.1007/978-1-60327-459-3_12

Ohrvik H. Nose Y. Wood L. K. Kim B. E. Gleber S. C. Ralle M. Thiele D. J. Ctr2 regulates biogenesis of a cleaved form of mammalian Ctr1 metal transporter lacking the copper- and cisplatin-binding ecto-domain Proc Natl Acad Sci U S A 2013 110 46 E4279 10.1073/pnas.1311749110 24167251 PMC3831961

Blair B. G. Larson C. A. Adams P. L. Abada P. B. Safaei R. Howell S. B. Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells Mol. Pharmacol. 2010 77 6 912 921 10.1124/mol.109.062836 20194531 PMC2879916

Samimi G. Varki N. M. Wilczynski S. Safaei R. Alberts D. S. Howell S. B. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients Clin. Cancer Res. 2003 9 5853 5859 14676106

Samimi G. Safaei R. Katano K. Holzer A. K. Rochdi M. Tomioka M. Goodman M. Howell S. B. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells Clin. Cancer Res. 2004 10 14 4661 4669 10.1158/1078-0432.CCR-04-0137 15269138

Jentsch T. J. VRACs and other ion channels and transporters in the regulation of cell volume and beyond Nat Rev Mol Cell Biol 2016 17 5 293 307 10.1038/nrm.2016.29 27033257

Friard J. Rubera I. Duranton C. VRAC: unravelling the complexity of LRRC8 subunit regulation by oxidation J Physiol 2017 595 21 6593 6594 10.1113/JP275188 28940558 PMC5663822

Planells-Cases R. Lutter D. Guyader C. Gerhards N. M Ullrich F. Elger D. A Kucukosmanoglu A. Xu G. Voss F. K Reincke S M. Stauber T. Blomen V. A Vis D. J Wessels L. F Brummelkamp T. R Borst P. Rottenberg S. Jentsch T. J Subunit composition of VRAC channels determines substrate specificity and cellular resistance to P t-based anti-cancer drugs The EMBO journal 2015 34 24 2993 3008 10.15252/embj.201592409 26530471 PMC4687416

Pedersen S. F. Klausen T. K. Nilius B. The identification of a volume-regulated anion channel: an amazing Odyssey Acta Physiol (Oxf) 2015 213 4 868 881 10.1111/apha.12450 25565132

Roberts J. J. Thomson A. J. The mechanism of action of antitumor platinum compounds Prog. Nucleic Acid Res. Mol. Biol. 1979 22 71 133 10.1016/S0079-6603(08)60799-0 392602

Todd R. C. Lippard S. J. Inhibition of transcription by platinum antitumor compounds Metallomics 2009 1 4 280 291 10.1039/b907567d 20046924 PMC2752884

Ruthenium and Other Non-Platinum Metal Complexes in Cancer Chemotherapy ; Clinical Biochemistry and Medicine ; Progress in Clinical Biochemistry and Medicine ; Springer-Verlag , 1989 .

Kartalou M. Essigmann J. M. Recognition of cisplatin adducts by cellular proteins Mutat. Res. 2001 478 1–2 1 21 10.1016/S0027-5107(01)00142-7 11406166

Huang J. C. Zamble D. B. Reardon J. T. Lippard S. J. Sancar A. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease Proc Natl Acad Sci U S A 1994 91 22 10394 10398 10.1073/pnas.91.22.10394 7937961 PMC45026

Cocetta V. Ragazzi E. Montopoli M. Mitochondrial Involvement in Cisplatin Resistance Int J Mol Sci 2019 20 14 3384 10.3390/ijms20143384 31295873 PMC6678541

Penta J. S. Johnson F. M. Wachsman J. T. Copeland W. C. Mitochondrial DNA in human malignancy Mutat. Res. 2001 488 2 119 133 10.1016/S1383-5742(01)00053-9 11344040

Clayton D. A. Doda J. N. Friedberg E. C. The absence of a pyrimidine dimer repair mechanism in mammalian mitochondria Proceedings of the National Academy of Sciences 1974 71 7 2777 2781 10.1073/pnas.71.7.2777 PMC388554 4212385

LeDoux S. P. Wilson G. L. Beecham E. J. Stevnsner T. Wassermann K. Bohr V. A. Repair of mitochondrial DNA after various types of DNA damage in Chinese hamster ovary cells Carcinogenesis 1992 13 11 1967 1973 10.1093/carcin/13.11.1967 1423864

Matsuyama S. Reed J. Mitochondria-dependent apoptosis and cellular pH regulation Cell Death & Differentiation 2000 7 12 1155 1165 10.1038/sj.cdd.4400779 11175252

Sutton E. C. DeRose V. J. Early nucleolar responses differentiate mechanisms of cell death induced by oxaliplatin and cisplatin J. Biol. Chem. 2021 296 100633 10.1016/j.jbc.2021.100633 33819479 PMC8131322

Bruno P. M. Liu Y. Park G. Y. Murai J. Koch C. E. Eisen T. J. Pritchard J. R. Pommier Y. Lippard S. J. Hemann M. T. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress Nature medicine 2017 23 4 461 471 10.1038/nm.4291 PMC5520548 28263311

McDevitt C. E. Guerrero A. S. Smith H. M. DeRose V. J. Influence of Ring Modifications on Nucleolar Stress Caused by Oxaliplatin-Like Compounds ChemBioChem 2022 23 14 e202200130 10.1002/cbic.202200130 35475312

Sies H. Oxidative eustress: On constant alert for redox homeostasis Redox Biology 2021 41 101867 10.1016/j.redox.2021.101867 33657525 PMC7930632

Sies H. On the history of oxidative stress: Concept and some aspects of current development Current Opinion in Toxicology 2018 7 122 126 10.1016/j.cotox.2018.01.002

Vučetić M. Cormerais Y. Parks S. K. Pouysségur J. The central role of amino acids in cancer redox homeostasis: vulnerability points of the cancer redox code Frontiers in oncology 2017 7 319 10.3389/fonc.2017.00319 29312889 PMC5742588

Cairns R. A. Harris I. S. Mak T. W. Regulation of cancer cell metabolism Nature Reviews Cancer 2011 11 2 85 95 10.1038/nrc2981 21258394

Potęga A. Glutathione-Mediated Conjugation of Anticancer Drugs: An Overview of Reaction Mechanisms and Biological Significance for Drug Detoxification and Bioactivation Molecules 2022 27 16 5252 10.3390/molecules27165252 36014491 PMC9412641

Galluzzi L. Vitale I. Warren S. Adjemian S. Agostinis P. Martinez A. B. Chan T. A. Coukos G. Demaria S. Deutsch E. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death Journal for ImmunoTherapy of Cancer 2020 8 1 e000337 10.1136/jitc-2019-000337 32209603 PMC7064135

Casares N. Pequignot M. O. Tesniere A. Ghiringhelli F. o. Roux S. p. Chaput N. Schmitt E. Hamai A. Hervas-Stubbs S. Obeid M. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death Journal of Experimental Medicine 2005 202 12 1691 1701 10.1084/jem.20050915 16365148 PMC2212968

Wang J. Li J. Wu Y. Xu X. Qian X. Lei Y. Liu H. Zhang Z. Li Y. ROS-Responsive Nanocomplex of aPD-L1 and Cabazitaxel Improves Intratumor Delivery and Potentiates Radiation-Mediated Antitumor Immunity Nano Letters 2022 22 20 8312 8320 10.1021/acs.nanolett.2c03227 36226914

Nayagom B. Amara I. Habiballah M. Amrouche F. Beaune P. de Waziers I. Immunogenic cell death in a combined synergic gene- and immune-therapy against cancer OncoImmunology 2019 8 12 e1667743 10.1080/2162402X.2019.1667743 31741770 PMC6844315

Galluzzi L. Yamazaki T. Kroemer G. Linking cellular stress responses to systemic homeostasis Nature Reviews Molecular Cell Biology 2018 19 11 731 745 10.1038/s41580-018-0068-0 30305710

Li C. Zhang Y. Yan S. Zhang G. Wei W. Qi Z. Li B. Alternol triggers immunogenic cell death via reactive oxygen species generation OncoImmunology 2021 10 1 1952539 10.1080/2162402X.2021.1952539 34350063 PMC8296969

Venkateswaran K. Verma A. Bhatt N. A. Shrivastava A. Manda K. Raj G. H. Prasad A. Len C. Parmar S. V. Dwarakanath S. B. Emerging Roles of Calreticulin in Cancer: Implications for Therapy Current Protein & Peptide Science 2018 19 4 344 357 10.2174/1389203718666170111123253 28079009

Fucikova J. Kasikova L. Truxova I. Laco J. Skapa P. Ryska A. Spisek R. Relevance of the chaperone-like protein calreticulin for the biological behavior and clinical outcome of cancer Immunol. Lett. 2018 193 25 34 10.1016/j.imlet.2017.11.006 29175313

Giglio P. Gagliardi M. Bernardini R. Mattei M. Cotella D. Santoro C. Piacentini M. Corazzari M. Ecto-Calreticulin is essential for an efficient immunogenic cell death stimulation in mouse melanoma Genes & Immunity 2019 20 6 509 513 10.1038/s41435-018-0047-7 30282994

Obeid M. Tesniere A. Ghiringhelli F. Fimia G. M. Apetoh L. Perfettini J.-L. Castedo M. Mignot G. Panaretakis T. Casares N. Calreticulin exposure dictates the immunogenicity of cancer cell death Nature Medicine 2007 13 1 54 61 10.1038/nm1523 17187072

Garg A. D. Krysko D. V. Verfaillie T. Kaczmarek A. Ferreira G. B. Marysael T. Rubio N. Firczuk M. Mathieu C. Roebroek A. J. M. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death The EMBO Journal 2012 31 5 1062 1079 10.1038/emboj.2011.497 22252128 PMC3298003

Panaretakis T. Kepp O. Brockmeier U. Tesniere A. Bjorklund A.-C. Chapman D. C. Durchschlag M. Joza N. Pierron G. van Endert P. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death The EMBO Journal 2009 28 5 578 590 10.1038/emboj.2009.1 19165151 PMC2657583

Zhao L. Li D. Zhang Y. Huang Q. Zhang Z. Chen C. Xu C.-F. Chu X. Zhang Y. Yang X. HSP70-Promoter-Driven CRISPR/Cas9 System Activated by Reactive Oxygen Species for Multifaceted Anticancer Immune Response and Potentiated Immunotherapy ACS Nano 2022 16 9 13821 13833 10.1021/acsnano.2c01885 35993350

Xiu Z. Sun T. Yang Y. He Y. Yang S. Xue X. Yang W. Curcumin Enhanced Ionizing Radiation-Induced Immunogenic Cell Death in Glioma Cells through Endoplasmic Reticulum Stress Signaling Pathways Oxidative Medicine and Cellular Longevity 2022 2022 5424411 10.1155/2022/5424411 36238646 PMC9553401

Turubanova V. D. Balalaeva I. V. Mishchenko T. A. Catanzaro E. Alzeibak R. Peskova N. N. Efimova I. Bachert C. Mitroshina E. V. Krysko O. Immunogenic cell death induced by a new photodynamic therapy based on photosens and photodithazine Journal for ImmunoTherapy of Cancer 2019 7 1 350 10.1186/s40425-019-0826-3 31842994 PMC6916435

Turubanova V. D. Mishchenko T. A. Balalaeva I. V. Efimova I. Peskova N. N. Klapshina L. G. Lermontova S. A. Bachert C. Krysko O. Vedunova M. V. Novel porphyrazine-based photodynamic anti-cancer therapy induces immunogenic cell death Scientific Reports 2021 11 1 7205 10.1038/s41598-021-86354-4 33785775 PMC8010109

He C. Sun S. Zhang Y. Xie F. Li S. The role of irreversible electroporation in promoting M1 macrophage polarization via regulating the HMGB1-RAGE-MAPK axis in pancreatic cancer OncoImmunology 2021 10 1 1897295 10.1080/2162402X.2021.1897295 33763295 PMC7954423

Kroemer G. Kepp O. Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients OncoImmunology 2021 10 1 2005859 10.1080/2162402X.2021.2005859 34858731 PMC8632107

Luo Y. Chihara Y. Fujimoto K. Sasahira T. Kuwada M. Fujiwara R. Fujii K. Ohmori H. Kuniyasu H. High mobility group box 1 released from necrotic cells enhances regrowth and metastasis of cancer cells that have survived chemotherapy Eur. J. Cancer 2013 49 3 741 751 10.1016/j.ejca.2012.09.016 23040637

Baracco E. E. Stoll G. Van Endert P. Zitvogel L. Vacchelli E. Kroemer G. Contribution of annexin A1 to anticancer immunosurveillance OncoImmunology 2019 8 11 e1647760 10.1080/2162402X.2019.1647760 32923172 PMC7457921

Baracco , E. E. ; Petrazzuolo , A. ; Kroemer , G. Assessment of annexin A1 release during immunogenic cell death . In Methods in Enzymology ; Galluzzi , L. , Rudqvist , N.-P. Eds.; Academic Press , 2019 ; Vol. 629 , Chapter 5, pp 71 - 79 . 10.1016/bs.mie.2019.06.010 31727257

Arai H. Xiao Y. Loupakis F. Kawanishi N. Wang J. Battaglin F. Soni S. Zhang W. Mancao C. Salhia B. Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer Journal for ImmunoTherapy of Cancer 2020 8 2 e001714 10.1136/jitc-2020-001714 33172883 PMC7656952

Fucikova J. Kepp O. Kasikova L. Petroni G. Yamazaki T. Liu P. Zhao L. Spisek R. Kroemer G. Galluzzi L. Detection of immunogenic cell death and its relevance for cancer therapy Cell Death & Disease 2020 11 11 1013 10.1038/s41419-020-03221-2 33243969 PMC7691519

Kepp O. Bezu L. Yamazaki T. Di Virgilio F. Smyth M. J. Kroemer G. Galluzzi L. ATP and cancer immunosurveillance The EMBO Journal 2021 40 13 e108130 10.15252/embj.2021108130 34121201 PMC8246257

Zhang J. Sun X. Zhao X. Yang C. Shi M. Zhang B. Hu H. Qiao M. Chen D. Zhao X. Combining immune checkpoint blockade with ATP-based immunogenic cell death amplifier for cancer chemo-immunotherapy Acta Pharmaceutica Sinica B 2022 12 9 3694 3709 10.1016/j.apsb.2022.05.008 36176905 PMC9513492

Pan C. Wang Y. Liu Q. Hu Y. Fu J. Xie X. Zhang S. Xi M. Wen J. Phenotypic profiling and prognostic significance of immune infiltrates in esophageal squamous cell carcinoma OncoImmunology 2021 10 1 1883890 10.1080/2162402X.2021.1883890 33628625 PMC7889084

Sprooten , J. ; Vanmeerbeek , I. ; Datsi , A. ; Govaerts , J. ; Borràs , D. M. ; Naulaerts , S. ; Laureano , R. S. ; Calvet , A. ; Kuballa , M. ; Sabel , M. C. A lymph node-to-tumour PDL1 + macrophage circuit antagonizes dendritic cell immunotherapy bioRxiv 2023 , 2023.2003.2014.532534 . 10.1101/2023.03.14.532534

Spisek R. Charalambous A. Mazumder A. Vesole D. H. Jagannath S. Dhodapkar M. V. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications Blood 2007 109 11 4839 4845 10.1182/blood-2006-10-054221 17299090 PMC1885516

Serrano Del Valle A. Beltrán-Visiedo M. de Poo-Rodríguez V. Jiménez-Alduán N. Azaceta G. Díez R. Martínez-Lázaro B. Izquierdo I. Palomera L. Naval J. Ecto-calreticulin expression in multiple myeloma correlates with a failed anti-tumoral immune response and bad prognosis OncoImmunology 2022 11 1 2141973 10.1080/2162402X.2022.2141973 36338146 PMC9629093

Wiernicki B. Maschalidi S. Pinney J. Adjemian S. Vanden Berghe T. Ravichandran K. S. Vandenabeele P. Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity Nature Communications 2022 13 1 3676 10.1038/s41467-022-31218-2 PMC9237053 35760796

Gardai S. J. McPhillips K. A. Frasch S. C. Janssen W. J. Starefeldt A. Murphy-Ullrich J. E. Bratton D. L. Oldenborg P.-A. Michalak M. Henson P. M. Cell-Surface Calreticulin Initiates Clearance of Viable or Apoptotic Cells through < em > trans</em>-Activation of LRP on the Phagocyte Cell 2005 123 2 321 334 10.1016/j.cell.2005.08.032 16239148

Dudek A. M. Garg A. D. Krysko D. V. De Ruysscher D. Agostinis P. Inducers of immunogenic cancer cell death Cytokine & Growth Factor Reviews 2013 24 4 319 333 10.1016/j.cytogfr.2013.01.005 23391812

Krysko D. V. Garg A. D. Kaczmarek A. Krysko O. Agostinis P. Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy Nature Reviews Cancer 2012 12 12 860 875 10.1038/nrc3380 23151605

Wernitznig D. Kiakos K. Del Favero G. Harrer N. Machat H. Osswald A. Jakupec M. A. Wernitznig A. Sommergruber W. Keppler B. K. First-in-class ruthenium anticancer drug (KP1339/IT-139) induces an immunogenic cell death signature in colorectal spheroids in vitro† Metallomics 2019 11 6 1044 1048 10.1039/c9mt00051h 30942231

Tesniere A. Schlemmer F. Boige V. Kepp O. Martins I. Ghiringhelli F. Aymeric L. Michaud M. Apetoh L. Barault L. Immunogenic death of colon cancer cells treated with oxaliplatin Oncogene 2010 29 4 482 491 10.1038/onc.2009.356 19881547

Sen S. Karoscik K. Maier E. Arambula J. F. Immunogenic cell death-inducing metal complexes: From the benchtop to the clinic Current Opinion in Chemical Biology 2023 73 102277 10.1016/j.cbpa.2023.102277 36867977

Chang X. Bian M. Liu L. Yang J. Yang Z. Wang Z. Lu Y. Liu W. Induction of immunogenic cell death by novel platinum-based anticancer agents Pharmacol. Res. 2023 187 106556 10.1016/j.phrs.2022.106556 36403722

Martins I. Kepp O. Schlemmer F. Adjemian S. Tailler M. Shen S. Michaud M. Menger L. Gdoura A. Tajeddine N. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress Oncogene 2011 30 10 1147 1158 10.1038/onc.2010.500 21151176

Dudek-Perić A. M. Ferreira G. B. Muchowicz A. Wouters J. Prada N. Martin S. Kiviluoto S. Winiarska M. Boon L. Mathieu C. Antitumor Immunity Triggered by Melphalan Is Potentiated by Melanoma Cell Surface-Associated Calreticulin Cancer Res. 2015 75 8 1603 1614 10.1158/0008-5472.CAN-14-2089 25762540

Spranger S. Bao R. Gajewski T. F. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity Nature 2015 523 7559 231 235 10.1038/nature14404 25970248

Garg A. D. Maes H. van Vliet A. R. Agostinis P. Targeting the hallmarks of cancer with therapy-induced endoplasmic reticulum (ER) stress Molecular & Cellular Oncology 2015 2 1 e975089 10.4161/23723556.2014.975089 27308392 PMC4905250

Giglio P. Gagliardi M. Tumino N. Antunes F. Smaili S. Cotella D. Santoro C. Bernardini R. Mattei M. Piacentini M. PKR and GCN2 stress kinases promote an ER stress-independent eIF2α phosphorylation responsible for calreticulin exposure in melanoma cells OncoImmunology 2018 7 8 e1466765 10.1080/2162402X.2018.1466765 30221067 PMC6136861

Pfirschke C. Engblom C. Rickelt S. Cortez-Retamozo V. Garris C. Pucci F. Yamazaki T. Poirier-Colame V. Newton A. Redouane Y. Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy Immunity 2016 44 2 343 354 10.1016/j.immuni.2015.11.024 26872698 PMC4758865

Xin M. Lin D. Yan N. Li H. Li J. Huang Z. Oxaliplatin facilitates tumor-infiltration of T cells and natural-killer cells for enhanced tumor immunotherapy in lung cancer model Anti-Cancer Drugs 2022 33 2 117 10.1097/CAD.0000000000001248 34561996 PMC8734624

Sun F. Cui L. Li T. Chen S. Song J. Li D. Oxaliplatin induces immunogenic cells death and enhances therapeutic efficacy of checkpoint inhibitor in a model of murine lung carcinoma Journal of Receptors and Signal Transduction 2019 39 3 208 214 10.1080/10799893.2019.1655050 31441696

Zhu H. Shan Y. Ge K. Lu J. Kong W. Jia C. Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy Cellular Oncology 2020 43 6 1203 1214 10.1007/s13402-020-00552-2 32797385 PMC12990673

Wang W. Wu L. Zhang J. Wu H. Han E. Guo Q. Chemoimmunotherapy by combining oxaliplatin with immune checkpoint blockades reduced tumor burden in colorectal cancer animal model Biochem. Biophys. Res. Commun. 2017 487 1 1 7 10.1016/j.bbrc.2016.12.180 28042031

Kim W. Chu T. H. Nienhüser H. Jiang Z. Del Portillo A. Remotti H. E. White R. A. Hayakawa Y. Tomita H. Fox J. G. PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice Gastroenterology 2021 160 3 781 796 10.1053/j.gastro.2020.10.036 33129844 PMC7878361

Siew Y.-Y. Neo S.-Y. Yew H.-C. Lim S.-W. Ng Y.-C. Lew S.-M. Seetoh W.-G. Seow S.-V. Koh H.-L. Oxaliplatin regulates expression of stress ligands in ovarian cancer cells and modulates their susceptibility to natural killer cell-mediated cytotoxicity Int. Immunol. 2015 27 12 621 632 10.1093/intimm/dxv041 26138671

Maharjan R. Choi J. U. Kweon S. Pangeni R. Lee N. K. Park S. J. Chang K.-Y. Park J. W. Byun Y. A novel oral metronomic chemotherapy provokes tumor specific immunity resulting in colon cancer eradication in combination with anti-PD-1 therapy Biomaterials 2022 281 121334 10.1016/j.biomaterials.2021.121334 34974206

Gou H. F. Zhou L. Huang J. Chen X. C. Intraperitoneal oxaliplatin administration inhibits the tumor immunosuppressive microenvironment in an abdominal implantation model of colon cancer Mol Med Rep 2018 18 2 2335 2341 10.3892/mmr.2018.9219 29956798

Novohradsky V. Markova L. Kostrhunova H. Kasparkova J. Hoeschele J. Brabec V. A [Pt­(cis-1,3-diaminocycloalkane)­Cl2] analog exhibits hallmarks typical of immunogenic cell death inducers in model cancer cells Journal of Inorganic Biochemistry 2022 226 111628 10.1016/j.jinorgbio.2021.111628 34673378

Novohradsky V. Pracharova J. Kasparkova J. Imberti C. Bridgewater H. E. Sadler P. J. Brabec V. Induction of immunogenic cell death in cancer cells by a photoactivated platinum­(iv) prodrug Inorganic Chemistry Frontiers 2020 7 21 4150 4159 10.1039/D0QI00991A 34540235 PMC7611682

Wong D. Y. Q. Ong W. W. F. Ang W. H. Induction of Immunogenic Cell Death by Chemotherapeutic Platinum Complexes Angewandte Chemie International Edition 2015 54 22 6483 6487 10.1002/anie.201500934 25873535

Margiotta N. Marzano C. Gandin V. Osella D. Ravera M. Gabano E. Platts J. A. Petruzzella E. Hoeschele J. D. Natile G. Revisiting [PtCl2­(cis-1,4-DACH)]: An Underestimated Antitumor Drug with Potential Application to the Treatment of Oxaliplatin-Refractory Colorectal Cancer J. Med. Chem. 2012 55 16 7182 7192 10.1021/jm3006838 22788918

Papadia P. Gandin V. Barbanente A. Ruello A. G. Marzano C. Micoli K. Hoeschele J. D. Natile G. Margiotta N. A minimal structural variation can overcome tumour resistance of oxaliplatin: the case of 4,5-dehydrogenation of the cyclohexane ring RSC Advances 2019 9 56 32448 32452 10.1039/C9RA07760J 35529760 PMC9072990

Kasparkova J. Suchankova T. Halamikova A. Zerzankova L. Vrana O. Margiotta N. Natile G. Brabec V. Cytotoxicity, cellular uptake, glutathione and DNA interactions of an antitumor large-ring PtII chelate complex incorporating the cis-1,4-diaminocyclohexane carrier ligand Biochem. Pharmacol. 2010 79 4 552 564 10.1016/j.bcp.2009.09.019 19782655

Brabec V. Malina J. Margiotta N. Natile G. Kasparkova J. Thermodynamic and Mechanistic Insights into Translesion DNA Synthesis Catalyzed by Y-Family DNA Polymerase Across a Bulky Double-Base Lesion of an Antitumor Platinum Drug Chem.-Eur. J. 2012 18 48 15439 15448 10.1002/chem.201202117 23065963

Papadia P. Micoli K. Barbanente A. Ditaranto N. Hoeschele J. D. Natile G. Marzano C. Gandin V. Margiotta N. Platinum­(IV) Complexes of trans-1,2-diamino-4-cyclohexene: Prodrugs Affording an Oxaliplatin Analogue that Overcomes Cancer Resistance International Journal of Molecular Sciences 2020 21 7 2325 10.3390/ijms21072325 32230896 PMC7177638

Papadia P. Barbanente A. Ditaranto N. Hoeschele J. D. Natile G. Marzano C. Gandin V. Margiotta N. Effect of chirality on the anticancer activity of Pt­(ii) and Pt­(iv) complexes containing 1R,2R and 1S,2S enantiomers of the trans-1,2-diamino-4-cyclohexene ligand (DACHEX), an analogue of diaminocyclohexane used in oxaliplatin Dalton Transactions 2021 50 43 15655 15668 10.1039/D1DT02255E 34673864

Burnet , F. M. The Concept of Immunological Surveillance . In Immunological Aspects of Neoplasia ; Schwartz , R. S. , Ed.; S.Karger AG , 1970 ; Vol. 13 , p 1 . 10.1159/000386035 4921480

Radoja S. Rao T. D. Hillman D. Frey A. B. Mice Bearing Late-Stage Tumors Have Normal Functional Systemic T Cell Responses In Vitro and In Vivo1 The Journal of Immunology 2000 164 5 2619 2628 10.4049/jimmunol.164.5.2619 10679101

Schreiber R. D. Old L. J. Smyth M. J. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion Science 2011 331 6024 1565 1570 10.1126/science.1203486 21436444

Ballhausen A. Przybilla M. J. Jendrusch M. Haupt S. Pfaffendorf E. Seidler F. Witt J. Hernandez Sanchez A. Urban K. Draxlbauer M. The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution Nature Communications 2020 11 1 4740 10.1038/s41467-020-18514-5 PMC7506541 32958755

Llosa N. J. Cruise M. Tam A. Wicks E. C. Hechenbleikner E. M. Taube J. M. Blosser R. L. Fan H. Wang H. Luber B. S. The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints Cancer Discovery 2015 5 1 43 51 10.1158/2159-8290.CD-14-0863 25358689 PMC4293246

Shankaran V. Ikeda H. Bruce A. T. White J. M. Swanson P. E. Old L. J. Schreiber R. D. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity Nature 2001 410 6832 1107 1111 10.1038/35074122 11323675

Hanahan D. Weinberg R. A. Hallmarks of Cancer: The Next Generation Cell 2011 144 5 646 674 10.1016/j.cell.2011.02.013 21376230

Guinney J. Dienstmann R. Wang X. de Reyniès A. Schlicker A. Soneson C. Marisa L. Roepman P. Nyamundanda G. Angelino P. The consensus molecular subtypes of colorectal cancer Nature Medicine 2015 21 11 1350 1356 10.1038/nm.3967 PMC4636487 26457759

Becht E. de Reyniès A. Giraldo N. A. Pilati C. Buttard B. Lacroix L. Selves J. Sautès-Fridman C. Laurent-Puig P. Fridman W. H. Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy Clin. Cancer Res. 2016 22 16 4057 4066 10.1158/1078-0432.CCR-15-2879 26994146

Karpinski P. Rossowska J. Sasiadek M. M. Immunological landscape of consensus clusters in colorectal cancer Oncotarget 2017 8 62 105299 10.18632/oncotarget.22169 29285252 PMC5739639

Boissière-Michot F. Lazennec G. Frugier H. Jarlier M. Roca L. Duffour J. Du Paty E. Laune D. Blanchard F. Le Pessot F. Characterization of an adaptive immune response in microsatellite-instable colorectal cancer OncoImmunology 2014 3 6 e29256 10.4161/onci.29256 25101223 PMC4121339

Banerjea A. Ahmed S. Hands R. E. Huang F. Han X. Shaw P. M. Feakins R. Bustin S. A. Dorudi S. Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased immunogenicity Molecular Cancer 2004 3 1 21 10.1186/1476-4598-3-21 15298707 PMC514528

Fishel R. Lee J.-B. Mismatch repair DNA Replication, Recombination, and Repair: Molecular Mechanisms and Pathology 2016 305 339 10.1007/978-4-431-55873-6_12

Crespo M. Vilar E. Tsai S.-Y. Chang K. Amin S. Srinivasan T. Zhang T. Pipalia N. H Chen H. J. Witherspoon M. Gordillo M. Xiang J. Z. Maxfield F. R Lipkin S. Evans T. Chen S. Colonic organoids derived from human induced pluripotent stem cells for modeling colorectal cancer and drug testing Nature medicine 2017 23 7 878 884 10.1038/nm.4355 PMC6055224 28628110

Fearon E. R. Vogelstein B. A genetic model for colorectal tumorigenesis Cell 1990 61 5 759 767 10.1016/0092-8674(90)90186-I 2188735

Vogelstein B. Fearon E. R. Hamilton S. R. Kern S. E. Preisinger A. C. Leppert M. Smits A. M. M. Bos J. L. Genetic Alterations during Colorectal-Tumor Development New England Journal of Medicine 1988 319 9 525 532 10.1056/NEJM198809013190901 2841597

Vogelstein B. Papadopoulos N. Velculescu V. E. Zhou S. Diaz L. A. Kinzler K. W. Cancer Genome Landscapes Science 2013 339 6127 1546 1558 10.1126/science.1235122 23539594 PMC3749880

Flores-Hernández E. Velázquez D. M. Castañeda-Patlán M. C. Fuentes-García G. Fonseca-Camarillo G. Yamamoto-Furusho J. K. Romero-Avila M. T. García-Sáinz J. A. Robles-Flores M. Canonical and non-canonical Wnt signaling are simultaneously activated by Wnts in colon cancer cells Cellular Signalling 2020 72 109636 10.1016/j.cellsig.2020.109636 32283254

Dienstmann R. Vermeulen L. Guinney J. Kopetz S. Tejpar S. Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer Nature Reviews Cancer 2017 17 2 79 92 10.1038/nrc.2016.126 28050011

Campbell K. C. Rehemtulla A. Sunkara P. Hamstra D. Buhnerkempe M. Ross B. Oral D-methionine protects against cisplatin-induced hearing loss in humans: Phase 2 randomized clinical trial in India International Journal of Audiology 2022 61 8 621 631 10.1080/14992027.2021.1983215 34622731

Angelova M. Charoentong P. Hackl H. Fischer M. L. Snajder R. Krogsdam A. M. Waldner M. J. Bindea G. Mlecnik B. Galon J. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy Genome Biology 2015 16 1 64 10.1186/s13059-015-0620-6 25853550 PMC4377852

Huyghe N. Baldin P. Van den Eynde M. Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours? Gastroenterology Report 2020 8 1 11 24 10.1093/gastro/goz061 32104582 PMC7034232

Hui L. Chen Y. Tumor microenvironment: Sanctuary of the devil Cancer Letters 2015 368 1 7 13 10.1016/j.canlet.2015.07.039 26276713

Xiao Y. Yu D. Tumor microenvironment as a therapeutic target in cancer Pharmacology & Therapeutics 2021 221 107753 10.1016/j.pharmthera.2020.107753 33259885 PMC8084948

Wong S. H. Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications Nat Rev Gastroenterol Hepatol 2019 16 11 690 704 10.1038/s41575-019-0209-8 31554963

Garrett W. S. The gut microbiota and colon cancer Science 2019 364 6446 1133 1135 10.1126/science.aaw2367 31221845

Chen X. Wang G. Qin L. Hu B. Li J. Intestinal Microbiota Modulates the Antitumor Effect of Oncolytic Virus Vaccines in Colorectal Cancer Dig. Dis. Sci. 2024 69 1228 1241 10.1007/s10620-024-08346-4 38400885

Joo J. E. Chu Y. L. Georgeson P. Walker R. Mahmood K. Clendenning M. Meyers A. L. Como J. Joseland S. Preston S. G. Diepenhorst N. Toner J. Ingle D. J. Sherry N. L. Metz A. Lynch B. M. Milne R. L. Southey M. C. Hopper J. L. Win A. K. Macrae F. A. Winship I. M. Rosty C. Jenkins M. A. Buchanan D. D. Intratumoral presence of the genotoxic gut bacteria pks+ E. coli, Enterotoxigenic Bacteroides fragilis, and Fusobacterium nucleatum and their association with clinicopathological and molecular features of colorectal cancer Br. J. Cancer 2024 130 728 10.1038/s41416-023-02554-x 38200234 PMC10912205

Zhu H. Li M. Bi D. Yang H. Gao Y. Song F. Zheng J. Xie R. Zhang Y. Liu H. Yan X. Kong C. Zhu Y. Xu Q. Wei Q. Qin H. Fusobacterium nucleatum promotes tumor progression in KRAS p. G12D-mutant colorectal cancer by binding to DHX15 Nature Communications 2024 15 1688 10.1038/s41467-024-45572-w PMC10894276 38402201

Tilsed C. M. Casey T. H. de Jong E. Bosco A. Zemek R. M. Salmons J. Wan G. Millward M. J. Nowak A. K. Lake R. A. Retinoic Acid Induces an IFN-Driven Inflammatory Tumour Microenvironment, Sensitizing to Immune Checkpoint Therapy Frontiers in Oncology 2022 12 849793 10.3389/fonc.2022.849793 35402250 PMC8988133

Pagès F. Mlecnik B. Marliot F. Bindea G. Ou F.-S. Bifulco C. Lugli A. Zlobec I. Rau T. T. Berger M. D. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study The Lancet 2018 391 10135 2128 2139 10.1016/S0140-6736(18)30789-X 29754777

Mlecnik B. Bindea G. Angell H. K. Maby P. Angelova M. Tougeron D. Church S. E. Lafontaine L. Fischer M. Fredriksen T. Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability Immunity 2016 44 3 698 711 10.1016/j.immuni.2016.02.025 26982367

DiToro D. Basu R. Emerging Complexity in CD4+ T lineage programming and its implications in colorectal cancer Frontiers in Immunology 2021 12 694833 10.3389/fimmu.2021.694833 34489941 PMC8417887

Pages F. Berger A. Camus M. Sanchez-Cabo F. Costes A. Molidor R. Mlecnik B. Kirilovsky A. Nilsson M. Damotte D. Meatchi T. Bruneval P. Cugnenc P.-H. Trajanoski Z. Fridman W.-H. Galon J. Effector memory T cells, early metastasis, and survival in colorectal cancer New England journal of medicine 2005 353 25 2654 2666 10.1056/NEJMoa051424 16371631

Erdman S. E. Sohn J. J. Rao V. P. Nambiar P. R. Ge Z. Fox J. G. Schauer D. B. CD4+ CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice Cancer research 2005 65 10 3998 4004 10.1158/0008-5472.CAN-04-3104 15899788

Chuckran C. A. Cillo A. R. Moskovitz J. Overacre-Delgoffe A. Somasundaram A. S. Shan F. Magnon G. C. Kunning S. R. Abecassis I. Zureikat A. H. Luketich J. Pennathur A. Sembrat J. Rojas M. Merrick D. T. Taylor S. E. Orr B. Modugno F. Buckanovich R. Schoen R. E. Kim S. Duvvuri U. Zeh H. Edwards R. Kirkwood J. M. Coffman L. Ferris R. L. Bruno T. C. Vignali D. A. A. Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer Science translational medicine 2021 13 623 eabf8495 10.1126/scitranslmed.abf8495 34878821 PMC9022491

Goc J. Lv M. Bessman N. J. Flamar A.-L. Sahota S. Suzuki H. Teng F. Putzel G. G. Eberl G. Withers D. R. Arthur J. C. Shah M. A. Sonnenberg G. F. Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer Cell 2021 184 19 5015 5030 10.1016/j.cell.2021.07.029 34407392 PMC8454863

Brenner E. Schörg B. F. Ahmetlić F. Wieder T. Hilke F. J. Simon N. Schroeder C. Demidov G. Riedel T. Fehrenbacher B. Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours Nature Communications 2020 11 1 1335 10.1038/s41467-020-14987-6 PMC7067802 32165639

Rentschler M. Braumüller H. Briquez P. S. Wieder T. Cytokine-Induced Senescence in the Tumor Microenvironment and Its Effects on Anti-Tumor Immune Responses Cancers 2022 14 6 1364 10.3390/cancers14061364 35326515 PMC8946098

Bruni D. Angell H. K. Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy Nature Reviews Cancer 2020 20 11 662 680 10.1038/s41568-020-0285-7 32753728

Patnaik A. Weiss G. J. Rasco D. W. Blaydorn L. Mirabella A. Beeram M. Guo W. Lu S. Danaee H. McEachern K. Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial Cancer Chemotherapy and Pharmacology 2022 89 1 93 103 10.1007/s00280-021-04358-3 34750637 PMC8739161

Lenz H.-J. Van Cutsem E. Luisa Limon M. Wong K. Y. M. Hendlisz A. Aglietta M. Garcia-Alfonso P. Neyns B. Luppi G. Cardin D. B. Dragovich T. Shah U. Abdullaev S. Gricar J. Ledeine J.-M. Overman M. J. Lonardi S. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study Journal of Clinical Oncology 2022 40 2 161 170 10.1200/JCO.21.01015 34637336

Overman M. J. Lonardi S. Wong K. Y. M. Lenz H.-J. Gelsomino F. Aglietta M. Morse M. A. Van Cutsem E. McDermott R. Hill A. Sawyer M. B. Hendlisz A. Neyns B. Svrcek M. Moss R. A. Ledeine J.-M. Cao Z. A. Kamble S. Kopetz S. Andre T. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer Journal of Clinical Oncology 2018 36 8 773 779 10.1200/JCO.2017.76.9901 29355075

Overman M. J. McDermott R. Leach J. L. Lonardi S. Lenz H.-J. Morse M. A. Desai J. Hill A. Axelson M. Moss R. A. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study The Lancet Oncology 2017 18 9 1182 1191 10.1016/S1470-2045(17)30422-9 28734759 PMC6207072

Chalabi M. Fanchi L. F. Dijkstra K. K. Van den Berg J. G. Aalbers A. G. Sikorska K. Lopez-Yurda M. Grootscholten C. Beets G. L. Snaebjornsson P. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers Nature Medicine 2020 26 4 566 576 10.1038/s41591-020-0805-8 32251400

Le D. T. Durham J. N. Smith K. N. Wang H. Bartlett B. R. Aulakh L. K. Lu S. Kemberling H. Wilt C. Luber B. S. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade Science 2017 357 6349 409 413 10.1126/science.aan6733 28596308 PMC5576142

Le D. T. Uram J. N. Wang H. Bartlett B. R. Kemberling H. Eyring A. D. Skora A. D. Luber B. S. Azad N. S. Laheru D. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency New England Journal of Medicine 2015 372 26 2509 2520 10.1056/NEJMoa1500596 26028255 PMC4481136

Le D. T. Kim T. W. Van Cutsem E. Geva R. Jager D. Hara H. Burge M. O’Neil B. Kavan P. Yoshino T. Guimbaud R. Taniguchi H. Elez E. Al-Batran S.-E. Boland P. M. Crocenzi T. Atreya C. E. Cui Y. Dai T. Marinello P. Diaz Jr L. A. Andre T. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164 Journal of Clinical Oncology 2020 38 1 11 19 10.1200/JCO.19.02107 31725351 PMC7031958

Le D. T. Diaz L. A. Jr. Kim T. W. Van Cutsem E. Geva R. Jäger D. Hara H. Burge M. O’Neil B. H. Kavan P. Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164 Eur. J. Cancer 2023 186 185 195 10.1016/j.ejca.2023.02.016 37141828

O’Neil B. H. Wallmark J. M. Lorente D. Elez E. Raimbourg J. Gomez-Roca C. Ejadi S. Piha-Paul S. A. Stein M. N. Abdul Razak A. R. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma PLOS ONE 2017 12 12 e0189848 10.1371/journal.pone.0189848 29284010 PMC5746232

Galon J. Costes A. Sanchez-Cabo F. Kirilovsky A. Mlecnik B. Lagorce-Pagès C. Tosolini M. Camus M. Berger A. Wind P. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome Science 2006 313 5795 1960 1964 10.1126/science.1129139 17008531

Schürch C. M. Bhate S. S. Barlow G. L. Phillips D. J. Noti L. Zlobec I. Chu P. Black S. Demeter J. McIlwain D. R. Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front Cell 2020 182 5 1341 1359 10.1016/j.cell.2020.07.005 32763154 PMC7479520

Niogret J. Berger H. Rebe C. Mary R. Ballot E. Truntzer C. Thibaudin M. Derangère V. Hibos C. Hampe L. Follicular helper-T cells restore CD8 + -dependent antitumor immunity and anti-PD-L1/PD-1 efficacy Journal for ImmunoTherapy of Cancer 2021 9 6 e002157 10.1136/jitc-2020-002157 34103351 PMC8190041

Liu Y. Cao X. The origin and function of tumor-associated macrophages Cellular & Molecular Immunology 2015 12 1 1 4 10.1038/cmi.2014.83 25220733 PMC4654376

Qian B.-Z. Pollard J. W. Macrophage Diversity Enhances Tumor Progression and Metastasis Cell 2010 141 1 39 51 10.1016/j.cell.2010.03.014 20371344 PMC4994190

Yang L. Zhang Y. Tumor-associated macrophages: from basic research to clinical application Journal of Hematology & Oncology 2017 10 1 58 10.1186/s13045-017-0430-2 28241846 PMC5329931

Mantovani A. Marchesi F. Malesci A. Laghi L. Allavena P. Tumour-associated macrophages as treatment targets in oncology Nature Reviews Clinical Oncology 2017 14 7 399 416 10.1038/nrclinonc.2016.217 PMC5480600 28117416

Zhang S. Li X. Zhu L. Ming S. Wang H. Xie J. Ren L. Huang J. Liang D. Xiong L. Wang Y. Zhang D. Gong S. Wu Y. Geng L. CD163+ macrophages suppress T cell response by producing TGF-β in pediatric colorectal polyps International Immunopharmacology 2021 96 107644 10.1016/j.intimp.2021.107644 33878617

Zhang X.-L. Hu L.-P. Yang Q. Qin W.-T. Wang X. Xu C.-J. Tian G.-A. Yang X.-M. Yao L.-L. Zhu L. Nie H.-Z. Li Q. Xu Q. Zhang Z.-G. Zhang Y.-L. Li J. Wang Y.-H. Jiang S.-H. CTHRC1 promotes liver metastasis by reshaping infiltrated macrophages through physical interactions with TGF-β receptors in colorectal cancer Oncogene 2021 40 23 3959 3973 10.1038/s41388-021-01827-0 33986509

Shang S. Yang C. Chen F. Xiang R.-s. Zhang H. Dai S.-y. Liu J. Lv X.-x. Zhang C. Liu X.-t. Zhang Q. Lu S.-b. Song J.-w. Yu J.-j. Zhou J.-c. Zhang X.-w. Cui B. Li P.-p. Zhu S.-t. Zhang H.-z. Hua F. ID1 expressing macrophages support cancer cell stemness and limit CD8+ T cell infiltration in colorectal cancer Nature Communications 2023 14 1 7661 10.1038/s41467-023-43548-w PMC10667515 37996458

Bindea G. Mlecnik B. Tosolini M. Kirilovsky A. Waldner M. Obenauf A. C. Angell H. Fredriksen T. Lafontaine L. Berger A. Bruneval P. Fridman W. H. Becker C. Pages F. Speicher M. R. Trajanoski Z. Galon J. Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer Immunity 2013 39 4 782 795 10.1016/j.immuni.2013.10.003 24138885

Gao L. Zhou Y. Zhou S.-X. Yu X.-J. Xu J.-M. Zuo L. Luo Y.-H. Li X.-A. PLD4 promotes M1 macrophages to perform antitumor effects in colon cancer cells Oncol. Rep. 2017 37 1 408 416 10.3892/or.2016.5216 27840999

Cheng Y. Zhu Y. Xu W. Xu J. Yang M. Chen P. Zhao J. Geng L. Gong S. PKCα in colon cancer cells promotes M1 macrophage polarization via MKK3/6-P38 MAPK pathway Molecular Carcinogenesis 2018 57 8 1017 1029 10.1002/mc.22822 29637628

Lian G. Chen S. Ouyang M. Li F. Chen L. Yang J. Colon Cancer Cell Secretes EGF to Promote M2 Polarization of TAM Through EGFR/PI3K/AKT/mTOR Pathway Technology in Cancer Research & Treatment 2019 18 1533033819849068 10.1177/1533033819849068 31088266 PMC6535704

Zhang L.-l. Zhang L.-f. Shi Y.-b. Down-regulated paxillin suppresses cell proliferation and invasion by inhibiting M2 macrophage polarization in colon cancer Biological Chemistry 2018 399 11 1285 1295 10.1515/hsz-2018-0002 29924724

Colegio O. R. Chu N.-Q. Szabo A. L. Chu T. Rhebergen A. M. Jairam V. Cyrus N. Brokowski C. E. Eisenbarth S. C. Phillips G. M. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid Nature 2014 513 7519 559 563 10.1038/nature13490 25043024 PMC4301845

Chanmee T. Ontong P. Konno K. Itano N. Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment Cancers 2014 6 3 1670 1690 10.3390/cancers6031670 25125485 PMC4190561

Han Q. Shi H. Liu F. CD163+ M2-type tumor-associated macrophage support the suppression of tumor-infiltrating T cells in osteosarcoma International Immunopharmacology 2016 34 101 106 10.1016/j.intimp.2016.01.023 26938675

Liu J. Zhang N. Li Q. Zhang W. Ke F. Leng Q. Wang H. Chen J. Wang H. Tumor-Associated Macrophages Recruit CCR6+ Regulatory T Cells and Promote the Development of Colorectal Cancer via Enhancing CCL20 Production in Mice PLOS ONE 2011 6 4 e19495 10.1371/journal.pone.0019495 21559338 PMC3084880

Del Zotto G. Marcenaro E. Vacca P. Sivori S. Pende D. Della Chiesa M. Moretta F. Ingegnere T. Mingari M. C. Moretta A. Markers and function of human NK cells in normal and pathological conditions Cytometry Part B: Clinical Cytometry 2017 92 2 100 114 10.1002/cyto.b.21508 28054442

Tarazona R. Lopez-Sejas N. Guerrero B. Hassouneh F. Valhondo I. Pera A. Sanchez-Correa B. Pastor N. Duran E. Alonso C. Current progress in NK cell biology and NK cell-based cancer immunotherapy Cancer Immunology, Immunotherapy 2020 69 5 879 899 10.1007/s00262-020-02532-9 32130453 PMC11027864

Imai K. Matsuyama S. Miyake S. Suga K. Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population The Lancet 2000 356 9244 1795 1799 10.1016/S0140-6736(00)03231-1 11117911

Tartter P. I. Steinberg B. Barron D. M. Martinelli G. The Prognostic Significance of Natural Killer Cytotoxicity in Patients With Colorectal Cancer Archives of Surgery 1987 122 11 1264 1268 10.1001/archsurg.1987.01400230050009 3675190

Coca S. Perez-Piqueras J. Martinez D. Colmenarejo A. Saez M. A. Vallejo C. Martos J. A. Moreno M. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma Cancer 1997 79 12 2320 2328 10.1002/(SICI)1097-0142(19970615)79:12<2320::AID-CNCR5>3.0.CO;2-P 9191519

Peng Y.-P. Zhu Y. Zhang J.-J. Xu Z.-K. Qian Z.-Y. Dai C.-C. Jiang K.-R. Wu J.-L. Gao W.-T. Li Q. Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer Journal of Translational Medicine 2013 11 1 262 10.1186/1479-5876-11-262 24138752 PMC3854023

Rocca Y. S. Roberti M. P. Juliá E. P. Pampena M. B. Bruno L. Rivero S. Huertas E. Sánchez Loria F. Pairola A. Caignard A. Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15 Frontiers in Immunology 2016 7 413 10.3389/fimmu.2016.00413 27777574 PMC5056190

Rocca Y. S. Roberti M. P. Arriaga J. M. Amat M. Bruno L. Pampena M. B. Huertas E. Loria F. S. Pairola A. Bianchini M. Altered phenotype in peripheral blood and tumor-associated NK cells from colorectal cancer patients Innate Immunity 2013 19 1 76 85 10.1177/1753425912453187 22781631

Schleypen J. S. Baur N. Kammerer R. Nelson P. J. Rohrmann K. Gröne E. F. Hohenfellner M. Haferkamp A. Pohla H. Schendel D. J. Cytotoxic Markers and Frequency Predict Functional Capacity of Natural Killer Cells Infiltrating Renal Cell Carcinoma Clin. Cancer Res. 2006 12 3 718 725 10.1158/1078-0432.CCR-05-0857 16467081

Schleypen J. S. von Geldern M. Weiß E. H. Kotzias N. Rohrmann K. Schendel D. J. Falk C. S. Pohla H. Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes Int. J. Cancer 2003 106 6 905 912 10.1002/ijc.11321 12918068

Sers C. Kuner R. Falk C. S. Lund P. Sueltmann H. Braun M. Buness A. Ruschhaupt M. Conrad J. Mang-Fatehi S. Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells Int. J. Cancer 2009 125 7 1626 1639 10.1002/ijc.24557 19569244

Anfossi N. André P. Guia S. Falk C. S. Roetynck S. Stewart C. A. Breso V. Frassati C. Reviron D. Middleton D. Human NK Cell Education by Inhibitory Receptors for MHC Class I Immunity 2006 25 2 331 342 10.1016/j.immuni.2006.06.013 16901727

Gabrilovich D. I. Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system Nature Reviews Immunology 2009 9 3 162 174 10.1038/nri2506 PMC2828349 19197294

OuYang L.-Y. Wu X.-J. Ye S.-B. Zhang R.-x. Li Z.-L. Liao W. Pan Z.-Z. Zheng L.-M. Zhang X.-S. Wang Z. Tumor-induced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer Journal of Translational Medicine 2015 13 1 47 10.1186/s12967-015-0410-7 25638150 PMC4357065

Zhang B. Wang Z. Wu L. Zhang M. Li W. Ding J. Zhu J. Wei H. Zhao K. Circulating and Tumor-Infiltrating Myeloid-Derived Suppressor Cells in Patients with Colorectal Carcinoma PLOS ONE 2013 8 2 e57114 10.1371/journal.pone.0057114 23437326 PMC3577767

Kobayashi M. Chung J.-S. Beg M. Arriaga Y. Verma U. Courtney K. Mansour J. Haley B. Khan S. Horiuchi Y. Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the In Vitro Integrity of T Cells from Cancer Patients Clin. Cancer Res. 2019 25 2 828 838 10.1158/1078-0432.CCR-18-0330 30049749 PMC7315386

Zea A. H. Rodriguez P. C. Atkins M. B. Hernandez C. Signoretti S. Zabaleta J. McDermott D. Quiceno D. Youmans A. O’Neill A. Arginase-Producing Myeloid Suppressor Cells in Renal Cell Carcinoma Patients: A Mechanism of Tumor Evasion Cancer Res. 2005 65 8 3044 3048 10.1158/0008-5472.CAN-04-4505 15833831

Bronte V. Zanovello P. Regulation of immune responses by L-arginine metabolism Nature Reviews Immunology 2005 5 8 641 654 10.1038/nri1668 16056256

Zhao F. Hoechst B. Duffy A. Gamrekelashvili J. Fioravanti S. Manns M. P. Greten T. F. Korangy F. S100A9 a new marker for monocytic human myeloid-derived suppressor cells Immunology 2012 136 2 176 183 10.1111/j.1365-2567.2012.03566.x 22304731 PMC3403264

Kusmartsev S. A. Li Y. Chen S.-H. Gr-1+ Myeloid Cells Derived from Tumor-Bearing Mice Inhibit Primary T Cell Activation Induced Through CD3/CD28 Costimulation1 The Journal of Immunology 2000 165 2 779 785 10.4049/jimmunol.165.2.779 10878351

Lee H.-O. Hong Y. Etlioglu H. E. Cho Y. B. Pomella V. Van den Bosch B. Vanhecke J. Verbandt S. Hong H. Min J.-W. Kim N. Eum H. H. Qian J. Boeckx B. Lambrechts D. Tsantoulis P. De Hertogh G. Chung W. Lee T. An M. Shin H.-T. Joung J.-G. Jung M.-H. Ko G. Wirapati P. Kim S. H. Kim H. C. Yun S. H. Tan I. B. H. Ranjan B. Lee W. Y. Kim T.-Y. Choi J. K. Kim Y.-J. Prabhakar S. Tejpar S. Park W.-Y. Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer Nature genetics 2020 52 6 594 603 10.1038/s41588-020-0636-z 32451460

Vermeulen L. De Sousa E Melo F. van der Heijden M. Cameron K. de Jong J. H. Borovski T. Tuynman J. B. Todaro M. Merz C. Rodermond H. Sprick M. R. Kemper K. Richel D. J. Stassi G. Medema J. P. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment Nature cell biology 2010 12 5 468 476 10.1038/ncb2048 20418870

Koncina E. Nurmik M. Pozdeev V. I. Gilson C. Tsenkova M. Begaj R. Stang S. Gaigneaux A. Weindorfer C. Rodriguez F. Schmoetten M. Klein E. Karta J. Atanasova V. S. Grzyb K. Ullmann P. Halder R. Hengstschlager M. Graas J. Augendre V. Karapetyan Y. E. Kerger L. Zuegel N. Skupin A. Haan S. Meiser J. Dolznig H. Letellier E. IL1R1+ cancer-associated fibroblasts drive tumor development and immunosuppression in colorectal cancer Nature communications 2023 14 1 4251 10.1038/s41467-023-39953-w PMC10352362 37460545

Lu J. Ye X. Fan F. Xia L. Bhattacharya R. Bellister S. Tozzi F. Sceusi E. Zhou Y. Tachibana I. Maru D. M. Hawke D. H. Rak J. Mani S. A. Zweidler-McKay P. Ellis L. M. Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1 Cancer cell 2013 23 2 171 185 10.1016/j.ccr.2012.12.021 23375636 PMC3574187

Waldner M. J. Neurath M. F. TGFβ and the tumor microenvironment in colorectal cancer Cells 2023 12 8 1139 10.3390/cells12081139 37190048 PMC10137236

Sun W. Cui J. Ge Y. Wang J. Yu Y. Han B. Liu B. Tumor stem cell-derived exosomal microRNA-17–5p inhibits anti-tumor immunity in colorectal cancer via targeting SPOP and overexpressing PD-L1 Cell Death Discovery 2022 8 223 10.1038/s41420-022-00919-4 35461336 PMC9035163

Matsumura T Sugimachi K Iinuma H Takahashi Y Kurashige J Sawada G Ueda M Uchi R Ueo H Takano Y Shinden Y Eguchi H Yamamoto H Doki Y Mori M Ochiya T Mimori K Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer British journal of cancer 2015 113 2 275 281 10.1038/bjc.2015.201 26057451 PMC4506387

Hodi F. S. O’Day S. J. McDermott D. F. Weber R. W. Sosman J. A. Haanen J. B. Gonzalez R. Robert C. Schadendorf D. Hassel J. C. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma New England Journal of Medicine 2010 363 8 711 723 10.1056/NEJMoa1003466 20525992 PMC3549297

Parkhurst M. R. Yang J. C. Langan R. C. Dudley M. E. Nathan D.-A. N. Feldman S. A. Davis J. L. Morgan R. A. Merino M. J. Sherry R. M. T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis Molecular Therapy 2011 19 3 620 626 10.1038/mt.2010.272 21157437 PMC3048186

Tran E. Robbins P. F. Lu Y.-C. Prickett T. D. Gartner J. J. Jia L. Pasetto A. Zheng Z. Ray S. Groh E. M. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer New England Journal of Medicine 2016 375 23 2255 2262 10.1056/NEJMoa1609279 27959684 PMC5178827

Rosenberg S. A. Yang J. C. Restifo N. P. Cancer immunotherapy: moving beyond current vaccines Nature Medicine 2004 10 9 909 915 10.1038/nm1100 PMC1435696 15340416

Nagorsen D. Thiel E. Clinical and Immunologic Responses to Active Specific Cancer Vaccines in Human Colorectal Cancer Clin. Cancer Res. 2006 12 10 3064 3069 10.1158/1078-0432.CCR-05-2788 16707603

Sasada T. Kibe S. Akagi Y. Itoh K. Personalized peptide vaccination for advanced colorectal cancer OncoImmunology 2015 4 5 e1005512 10.1080/2162402X.2015.1005512 26155407 PMC4485709

Sahin U. Türeci Ö. Personalized vaccines for cancer immunotherapy Science 2018 359 6382 1355 1360 10.1126/science.aar7112 29567706

Robert C. A decade of immune-checkpoint inhibitors in cancer therapy Nature Communications 2020 11 1 3801 10.1038/s41467-020-17670-y PMC7393098 32732879

Diaz , L. A. , Jr. How is Immunotherapy for Colorectal Cancer Changing the Outlook for Patients? ; Cancer Research Institute (CRI) , 2023 ; https://www.cancerresearch.org/cancer-types/colorectal-cancer (accessed 2023-10-13).

Diaz L. A. Jr. Shiu K.-K. Kim T.-W. Jensen B. V. Jensen L. H. Punt C. Smith D. Garcia-Carbonero R. Benavides M. Gibbs P. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study The Lancet Oncology 2022 23 5 659 670 10.1016/S1470-2045(22)00197-8 35427471 PMC9533375

van Vugt M. J. H. Stone J. A. De Greef R. H. J. M. M. Snyder E. S. Lipka L. Turner D. C. Chain A. Lala M. Li M. Robey S. H. Kondic A. G. De Alwis D. Mayawala K. Jain L. Freshwater T. Immunogenicity of pembrolizumab in patients with advanced tumors Journal for ImmunoTherapy of Cancer 2019 7 1 212 10.1186/s40425-019-0663-4 31395089 PMC6686242

Cristescu R. Aurora-Garg D. Albright A. Xu L. Liu X. Q. Loboda A. Lang L. Jin F. Rubin E. H. Snyder A. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors Journal for ImmunoTherapy of Cancer 2022 10 1 e003091 10.1136/jitc-2021-003091 35101941 PMC8804694

Ott P. A. Bang Y.-J. Piha-Paul S. A. Razak A. R. A. Bennouna J. Soria J.-C. Rugo H. S. Cohen R. B. O’Neil B. H. Mehnert J. M. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028 Journal of Clinical Oncology 2019 37 4 318 327 10.1200/JCO.2018.78.2276 30557521

Kalyan A. Kircher S. Shah H. Mulcahy M. Benson A. Updates on immunotherapy for colorectal cancer Journal of Gastrointestinal Oncology 2018 9 1 160 169 10.21037/jgo.2018.01.17 29564182 PMC5848033

Ganesh K. Stadler Z. K. Cercek A. Mendelsohn R. B. Shia J. Segal N. H. Diaz L. A. Immunotherapy in colorectal cancer: rationale, challenges and potential Nature Reviews Gastroenterology & Hepatology 2019 16 6 361 375 10.1038/s41575-019-0126-x 30886395 PMC7295073

Chung K. Y. Gore I. Fong L. Venook A. Beck S. B. Dorazio P. Criscitiello P. J. Healey D. I. Huang B. Gomez-Navarro J. Phase II Study of the Anti-Cytotoxic T-Lymphocyte-Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer Journal of Clinical Oncology 2010 28 21 3485 3490 10.1200/JCO.2010.28.3994 20498386

Brahmer J. R. Drake C. G. Wollner I. Powderly J. D. Picus J. Sharfman W. H. Stankevich E. Pons A. Salay T. M. McMiller T. L. Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates Journal of Clinical Oncology 2010 28 19 3167 3175 10.1200/JCO.2009.26.7609 20516446 PMC4834717

Topalian S. L. Hodi F. S. Brahmer J. R. Gettinger S. N. Smith D. C. McDermott D. F. Powderly J. D. Carvajal R. D. Sosman J. A. Atkins M. B. Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer New England Journal of Medicine 2012 366 26 2443 2454 10.1056/NEJMoa1200690 22658127 PMC3544539

Patnaik A. Kang S. P. Rasco D. Papadopoulos K. P. Elassaiss-Schaap J. Beeram M. Drengler R. Chen C. Smith L. Espino G. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors Clin. Cancer Res. 2015 21 19 4286 4293 10.1158/1078-0432.CCR-14-2607 25977344

Williams D. S. Mouradov D. Jorissen R. N. Newman M. R. Amini E. Nickless D. K. Teague J. A. Fang C. G. Palmieri M. Parsons M. J. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes Gut 2019 68 3 465 474 10.1136/gutjnl-2017-315664 29382774

Gong J. Wang C. Lee P. P. Chu P. Fakih M. Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a POLE Mutation Journal of the National Comprehensive Cancer Network J Natl Compr Canc Netw 2017 15 2 142 147 10.6004/jnccn.2017.0016 28188185

Domingo E. Freeman-Mills L. Rayner E. Glaire M. Briggs S. Vermeulen L. Fessler E. Medema J. P. Boot A. Morreau H. van Wezel T. Liefers G.-J. Lothe R. A Danielsen S. A Sveen A. Nesbakken A. Zlobec I. Lugli A. Koelzer V. H Berger M. D Castellvi-Bel S. Munoz J. de Bruyn M. Nijman H. W Novelli M. Lawson K. Oukrif D. Frangou E. Dutton P. Tejpar S. Delorenzi M. Kerr R. Kerr D. Tomlinson I. Church D. N Somatic < em > POLE</em> proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study The Lancet Gastroenterology & Hepatology 2016 1 3 207 216 10.1016/S2468-1253(16)30014-0 28404093

Mestrallet G. Brown M. Bozkus C. C. Bhardwaj N. Immune escape and resistance to immunotherapy in mismatch repair deficient tumors Frontiers in Immunology 2023 14 164 10.3389/fimmu.2023.1210164 PMC10363668 37492581

Wang Y. Tong Z. Zhang W. Zhang W. Buzdin A. Mu X. Yan Q. Zhao X. Chang H.-H. Duhon M. FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients Frontiers in Oncology 2021 11 683419 10.3389/fonc.2021.683419 34164344 PMC8216110

Caraglia M. Correale P. Giannicola R. Staropoli N. Botta C. Pastina P. Nesci A. Caporlingua N. Francini E. Ridolfi L. Mini E. Roviello G. Ciliberto D. Agostino R. M. Strangio A. Azzarello D. Nardone V. Falzea A. Cappabianca S. Bocchetti M. D'Arrigo G. Tripepi G. Tassone P. Addeo R. Giordano A. Pirtoli L. Francini G. Tagliaferri P. GOLFIG chemo-immunotherapy in metastatic colorectal cancer patients. A critical review on a long-lasting follow-up Frontiers in oncology 2019 9 1102 10.3389/fonc.2019.01102 31781481 PMC6857002

Correale P. Cusi M. G. Tsang K. Y. Del Vecchio M. T. Marsili S. Placa M. L. Intrivici C. Aquino A. Micheli L. Nencini C. Ferrari F. Giorgi G. Bonmassar E. Francini G. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients Journal of Clinical Oncology 2005 23 35 8950 8958 10.1200/JCO.2005.12.147 16061910

Correale P. Tagliaferri P. Fioravanti A. Del Vecchio M. T. Remondo C. Montagnani F. Rotundo M. S. Ginanneschi C. Martellucci I. Francini E. Cusi M. G. Tassone P. Francini G. Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine+ FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial) Clin. Cancer Res. 2008 14 13 4192 4199 10.1158/1078-0432.CCR-07-5278 18593999

Zhou P. Wang Y. Qin S. Han Y. Yang Y. Zhao L. Zhou Q. Zhuo W. Abscopal effect triggered by radiation sequential mono-immunotherapy resulted in a complete remission of PMMR sigmoid colon cancer Frontiers in Immunology 2023 14 1139527 10.3389/fimmu.2023.1139527 37020543 PMC10067748

Liersch T. Meller J. Kulle B. Behr T. M. Markus P. Langer C. Ghadimi B. M. Wegener W. A. Kovacs J. Horak I. D. Becker H. Goldenberg D. M. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results J Clin Oncol 2005 23 27 6763 6770 10.1200/JCO.2005.18.622 16170184

Manzoni M. Rovati B. Ronzoni M. Loupakis F. Mariucci S. Ricci V. Gattoni E. Salvatore L. Tinelli C. Villa E. Danova M. Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer Oncology 2011 79 3–4 187 196 10.1159/000320609 21358206

Inoue Y. Hazama S. Suzuki N. Tokumitsu Y. Kanekiyo S. Tomochika S. Tsunedomi R. Tokuhisa Y. Iida M. Sakamoto K. Takeda S. Ueno T. Yoshino S. Nagano H. Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer Cancer science 2017 108 3 455 460 10.1111/cas.13162 28075526 PMC5378263

Hellmann M.D. Kim T.-W. Lee C.B. Goh B.-C. Miller W.H. Oh D.-Y. Jamal R. Chee C.-E. Chow L.Q.M. Gainor J.F. Desai J. Solomon B.J. Das Thakur M. Pitcher B. Foster P. Hernandez G. Wongchenko M.J. Cha E. Bang Y.-J. Siu L.L. Bendell J. Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors Annals of Oncology 2019 30 7 1134 1142 10.1093/annonc/mdz113 30918950 PMC6931236

Eng C. Kim T. W. Bendell J. Argiles G. Tebbutt N. C Di Bartolomeo M. Falcone A. Fakih M. Kozloff M. Segal N. H Sobrero A. Yan Y. Chang I. Uyei A. Roberts L. Ciardiello F. Ahn J. Asselah J Badarinath S Baijal S Begbie S Berry S Canon J. Carbone R. Cervantes A Cha Y. Chang K Chaudhry A Chmielowska E Cho S. Chu D Couture F Cultrera J Cunningham D Van Cutsem E Cuyle P. Davies J Dowden S Dvorkin M Ganju V Garcia R. Kerr R Kim T. King K Kortmansky J Kozloff M Lam K. Lee J Lee A. Lesperance B Luppi G Ma B Maiello E Mandanas R Marshall J Marx G Mullamitha S Nechaeva M Park J. Pavlakis N Ponce C. Potemski P Raouf S Reeves J Segal N Siena S Smolin A Streb J. Strickland A Szutowicz-Zielinska E Tabernero J. Tan B Valera J. Van den Eynde M Vergauwe P Vickers M Womack M Wroblewska M Young R Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial The lancet oncology 2019 20 6 849 861 10.1016/S1470-2045(19)30027-0 31003911

Chen S. Li X. Chen R. Yin M. Zheng Q. Cetuximab intensifies the ADCC activity of adoptive NK cells in a nude mouse colorectal cancer xenograft model Oncology Letters 2016 12 3 1868 1876 10.3892/ol.2016.4835 27602116 PMC4998150

Veluchamy J. P. Spanholtz J. Tordoir M. Thijssen V. L. Heideman D. A. Verheul H. M. de Gruijl T. D. van der Vliet H. J. Combination of NK cells and cetuximab to enhance anti-tumor responses in RAS mutant metastatic colorectal cancer PloS one 2016 11 6 e0157830 10.1371/journal.pone.0157830 27314237 PMC4912059

Baraibar I. Mirallas O. Saoudi N. Ros J. Salvà F. Tabernero J. Élez E. Combined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer Cancers 2021 13 24 6311 10.3390/cancers13246311 34944931 PMC8699573

Chen L. Jiang X. Li Y. Zhang Q. Li Q. Zhang X. Zhang M. Yu Q. Gao D. How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC Clinical Immunology 2022 237 108962 10.1016/j.clim.2022.108962 35227870

Kim C. W. Chon H. J. Kim C. Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer Cancers 2021 13 19 4906 10.3390/cancers13194906 34638390 PMC8507875

Changjiang Y. Long Z. Yilin L. Shan W. Yingjiang Y. Zhanlong S. Current progress of immune checkpoint inhibitors for advanced colorectal cancer: concentrating on the efficacy improvement Critical Reviews in Oncology/Hematology 2023 200 104204 10.1016/j.critrevonc.2023.104204 37984588

Vincent J. Mignot G. Chalmin F. Ladoire S. Bruchard M. Chevriaux A. Martin F. Apetoh L. Rébé C. Ghiringhelli F. 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity Cancer Res. 2010 70 8 3052 3061 10.1158/0008-5472.CAN-09-3690 20388795

Kanterman J. Sade-Feldman M. Biton M. Ish-Shalom E. Lasry A. Goldshtein A. Hubert A. Baniyash M. Adverse Immunoregulatory Effects of 5FU and CPT11 Chemotherapy on Myeloid-Derived Suppressor Cells and Colorectal Cancer Outcomes Cancer Res. 2014 74 21 6022 6035 10.1158/0008-5472.CAN-14-0657 25209187

Philip M. Fairchild L. Sun L. Horste E. L. Camara S. Shakiba M. Scott A. C. Viale A. Lauer P. Merghoub T. Chromatin states define tumour-specific T cell dysfunction and reprogramming Nature 2017 545 7655 452 456 10.1038/nature22367 28514453 PMC5693219

Guan Y. Kraus S. G. Quaney M. J. Daniels M. A. Mitchem J. B. Teixeiro E. FOLFOX Chemotherapy Ameliorates CD8 T Lymphocyte Exhaustion and Enhances Checkpoint Blockade Efficacy in Colorectal Cancer Frontiers in Oncology 2020 10 586 10.3389/fonc.2020.00586 32391270 PMC7190812

Dosset M. Vargas T. R. Lagrange A. Boidot R. Végran F. Roussey A. Chalmin F. Dondaine L. Paul C. Marie-Joseph E. L. PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer OncoImmunology 2018 7 6 e1433981 10.1080/2162402X.2018.1433981 29872568 PMC5980491

Alimohammadi R. Mahmoodi Chalbatani G. Alimohammadi M. Ghaffari-Nazari H. Rahimi A. Mortaz E. Mossafa N. Boon L. Jalali S. A. Dual blockage of both PD-L1 and CD47 enhances the therapeutic effect of oxaliplatin and FOLFOX in CT-26 mice tumor model Scientific Reports 2023 13 1 2472 10.1038/s41598-023-29363-9 36774400 PMC9922272

Golchin S. Alimohammadi R. Rostami Nejad M. Jalali S. A. Synergistic antitumor effect of anti-PD-L1 combined with oxaliplatin on a mouse tumor model Journal of Cellular Physiology 2019 234 11 19866 19874 10.1002/jcp.28585 30941773

Song W. Shen L. Wang Y. Liu Q. Goodwin T. J. Li J. Dorosheva O. Liu T. Liu R. Huang L. Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap Nature Communications 2018 9 1 2237 10.1038/s41467-018-04605-x PMC5993831 29884866

Limagne E. Thibaudin M. Nuttin L. Spill A. Derangère V. Fumet J.-D. Amellal N. Peranzoni E. Cattan V. Ghiringhelli F. Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages Cancer Immunology Research 2019 7 12 1958 1969 10.1158/2326-6066.CIR-19-0228 31611243

Park S.-J. Ye W. Xiao R. Silvin C. Padget M. Hodge J. W. Van Waes C. Schmitt N. C. Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer Oral Oncology 2019 95 127 135 10.1016/j.oraloncology.2019.06.016 31345380 PMC6662630

Segal N. H. Tie J. Kopetz S. Ducreux M. P. Chen E. Dienstmann R. Hollebecque A. Reilley M. Elez Fernandez M. E. Cosaert J. 160P COLUMBIA-1: A phase Ib/II, open-label, randomized, multicenter study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab as first-line (1L) therapy in metastatic microsatellite-stable colorectal cancer (MSS-mCRC) Immuno-Oncology and Technology 2022 16 100272 10.1016/j.iotech.2022.100272

Kim R. D. Tehfe M. Kavan P. Chaves J. Kortmansky J. S. Chen E. X. Lieu C. H. Wong L. Fakih M. Spencer K. R. Zhao Q. Predoiu R. Li C. Carpenter D. Leconte P. Chiorean E. G. Pembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI for metastatic colorectal cancer (CRC) in KEYNOTE-651: Long-term follow-up of cohorts B and D Journal of Clinical Oncology 2022 40 3521 3521 10.1200/JCO.2022.40.16_suppl.3521

Conca V. Antoniotti C. Bergamo F. Pietrantonio F. Rossini D. Scartozzi M. Perissinotto E. Leone A. G. Valeria P. Borelli B. Cavanna L. Latiano T. P. Santini D. Masi G. Salvatore L. Frassineti L. Leone F. Tamberi S. Boni L. Cremolini C. Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO Journal of Clinical Oncology 2023 41 3575 3575 10.1200/JCO.2023.41.16_suppl.3575

Stein A. Binder M. Goekkurt E. Lorenzen S. Riera-Knorrenschild J. Depenbusch R. Ettrich T. J. Doerfel S. Al-Batran S.-E. Karthaus M. Pelzer U. Simnica D. Waberer L. Hinke A. Bokemeyer C. Hegewisch-Becker S. Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216) Journal of Clinical Oncology 2020 38 96 96 10.1200/JCO.2020.38.4_suppl.96

Tintelnot J. Ristow I. Sauer M. Simnica D. Schultheiß C. Scholz R. Goekkurt E. von Wenserski L. Willscher E. Paschold L. Translational analysis and final efficacy of the AVETUX trial - Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer Frontiers in Oncology 2022 12 993661 10.3389/fonc.2022.993611 PMC9808039 36605436

Ghiringhelli F. Chibaudel B. Taieb J. Bennouna J. Martin-Babau J. Fonck M. Borg C. Cohen R. Thibaudin M. Limagne E. Fumet J.-D. Durvalumab and tremelimumab in combination with FOLFOX in patients with RAS-mutated, microsatellite-stable, previously untreated metastatic colorectal cancer (MCRC): Results of the first intermediate analysis of the phase Ib/II MEDETREME trial Journal of Clinical Oncology 2020 38 3006 3006 10.1200/JCO.2020.38.15_suppl.3006

Thibaudin M. Fumet J.-D. Chibaudel B. Bennouna J. Borg C. Martin-Babau J. Cohen R. Fonck M. Taieb J. Limagne E. First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial Nature Medicine 2023 29 8 2087 2098 10.1038/s41591-023-02497-z PMC10427431 37563240

Fang X. Zhong C. Zhu N. Weng S. Hu H. Wang J. Xiao Q. Wang J. Song Y. Sun L. Xu D. Liao X. Dong C. Zhang S. Li J. Ding K.-F. Yuan Y. A phase 2 trial of sintilimab (IBI 308) in combination with CAPEOX and bevacizumab (BBCAPX) as first-line treatment in patients with RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer Journal of Clinical Oncology 2022 40 3563 3563 10.1200/JCO.2022.40.16_suppl.3563

Yuan Y. Fang X. Zhu N. Zhong C. Wang L.-H. Li J. Weng S. Hu H. Dong C. Li D. Song Y. Xu D. Wang J. Sun L. Wang J. Liao X. Yu N. Zhang S. Ding K.-F. Updated results and biomarker analyses from the phase 2 trial (BBCAPX study) of sintilimab plus bevacizumab and CapeOx as first-line treatment in patients with RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer Journal of Clinical Oncology 2023 41 2606 2606 10.1200/JCO.2023.41.16_suppl.2606

Fang X. Zhu N. Zhong C. Wang L. Li J. Weng S. Hu H. Dong C. Li D. Song Y. Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial eClinicalMedicine 2023 62 102123 10.1016/j.eclinm.2023.102123 37554125 PMC10404864

Tougeron D. Emile J. F. Kim S. Monterymard C. Gilabert M. Jérémie B. Lievre A. Dahan L. Laurent-puig P. Mineur L. Pembrolizumab in combination with xelox bevacizumab in patients with microsatellite stable (MSS) metastatic colorectal cancer and a high immune infiltrate: a proof of concept study. FFCD 1703 POCHI Journal for ImmunoTherapy of Cancer 2020 8 A206 A206 10.1136/jitc-2020-SITC2020.0337

Krauss J. C. Yothers G. George T. J. Wade J. L. Basu Mallick A. B. Lee J. J. Huggins-Puhalla S. L. Allegra C. J. Jacobs S. A. Wolmark N. NSABP FC-10: A phase Ib study of pembrolizumab (pembro) in combination with pemetrexed (pem) and oxaliplatin (oxali) in patients with chemo-refractory metastatic colorectal cancer (mCRC) Journal of Clinical Oncology 2022 40 3569 3569 10.1200/JCO.2022.40.16_suppl.3569

Wang A. Zhang P. Yu D. Zhu H. Lu S. Lyu Y. Hu Z. Ruan C. Wang Y. Gao W. Zhang J. Zhou H. Safety and Efficacy of CAPOX Combined with Bevacizumab plus Pembrolizumab as Neoadjuvant Treatment of pMMR/MSS Type Locally Advanced Colorectal Cancer Patients: Study Protocol for a Single-arm, Phase Ib, Prospective Trial (COBP) Research Square 2023 3 rs-3334504 10.21203/rs.3.rs-3334504/v1

Herting C. J. Farren M. R. Tong Y. Liu Z. O’Neil B. Bekaii-Saab T. Noonan A. McQuinn C. Mace T. A. Shaib W. A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14–186 Cancer Immunology, Immunotherapy 2021 70 11 3337 3348 10.1007/s00262-021-02986-5 34160684 PMC8511095

Shahda S. Noonan A. M. Bekaii-Saab T. S. O'Neil B. H. Sehdev A. Shaib W. L. Helft P. R. Loehrer P. J. Tong Y. Liu Z. El-Rayes B. F. A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer Journal of Clinical Oncology 2017 35 3541 3541 10.1200/JCO.2017.35.15_suppl.3541

Lenz H.-J. Parikh A. R. Spigel D. R. Cohn A. L. Yoshino T. Kochenderfer M. D. Elez E. Shao S. H. Deming D. A. Holdridge R. C. Larson T. Chen E. Mahipal A. Ucar A. Cullen D. Baskin-Bey E. S Ledeine J.-M. Hammell A. Tabernero J. Nivolumab (NIVO) + 5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9 × 8 Journal of Clinical Oncology 2022 40 8 8 10.1200/JCO.2022.40.4_suppl.008

Antoniotti C. Rossini D. Pietrantonio F. Catteau A. Salvatore L. Lonardi S. Boquet I. Tamberi S. Marmorino F. Moretto R. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial The Lancet Oncology 2022 23 7 876 887 10.1016/S1470-2045(22)00274-1 35636444

Antoniotti C. Rossini D. Pietrantonio F. Salvatore L. Marmorino F. Ambrosini M. Lonardi S. Bensi M. Moretto R. Tamberi S. Toma I. Passardi A. De Grandis M. C. Conca V. Palermo F. Cappetta A. Catteau A. Boni L. Galon J. Cremolini C. FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer (mCRC): Updated and overall survival results of the phase II randomized AtezoTRIBE study Journal of Clinical Oncology 2023 41 3500 3500 10.1200/JCO.2023.41.16_suppl.3500

Cremolini C. Rossini D. Antoniotti C. Pietrantonio F. Lonardi S. Salvatore L. Marmorino F. Borelli B. Ambrosini M. Barsotti G. LBA20 FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: Results of the phase II randomized AtezoTRIBE study by GONO Annals of Oncology 2021 32 S1294 S1295 10.1016/j.annonc.2021.08.2094

Marmorino F. Piccinno G. Rossini D. Ghelardi F. Murgioni S. Salvatore L. Nasca V. Antoniotti C. Daniel F. Schietroma F. SO-22 Gut microbiome composition as predictor of the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: A translational analysis of the AtezoTRIBE study Annals of Oncology 2023 34 S171 10.1016/j.annonc.2023.04.494

Damato A. Iachetta F. Normanno N. Bergamo F. Maiello E. Zaniboni A. Antonuzzo L. Nasti G. Tonini G. Bordonaro R. Di Fabio F. Romagnani A. Berselli A. Pinto C. NIVACOR: Phase II study of nivolumab in combination with FOLFOXIRI/bevacizumab in first-line chemotherapy for advanced colorectal cancer RASm/BRAFm patients Journal of Clinical Oncology 2020 38 TPS4118 TPS4118 10.1200/JCO.2020.38.15_suppl.TPS4118

Damato A. Bergamo F. Antonuzzo L. Nasti G. Pietrantonio F. Tonini G. Maiello E. Bordonaro R. Rosati G. Romagnani A. Iachetta F. Larocca M. Maglietta G. Normanno N. Pinto C. Phase II study of nivolumab in combination with FOLFOXIRI/bevacizumab as first-line treatment in patients with advanced colorectal cancer RAS/BRAF mutated (mut): NIVACOR trial (GOIRC-03–2018) Journal of Clinical Oncology 2022 40 3509 3509 10.1200/JCO.2022.40.16_suppl.3509

Olson R. Perencevich N. Malcolm A. Chaffey J. Wilson R. Patterns of recurrence following curative resection of adenocarcinoma of the colon and rectum Cancer 1980 45 12 2969 2974 10.1002/1097-0142(19800615)45:12<2969::AID-CNCR2820451214>3.0.CO;2-7 7388740

Labianca R. Beretta G. D. Kildani B. Milesi L. Merlin F. Mosconi S. Pessi M. A. Prochilo T. Quadri A. Gatta G. de Braud F. Wils J. Colon cancer Critical reviews in oncology/hematology 2010 74 2 106 133 10.1016/j.critrevonc.2010.01.010 20138539

Scheer M. Sloots C. Van der Wilt G. Ruers T. Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases Annals of oncology 2008 19 11 1829 1835 10.1093/annonc/mdn398 18662955

Shinji S. Yamada T. Matsuda A. Sonoda H. Ohta R. Iwai T. Takeda K. Yonaga K. Masuda Y. Yoshida H. Recent Advances in the Treatment of Colorectal Cancer: A Review Journal of Nippon Medical School 2022 89 3 246 254 10.1272/jnms.JNMS.2022_89-310 35082204

Seretny M. Currie G. L. Sena E. S. Ramnarine S. Grant R. MacLeod M. R. Colvin L. A. Fallon M. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis Pain 2014 155 12 2461 2470 10.1016/j.pain.2014.09.020 25261162

Nicolay N. H. Berry D. P. Sharma R. A. Liver metastases from colorectal cancer: radioembolization with systemic therapy Nature Reviews Clinical Oncology 2009 6 12 687 697 10.1038/nrclinonc.2009.165 19884901

Das A. Giuliani M. Bezjak A. Radiotherapy for Lung Metastases: Conventional to Stereotactic Body Radiation Therapy Seminars in Radiation Oncology 2023 33 2 172 180 10.1016/j.semradonc.2022.11.007 36990634

Alrabiah K. Liao G. Shen Q. Chiang C.-L. Dawson L. A. The evolving role of radiation therapy as treatment for liver metastases Journal of the National Cancer Center 2022 2 3 183 187 10.1016/j.jncc.2022.06.004 39036451 PMC11256533

Häfner M. F. Debus J. Radiotherapy for Colorectal Cancer: Current Standards and Future Perspectives Viszeralmedizin 2016 32 3 172 177 10.1159/000446486 PMC4945782 27493944

de Azevedo J. M. Vailati B. B. Julião G. P. S. Fernandez L. M. Perez R. O. Current Surgical Strategies in the Management of Rectal Cancer Current Colorectal Cancer Reports 2019 15 1 18 27 10.1007/s11888-019-00428-0

Benson A. B. Venook A. P. Al-Hawary M. M. Azad N. Chen Y.-J. Ciombor K. K. Cohen S. Cooper H. S. Deming D. Garrido-Laguna I. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology Journal of the National Comprehensive Cancer Network 2022 20 10 1139 1167 10.6004/jnccn.2022.0051 36240850

Colorectal Cancer: The Diagnosis and Management of Colorectal Cancer , 2011 .

Cammà C. Giunta M. Fiorica F. Pagliaro L. Craxì A. Cottone M. Preoperative Radiotherapy for Resectable Rectal CancerA Meta-analysis JAMA 2000 284 8 1008 1015 10.1001/jama.284.8.1008 10944647

van Gijn W. Marijnen C. A. M. Nagtegaal I. D. Kranenbarg E. M.-K. Putter H. Wiggers T. Rutten H. J. T. Påhlman L. Glimelius B. van de Velde C. J. H. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial The Lancet Oncology 2011 12 6 575 582 10.1016/S1470-2045(11)70097-3 21596621

Kapiteijn E. Marijnen C. A. M. Nagtegaal I. D. Putter H. Steup W. H. Wiggers T. Rutten H. J. T. Pahlman L. Glimelius B. van Krieken J. H. J. M. Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer New England Journal of Medicine 2001 345 9 638 646 10.1056/NEJMoa010580 11547717

Sauer R. Becker H. Hohenberger W. Rödel C. Wittekind C. Fietkau R. Martus P. Tschmelitsch J. Hager E. Hess C. F. Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer New England Journal of Medicine 2004 351 17 1731 1740 10.1056/NEJMoa040694 15496622

Allegra C. J. Yothers G. O’Connell M. J. Beart R. W. Wozniak T. F. Pitot H. C. Shields A. F. Landry J. C. Ryan D. P. Arora A. Evans L. S. Bahary N. Soori G. Eakle J. F. Robertson J. M. Moore D. F. Mullane M. R. Marchello B. T. Ward P. J. Sharif S. Roh M. S. Wolmark N. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial JNCI: Journal of the National Cancer Institute 2015 107 11 djv248 10.1093/jnci/djv248 26374429 PMC4849360

Uehara K. Nagino M. Neoadjuvant treatment for locally advanced rectal cancer: a systematic review Surgery Today 2016 46 2 161 168 10.1007/s00595-015-1218-z 26170102

Dijkstra E. A. Hospers G. A. P. Kranenbarg E. M.-K. Fleer J. Roodvoets A. G. H. Bahadoer R. R. Guren M. G. Tjalma J. J. J. Putter H. Crolla R. M. P. H. Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer - The RAPIDO trial Radiotherapy and Oncology 2022 171 69 76 10.1016/j.radonc.2022.04.013 35447283

Joo J. H. Park J.-h. Kim J. C. Yu C. S. Lim S.-B. Park I. J. Kim T. W. Hong Y. S. Kim K.-p. Yoon S. M. Park J. Kim J. H. Local Control Outcomes Using Stereotactic Body Radiation Therapy for Liver Metastases From Colorectal Cancer International Journal of Radiation Oncology *Biology* Physics 2017 99 4 876 883 10.1016/j.ijrobp.2017.07.030 29063852

Tam S. Y. Wu V. W. C. A Review on the Special Radiotherapy Techniques of Colorectal Cancer Frontiers in Oncology 2019 9 208 10.3389/fonc.2019.00208 31001474 PMC6454863

Tonkens R. An overview of the drug development process Physician Executive 2005 31 3 48 16048163

Dowden H. Munro J. Trends in clinical success rates and therapeutic focus Nat. Rev. Drug Discov 2019 18 7 495 496 10.1038/d41573-019-00074-z 31267067

Moffat J. G. Vincent F. Lee J. A. Eder J. Prunotto M. Opportunities and challenges in phenotypic drug discovery: an industry perspective Nature reviews Drug discovery 2017 16 8 531 543 10.1038/nrd.2017.111 28685762

Minchinton A. I. Tannock I. F. Drug penetration in solid tumours Nature Reviews Cancer 2006 6 8 583 592 10.1038/nrc1893 16862189

Dewhirst M. W. Secomb T. W. Transport of drugs from blood vessels to tumour tissue Nature Reviews Cancer 2017 17 12 738 750 10.1038/nrc.2017.93 29123246 PMC6371795

Ida S. Ozaki N. Araki K. Hirashima K. Zaitsu Y. Taki K. Sakamoto Y. Miyamoto Y. Oki E. Morita M. Watanabe M. Maehara Y. Yamamura K.-i. Baba H. Ohmuraya M. SPINK1 status in colorectal cancer, impact on proliferation, and role in colitis-associated cancer Molecular Cancer Research 2015 13 7 1130 1138 10.1158/1541-7786.MCR-14-0581 25804623

Wei , Y. ; Au , J. L.-S. Role of tumour microenvironment in chemoresistance . In Integration/Interaction of Oncologic Growth ; Cancer Growth and Progression ; Meadows , G. G. , Ed.; Springer , 2005 ; Vol. 15 , pp 285 – 321 .

Han Y. Cho U. Kim S. Park I. S. Cho J. H. Dhanasekaran D. N. Song Y. S. Tumour microenvironment on mitochondrial dynamics and chemoresistance in cancer Free radical research 2018 52 11–12 1271 1287 10.1080/10715762.2018.1459594 29607684

De Visser K. E. Eichten A. Coussens L. M. Paradoxical roles of the immune system during cancer development Nature reviews cancer 2006 6 1 24 37 10.1038/nrc1782 16397525

Zhong B. Cheng B. Huang X. Xiao Q. Niu Z. Chen Y.-f. Yu Q. Wang W. Wu X.-J. Colorectal cancer-associated fibroblasts promote metastasis by up-regulating LRG1 through stromal IL-6/STAT3 signaling Cell death & disease 2022 13 16 10.1038/s41419-021-04461-6 PMC8688517 34930899

Pape J. Magdeldin T. Stamati K. Nyga A. Loizidou M. Emberton M. Cheema U. Cancer-associated fibroblasts mediate cancer progression and remodel the tumouroid stroma British journal of cancer 2020 123 7 1178 1190 10.1038/s41416-020-0973-9 32641866 PMC7524802

Nagasaki T. Hara M. Nakanishi H. Takahashi H. Sato M. Takeyama H. Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: Anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction British journal of cancer 2014 110 2 469 478 10.1038/bjc.2013.748 24346288 PMC3899773

Kondo J. Ekawa T. Endo H. Yamazaki K. Tanaka N. Kukita Y. Okuyama H. Okami J. Imamura F. Ohue M. High-throughput screening in colorectal cancer tissue-originated spheroids Cancer Sci 2019 110 1 345 355 10.1111/cas.13843 30343529 PMC6317944

Sensi F. D’Angelo E. Piccoli M. Pavan P. Mastrotto F. Caliceti P. Biccari A. Corallo D. Urbani L. Fassan M. Recellularized Colorectal Cancer Patient-derived Scaffolds as in vitro Pre-clinical 3D Model for Drug Screening Cancers (Basel) 2020 12 3 681 10.3390/cancers12030681 32183226 PMC7140024

Finnberg N. K. Gokare P. Lev A. Grivennikov S. I. MacFarlane A. W. Campbell K. S. Winters R. M. Kaputa K. Farma J. M. Abbas A. E.-S. Grasso L. Nicolaides N. C. El-Deiry W. S. Application of 3D tumoroid systems to define immune and cytotoxic therapeutic responses based on tumoroid and tissue slice culture molecular signatures Oncotarget 2017 8 40 66747 10.18632/oncotarget.19965 28977993 PMC5620133

Lee S. H. Hong J. H. Park H. K. Park J. S. Kim B. K. Lee J. Y. Jeong J. Y. Yoon G. S. Inoue M. Choi G. S. Colorectal cancer-derived tumor spheroids retain the characteristics of original tumors Cancer Lett 2015 367 1 34 42 10.1016/j.canlet.2015.06.024 26185002

Adriani G. Pavesi A. The OrganiX microfluidic system to recreate the complex tumour microenvironment Nature Reviews Immunology 2024 24 5 307 307 10.1038/s41577-024-01011-x 38413814

Yau J. N. N. Yempala T. Muthuramalingam R. P. K. Giustarini G. Teng G. Ang W. H. Gibson D. Adriani G. Pastorin G. Fluorescence-Guided Spatial Drug Screening in 3D Colorectal Cancer Spheroids Advanced Healthcare Materials 2024 13 2400203 10.1002/adhm.202400203 38774999

Petreus T. Cadogan E. Hughes G. Smith A. Pilla Reddy V. Lau A. O’Connor M. J. Critchlow S. Ashford M. Oplustil O’Connor L. Tumour-on-chip microfluidic platform for assessment of drug pharmacokinetics and treatment response Commun Biol 2021 4 1 1001 10.1038/s42003-021-02526-y 34429505 PMC8385015

Mulholland T. McAllister M. Patek S. Flint D. Underwood M. Sim A. Edwards J. Zagnoni M. Drug screening of biopsy-derived spheroids using a self-generated microfluidic concentration gradient Sci Rep 2018 8 1 14672 10.1038/s41598-018-33055-0 30279484 PMC6168499

Ong L. J. Y. Chia S. Wong S. Q. R. Zhang X. Chua H. Loo J. M. Chua W. Y. Chua C. Tan E. Hentze H. Tan I. B. DasGupta R. Toh Y.-C. A comparative study of tumour-on-chip models with patient-derived xenografts for predicting chemotherapy efficacy in colorectal cancer patients Frontiers in Bioengineering and Biotechnology 2022 10 952726 10.3389/fbioe.2022.952726 36147524 PMC9488115

Zhang Y. S. Yue K. Aleman J. Mollazadeh-Moghaddam K. Bakht S. M. Yang J. Jia W. Dell’Erba V. Assawes P. Shin S. R. Dokmeci M. R. Oklu R. Khademhosseini A. 3D bioprinting for tissue and organ fabrication Annals of biomedical engineering 2017 45 148 163 10.1007/s10439-016-1612-8 27126775 PMC5085899

Agarwal S. Saha S. Balla V. K. Pal A. Barui A. Bodhak S. Current developments in 3D bioprinting for tissue and organ regeneration-a review Frontiers in Mechanical Engineering 2020 6 589171 10.3389/fmech.2020.589171

Vitale S. Calapà F. Colonna F. Luongo F. Biffoni M. De Maria R. Fiori M. E. Advancements in 3D In Vitro Models for Colorectal Cancer Advanced Science 2024 11 32 2405084 10.1002/advs.202405084 38962943 PMC11348154

Yau J. N. N. Adriani G. Three-dimensional heterotypic colorectal cancer spheroid models for evaluation of drug response Frontiers in Oncology 2023 13 1148930 10.3389/fonc.2023.1148930 37469395 PMC10352797

Baiao A. Dias S. Soares A. F. Pereira C. L. Oliveira C. Sarmento B. Advances in the use of 3D colorectal cancer models for novel drug discovery Expert opinion on drug discovery 2022 17 6 569 580 10.1080/17460441.2022.2056162 35343351

Teixeira N. Baião A. Dias S. Sarmento B. The progress and challenges in modeling colorectal cancer and the impact on novel drug discovery Expert Opinion on Drug Discovery 2025 20 565 10.1080/17460441.2024.2404238 39282980

Neto C. D. Rocha J. Gaspar M. M. Reis C. P. Experimental Murine Models for Colorectal Cancer Research Cancers 2023 15 9 2570 10.3390/cancers15092570 37174036 PMC10177088

Johnson R. L. Fleet J. C. Animal models of colorectal cancer Cancer and Metastasis Reviews 2013 32 39 61 10.1007/s10555-012-9404-6 23076650 PMC3572245

Nascimento-Gonçalves E. Mendes B. A. L. Silva-Reis R. Faustino-Rocha A. I. Gama A. Oliveira P. A. Animal Models of Colorectal Cancer: From Spontaneous to Genetically Engineered Models and Their Applications Veterinary Sciences 2021 8 4 59 10.3390/vetsci8040059 33916402 PMC8067250

Kobaek-Larsen M. Thorup I. Diederichsen A. Fenger C. Hoitinga M. R. Review of colorectal cancer and its metastases in rodent models: comparative aspects with those in humans Comparative Medicine 2000 50 16 26 10987662

Treuting , P. M. ; Dintzis , S. M. ; Montine , K. S. Comparative Anatomy and Histology: A Mouse, Rat, and Human Atlas ; Academic Press , 2017 .

Kucherlapati M. H. Mouse models in colon cancer, inferences, and implications iScience 2023 26 6 106958 10.1016/j.isci.2023.106958 37332609 PMC10272511

Oliveira R. C. Abrantes A. M. Tralhão J. G. Botelho M. F. The role of mouse models in colorectal cancer researchThe need and the importance of the orthotopic models Animal Models and Experimental Medicine 2020 3 1 1 8 10.1002/ame2.12102 32318654 PMC7167241

O’Neill A. M. Burrington C. M. Gillaspie E. A. Lynch D. T. Horsman M. J. Greene M. W. High-fat Western diet-induced obesity contributes to increased tumor growth in mouse models of human colon cancer Nutr. Res. (N.Y.) 2016 36 12 1325 1334 10.1016/j.nutres.2016.10.005 27866828

De-Souza A. S. C. Costa-Casagrande T. A. Animal models for colorectal cancer ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo) 2018 31 e1369 10.1590/0102-672020180001e1369 PMC6044195 29972397

Miyamoto M. Tani Y. A study on colon cancer-prone rats of WF-Osaka strain Med. J. Osaka Univ. 1989 38 1 12 2485390

Mehta R. S. Song M. Nishihara R. Drew D. A. Wu K. Qian Z. R. Fung T. T. Hamada T. Masugi Y. da Silva A. Dietary Patterns and Risk of Colorectal Cancer: Analysis by Tumor Location and Molecular Subtypes Gastroenterology 2017 152 8 1944 1953 10.1053/j.gastro.2017.02.015 28249812 PMC5447483

Liu L. Yan Q. Chen Z. Wei X. Li L. Tang D. Tan J. Xu C. Yu C. Lai Y. Overview of research progress and application of experimental models of colorectal cancer Frontiers in Pharmacology 2023 14 1193213 10.3389/fphar.2023.1193213 37469864 PMC10352992

Jackstadt R. Sansom O. J. Mouse models of intestinal cancer The Journal of Pathology 2016 238 2 141 151 10.1002/path.4645 26414675 PMC4832380

Bourn M. D. Batchelor D. V. B. Ingram N. McLaughlan J. R. Coletta P. L. Evans S. D. Peyman S. A. High-throughput microfluidics for evaluating microbubble enhanced delivery of cancer therapeutics in spheroid cultures J. Controlled Release 2020 326 13 24 10.1016/j.jconrel.2020.06.011 32562855

Carvalho M. Barata D. Teixeira L. Giselbrecht S. Reis R. Oliveira J. Truckenmüller R. Habibovic P. Colorectal tumor-on-a-chip system: A 3D tool for precision onco-nanomedicine Science advances 2019 5 eaaw1317 10.1126/sciadv.aaw1317 31131324 PMC6531003

Wang T. Green R. Howell M. Martinez T. Dutta R. Mohapatra S. Mohapatra S. S. The design and characterization of a gravitational microfluidic platform for drug sensitivity assay in colorectal perfused tumoroid cultures Nanomedicine 2020 30 102294 10.1016/j.nano.2020.102294 32861031

Reidy E. Leonard N. A. Treacy O. Ryan A. E. A 3D View of Colorectal Cancer Models in Predicting Therapeutic Responses and Resistance Cancers (Basel) 2021 13 2 227 10.3390/cancers13020227 33435170 PMC7827038

Castro F. Leite Pereira C. Helena Macedo M. Almeida A. Jose Silveira M. Dias S. Patricia Cardoso A. Jose Oliveira M. Sarmento B. Advances on colorectal cancer 3D models: The needed translational technology for nanomedicine screening Adv Drug Deliv Rev 2021 175 113824 10.1016/j.addr.2021.06.001 34090966

Pinho D. Santos D. Vila A. Carvalho S. Establishment of colorectal cancer organoids in microfluidic-based system Micromachines 2021 12 5 497 10.3390/mi12050497 33924829 PMC8146416

Chen H. Cheng Y. Wang X. Wang J. Shi X. Li X. Tan W. Tan Z. 3D printed in vitro tumor tissue model of colorectal cancer Theranostics 2020 10 26 12127 12143 10.7150/thno.52450 33204333 PMC7667682

Sbirkov Y. Molander D. Milet C. Bodurov I. Atanasov B. Penkov R. Belev N. Forraz N. McGuckin C. Sarafian V. A colorectal cancer 3D bioprinting workflow as a platform for disease modeling and chemotherapeutic screening Frontiers in Bioengineering and Biotechnology 2021 9 755563 10.3389/fbioe.2021.755563 34869264 PMC8638705

Cadamuro F. Marongiu L. Marino M. Tamini N. Nespoli L. Zucchini N. Terzi A. Altamura D. Gao Z. Giannini C. Bindi G. Smith A. Magni F. Bertini S. Granucci F. Nicotra F. Russo L. 3D bioprinted colorectal cancer models based on hyaluronic acid and signalling glycans Carbohydr. Polym. 2023 302 120395 10.1016/j.carbpol.2022.120395 36604073

Jeong S. Y. Lee J. H. Shin Y. Chung S. Kuh H. J. Co-Culture of Tumor Spheroids and Fibroblasts in a Collagen Matrix-Incorporated Microfluidic Chip Mimics Reciprocal Activation in Solid Tumor Microenvironment PLoS One 2016 11 7 e0159013 10.1371/journal.pone.0159013 27391808 PMC4938568

Lee J. M. Park D. Y. Yang L. Kim E. J. Ahrberg C. D. Lee K. B. Chung B. G. Generation of uniform-sized multicellular tumor spheroids using hydrogel microwells for advanced drug screening Sci Rep 2018 8 1 17145 10.1038/s41598-018-35216-7 30464248 PMC6249215

Voß H. Wurlitzer M. Smit D. J. Ewald F. Alawi M. Spohn M. Indenbirken D. Omidi M. David K. Juhl H. Simon R. Sauter G. Fischer L. Izbicki J. R. Molloy M. P. Nashan B. Schluter H. Jucker M. Differential regulation of extracellular matrix proteins in three recurrent liver metastases of a single patient with colorectal cancer Clinical & Experimental Metastasis 2020 37 649 656 10.1007/s10585-020-10058-8 33099724 PMC7666585

Zoetemelk M. Rausch M. Colin D. J. Dormond O. Nowak-Sliwinska P. Short-term 3D culture systems of various complexity for treatment optimization of colorectal carcinoma Sci Rep 2019 9 1 7103 10.1038/s41598-019-42836-0 31068603 PMC6506470

Bauleth-Ramos T. Feijão T. Gonçalves A. Shahbazi M.-A. Liu Z. Barrias C. Oliveira M. J. Granja P. Santos H. A. Sarmento B. Colorectal cancer triple co-culture spheroid model to assess the biocompatibility and anticancer properties of polymeric nanoparticles J. Controlled Release 2020 323 398 411 10.1016/j.jconrel.2020.04.025 32320816

Carvalho S. Silveira M. J. Domingues M. Ferreira B. Pereira C. L. Palmira Gremião M. Sarmento B. Multicellular Quadruple Colorectal Cancer Spheroids as an In Vitro Tool for Anti-angiogenic Potential Evaluation of Nanoparticles Advanced Therapeutics 2023 6 2200282 10.1002/adtp.202200282

Nakagawa H. Liyanarachchi S. Davuluri R. V. Auer H. Martin E. W. De La Chapelle A. Frankel W. L. Role of cancer-associated stromal fibroblasts in metastatic colon cancer to the liver and their expression profiles Oncogene 2004 23 44 7366 7377 10.1038/sj.onc.1208013 15326482

Mueller L. Goumas F. A. Affeldt M. Sandtner S. Gehling U. M. Brilloff S. Walter J. Karnatz N. Lamszus K. Rogiers X. Broering D. C. Stromal fibroblasts in colorectal liver metastases originate from resident fibroblasts and generate an inflammatory microenvironment The American journal of pathology 2007 171 5 1608 1618 10.2353/ajpath.2007.060661 17916596 PMC2043521

Jin G Yang Y Liu K Zhao J Chen X Liu H Bai R Li X Jiang Y Zhang X Lu J Dong Z Combination curcumin and (-)-epigallocatechin-3-gallate inhibits colorectal carcinoma microenvironment-induced angiogenesis by JAK/STAT3/IL-8 pathway Oncogenesis 2017 6 10 e384 10.1038/oncsis.2017.84 28967875 PMC5668882

Zhong X. Chen B. Yang Z. The role of tumor-associated macrophages in colorectal carcinoma progression Cellular Physiology and Biochemistry 2018 45 1 356 365 10.1159/000486816 29402795

Baier P. K. Wolff-Vorbeck G. Eggstein S. Baumgartner U. Hopt U. T. Cytokine expression in colon carcinoma Anticancer Research 2005 25 3B 2135 2139 16158955

Wei C. Yang C. Wang S. Shi D. Zhang C. Lin X. Liu Q. Dou R. Xiong B. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis Molecular cancer 2019 18 64 10.1186/s12943-019-0976-4 30927925 PMC6441214

Lamberti M. J. Morales Vasconsuelo A. B. Ferrara M. G. Rumie Vittar N. B. Recapitulation of hypoxic tumor-stroma microenvironment to study photodynamic therapy implications Photochem. Photobiol. 2020 96 4 897 905 10.1111/php.13220 32012283

Santoyo-Ramos P. Likhatcheva M. García-Zepeda E. A. Castañeda-Patlán M. C. Robles-Flores M. Hypoxia-inducible factors modulate the stemness and malignancy of colon cancer cells by playing opposite roles in canonical Wnt signaling PloS one 2014 9 11 e112580 10.1371/journal.pone.0112580 25396735 PMC4232394

Nagaraju G. P. Bramhachari P. V. Raghu G. El-Rayes B. F. Hypoxia inducible factor-1α: Its role in colorectal carcinogenesis and metastasis Cancer letters 2015 366 1 11 18 10.1016/j.canlet.2015.06.005 26116902

Tang Y.-A. Chen Y.-f. Bao Y. Mahara S. Yatim S. M. J. M. Oguz G. Lee P. L. Feng M. Cai Y. Tan E. Y. Fong S. S. Yang Z.-h. Lan P. Wu X.-j. Yu Q. Hypoxic tumor microenvironment activates GLI2 via HIF-1α and TGF-β2 to promote chemoresistance in colorectal cancer Proceedings of the National Academy of Sciences 2018 115 26 E5990 10.1073/pnas.1801348115 PMC6042102 29891662

Dong S. Liang S. Cheng Z. Zhang X. Luo L. Li L. Zhang W. Li S. Xu Q. Zhong M. Zhu J. Zhang G. Hu S. ROS/PI3K/Akt and Wnt/β-catenin signalings activate HIF-1α-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer Journal of Experimental & Clinical Cancer Research 2022 41 15 10.1186/s13046-021-02229-6 34998404 PMC8742403

Venkatachalam K. Vinayagam R. Arokia Vijaya Anand M. Isa N. M. Ponnaiyan R. Biochemical and molecular aspects of 1,2-dimethylhydrazine (DMH)-induced colon carcinogenesis: a review Toxicology Research 2020 9 1 2 18 10.1093/toxres/tfaa004 32440334 PMC7233314

El Joumaa M. M. Taleb R. I. Rizk S. Borjac J. M. Protective effect of Matricaria chamomilla extract against 1,2-dimethylhydrazine-induced colorectal cancer in mice Journal of Complementary and Integrative Medicine 2020 17 3 20190143 10.1515/jcim-2019-0143 32229665

Ertekin T. Ekinci N. Karaca O. Nisari M. Canoz O. Ulger H. Effect of Angiostatin on 1,2-dimethylhydrazine-induced colon cancer in mice Toxicology and Industrial Health 2013 29 6 490 497 10.1177/0748233712440137 22393105

Shree A. Islam J. Sultana S. Quercetin ameliorates reactive oxygen species generation, inflammation, mucus depletion, goblet disintegration, and tumor multiplicity in colon cancer: Probable role of adenomatous polyposis coli, β-catenin Phytotherapy Research 2021 35 4 2171 2184 10.1002/ptr.6969 33350534

Eissa M. M. Ismail C. A. El-Azzouni M. Z. Ghazy A. A. Hadi M. A. Immuno-therapeutic potential of Schistosoma mansoni and Trichinella spiralis antigens in a murine model of colon cancer Investigational New Drugs 2019 37 1 47 56 10.1007/s10637-018-0609-6 29808307

Zhu Q. Jin Z. Wu W. Gao R. Guo B. Gao Z. Yang Y. Qin H. Analysis of the Intestinal Lumen Microbiota in an Animal Model of Colorectal Cancer PLOS ONE 2014 9 3 e90849 10.1371/journal.pone.0090849 24603888 PMC3946251

Wang C. Qiao X. Wang J. Yang J. Yang C. Qiao Y. Guan Y. Wen A. Jiang L. Amelioration of DMH-induced colon cancer by eupafolin through the reprogramming of apoptosis-associated p53/Bcl2/Bax signaling in rats European Journal of Inflammation 2022 20 20587392211069771 10.1177/20587392211069771

Babu S. S. N. Singla S. Jena G. Role of Combination Treatment of Aspirin and Zinc in DMH-DSS-induced Colon Inflammation, Oxidative Stress and Tumour Progression in Male BALB/c Mice Biological Trace Element Research 2023 201 3 1327 1343 10.1007/s12011-022-03241-3 35438409

Lin P.-Y. Li S.-C. Lin H.-P. Shih C.-K. Germinated brown rice combined with Lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis inhibits colorectal carcinogenesis in rats Food Science & Nutrition 2019 7 1 216 224 10.1002/fsn3.864 30680175 PMC6341155

Fragoso M. F. Romualdo G. R. Vanderveer L. A. Franco-Barraza J. Cukierman E. Clapper M. L. Carvalho R. F. Barbisan L. F. Lyophilized açaí pulp (Euterpe oleracea Mart) attenuates colitis-associated colon carcinogenesis while its main anthocyanin has the potential to affect the motility of colon cancer cells Food Chem. Toxicol. 2018 121 237 245 10.1016/j.fct.2018.08.078 30194994

Tian Y. Zuo L. Guan B. Wu H. He Y. Xu Z. Shen M. Hu J. Qian J. Microbiota from patients with ulcerative colitis promote colorectal carcinogenesis in mice Nutrition 2022 102 111712 10.1016/j.nut.2022.111712 35802940

Arango-Varela S. S. Luzardo-Ocampo I. Maldonado-Celis M. E. Andean berry (Vaccinium meridionale Swartz) juice, in combination with Aspirin, displayed antiproliferative and pro-apoptotic mechanisms in vitro while exhibiting protective effects against AOM-induced colorectal cancer in vivo Food Research International 2022 157 111244 10.1016/j.foodres.2022.111244 35761556

Bähr I. Jaeschke L. Nimptsch K. Janke J. Herrmann P. Kobelt D. Kielstein H. Pischon T. Stein U. Obesity, colorectal cancer and MACC1 expression: A possible novel molecular association Int. J. Oncol. 2022 60 2 17 10.3892/ijo.2022.5307 35014688 PMC8776326

Dikeocha I. J. Al-Kabsi A. M. Chiu H.-T. Alshawsh M. A. Faecalibacterium prausnitzii Ameliorates Colorectal Tumorigenesis and Suppresses Proliferation of HCT116 Colorectal Cancer Cells Biomedicines 2022 10 5 1128 10.3390/biomedicines10051128 35625865 PMC9138996

Mundo A. I. Muhammad A. Balza K. Nelson C. E. Muldoon T. J. Longitudinal examination of perfusion and angiogenesis markers in primary colorectal tumors shows distinct signatures for metronomic and maximum-tolerated dose strategies Neoplasia 2022 32 100825 10.1016/j.neo.2022.100825 35901621 PMC9326335

Ma F. Song Y. Sun M. Wang A. Jiang S. Mu G. Tuo Y. Exopolysaccharide Produced by Lactiplantibacillus plantarum-12 Alleviates Intestinal Inflammation and Colon Cancer Symptoms by Modulating the Gut Microbiome and Metabolites of C57BL/6 Mice Treated by Azoxymethane/Dextran Sulfate Sodium Salt Foods 2021 10 12 3060 10.3390/foods10123060 34945611 PMC8701795

Tajasuwan L. Kettawan A. Rungruang T. Wunjuntuk K. Prombutara P. Muangnoi C. Kettawan A. K. Inhibitory Effect of Dietary Defatted Rice Bran in an AOM/DSS-Induced Colitis-Associated Colorectal Cancer Experimental Animal Model Foods 2022 11 21 3488 10.3390/foods11213488 36360101 PMC9654186

Ferreira-Lazarte A. Fernández J. Gallego-Lobillo P. Villar C. J. Lombó F. Moreno F. J. Villamiel M. Behaviour of citrus pectin and modified citrus pectin in an azoxymethane/dextran sodium sulfate (AOM/DSS)-induced rat colorectal carcinogenesis model International Journal of Biological Macromolecules 2021 167 1349 1360 10.1016/j.ijbiomac.2020.11.089 33202274

Schepelmann M. Kupper N. Gushchina V. Mesteri I. Manhardt T. Moritsch S. Müller C. Piatek K. Salzmann M. Vlasaty A. AOM/DSS Induced Colitis-Associated Colorectal Cancer in 14-Month-Old Female Balb/C and C57/Bl6 MiceA Pilot Study International Journal of Molecular Sciences 2022 23 9 5278 10.3390/ijms23095278 35563665 PMC9104960

Yang M. Zhang F. Yang C. Wang L. Sung J. Garg P. Zhang M. Merlin D. Oral Targeted Delivery by Nanoparticles Enhances Efficacy of an Hsp90 Inhibitor by Reducing Systemic Exposure in Murine Models of Colitis and Colitis-Associated Cancer Journal of Crohn’s and Colitis 2020 14 130 141 10.1093/ecco-jcc/jjz113 31168612

Osawa E. Nakajima A. Fujisawa T. Kawamura Y. I. Toyama-Sorimachi N. Nakagama H. Dohi T. Predominant T helper type 2-inflammatory responses promote murine colon cancers Int. J. Cancer 2006 118 9 2232 2236 10.1002/ijc.21639 16331625

Song M. Chan A. T. Sun J. Influence of the Gut Microbiome, Diet, and Environment on Risk of Colorectal Cancer Gastroenterology 2020 158 2 322 340 10.1053/j.gastro.2019.06.048 31586566 PMC6957737

Kannen V. Hintzsche H. Zanette D. L. Silva W. A. Jr. Garcia S. B. Waaga-Gasser A. M. Stopper H. Antiproliferative Effects of Fluoxetine on Colon Cancer Cells and in a Colonic Carcinogen Mouse Model PLOS ONE 2012 7 11 e50043 10.1371/journal.pone.0050043 23209640 PMC3507893

Frajacomo F. T. Kannen V. Deminice R. Geraldino T. H. Pereira-Da-Silva G. Uyemura S. A. Jordão A. A. Jr Garcia S. B. Aerobic training activates interleukin 10 for colon anticarcinogenic effects Med Sci Sports Exerc 2015 47 9 1806 1813 10.1249/MSS.0000000000000623 25628174

Machado V. F. Parra R. S. Leite C. A. Minto S. B. Cunha T. M. Cunha F. d. Q. Garcia S. B. Feitosa M. R. da Rocha J. J. R. Feres O. Experimental Model of Rectal Carcinogenesis Induced by N-Methyl-N-Nitrosoguanidine in Mice with Endoscopic Evaluation International Journal of Medical Sciences 2020 17 16 2505 2510 10.7150/ijms.48231 33029093 PMC7532479

Qayum A. Singh J. Kumar A. Shah S. M. Srivastava S. Kushwaha M. Magotra A. Nandi U. Malik R. Shah B. A. 2-Pyridin-4-yl-methylene-beta-boswellic Acid–A Potential Candidate for Targeting O6-Methylguanine–DNA Methyltransferase Epi-transcriptional Reprogramming in KRAS G13D–Microsatellite Stable, G12V–Microsatellite Instable Mutant Colon Cancer ACS Pharmacology & Translational Science 2022 5 5 306 320 10.1021/acsptsci.1c00228 35592435 PMC9112411

Ahmed H. H. El-Abhar H. S. Hassanin E. A. K. Abdelkader N. F. Shalaby M. B. Punica granatum suppresses colon cancer through downregulation of Wnt/β-Catenin in rat model Revista Brasileira de Farmacognosia 2017 27 5 627 635 10.1016/j.bjp.2017.05.010

Nakayama Y. Inoue Y. Minagawa N. Onitsuka K. Nagata J. Shibao K. Hirata K. Sako T. Nagata N. Yamaguchi K. Chemopreventive Effect of 4-[3,5-Bis­(trimethylsilyl) benzamido] Benzoic Acid (TAC-101) on MNU-induced Colon Carcinogenesis in a Rat Model Anticancer Res. 2009 29 6 2059 2065 19528465

Yang X. Peng H. Luo Z. Luo A. Cai M. Xu L. Wang H. The dietary carcinogen PhIP activates p53-dependent DNA damage response in the colon of CYP1A-humanized mice BioFactors 2021 47 4 612 626 10.1002/biof.1730 33811687

Chen J. X. Liu A. Lee M.-J. Wang H. Yu S. Chi E. Reuhl K. Suh N. Yang C. S. δ- and γ-tocopherols inhibit phIP/DSS-induced colon carcinogenesis by protection against early cellular and DNA damages Molecular Carcinogenesis 2017 56 1 172 183 10.1002/mc.22481 27175800 PMC5647579

Cefalì M. Epistolio S. Palmarocchi M. C. Frattini M. De Dosso S. Research progress on KRAS mutations in colorectal cancer Journal of Cancer Metastasis and Treatment 2021 7 26 10.20517/2394-4722.2021.61

Peehl D. M. Badea C. T. Chenevert T. L. Daldrup-Link H. E. Ding L. Dobrolecki L. E. Houghton A. M. Kinahan P. E. Kurhanewicz J. Lewis M. T. Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials Tomography 2023 9 2 657 680 10.3390/tomography9020053 36961012 PMC10037611

Chandra R. Karalis J. D. Liu C. Murimwa G. Z. Voth Park J. Heid C. A. Reznik S. I. Huang E. Minna J. D. Brekken R. A. The Colorectal Cancer Tumor Microenvironment and Its Impact on Liver and Lung Metastasis Cancers 2021 13 24 6206 10.3390/cancers13246206 34944826 PMC8699466

Evans J. P. Sutton P. A. Winiarski B. K. Fenwick S. W. Malik H. Z. Vimalachandran D. Tweedle E. M. Costello E. Palmer D. H. Park B. K. From mice to men: Murine models of colorectal cancer for use in translational research Critical Reviews in Oncology/Hematology 2016 98 94 105 10.1016/j.critrevonc.2015.10.009 26558688

Fu X. Y. Besterman J. M. Monosov A. Hoffman R. M. Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens Proceedings of the National Academy of Sciences 1991 88 20 9345 9349 10.1073/pnas.88.20.9345 PMC52711 1924398

Chang Y. J. Hsu W. H. Chang C. H. Lan K. L. Ting G. Lee T. W. Combined therapeutic efficacy of 188Re-liposomes and sorafenib in an experimental colorectal cancer liver metastasis model by intrasplenic injection of C26-luc murine colon cancer cells Mol Clin Oncol 2014 2 3 380 384 10.3892/mco.2014.246 24772304 PMC3999117

Chen J. Liao S. Xiao Z. Pan Q. Wang X. Shen K. Wang S. Yang L. Guo F. Liu H.-f. The development and improvement of immunodeficient mice and humanized immune system mouse models Frontiers in Immunology 2022 13 7579 10.3389/fimmu.2022.1007579 PMC9626807 36341323

Pourquier P. Azzi J. La dérive génétique des lignées cancéreuses en culture affecte la réponse aux agents anticancéreux Bulletin du Cancer 2019 106 1 9 10 10.1016/j.bulcan.2018.12.002 30595222

Greenlee J. D. King M. R. A syngeneic MC38 orthotopic mouse model of colorectal cancer metastasis Biology Methods and Protocols 2022 7 1 bpac024 10.1093/biomethods/bpac024 36225595 PMC9550231

Cho S.-Y. Patient-derived xenografts as compatible models for precision oncology Laboratory animal research 2020 36 14 10.1186/s42826-020-00045-1 32461927 PMC7238616

Aytes A. Molleví D. G. Martinez-Iniesta M. Nadal M. Vidal A. Morales A. Salazar R. Capellà G. Villanueva A. Stromal interaction molecule 2 (STIM2) is frequently overexpressed in colorectal tumors and confers a tumor cell growth suppressor phenotype Molecular Carcinogenesis 2012 51 9 746 753 10.1002/mc.20843 22125164

Cho S.-Y. Sung C. O. Chae J. Lee J. Na D. Kang W. Kang J. Min S. Lee A. Kwak E. Alterations in the Rho pathway contribute to Epstein-Barr virus-induced lymphomagenesis in immunosuppressed environments Blood, The Journal of the American Society of Hematology 2018 131 17 1931 1941 10.1158/1535-7163.TARG-17-A181 PMC5921963 29475961

Wang E. Xiang K. Zhang Y. Wang X.-F. Patient-derived organoids (PDOs) and PDO-derived xenografts (PDOXs): New opportunities in establishing faithful pre-clinical cancer models Journal of the National Cancer Center 2022 2 4 263 276 10.1016/j.jncc.2022.10.001 39036550 PMC11256726

De Angelis M. L. Francescangeli F. Nicolazzo C. Xhelili E. La Torre F. Colace L. Bruselles A. Macchia D. Vitale S. Gazzaniga P. An Orthotopic Patient-Derived Xenograft (PDX) Model Allows the Analysis of Metastasis-Associated Features in Colorectal Cancer Frontiers in Oncology 2022 12 869485 10.3389/fonc.2022.869485 35837106 PMC9275818

Yang R. Yu Y. Patient-derived organoids in translational oncology and drug screening Cancer Letters 2023 562 216180 10.1016/j.canlet.2023.216180 37061121

Yang Y.-S. Liu C.-Y. Wen D. Gao D.-Z. Lin S. He H.-f. Zhao X.-F. Recent advances in the development of transplanted colorectal cancer mouse models Translational Research 2022 249 128 143 10.1016/j.trsl.2022.07.003 35850446

Shibata H. Toyama K. Shioya H. Ito M. Hirota M. Hasegawa S. Matsumoto H. Takano H. Akiyama T. Toyoshima K. Kanamaru R. Kanegae Y. Saito I. Nakamura Y. Shiba K. Noda T. Rapid Colorectal Adenoma Formation Initiated by Conditional Targeting of the < i > Apc</i> Gene Science 1997 278 5335 120 123 10.1126/science.278.5335.120 9311916

Xue Y. Johnson R. DeSmet M. Snyder P. W. Fleet J. C. Generation of a Transgenic Mouse for Colorectal Cancer Research with Intestinal Cre Expression Limited to the Large Intestine Molecular Cancer Research 2010 8 8 1095 1104 10.1158/1541-7786.MCR-10-0195 20663863 PMC2923672

Sakamoto K. Lin B. Nunomura K. Izawa T. Nakagawa S. The K-Ras­(G12D)-inhibitory peptide KS-58 suppresses growth of murine CT26 colorectal cancer cell-derived tumors Scientific Reports 2022 12 1 8121 10.1038/s41598-022-12401-3 35581303 PMC9114382

Hung K. E. Maricevich M. A. Richard L. G. Chen W. Y. Richardson M. P. Kunin A. Bronson R. T. Mahmood U. Kucherlapati R. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment Proceedings of the National Academy of Sciences 2010 107 4 1565 1570 10.1073/pnas.0908682107 PMC2824379 20080688

Herberg M. Siebert S. Quaas M. Thalheim T. Rother K. Hussong M. Altmüller J. Kerner C. Galle J. Schweiger M. R. Loss of Msh2 and a single-radiation hit induce common, genome-wide, and persistent epigenetic changes in the intestine Clinical Epigenetics 2019 11 1 65 10.1186/s13148-019-0639-8 31029155 PMC6486978

Choi S. H. Huang A. Y. Letterio J. J. Kim B.-G. Smad4-deficient T cells promote colitis-associated colon cancer via an IFN-γ-dependent suppression of 15-hydroxyprostaglandin dehydrogenase Frontiers in Immunology 2022 13 932412 10.3389/fimmu.2022.932412 36045676 PMC9420841

Bennecke M. Kriegl L. Bajbouj M. Retzlaff K. Robine S. Jung A. Arkan M. C. Kirchner T. Greten F. R. <em > Ink4a/Arf</em> and Oncogene-Induced Senescence Prevent Tumor Progression during Alternative Colorectal Tumorigenesis Cancer Cell 2010 18 2 135 146 10.1016/j.ccr.2010.06.013 20708155

Steffensen I.-L. Alexander J. Impact of genetic background on spontaneous or 2-amino-1-methyl-6-phenylimidazo­[4,5-b]­pyridine (PhIP)-induced intestinal tumorigenesis in Min/+ mice Cancer Letters 2006 240 2 289 296 10.1016/j.canlet.2005.09.015 16343741

Oshima H. Nakayama M. Han T.-S. Naoi K. Ju X. Maeda Y. Robine S. Tsuchiya K. Sato T. Sato H. Suppressing TGFβ Signaling in Regenerating Epithelia in an Inflammatory Microenvironment Is Sufficient to Cause Invasive Intestinal Cancer Cancer Res. 2015 75 4 766 776 10.1158/0008-5472.CAN-14-2036 25687406

Sakai E. Nakayama M. Oshima H. Kouyama Y. Niida A. Fujii S. Ochiai A. Nakayama K. I. Mimori K. Suzuki Y. Combined Mutation of Apc, Kras, and Tgfbr2 Effectively Drives Metastasis of Intestinal Cancer Cancer Res. 2018 78 5 1334 1346 10.1158/0008-5472.CAN-17-3303 29282223

Takaku K. Oshima M. Miyoshi H. Matsui M. Seldin M. F. Taketo M. M. Intestinal Tumorigenesis in Compound Mutant Mice of both < em > Dpc4</em>(<em > Smad4</em>) and < em > Apc</em> Genes Cell 1998 92 5 645 656 10.1016/S0092-8674(00)81132-0 9506519

Grim J. E. Knoblaugh S. E. Guthrie K. A. Hagar A. Swanger J. Hespelt J. Delrow J. J. Small T. Grady W. M. Nakayama K. I. Fbw7 and p53 Cooperatively Suppress Advanced and Chromosomally Unstable Intestinal Cancer Mol. Cell. Biol. 2012 32 11 2160 2167 10.1128/MCB.00305-12 22473991 PMC3372235

Cagan R. L. Zon L. I. White R. M. Modeling Cancer with Flies and Fish Developmental Cell 2019 49 3 317 324 10.1016/j.devcel.2019.04.013 31063751 PMC6506185

Wangler M. F. Yamamoto S. Chao H.-T. Posey J. E. Westerfield M. Postlethwait J. Network M. o. t. U. D. Hieter P. Boycott K. M. Campeau P. M. Bellen H. J. Model Organisms Facilitate Rare Disease Diagnosis and Therapeutic Research Genetics 2017 207 9 27 10.1534/genetics.117.203067 28874452 PMC5586389

Munnik C. Xaba M. P. Malindisa S. T. Russell B. L. Sooklal S. A. Drosophila melanogaster: A platform for anticancer drug discovery and personalized therapies Frontiers in Genetics 2022 13 949241 10.3389/fgene.2022.949241 36003330 PMC9393232

Richardson , H. E. ; Willoughby , L. ; Humbert , P. O. Screening for Anti-cancer Drugs in Drosophila . In Encyclopedia of Life Sciences , 2015 ; pp 1 – 14 . 10.1002/9780470015902.a0022535

Schartl M. Lu Y. Validity of Xiphophorus fish as models for human disease Disease Models & Mechanisms 2024 17 1 50382 10.1242/dmm.050382 PMC10855230 38299666

Gamble J. T. Elson D. J. Greenwood J. A. Tanguay R. L. Kolluri S. K. The Zebrafish Xenograft Models for Investigating Cancer and Cancer Therapeutics Biology 2021 10 4 252 10.3390/biology10040252 33804830 PMC8063817

Yan C. Brunson D. C. Tang Q. Do D. Iftimia N. A. Moore J. C. Hayes M. N. Welker A. M. Garcia E. G. Dubash T. D. Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish Cell 2019 177 7 1903 1914 10.1016/j.cell.2019.04.004 31031007 PMC6570580

Gordon I. Paoloni M. Mazcko C. Khanna C. The Comparative Oncology Trials Consortium: Using Spontaneously Occurring Cancers in Dogs to Inform the Cancer Drug Development Pathway PLOS Medicine 2009 6 10 e1000161 10.1371/journal.pmed.1000161 19823573 PMC2753665

Nasir L. Devlin P. McKevitt T. Rutteman G. Argyle D. J. Telomere Lengths and Telomerase Activity in Dog Tissues: A Potential Model System to Study Human Telomere and Telomerase Biology Neoplasia 2001 3 4 351 359 10.1038/sj.neo.7900173 11571635 PMC1505860

Tang J. Le S. Sun L. Yan X. Zhang M. MacLeod J. LeRoy B. Northrup N. Ellis A. Yeatman T. J. Liang Y. Zwick M. E. Zhao S. Copy number abnormalities in sporadic canine colorectal cancers Genome research 2010 20 3 341 350 10.1101/gr.092726.109 20086242 PMC2840980

Wang J. Wang T. Sun Y. Feng Y. Kisseberth W. C. Henry C. J. Mok I. Lana S. E. Dobbin K. Northrup N. Proliferative and Invasive Colorectal Tumors in Pet Dogs Provide Unique Insights into Human Colorectal Cancer Cancers 2018 10 9 330 10.3390/cancers10090330 30223484 PMC6162437

Wu K. Rodrigues L. Post G. Harvey G. White M. Miller A. Lambert L. Lewis B. Lopes C. Zou J. Analyses of canine cancer mutations and treatment outcomes using real-world clinico-genomics data of 2119 dogs npj Precision Oncology 2023 7 1 8 10.1038/s41698-023-00346-3 36658200 PMC9852553

Wernersson R. Schierup M. H. Jørgensen F. G. Gorodkin J. Panitz F. Stærfeldt H.-H. Christensen O. F. Mailund T. Hornshøj H. Klein A. Pigs in sequence space: A 0.66X coverage pig genome survey based on shotgun sequencing BMC Genomics 2005 6 1 70 10.1186/1471-2164-6-70 15885146 PMC1142312

Denayer T. Stöhr T. Van Roy M. Animal models in translational medicine: Validation and prediction New Horizons in Translational Medicine 2017 2 5 11 10.1016/j.nhtm.2014.08.001

Callesen M. M. Árnadóttir S. S. Lyskjær I. Ørntoft M.-B. W. Høyer S. Dagnæs-Hansen F. Liu Y. Li R. Callesen H. Rasmussen M. H. A genetically inducible porcine model of intestinal cancer Molecular Oncology 2017 11 11 1616 1629 10.1002/1878-0261.12136 28881081 PMC5664002

Deycmar S. Gomes B. Charo J. Ceppi M. Cline J. M. Spontaneous, naturally occurring cancers in non-human primates as a translational model for cancer immunotherapy Journal for ImmunoTherapy of Cancer 2023 11 1 e005514 10.1136/jitc-2022-005514 36593067 PMC9808758

Messaoudi I. Estep R. Robinson B. Wong S. W. Nonhuman Primate Models of Human Immunology Antioxidants & Redox Signaling 2011 14 2 261 273 10.1089/ars.2010.3241 20524846 PMC3014769

Valverde C. R. Tarara R. P. Griffey S. M. Roberts J. A. Spontaneous Intestinal Adenocarcinoma in Geriatric Macaques (Macacasp.) Comparative Medicine 2000 50 5 540 544 11099139

Zhou J. Kang Y. Chen L. Wang H. Liu J. Zeng S. Yu L. The drug-resistance mechanisms of five platinum-based antitumor agents Frontiers in pharmacology 2020 11 343 10.3389/fphar.2020.00343 32265714 PMC7100275

Oun R. Moussa Y. E. Wheate N. J. The side effects of platinum-based chemotherapy drugs: a review for chemists Dalton Transactions 2018 47 19 6645 6653 10.1039/C8DT00838H 29632935

Akaboshi M. Kawai K. Maki H. Akuta K. Ujeno Y. Miyahara T. The Number of Platinum Atoms Binding to DNA, RNA and Protein Molecules of HeLa Cells Treated with Cisplatin at Its Mean Lethal Concentration Jpn. J. Cancer Res. 1992 83 5 522 526 10.1111/j.1349-7006.1992.tb01959.x 1618702 PMC5918865

Ozkok A. Edelstein C. L. Pathophysiology of Cisplatin-Induced Acute Kidney Injury BioMed Research International 2014 2014 1 17 10.1155/2014/967826 PMC4140112 25165721

Yao X. Panichpisal K. Kurtzman N. Nugent K. Cisplatin nephrotoxicity: a review The American journal of the medical sciences 2007 334 2 115 124 10.1097/MAJ.0b013e31812dfe1e 17700201

Miller R. P. Tadagavadi R. K. Ramesh G. Reeves W. B. Mechanisms of cisplatin nephrotoxicity Toxins 2010 2 11 2490 2518 10.3390/toxins2112490 22069563 PMC3153174

Motohashi H. Inui K.-i. Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney The AAPS journal 2013 15 581 588 10.1208/s12248-013-9465-7 23435786 PMC3675737

Megyesi J. Safirstein R. L. Price P. M. Induction of p21WAF1/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure The Journal of clinical investigation 1998 101 4 777 782 10.1172/JCI1497 9466972 PMC508625

Brady H. R. Kone B. C. Stromski M. E. Zeidel M. L. Giebisch G. Gullans S. R. Mitochondrial injury: an early event in cisplatin toxicity to renal proximal tubules American Journal of Physiology-Renal Physiology 1990 258 5 F1181 F1187 10.1152/ajprenal.1990.258.5.F1181 2159714

Lieberthal W. Triaca V. Levine J. Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis American Journal of Physiology-Renal Physiology 1996 270 4 F700 F708 10.1152/ajprenal.1996.270.4.F700 8967349

Santos N. A. G. Catão C. S. Martins N. M. Curti C. Bianchi M. L. P. Santos A. C. Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria Arch. Toxicol. 2007 81 7 495 504 10.1007/s00204-006-0173-2 17216432

Gai Z. Gui T. Kullak-Ublick G. A. Li Y. Visentin M. The Role of Mitochondria in Drug-Induced Kidney Injury Frontiers in Physiology 2020 11 1079 10.3389/fphys.2020.01079 33013462 PMC7500167

Wang Q. Shen X. Chen G. Du J. Drug Resistance in Colorectal Cancer: From Mechanism to Clinic Cancers 2022 14 12 2928 10.3390/cancers14122928 35740594 PMC9221177

Vasan N. Baselga J. Hyman D. M. A view on drug resistance in cancer Nature 2019 575 7782 299 309 10.1038/s41586-019-1730-1 31723286 PMC8008476

Wang X. Zhang H. Chen X. Drug resistance and combating drug resistance in cancer Cancer Drug Resistance 2019 10.20517/cdr.2019.10 PMC8315569 34322663

Longley D. Johnston P. Molecular mechanisms of drug resistance The Journal of Pathology 2005 205 2 275 292 10.1002/path.1706 15641020

Kurter H. Yeşil J. Daskin E. Çalibaşi Koçal G. Ellidokuz H. Başbinar Y. Drug Resistance Mechanisms on Colorectal Cancer Journal of Basic and Clinical Health Sciences 2021 5 88 93 10.30621/jbachs.869310

Hashemi M. Esbati N. Rashidi M. Gholami S. Raesi R. Bidoki S. S. Goharrizi M. A. S. B. Motlagh Y. S. M. Khorrami R. Tavakolpournegari A. Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancer Translational Oncology 2024 40 101846 10.1016/j.tranon.2023.101846 38042134 PMC10716031

Noordhuis P. Laan A. C. Van De Born K. Honeywell R. J. Peters G. J. Coexisting Molecular Determinants of Acquired Oxaliplatin Resistance in Human Colorectal and Ovarian Cancer Cell Lines International Journal of Molecular Sciences 2019 20 15 3619 10.3390/ijms20153619 31344863 PMC6696456

Hammond W. A. Swaika A. Mody K. Pharmacologic resistance in colorectal cancer: a review Therapeutic Advances in Medical Oncology 2016 8 1 57 84 10.1177/1758834015614530 26753006 PMC4699262

Myint K. Biswas R. Li Y. Jong N. Jamieson S. Liu J. Han C. Squire C. Merien F. Lu J. Identification of MRP2 as a targetable factor limiting oxaliplatin accumulation and response in gastrointestinal cancer Scientific Reports 2019 9 1 2245 10.1038/s41598-019-38667-8 30783141 PMC6381153

Shirota Y. Stoehlmacher J. Brabender J. Xiong Y.-P. Uetake H. Danenberg K. D. Groshen S. Tsao-Wei D. D. Danenberg P. V. Lenz H.-J. ERCC1 and Thymidylate Synthase mRNA Levels Predict Survival for Colorectal Cancer Patients Receiving Combination Oxaliplatin and Fluorouracil Chemotherapy Journal of Clinical Oncology 2001 19 23 4298 4304 10.1200/JCO.2001.19.23.4298 11731512

Baba H. Watanabe M. Okabe H. Miyamoto Y. Sakamoto Y. Baba Y. Iwatsuki M. Chikamoto A. Beppu T. Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer Br. J. Cancer 2012 107 12 1950 1955 10.1038/bjc.2012.502 23169295 PMC3516688

Köberle B. Schoch S. Platinum Complexes in Colorectal Cancer and Other Solid Tumors Cancers 2021 13 9 2073 10.3390/cancers13092073 33922989 PMC8123298

Le Roy B. Tixier L. Pereira B. Sauvanet P. Buc E. Pétorin C. Déchelotte P. Pezet D. Balayssac D. Assessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control Study PLOS ONE 2016 11 2 e0148739 10.1371/journal.pone.0148739 26859833 PMC4747515

Linares J. Sallent-Aragay A. Badia-Ramentol J. Recort-Bascuas A. Méndez A. Manero-Rupérez N. Re D. L. Rivas E. I. Guiu M. Zwick M. Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy Nature Communications 2023 14 1 746 10.1038/s41467-023-36334-1 PMC9918738 36765091

Moutinho C. Martinez-Cardús A. Santos C. Navarro-Pérez V. Martínez-Balibrea E. Musulen E. Carmona F. J. Sartore-Bianchi A. Cassingena A. Siena S. Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal Cancer JNCI: Journal of the National Cancer Institute 2014 106 1 djt322 10.1093/jnci/djt322 24273214 PMC3906989

Tang Y. Durand S. Dalle S. Caramel J. EMT-Inducing Transcription Factors, Drivers of Melanoma Phenotype Switching, and Resistance to Treatment Cancers 2020 12 8 2154 10.3390/cancers12082154 32759677 PMC7465730

Ruiz De Porras V. Bystrup S. Martínez-Cardús A. Pluvinet R. Sumoy L. Howells L. James M. I. Iwuji C. Manzano J. L. Layos L. Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway Scientific Reports 2016 6 1 24675 10.1038/srep24675 27091625 PMC4835769

Luo M. Yang X. Chen H.-N. Nice E. C. Huang C. Drug resistance in colorectal cancer: An epigenetic overview Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2021 1876 2 188623 10.1016/j.bbcan.2021.188623 34481016

Chen L. Yang F. Chen S. Tai J. Mechanisms on chemotherapy resistance of colorectal cancer stem cells and research progress of reverse transformation: A mini-review Frontiers in Medicine 2022 9 995882 10.3389/fmed.2022.995882 36172536 PMC9510709

Flis S. Gnyszka A. Flis K. DNA methyltransferase inhibitors improve the effect of chemotherapeutic agents in SW48 and HT-29 colorectal cancer cells PloS One 2014 9 3 e92305 10.1371/journal.pone.0092305 24676085 PMC3967992

Tanaka S. Hosokawa M. Ueda K. Iwakawa S. Effects of Decitabine on Invasion and Exosomal Expression of miR-200c and miR-141 in Oxaliplatin-Resistant Colorectal Cancer Cells Biol. Pharm. Bull. 2015 38 9 1272 1279 10.1248/bpb.b15-00129 26179333

Alzoubi S. Brody L. Rahman S. Mahul-Mellier A.-L. Mercado N. Ito K. El-Bahrawy M. Silver A. Boobis A. Bell J. D. Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer Oncotarget 2016 7 28 44505 44521 10.18632/oncotarget.9887 27283986 PMC5190114

Wang Q. Chen X. Jiang Y. Liu S. Liu H. Sun X. Zhang H. Liu Z. Tao Y. Li C. Elevating H3K27me3 level sensitizes colorectal cancer to oxaliplatin Journal of Molecular Cell Biology 2020 12 2 125 137 10.1093/jmcb/mjz032 31065671 PMC7109602

Liang Y. Zhu D. Zhu L. Hou Y. Hou L. Huang X. Li L. Wang Y. Li L. Zou H. Dichloroacetate Overcomes Oxaliplatin Chemoresistance in Colorectal Cancer through the miR-543/PTEN/Akt/mTOR Pathway Journal of Cancer 2019 10 24 6037 6047 10.7150/jca.34650 31762813 PMC6856576

Liang H. Xu Y. Zhang Q. Yang Y. Mou Y. Gao Y. Chen R. Chen C. Dai P. MiR-483–3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells Artificial Cells, Nanomedicine, and Biotechnology 2019 47 1 725 736 10.1080/21691401.2019.1569530 30861353

Hoseini S. H. Enayati P. Nazari M. Babakhanzadeh E. Rastgoo M. Sohrabi N. B. Biomarker Profile of Colorectal Cancer: Current Findings and Future Perspective Journal of Gastrointestinal Cancer 2024 55 497 10.1007/s12029-023-00990-9 38168859

Ashouri K. Wong A. Mittal P. Torres-Gonzalez L. Lo J. H. Soni S. Algaze S. Khoukaz T. Zhang W. Yang Y. Millstein J. Lenz H.-J. Battaglin F. Exploring Predictive and Prognostic Biomarkers in Colorectal Cancer: A Comprehensive Review Cancers 2024 16 16 2796 10.3390/cancers16162796 39199569 PMC11353018

Zygulska A. L. Pierzchalski P. Novel diagnostic biomarkers in colorectal cancer International journal of molecular sciences 2022 23 2 852 10.3390/ijms23020852 35055034 PMC8776048

Koncina E. Haan S. Rauh S. Letellier E. Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges Cancers 2020 12 2 319 10.3390/cancers12020319 32019056 PMC7072488

Leowattana W. Leowattana P. Leowattana T. Systemic treatment for metastatic colorectal cancer World journal of gastroenterology 2023 29 10 1569 10.3748/wjg.v29.i10.1569 36970592 PMC10037252

Thanki K. Edward Nicholls M. Gomez G. Gajjar A. James Senagore A. Rashidi L. Qiu S. Szabo C. Richard Hellmich M. Chao C. Consensus molecular subtypes of colorectal cancer and their clinical implications International biological and biomedical journal 2017 3 3 105 111 28825047 PMC5557054

Roepman P. Schlicker A. Tabernero J. Majewski I. Tian S. Moreno V. Snel M. H. Chresta C. M. Rosenberg R. Nitsche U. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition Int. J. Cancer 2014 134 3 552 562 10.1002/ijc.28387 23852808 PMC4234005

Lin Q. Luo L. Wang H. A new oxaliplatin resistance-related gene signature with strong predicting ability in colon cancer identified by comprehensive profiling Frontiers in Oncology 2021 11 644956 10.3389/fonc.2021.644956 34026619 PMC8138443

Cheraghi-shavi T. Jalal R. Minuchehr Z. TGM2, HMGA2, FXYD3, and LGALS4 genes as biomarkers in acquired oxaliplatin resistance of human colorectal cancer: A systems biology approach PLOS ONE 2023 18 8 e0289535 10.1371/journal.pone.0289535 37535601 PMC10399784

Zhang Z. Lu T. Zhang Z. Liu Z. Qian R. Qi R. Zhou F. Li M. Unraveling the immune landscape and therapeutic biomarker PMEPA1 for oxaliplatin resistance in colorectal cancer: A comprehensive approach Biochem. Pharmacol. 2024 222 116117 10.1016/j.bcp.2024.116117 38461903

Gnoni A. Russo A. Silvestris N. Maiello E. Vacca A. Marech I. Numico G. Paradiso A. Lorusso V. Azzariti A. Pharmacokinetic and metabolism determinants of fluoropyrimidines and oxaliplatin activity in treatment of colorectal patients Current Drug Metabolism 2011 12 10 918 931 10.2174/138920011798062300 21787270

Zhao P. Li L. Jiang X. Li Q. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy Journal of hematology & oncology 2019 12 54 10.1186/s13045-019-0738-1 31151482 PMC6544911

Taieb J. Shi Q. Pederson L. Alberts S. Wolmark N. Van Cutsem E. de Gramont A. Kerr R. Grothey A. Lonardi S. Yoshino T. Yothers G. Sinicrope F.A. Zaanan A. Andre T. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies Annals of Oncology 2019 30 9 1466 1471 10.1093/annonc/mdz208 31268130 PMC7360150

Escalante P. I. Quinones L. A. Contreras H. R. Epithelial-mesenchymal transition and MicroRNAs in colorectal cancer chemoresistance to FOLFOX Pharmaceutics 2021 13 1 75 10.3390/pharmaceutics13010075 33429840 PMC7827270

Mao L. Li Y. Zhao J. Li Q. Yang B. Wang Y. Zhu Z. Sun H. Zhai Z. Transforming growth factor-β1 contributes to oxaliplatin resistance in colorectal cancer via epithelial to mesenchymal transition Oncology Letters 2017 14 1 647 654 10.3892/ol.2017.6209 28693217 PMC5494727

Yuan S. Tao F. Zhang X. Zhang Y. Sun X. Wu D. Role of Wnt/β-Catenin Signaling in the Chemoresistance Modulation of Colorectal Cancer BioMed Research International 2020 2020 1 9390878 10.1155/2020/9390878 32258160 PMC7109575

Hua Q. Lu Y. Wang D. Da J. Peng W. Sun G. Gu K. Wang H. Zhu Y. KIAA1199 promotes oxaliplatin resistance and epithelial mesenchymal transition of colorectal cancer via protein O-GlcNAcylation Translational Oncology 2023 28 101617 10.1016/j.tranon.2023.101617 36610242 PMC9850197

Sfakianaki M. Papadaki C. Tzardi M. Trypaki M. Manolakou S. Messaritakis I. Saridaki Z. Athanasakis E. Mavroudis D. Tsiaoussis J. Gouvas N. Souglakos J. PKM2 expression as biomarker for resistance to oxaliplatin-based chemotherapy in colorectal cancer Cancers 2020 12 8 2058 10.3390/cancers12082058 32722474 PMC7465271

Yan D. Tu L. Yuan H. Fang J. Cheng L. Zheng X. Wang X. WBSCR22 confers oxaliplatin resistance in human colorectal cancer Scientific Reports 2017 7 1 15443 10.1038/s41598-017-15749-z 29133897 PMC5684350

Zhang N. Hu X. Du Y. Du J. The role of miRNAs in colorectal cancer progression and chemoradiotherapy Biomedicine & Pharmacotherapy 2021 134 111099 10.1016/j.biopha.2020.111099 33338745

Lulli M. Napoli C. Landini I. Mini E. Lapucci A. Role of Non-Coding RNAs in Colorectal Cancer: Focus on Long Non-Coding RNAs International Journal of Molecular Sciences 2022 23 21 13431 10.3390/ijms232113431 36362222 PMC9654895

Luo Z.-D. Wang Y.-F. Zhao Y.-X. Yu L.-C. Li T. Fan Y.-J. Zeng S.-J. Zhang Y.-L. Zhang Y. Zhang X. Emerging roles of non-coding RNAs in colorectal cancer oxaliplatin resistance and liquid biopsy potential World Journal of Gastroenterology 2023 29 1 1 10.3748/wjg.v29.i1.1 36683709 PMC9850945

Hussen B. M. Abdullah S. R. Mohammed A. A. Rasul M. F. Hussein A. M. Eslami S. Glassy M. C. Taheri M. Advanced strategies of targeting circular RNAs as therapeutic approaches in colorectal cancer drug resistance Pathology-Research and Practice 2024 260 155402 10.1016/j.prp.2024.155402 38885593

Liu T. Zhang X. Du L. Wang Y. Liu X. Tian H. Wang L. Li P. Zhao Y. Duan W. Xie Y. Sun Z. Wang C. RETRACTED ARTICLE: Exosome-transmitted miR-128–3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer Molecular cancer 2019 18 43 10.1186/s12943-019-0981-7 30890168 PMC6423768

Li Y. Gong P. Hou J.-x. Huang W. Ma X.-p. Wang Y.-l. Li J. Cui X.-b. Li N. miR-34a regulates multidrug resistance via positively modulating OAZ2 signaling in colon cancer cells Journal of immunology research 2018 2018 7498514 10.1155/2018/7498514 30175154 PMC6098920

Ning T. Li J. He Y. Zhang H. Wang X. Deng T. Liu R. Li H. Bai M. Fan Q. Zhu K. Ying G. Ba Y. Exosomal miR-208b related with oxaliplatin resistance promotes Treg expansion in colorectal cancer Molecular Therapy 2021 29 9 2723 2736 10.1016/j.ymthe.2021.04.028 33905821 PMC8417448

Zhuang Y.-y. Zhong W. Xia Z.-s. Lin S.-z. Chan M. c. Jiang K. Li W.-f. Xu X.-y. miR-5000–3p confers oxaliplatin resistance by targeting ubiquitin-specific peptidase 49 in colorectal cancer Cell Death Discovery 2021 7 1 129 10.1038/s41420-021-00494-0 34075026 PMC8169888

Jiang X. Li Q. Zhang S. Song C. Zheng P. Long noncoding RNA GIHCG induces cancer progression and chemoresistance and indicates poor prognosis in colorectal cancer OncoTargets and therapy 2019 12 1059 1070 10.2147/OTT.S192290 30799935 PMC6369849

Li T. Jin X. Dong J. Deng H. Long noncoding RNA ARSR is associated with a poor prognosis in patients with colorectal cancer The Journal of Gene Medicine 2020 22 10 e3241 10.1002/jgm.3241 32558022

Li Q. Sun H. Luo D. Gan L. Mo S. Dai W. Liang L. Yang Y. Xu M. Li J. Zheng P. Li X. Li Y. Wang Z. Lnc-RP11–536 K7. 3/SOX2/HIF-1α signaling axis regulates oxaliplatin resistance in patient-derived colorectal cancer organoids Journal of Experimental & Clinical Cancer Research 2021 40 348 10.1186/s13046-021-02143-x 34740372 PMC8570024

Gao R. Fang C. Xu J. Tan H. Li P. Ma L. LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145 Arch. Biochem. Biophys. 2019 663 183 191 10.1016/j.abb.2019.01.005 30639170

Sun J. Zhou H. Bao X. Wu Y. Jia H. Zhao H. Liu G. lncRNA TUG1 Facilitates Colorectal Cancer Stem Cell Characteristics and Chemoresistance by Enhancing GATA6 Protein Stability Stem Cells International 2021 2021 1075481 10.1155/2021/1075481 34858502 PMC8632465

Zhang Y. Li C. Liu X. Wang Y. Zhao R. Yang Y. Zheng X. Zhang Y. Zhang X. circHIPK3 promotes oxaliplatin-resistance in colorectal cancer through autophagy by sponging miR-637 EBioMedicine 2019 48 277 288 10.1016/j.ebiom.2019.09.051 31631038 PMC6838436

Lin Y.-C. Yu Y.-S. Lin H.-H. Hsiao K.-Y. Oxaliplatin-Induced DHX9 Phosphorylation Promotes Oncogenic Circular RNA CCDC66 Expression and Development of Chemoresistance Cancers 2020 12 3 697 10.3390/cancers12030697 32187976 PMC7140115

Pan Z. Zheng J. Zhang J. Lin J. Lai J. Lyu Z. Feng H. Wang J. Wu D. Li Y. A Novel Protein Encoded by Exosomal CircATG4B Induces Oxaliplatin Resistance in Colorectal Cancer by Promoting Autophagy Advanced Science 2022 9 35 2204513 10.1002/advs.202204513 36285810 PMC9762280

Laforgia M. Laface C. Calabrò C. Ferraiuolo S. Ungaro V. Tricarico D. Gadaleta C. D. Nardulli P. Ranieri G. Peripheral Neuropathy under Oncologic Therapies: A Literature Review on Pathogenetic Mechanisms International Journal of Molecular Sciences 2021 22 4 1980 10.3390/ijms22041980 33671327 PMC7922628

Yang Y. Zhao B. Gao X. Sun J. Ye J. Li J. Cao P. Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development Journal of Experimental & Clinical Cancer Research 2021 40 1 331 10.1186/s13046-021-02141-z 34686205 PMC8532307

Bonhof C. S. Van De Poll-Franse L. V. Wasowicz D. K. Beerepoot L. V. Vreugdenhil G. Mols F. The course of peripheral neuropathy and its association with health-related quality of life among colorectal cancer patients Journal of Cancer Survivorship 2021 15 2 190 200 10.1007/s11764-020-00923-6 33185839 PMC7966630

Postma T. J. Aaronson N. K. Heimans J. J. Muller M. J. Hildebrand J. G. Delattre J. Y. Hoang-Xuan K. Lantéri-Minet M. Grant R. Huddart R. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20 Eur. J. Cancer 2005 41 8 1135 1139 10.1016/j.ejca.2005.02.012 15911236

Jordan B. Margulies A. Cardoso F. Cavaletti G. Haugnes H. S. Jahn P. Le Rhun E. Preusser M. Scotté F. Taphoorn M. J. B. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO–EONS–EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up Annals of Oncology 2020 31 10 1306 1319 10.1016/j.annonc.2020.07.003 32739407

Loprinzi C. L. Lacchetti C. Bleeker J. Cavaletti G. Chauhan C. Hertz D. L. Kelley M. R. Lavino A. Lustberg M. B. Paice J. A. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update Journal of Clinical Oncology 2020 38 28 3325 3348 10.1200/JCO.20.01399 32663120

Egashira N. Pathological Mechanisms and Preventive Strategies of Oxaliplatin-Induced Peripheral Neuropathy Frontiers in Pain Research 2021 2 804260 10.3389/fpain.2021.804260 35295491 PMC8915546

Rosson G. D. Chemotherapy-Induced Neuropathy Clinics in Podiatric Medicine and Surgery 2006 23 3 637 649 10.1016/j.cpm.2006.04.009 16958394

Branca J. J. V. Carrino D. Gulisano M. Ghelardini C. Di Cesare Mannelli L. Pacini A. Oxaliplatin-Induced Neuropathy: Genetic and Epigenetic Profile to Better Understand How to Ameliorate This Side Effect Frontiers in Molecular Biosciences 2021 8 643824 10.3389/fmolb.2021.643824 34026827 PMC8138476

Alberti P. Canta A. Chiorazzi A. Fumagalli G. Meregalli C. Monza L. Pozzi E. Ballarini E. Rodriguez-Menendez V. Oggioni N. Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity Neuropharmacology 2020 164 107905 10.1016/j.neuropharm.2019.107905 31811874

Joseph E. K. Levine J. D. Comparison of Oxaliplatin- and Cisplatin-Induced Painful Peripheral Neuropathy in the Rat The Journal of Pain 2009 10 5 534 541 10.1016/j.jpain.2008.12.003 19231296 PMC2741410

Cavaletti G. Marmiroli P. Management of Oxaliplatin-Induced Peripheral Sensory Neuropathy Cancers 2020 12 6 1370 10.3390/cancers12061370 32471028 PMC7352541

Kerckhove N. Collin A. Condé S. Chaleteix C. Pezet D. Balayssac D. Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review Frontiers in Pharmacology 2017 8 86 10.3389/fphar.2017.00086 28286483 PMC5323411

Huang K. M. Leblanc A. F. Uddin M. E. Kim J. Y. Chen M. Eisenmann E. D. Gibson A. A. Li Y. Hong K. W. DiGiacomo D. Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice The Journal of Clinical Investigation 2020 130 9 4601 4606 10.1172/JCI136796 32484793 PMC7456253

Fujita S. Hirota T. Sakiyama R. Baba M. Ieiri I. Identification of drug transporters contributing to oxaliplatin-induced peripheral neuropathy Journal of Neurochemistry 2019 148 3 373 385 10.1111/jnc.14607 30295925

Jong N. N. Nakanishi T. Liu J. J. Tamai I. McKeage M. J. Oxaliplatin Transport Mediated by Organic Cation/Carnitine Transporters OCTN1 and OCTN2 in Overexpressing Human Embryonic Kidney 293 Cells and Rat Dorsal Root Ganglion Neurons Journal of Pharmacology and Experimental Therapeutics 2011 338 2 537 547 10.1124/jpet.111.181297 21606177

Canta A. Pozzi E. Carozzi V. Mitochondrial Dysfunction in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Toxics 2015 3 2 198 223 10.3390/toxics3020198 29056658 PMC5634687

Areti A. Yerra V. G. Naidu V. Kumar A. Oxidative stress and nerve damage: Role in chemotherapy induced peripheral neuropathy Redox Biology 2014 2 289 295 10.1016/j.redox.2014.01.006 24494204 PMC3909836

Calls A. Torres-Espin A. Tormo M. Martínez-Escardó L. Bonet N. Casals F. Navarro X. Yuste V. J. Udina E. Bruna J. A transient inflammatory response contributes to oxaliplatin neurotoxicity in mice Annals of Clinical and Translational Neurology 2022 9 12 1985 1998 10.1002/acn3.51691 36369764 PMC9735376

Staff N. P. Cavaletti G. Islam B. Lustberg M. Psimaras D. Tamburin S. Platinum-induced peripheral neurotoxicity: From pathogenesis to treatment Journal of the Peripheral Nervous System 2019 24 S26 10.1111/jns.12335 31647151 PMC6818741

Argyriou A. A. Polychronopoulos P. Iconomou G. Chroni E. Kalofonos H. P. A review on oxaliplatin-induced peripheral nerve damage Cancer Treatment Reviews 2008 34 4 368 377 10.1016/j.ctrv.2008.01.003 18281158

Wei G. Gu Z. Gu J. Yu J. Huang X. Qin F. Li L. Ding R. Huo J. Platinum accumulation in oxaliplatin-induced peripheral neuropathy Journal of the Peripheral Nervous System 2021 26 1 35 42 10.1111/jns.12432 33462873 PMC7986112

Calls A. Carozzi V. Navarro X. Monza L. Bruna J. Pathogenesis of platinum-induced peripheral neurotoxicity: Insights from preclinical studies Exp. Neurol. 2020 325 113141 10.1016/j.expneurol.2019.113141 31865195

Schmitt L.-I. Leo M. Kleinschnitz C. Hagenacker T. Oxaliplatin Modulates the Characteristics of Voltage-Gated Calcium Channels and Action Potentials in Small Dorsal Root Ganglion Neurons of Rats Molecular Neurobiology 2018 55 12 8842 8855 10.1007/s12035-018-1029-5 29603093

Gamelin L. Capitain O. Morel A. Dumont A. Traore S. Anne L. B. Gilles S. Boisdron-Celle M. Gamelin E. Predictive Factors of Oxaliplatin Neurotoxicity: The Involvement of the Oxalate Outcome Pathway Clin. Cancer Res. 2007 13 21 6359 6368 10.1158/1078-0432.CCR-07-0660 17975148

Park S. B. Lin C. S.-Y. Krishnan A. V. Goldstein D. Friedlander M. L. Kiernan M. C. Dose Effects of Oxaliplatin on Persistent and Transient Na+ Conductances and the Development of Neurotoxicity PLoS ONE 2011 6 4 e18469 10.1371/journal.pone.0018469 21494615 PMC3072981

Wilson R. H. Lehky T. Thomas R. R. Quinn M. G. Floeter M. K. Grem J. L. Acute Oxaliplatin-Induced Peripheral Nerve Hyperexcitability Journal of Clinical Oncology 2002 20 7 1767 1774 10.1200/JCO.2002.07.056 11919233

Sakurai M. Egashira N. Kawashiri T. Yano T. Ikesue H. Oishi R. Oxaliplatin-induced neuropathy in the rat: Involvement of oxalate in cold hyperalgesia but not mechanical allodynia Pain 2009 147 1 165 174 10.1016/j.pain.2009.09.003 19782472

Chukyo A. Chiba T. Kambe T. Yamamoto K. Kawakami K. Taguchi K. Abe K. Oxaliplatin-induced changes in expression of transient receptor potential channels in the dorsal root ganglion as a neuropathic mechanism for cold hypersensitivity Neuropeptides 2018 67 95 101 10.1016/j.npep.2017.12.002 29274843

Canta A. Chiorazzi A. Pozzi E. Fumagalli G. Monza L. Meregalli C. Carozzi V. A. Rodriguez-Menendez V. Oggioni N. Näsström J. Calmangafodipir Reduces Sensory Alterations and Prevents Intraepidermal Nerve Fibers Loss in a Mouse Model of Oxaliplatin Induced Peripheral Neurotoxicity Antioxidants 2020 9 7 594 10.3390/antiox9070594 32645985 PMC7402145

Narayanan S. Kawaguchi T. Peng X. Qi Q. Liu S. Yan L. Takabe K. Tumor infiltrating lymphocytes and macrophages improve survival in microsatellite unstable colorectal cancer Scientific reports 2019 9 13455 10.1038/s41598-019-49878-4 31530839 PMC6748965

Tang H. Wang Y. Chlewicki L. K. Zhang Y. Guo J. Liang W. Wang J. Wang X. Fu Y.-X. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade Cancer cell 2016 29 3 285 296 10.1016/j.ccell.2016.02.004 26977880 PMC4794755

Angelova M. Charoentong P. Hackl H. Fischer M. L Snajder R. Krogsdam A. M Waldner M. J Bindea G. Mlecnik B. Galon J. Trajanoski Z. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy Genome biology 2015 16 1 17 10.1186/s13059-015-0620-6 25853550 PMC4377852

Mandal R. Samstein R. M. Lee K.-W. Havel J. J. Wang H. Krishna C. Sabio E. Y. Makarov V. Kuo F. Blecua P. Ramaswamy A. T. Durham J. N. Bartlett B. Ma X. Srivastava R. Middha S. Zehir A. Hechtman J. F. Morris L. G. Weinhold N. Riaz N. Le D. T. Diaz L. A. Chan T. A. Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response Science 2019 364 6439 485 491 10.1126/science.aau0447 31048490 PMC6685207

Lichtenstern C. R. Ngu R. K. Shalapour S. Karin M. Immunotherapy, inflammation and colorectal cancer Cells 2020 9 3 618 10.3390/cells9030618 32143413 PMC7140520

Gurjao C. Liu D. Hofree M. AlDubayan S. H. Wakiro I. Su M.-J. Felt K. Gjini E. Brais L. K. Rotem A. Rosenthal M. H. Rozenblatt-Rosen O. Rodig S. Ng K. Van Allen E. M. Corsello S. M. Ogino S. Regev A. Nowak J. A. Giannakis M. Intrinsic resistance to immune checkpoint blockade in a mismatch repair-deficient colorectal cancer Cancer immunology research 2019 7 8 1230 1236 10.1158/2326-6066.CIR-18-0683 31217164 PMC6679789

Mulet-Margalef N. Linares J. Badia-Ramentol J. Jimeno M. Sanz Monte C. Manzano Mozo J. L. Calon A. Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape Cancers 2023 15 4 1022 10.3390/cancers15041022 36831367 PMC9954007

O’Rourke T. J. Weiss G. R. New P. Burris H. III Rodriguez G. Eckhardt J. Hardy J. Kuhn J. G. Fields S. Clark G. M. Von Hoff D. D. Phase I clinical trial of ormaplatin (tetraplatin, NSC 363812) Anti-Cancer Drugs 1994 5 5 520 526 10.1097/00001813-199410000-00002 7858283

Dong J. Ren Y. Huo S. Shen S. Xu J. Tian H. Shi T. Reduction of ormaplatin and cis-diamminetetrachloroplatinum (IV) by ascorbic acid and dominant thiols in human plasma: kinetic and mechanistic analyses Dalton Transactions 2016 45 28 11326 11337 10.1039/C6DT01804A 27327648

Anderson H. Wagstaff J. Crowther D. Swindell R. Lind M. J. McGregor J. Timms M. Brown D. Palmer P. Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer European Journal of Cancer and Clinical Oncology 1988 24 9 1471 1479 10.1016/0277-5379(88)90338-0 3053207

Pendyala L. Greco W. Cowens J. Madajewicz S. Creaven P. Pharmacokinetics of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV (CHIP) in patients with advanced cancer Cancer chemotherapy and pharmacology 1983 11 23 28 10.1007/BF00257411 6883623

Sternberg C. N. Petrylak D. P. Sartor O. Witjes J. A. Demkow T. Ferrero J.-M. Eymard J.-C. Falcon S. Calabro F. James N. Bodrogi I. Harper P. Wirth M. Berry W. Petrone M. E. McKearn T. J. Noursalehi M. George M. Rozencweig M. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial Journal of clinical oncology 2009 27 32 5431 10.1200/JCO.2008.20.1228 19805692

Carr J. L. Tingle M. D. McKeage M. J. Rapid biotransformation of satraplatin by human red blood cells in vitro Cancer Chemother Pharmacol 2002 50 1 9 15 10.1007/s00280-002-0462-2 12111106

Fridman W. H. Meylan M. Pupier G. Calvez A. Hernandez I. Sautès-Fridman C. Tertiary lymphoid structures and B cells: An intratumoral immunity cycle Immunity 2023 56 2254 10.1016/j.immuni.2023.08.009 37699391

Zhang E. Ding C. Li S. Zhou X. Aikemu B. Fan X. Sun J. Zheng M. Yang X. Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy Biomarker Research 2023 11 1 28 10.1186/s40364-023-00460-1 36890557 PMC9997025

Edin S. Kaprio T. Hagström J. Larsson P. Mustonen H. Böckelman C. Strigård K. Gunnarsson U. Haglund C. Palmqvist R. The prognostic importance of CD20+ B lymphocytes in colorectal cancer and the relation to other immune cell subsets Scientific reports 2019 9 19997 10.1038/s41598-019-56441-8 31882709 PMC6934737

Zhang C. Fei Y. Wang H. Hu S. Liu C. Hu R. Du Q. CAFs orchestrates tumor immune microenvironmentA new target in cancer therapy? Frontiers in Pharmacology 2023 14 1113378 10.3389/fphar.2023.1113378 37007004 PMC10064291

Chen W.-Z. Jiang J.-X. Yu X.-Y. Xia W.-J. Yu P.-X. Wang K. Zhao Z.-Y. Chen Z.-G. Endothelial cells in colorectal cancer World journal of gastrointestinal oncology 2019 11 11 946 10.4251/wjgo.v11.i11.946 31798776 PMC6883186

Bhat A. A. Nisar S. Singh M. Ashraf B. Masoodi T. Prasad C. P. Sharma A. Maacha S. Karedath T. Hashem S. Cytokine- and chemokine-induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapy Cancer Communications 2022 42 8 689 715 10.1002/cac2.12295 35791509 PMC9395317

Tan F. Huang Y. Pei Q. Liu H. Pei H. Zhu H. Matrix stiffness mediates stemness characteristics via activating the Yes-associated protein in colorectal cancer cells Journal of cellular biochemistry 2019 120 2 2213 2225 10.1002/jcb.27532 30218452

Xu Z. Wang Z. Deng Z. Zhu G. Recent advances in the synthesis, stability, and activation of platinum (IV) anticancer prodrugs Coordination Chemistry Reviews 2021 442 213991 10.1016/j.ccr.2021.213991

Wexselblatt E. Gibson D. What do we know about the reduction of Pt­(IV) pro-drugs? J Inorg Biochem 2012 117 220 229 10.1016/j.jinorgbio.2012.06.013 22877926

Guo D. Xu S. Huang Y. Jiang H. Yasen W. Wang N. Su Y. Qian J. Li J. Zhang C. Platinum­(IV) complex-based two-in-one polyprodrug for a combinatorial chemo-photodynamic therapy Biomaterials 2018 177 67 77 10.1016/j.biomaterials.2018.05.052 29885587

Lopez-Sanchez A. Bertrand H. C. Pt­(iv) anticancer prodrugs bearing an oxaliplatin scaffold: what do we know about their bioactivity? Inorganic Chemistry Frontiers 2024 11 6 1639 1667 10.1039/D3QI02602G

Bhargava A. Vaishampayan U. N. Satraplatin: leading the new generation of oral platinum agents Expert Opin Investig Drugs 2009 18 11 1787 1797 10.1517/13543780903362437 PMC3856359 19888874

Di Lorenzo G. Buonerba C. Autorino R. De Placido S. Sternberg C. N. Castration-resistant prostate cancer: current and emerging treatment strategies Drugs 2010 70 983 1000 10.2165/10898600-000000000-00000 20481655

Hall M. D. Hambley T. W. Platinum (IV) antitumour compounds: their bioinorganic chemistry Coord. Chem. Rev. 2002 232 1–2 49 67 10.1016/S0010-8545(02)00026-7

Dolman R. C. Deacon G. B. Hambley T. W. Studies of the binding of a series of platinum (IV) complexes to plasma proteins Journal of inorganic biochemistry 2002 88 3–4 260 267 10.1016/S0162-0134(01)00360-9 11897339

Babak M. V. Zhi Y. Czarny B. Toh T. B. Hooi L. Chow E. K. Ang W. H. Gibson D. Pastorin G. Dual-Targeting Dual-Action Platinum­(IV) Platform for Enhanced Anticancer Activity and Reduced Nephrotoxicity Angew. Chem., Int. Ed. Engl. 2019 58 24 8109 8114 10.1002/anie.201903112 30945417

Hall M. D. Dolman R. C. Hambley T. W. Platinum (IV) anticancer complexes Metal ions in biological systems 2004 42 297 322 10.1201/b12414-9 15206106

Xu Z. Wang Z. Deng Z. Zhu G. Recent advances in the synthesis, stability, and activation of platinum (IV) anticancer prodrugs Coord. Chem. Rev. 2021 442 213991 10.1016/j.ccr.2021.213991

Choi S. Filotto C. Bisanzo M. Delaney S. Lagasee D. Whitworth J. L. Jusko A. Li C. Wood N. A. Willingham J. Schwenker A. Spaulding K. Reduction and anticancer activity of platinum (IV) complexes Inorganic Chemistry 1998 37 10 2500 2504 10.1021/ic971047x

Ma J. Wang Q. Huang Z. Yang X. Nie Q. Hao W. Wang P. G. Wang X. Glycosylated Platinum­(IV) Complexes as Substrates for Glucose Transporters (GLUTs) and Organic Cation Transporters (OCTs) Exhibited Cancer Targeting and Human Serum Albumin Binding Properties for Drug Delivery J. Med. Chem. 2017 60 13 5736 5748 10.1021/acs.jmedchem.7b00433 28603992

Ma Z. Y. Wang D. B. Song X. Q. Wu Y. G. Chen Q. Zhao C. L. Li J. Y. Cheng S. H. Xu J. Y. Chlorambucil-conjugated platinum­(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo Eur. J. Med. Chem. 2018 157 1292 1299 10.1016/j.ejmech.2018.08.065 30195239

Chen H. Wang X. Gou S. A cisplatin-based platinum­(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer J Inorg Biochem 2019 193 133 142 10.1016/j.jinorgbio.2019.01.014 30731264

Kido Y. Khokhar A. R. Al-Baken S. Siddik Z. H. Modulation of Cytotoxicity and Cellular Pharmacology of 1,2-Diaminocyclohexane Platinum­(IV) Complexes Mediated by Axial and Equatorial Ligands1 Cancer Res. 1993 53 19 4567 4572 8402629

Ang W. H. Pilet S. Scopelliti R. Bussy F. Juillerat-Jeanneret L. Dyson P. J. Synthesis and Characterization of Platinum­(IV) Anticancer Drugs with Functionalized Aromatic Carboxylate Ligands: Influence of the Ligands on Drug Efficacies and Uptake J. Med. Chem. 2005 48 25 8060 8069 10.1021/jm0506468 16335930

Chin C. F. Tian Q. Setyawati M. I. Fang W. Tan E. S. Q. Leong D. T. Ang W. H. Tuning the Activity of Platinum­(IV) Anticancer Complexes through Asymmetric Acylation J. Med. Chem. 2012 55 17 7571 7582 10.1021/jm300580y 22876932

Ravera M. Gabano E. Zanellato I. Bonarrigo I. Escribano E. Moreno V. Font-Bardia M. Calvet T. Osella D. Synthesis, characterization and antiproliferative activity on mesothelioma cell lines of bis­(carboxylato)­platinum­(iv) complexes based on picoplatin Dalton Transactions 2012 41 11 3313 3320 10.1039/c2dt11874b 22286213

Varbanov H. P. Valiahdi S. M. Kowol C. R. Jakupec M. A. Galanski M. S. Keppler B. K. Novel tetracarboxylatoplatinum­(iv) complexes as carboplatin prodrugs Dalton Transactions 2012 41 47 14404 14415 10.1039/C2DT31366A 22886297

Pathak R. K. Marrache S. Choi J. H. Berding T. B. Dhar S. The Prodrug Platin-A: Simultaneous Release of Cisplatin and Aspirin Angewandte Chemie International Edition 2014 53 7 1963 1967 10.1002/anie.201308899 24453035

Cheng Q. Shi H. Wang H. Min Y. Wang J. Liu Y. The ligation of aspirin to cisplatin demonstrates significant synergistic effects on tumor cells Chemical Communications 2014 50 56 7427 7430 10.1039/C4CC00419A 24777030

Neumann W. Crews B. C. Marnett L. J. Hey-Hawkins E. Conjugates of Cisplatin and Cyclooxygenase Inhibitors as Potent Antitumor Agents Overcoming Cisplatin Resistance ChemMedChem 2014 9 6 1150 1153 10.1002/cmdc.201402074 24801194 PMC4136547

Neumann W. Crews B. C. Sárosi M. B. Daniel C. M. Ghebreselasie K. Scholz M. S. Marnett L. J. Hey-Hawkins E. Conjugation of Cisplatin Analogues and Cyclooxygenase Inhibitors to Overcome Cisplatin Resistance ChemMedChem 2015 10 1 183 192 10.1002/cmdc.201402353 25318459 PMC4480879

Curci A. Denora N. Iacobazzi R. M. Ditaranto N. Hoeschele J. D. Margiotta N. Natile G. Synthesis, characterization, and in vitro cytotoxicity of a Kiteplatin-Ibuprofen Pt­(IV) prodrug Inorg. Chim. Acta 2018 472 221 228 10.1016/j.ica.2017.07.019

Tan J. Li C. Wang Q. Li S. Chen S. Zhang J. Wang P. C. Ren L. Liang X.-J. A Carrier-Free Nanostructure Based on Platinum­(IV) Prodrug Enhances Cellular Uptake and Cytotoxicity Molecular Pharmaceutics 2018 15 4 1724 1728 10.1021/acs.molpharmaceut.8b00070 29522683 PMC7057395

Tolan D. A. Abdel-Monem Y. K. El-Nagar M. A. Anti-tumor platinum (IV) complexes bearing the anti-inflammatory drug naproxen in the axial position Appl. Organomet. Chem. 2019 33 3 e4763 10.1002/aoc.4763

Song X.-Q. Ma Z.-Y. Wu Y.-G. Dai M.-L. Wang D.-B. Xu J.-Y. Liu Y. New NSAID-Pt­(IV) prodrugs to suppress metastasis and invasion of tumor cells and enhance anti-tumor effect in vitro and in vivo Eur. J. Med. Chem. 2019 167 377 387 10.1016/j.ejmech.2019.02.041 30784875

Ravera M. Zanellato I. Gabano E. Perin E. Rangone B. Coppola M. Osella D. Antiproliferative Activity of Pt­(IV) Conjugates Containing the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Ketoprofen and Naproxen † International Journal of Molecular Sciences 2019 20 12 3074 10.3390/ijms20123074 31238499 PMC6627341

Chen Y. Wang Q. Li Z. Liu Z. Zhao Y. Zhang J. Liu M. Wang Z. Li D. Han J. Naproxen platinum­(iv) hybrids inhibiting cycloxygenases and matrix metalloproteinases and causing DNA damage: synthesis and biological evaluation as antitumor agents in vitro and in vivo Dalton Transactions 2020 49 16 5192 5204 10.1039/D0DT00424C 32236281

Jin S. Muhammad N. Sun Y. Tan Y. Yuan H. Song D. Guo Z. Wang X. Multispecific Platinum­(IV) Complex Deters Breast Cancer via Interposing Inflammation and Immunosuppression as an Inhibitor of COX-2 and PD-L1 Angewandte Chemie International Edition 2020 59 51 23313 23321 10.1002/anie.202011273 32897000

Li Z. Wang Q. Li L. Chen Y. Cui J. Liu M. Zhang N. Liu Z. Han J. Wang Z. Ketoprofen and Loxoprofen Platinum­(IV) Complexes Displaying Antimetastatic Activities by Inducing DNA Damage, Inflammation Suppression, and Enhanced Immune Response J. Med. Chem. 2021 64 24 17920 17935 10.1021/acs.jmedchem.1c01236 34852203

Spector D. V. Pavlov K. G. Akasov R. A. Vaneev A. N. Erofeev A. S. Gorelkin P. V. Nikitina V. N. Lopatukhina E. V. Semkina A. S. Vlasova K. Y. Pt­(IV) Prodrugs with Non-Steroidal Anti-inflammatory Drugs in the Axial Position J. Med. Chem. 2022 65 12 8227 8244 10.1021/acs.jmedchem.1c02136 35675651

Yang J. Sun X. Mao W. Sui M. Tang J. Shen Y. Conjugate of Pt­(IV)-Histone Deacetylase Inhibitor as a Prodrug for Cancer Chemotherapy Molecular Pharmaceutics 2012 9 10 2793 2800 10.1021/mp200597r 22953987

Alessio M. Zanellato I. Bonarrigo I. Gabano E. Ravera M. Osella D. Antiproliferative activity of Pt­(IV)-bis­(carboxylato) conjugates on malignant pleural mesothelioma cells Journal of Inorganic Biochemistry 2013 129 52 57 10.1016/j.jinorgbio.2013.09.003 24080480

Novohradsky V. Zerzankova L. Stepankova J. Vrana O. Raveendran R. Gibson D. Kasparkova J. Brabec V. Antitumor platinum­(IV) derivatives of oxaliplatin with axial valproato ligands Journal of Inorganic Biochemistry 2014 140 72 79 10.1016/j.jinorgbio.2014.07.004 25063910

Novohradsky V. Zerzankova L. Stepankova J. Vrana O. Raveendran R. Gibson D. Kasparkova J. Brabec V. New insights into the molecular and epigenetic effects of antitumor Pt­(IV)-valproic acid conjugates in human ovarian cancer cells Biochem. Pharmacol. 2015 95 3 133 144 10.1016/j.bcp.2015.04.003 25888926

Ravera M. Gabano E. Zanellato I. Gallina A. Perin E. Arrais A. Cantamessa S. Osella D. Cisplatin and valproate released from the bifunctional [Pt­(IV)­Cl2­(NH3)­2­(valproato)­2] antitumor prodrug or from liposome formulations: who does what? Dalton Transactions 2017 46 5 1559 1566 10.1039/C6DT03749F 28091654

Novohradsky V. Zanellato I. Marzano C. Pracharova J. Kasparkova J. Gibson D. Gandin V. Osella D. Brabec V. Epigenetic and antitumor effects of platinum­(IV)-octanoato conjugates Scientific Reports 2017 7 1 3751 10.1038/s41598-017-03864-w 28623355 PMC5473904

Gabano E. Ravera M. Zanellato I. Tinello S. Gallina A. Rangone B. Gandin V. Marzano C. Bottone M. G. Osella D. An unsymmetric cisplatin-based Pt­(iv) derivative containing 2-(2-propynyl)­octanoate: a very efficient multi-action antitumor prodrug candidate Dalton Transactions 2017 46 41 14174 14185 10.1039/C7DT02928D 28984330

Rangone B. Ferrari B. Astesana V. Masiello I. Veneroni P. Zanellato I. Osella D. Bottone M. G. A new platinum-based prodrug candidate: Its anticancer effects in B50 neuroblastoma rat cells Life Sciences 2018 210 166 176 10.1016/j.lfs.2018.08.048 30144454

Gabano E. Rangone B. Perin E. Caron G. Ermondi G. Vallaro M. Gandin V. Marzano C. Barbanente A. Margiotta N. Pt­(iv) complexes based on cyclohexanediamines and the histone deacetylase inhibitor 2-(2-propynyl)­octanoic acid: synthesis, characterization, cell penetration properties and antitumor activity Dalton Transactions 2021 50 13 4663 4672 10.1039/D0DT04135A 33725031

Raveendran R. Braude J. P. Wexselblatt E. Novohradsky V. Stuchlikova O. Brabec V. Gandin V. Gibson D. Pt­(iv) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action Chemical Science 2016 7 3 2381 2391 10.1039/C5SC04205D 29997781 PMC6003606

Almotairy A. R. Z. Gandin V. Morrison L. Marzano C. Montagner D. Erxleben A. Antitumor platinum­(IV) derivatives of carboplatin and the histone deacetylase inhibitor 4-phenylbutyric acid Journal of Inorganic Biochemistry 2017 177 1 7 10.1016/j.jinorgbio.2017.09.009 28918353

Kostrhunova H. Zajac J. Novohradsky V. Kasparkova J. Malina J. Aldrich-Wright J. R. Petruzzella E. Sirota R. Gibson D. Brabec V. A Subset of New Platinum Antitumor Agents Kills Cells by a Multimodal Mechanism of Action Also Involving Changes in the Organization of the Microtubule Cytoskeleton J. Med. Chem. 2019 62 10 5176 5190 10.1021/acs.jmedchem.9b00489 31030506

Lee V. E. Y. Lim Z. C. Chew S. L. Ang W. H. Strategy for Traceless Codrug Delivery with Platinum­(IV) Prodrug Complexes Using Self-Immolative Linkers Inorganic Chemistry 2021 60 3 1823 1831 10.1021/acs.inorgchem.0c03299 33464875

Ang W. H. Khalaila I. Allardyce C. S. Juillerat-Jeanneret L. Dyson P. J. Rational Design of Platinum­(IV) Compounds to Overcome Glutathione-S-Transferase Mediated Drug Resistance J. Am. Chem. Soc. 2005 127 5 1382 1383 10.1021/ja0432618 15686364

Zanellato I. Bonarrigo I. Sardi M. Alessio M. Gabano E. Ravera M. Osella D. Evaluation of Platinum-Ethacrynic Acid Conjugates in the Treatment of Mesothelioma ChemMedChem 2011 6 12 2287 2293 10.1002/cmdc.201100426 22025407

Lee K. G. Z. Babak M. V. Weiss A. Dyson P. J. Nowak-Sliwinska P. Montagner D. Ang W. H. Development of an Efficient Dual-Action GST-Inhibiting Anticancer Platinum­(IV) Prodrug ChemMedChem 2018 13 12 1210 1217 10.1002/cmdc.201800105 29637702

Dhar S. Lippard S. J. Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate Proceedings of the National Academy of Sciences 2009 106 52 22199 22204 10.1073/pnas.0912276106 PMC2799774 20007777

Xue X. You S. Zhang Q. Wu Y. Zou G.-z. Wang P. C. Zhao Y.-l. Xu Y. Jia L. Zhang X. Mitaplatin Increases Sensitivity of Tumor Cells to Cisplatin by Inducing Mitochondrial Dysfunction Molecular Pharmaceutics 2012 9 3 634 644 10.1021/mp200571k 22289032 PMC3310394

Cao Q. Zhou D.-J. Pan Z.-Y. Yang G.-G. Zhang H. Ji L.-N. Mao Z.-W. CAIXplatins: Highly Potent Platinum­(IV) Prodrugs Selective Against Carbonic Anhydrase IX for the Treatment of Hypoxic Tumors Angewandte Chemie International Edition 2020 59 42 18556 18562 10.1002/anie.202005362 32557982

Wang Z. Xu Z. Zhu G. A Platinum­(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance Angewandte Chemie International Edition 2016 55 50 15564 15568 10.1002/anie.201608936 27736029

Wang M. Li G. Jiang G. Cai J. Liu Z. Huang R. Huang X. Wang H. Novel NF-κB Inhibitor-Conjugated Pt­(IV) Prodrug to Enable Cancer Therapy through ROS/ER Stress and Mitochondrial Dysfunction and Overcome Multidrug Resistance J. Med. Chem. 2024 67 8 6218 6237 10.1021/acs.jmedchem.3c02182 38573870

Wang M. Li G. Jiang G. Cai J. Zhong W. Huang R. Liu Z. Huang X. Wang H. Dual-targeting tumor cells hybrids derived from Pt­(IV) species and NF-κB inhibitors enables cancer therapy through mitochondrial dysfunction and ER stress and overcomes cisplatin resistance Eur. J. Med. Chem. 2024 266 116095 10.1016/j.ejmech.2023.116095 38215589

Zhang R. Song X.-Q. Liu R.-P. Ma Z.-Y. Xu J.-Y. Fuplatin: An Efficient and Low-Toxic Dual-Prodrug J. Med. Chem. 2019 62 9 4543 4554 10.1021/acs.jmedchem.9b00128 31002510

Kastner A. Mendrina T. Babu T. Karmakar S. Poetsch I. Berger W. Keppler B. K. Gibson D. Heffeter P. Kowol C. R. Stepwise optimization of tumor-targeted dual-action platinum­(iv)-gemcitabine prodrugs Inorganic Chemistry Frontiers 2024 11 2 534 548 10.1039/D3QI02032K 38235273 PMC10790623

Zhang M. Li L. Li S. Liu Z. Zhang N. Sun B. Wang Z. Jia D. Liu M. Wang Q. Development of Clioquinol Platinum­(IV) Conjugates as Autophagy-Targeted Antimetastatic Agents J. Med. Chem. 2023 66 5 3393 3410 10.1021/acs.jmedchem.2c01895 36891739

Zhang M. Chen Y. Liu Z. Liu M. Wang Q. Series of Desloratadine Platinum­(IV) Hybrids Displaying Potent Antimetastatic Competence by Inhibiting Epithelial-Mesenchymal Transition and Arousing Immune Response J. Med. Chem. 2024 67 3 2031 2048 10.1021/acs.jmedchem.3c01845 38232132

Chen Y. Zhang M. He Y. Li S. Feng S. Liu Z. Zhang N. Liu M. Wang Q. Canadine Platinum­(IV) Complexes Targeting Epithelial-Mesenchymal Transition as Antiproliferative and Antimetastatic Agents J. Med. Chem. 2024 67 15 12868 12886 10.1021/acs.jmedchem.4c00843 39069665

Chen Y. Zhang M. Liu Z. Zhang N. Wang Q. Ursodeoxycholic Acid Platinum­(IV) Conjugates as Antiproliferative and Antimetastatic Agents: Remodel the Tumor Microenvironment through Suppressing JAK2/STAT3 Signaling J. Med. Chem. 2024 67 19 17551 17567 10.1021/acs.jmedchem.4c01549 39292635

Huang X. Huang R. Gou S. Wang Z. Liao Z. Wang H. Combretastatin A-4 Analogue: A Dual-Targeting and Tubulin Inhibitor Containing Antitumor Pt­(IV) Moiety with a Unique Mode of Action Bioconjugate Chemistry 2016 27 9 2132 2148 10.1021/acs.bioconjchem.6b00353 27494235

Huang X. Huang R. Wang Z. Li L. Gou S. Liao Z. Wang H. Pt­(IV) complexes conjugating with chalcone analogue as inhibitors of microtubule polymerization exhibited selective inhibition in human cancer cells Eur. J. Med. Chem. 2018 146 435 450 10.1016/j.ejmech.2018.01.075 29407969

Li L. Huang X. Huang R. Gou S. Wang Z. Wang H. Pt­(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance Eur. J. Med. Chem. 2018 156 666 679 10.1016/j.ejmech.2018.07.016 30031977

Huang X. Wang M. Wang C. Hu W. You Q. Yang Y. Yu C. Liao Z. Gou S. Wang H. Dual-targeting antitumor conjugates derived from platinum­(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance Bioorganic Chemistry 2019 92 103236 10.1016/j.bioorg.2019.103236 31494328

Schmidt C. Babu T. Kostrhunova H. Timm A. Basu U. Ott I. Gandin V. Brabec V. Gibson D. Are Pt­(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs? J. Med. Chem. 2021 64 15 11364 11378 10.1021/acs.jmedchem.1c00706 34342437

Suntharalingam K. Song Y. Lippard S. J. Conjugation of vitamin E analog α-TOS to Pt­(iv) complexes for dual-targeting anticancer therapy Chemical Communications 2014 50 19 2465 2468 10.1039/c3cc48740g 24452361 PMC3938893

Li C.-x. Zou Z.-r. Xu S. Shi J.-h. Zou Y. Yan M. Zhang X.-j. Pt­(IV)-PROTAC Complexes with Synergistic Antitumor Activity and Enhanced Membrane Permeability J. Med. Chem. 2025 68 8208 10.1021/acs.jmedchem.4c02909 40184539

Xu J. Chen S. Ng K.-Y. Chen X. Fu W. C. Zhu G. A platinated prodrug leveraging PROTAC technology for targeted protein degradation and enhanced antitumor efficacy Inorganic Chemistry Frontiers 2025 12 3981 10.1039/D5QI00605H

Yempala T. Babu T. Karmakar S. Nemirovski A. Ishan M. Gandin V. Gibson D. Expanding the Arsenal of PtIV Anticancer Agents: Multi-action PtIV Anticancer Agents with Bioactive Ligands Possessing a Hydroxy Functional Group Angewandte Chemie International Edition 2019 58 50 18218 18223 10.1002/anie.201910014 31599054

Babu T. Sarkar A. Karmakar S. Schmidt C. Gibson D. Multiaction Pt­(IV) Carbamate Complexes Can Codeliver Pt­(II) Drugs and Amine Containing Bioactive Molecules Inorganic Chemistry 2020 59 7 5182 5193 10.1021/acs.inorgchem.0c00445 32207294

Štarha P. Křikavová R. Platinum­(IV) and platinum­(II) anticancer complexes with biologically active releasable ligands Coord. Chem. Rev. 2024 501 215578 10.1016/j.ccr.2023.215578

Marotta C. Giorgi E. Binacchi F. Cirri D. Gabbiani C. Pratesi A. An overview of recent advancements in anticancer Pt­(IV) prodrugs: New smart drug combinations, activation and delivery strategies Inorg. Chim. Acta 2023 548 121388 10.1016/j.ica.2023.121388

Sahoo D. Deb P. Basu T. Bardhan S. Patra S. Sukul P. K. Advancements in platinum-based anticancer drug development: A comprehensive review of strategies, discoveries, and future perspectives Bioorg. Med. Chem. 2024 112 117894 10.1016/j.bmc.2024.117894 39214013

Aher S. Zhu J. Bhagat P. Borse L. Liu X. Pt­(IV) Complexes in the Search for Novel Platinum Prodrugs with Promising Activity Topics in Current Chemistry 2024 382 1 6 10.1007/s41061-023-00448-3 38400859

Petruzzella E. Sirota R. Solazzo I. Gandin V. Gibson D. Triple action Pt­(iv) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance Chemical Science 2018 9 18 4299 4307 10.1039/C8SC00428E 29780561 PMC5944384

Karmakar S. Kostrhunova H. Ctvrtlikova T. Novohradsky V. Gibson D. Brabec V. Platinum­(IV)-Estramustine Multiaction Prodrugs Are Effective Antiproliferative Agents against Prostate Cancer Cells J. Med. Chem. 2020 63 22 13861 13877 10.1021/acs.jmedchem.0c01400 33175515

Hu W. Fang L. Hua W. Gou S. Biotin-Pt (IV)-indomethacin hybrid: A targeting anticancer prodrug providing enhanced cancer cellular uptake and reversing cisplatin resistance Journal of Inorganic Biochemistry 2017 175 47 57 10.1016/j.jinorgbio.2017.07.002 28700961

Gupta A. Sasmal P. K. Multi-functional biotinylated platinum­(iv)-SAHA conjugate for tumor-targeted chemotherapy Dalton Transactions 2024 53 44 17829 17840 10.1039/D4DT01571A 39404606

Petruzzella E. Braude J. P. Aldrich-Wright J. R. Gandin V. Gibson D. A Quadruple-Action Platinum­(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell Lines Angewandte Chemie International Edition 2017 56 38 11539 11544 10.1002/anie.201706739 28759160

Karges J. Yempala T. Tharaud M. Gibson D. Gasser G. A Multi-action and Multi-target RuII-PtIV Conjugate Combining Cancer-Activated Chemotherapy and Photodynamic Therapy to Overcome Drug Resistant Cancers Angewandte Chemie International Edition 2020 59 18 7069 7075 10.1002/anie.201916400 32017379

Lee J. S. Kim J. Ye Y.-s. Kim T.-i. Materials and device design for advanced phototherapy systems Adv. Drug Delivery Rev. 2022 186 114339 10.1016/j.addr.2022.114339 35568104

Spector D. Pavlov K. Beloglazkina E. Krasnovskaya O. Recent advances in light-controlled activation of Pt (IV) prodrugs International Journal of Molecular Sciences 2022 23 23 14511 10.3390/ijms232314511 36498837 PMC9739791

Huang J. Ding W. Zhu X. Li B. Zeng F. Wu K. Wu X. Wang F. Ligand evolution in the photoactivatable platinum (IV) anticancer prodrugs Frontiers in Chemistry 2022 10 876410 10.3389/fchem.2022.876410 35755267 PMC9218644

Deng Z. Wang N. Liu Y. Xu Z. Wang Z. Lau T.-C. Zhu G. A photocaged, water-oxidizing, and nucleolus-targeted Pt (IV) complex with a distinct anticancer mechanism J. Am. Chem. Soc. 2020 142 17 7803 7812 10.1021/jacs.0c00221 32216337

Hall M. D. Daly H. L. Zhang J. Z. Zhang M. Alderden R. A. Pursche D. Foran G. J. Hambley T. W. Quantitative measurement of the reduction of platinum (IV) complexes using X-ray absorption near-edge spectroscopy (XANES) Metallomics 2012 4 6 568 575 10.1039/c2mt20053h 22569908

Varbanov H. P. Jakupec M. A. Roller A. Jensen F. Galanski M. S. Keppler B. K. Theoretical investigations and density functional theory based quantitative structure-activity relationships model for novel cytotoxic platinum (IV) complexes J. Med. Chem. 2013 56 1 330 344 10.1021/jm3016427 23214999 PMC3557934

Zhang J. Z. Bonnitcha P. Wexselblatt E. Klein A. V. Najajreh Y. Gibson D. Hambley T. W. Facile Preparation of Mono-, Di-and Mixed-Carboxylato Platinum (IV) Complexes for Versatile Anticancer Prodrug Design Chem.-Eur. J. 2013 19 5 1672 1676 10.1002/chem.201203159 23255183

Deng Z. Li C. Chen S. Zhou Q. Xu Z. Wang Z. Yao H. Hirao H. Zhu G. An intramolecular photoswitch can significantly promote photoactivation of Pt (IV) prodrugs Chemical Science 2021 12 19 6536 6542 10.1039/D0SC06839J 34040729 PMC8139284

Haber R. S. Rathan A. Weiser K. R. Pritsker A. Itzkowitz S. H. Bodian C. Slater G. Weiss A. Burstein D. E. GLUT1 glucose transporter expression in colorectal carcinoma Cancer 1998 83 1 34 40 10.1002/(SICI)1097-0142(19980701)83:1<34::AID-CNCR5>3.0.CO;2-E 9655290

Mi Q. Ma Y. Gao X. Liu R. Liu P. Mi Y. Fu X. Gao Q. 2-Deoxyglucose conjugated platinum (II) complexes for targeted therapy: design, synthesis, and antitumor activity Journal of Biomolecular Structure and Dynamics 2016 34 11 2339 2350 10.1080/07391102.2015.1114972 26524393

Wu M. Li H. Liu R. Gao X. Zhang M. Liu P. Fu Z. Yang J. Zhang-Negrerie D. Gao Q. Galactose conjugated platinum­(II) complex targeting the Warburg effect for treatment of non-small cell lung cancer and colon cancer Eur. J. Med. Chem. 2016 110 32 42 10.1016/j.ejmech.2016.01.016 26807543

Aronov O. Horowitz A. T. Gabizon A. Gibson D. Folate-Targeted PEG as a Potential Carrier for Carboplatin Analogs. Synthesis and in Vitro Studies Bioconjugate Chemistry 2003 14 3 563 574 10.1021/bc025642l 12757380

Vitols K. S. Montejano Y. Duffy T. Pope L. Grundler G. Huennekens F. M. Platinum-folate compounds: synthesis, properties and biological activity Advances in Enzyme Regulation 1987 26 17 27 10.1016/0065-2571(87)90004-5 3673704

Mitra K. Shettar A. Kondaiah P. Chakravarty A. R. Biotinylated Platinum­(II) Ferrocenylterpyridine Complexes for Targeted Photoinduced Cytotoxicity Inorganic Chemistry 2016 55 11 5612 5622 10.1021/acs.inorgchem.6b00680 27171926

Singh T. Kang D. H. Kim T. W. Kong H. J. Ryu J. S. Jeon S. Ahn T. S. Jeong D. Baek M. J. Im J. Intracellular delivery of oxaliplatin conjugate via cell penetrating peptide for the treatment of colorectal carcinoma in vitro and in vivo Int. J. Pharm. 2021 606 120904 10.1016/j.ijpharm.2021.120904 34293467

Sepay N. Kim T. W. Singh T. Paul M. Kong H. J. Ryu J. S. Ghosh N. Jeon S. Lee S. Ahn T. S. Targeted delivery of oxaliplatin to colorectal cancer using the cancer-specific cell-penetrating peptide BR2 Journal of Drug Delivery Science and Technology 2024 101 106261 10.1016/j.jddst.2024.106261

Wang Q. Huang Z. Ma J. Lu X. Zhang L. Wang X. George Wang P. Design, synthesis and biological evaluation of a novel series of glycosylated platinum­(iv) complexes as antitumor agents Dalton Transactions 2016 45 25 10366 10374 10.1039/C6DT01562J 27252024

Khoury A. Sakoff J. A. Gilbert J. Karan S. Gordon C. P. Aldrich-Wright J. R. Potent Platinum­(IV) Prodrugs That Incorporate a Biotin Moiety to Selectively Target Cancer Cells Pharmaceutics 2022 14 12 2780 10.3390/pharmaceutics14122780 36559273 PMC9853328

Zhao J. Hua W. Xu G. Gou S. Biotinylated platinum­(IV) complexes designed to target cancer cells Journal of Inorganic Biochemistry 2017 176 175 180 10.1016/j.jinorgbio.2017.08.017 28917640

Navas F. Chocarro-Calvo A. Iglesias-Hernández P. Fernández-García P. Morales V. García-Martínez J. M. Sanz R. De la Vieja A. García-Jiménez C. García-Muñoz R. A. Promising Anticancer Prodrugs Based on Pt­(IV) Complexes with Bis-organosilane Ligands in Axial Positions J. Med. Chem. 2024 67 8 6410 6424 10.1021/acs.jmedchem.3c02393 38592014 PMC11056991

McKeon A. M. Noonan J. Devocelle M. Murphy B. M. Griffith D. M. Platinum­(iv) oxaliplatin-peptide conjugates targeting memHsp70+ phenotype in colorectal cancer cells Chemical Communications 2017 53 82 11318 11321 10.1039/C7CC04764A 28967013

Ma Z.-Y. Ding X.-J. Zhu Z.-Z. Chen Q. Wang D.-B. Qiao X. Xu J.-Y. Pt­(iv) derivatives of cisplatin and oxaliplatin bearing an EMT-related TMEM16A/COX-2-selective dual inhibitor against colorectal cancer cells HCT116 RSC Medicinal Chemistry 2024 15 9 3239 3247 10.1039/D4MD00327F 39185449 PMC11342162

Deng Z. Chen S. Liu G. Zhu G. Unlocking the potential of platinum drugs: organelle-targeted small-molecule platinum complexes for improved anticancer performance RSC Chemical Biology 2023 4 12 1003 1013 10.1039/D3CB00087G 38033725 PMC10685827

Peng K. Zheng Y. Xia W. Mao Z.-W. Organometallic anti-tumor agents: targeting from biomolecules to dynamic bioprocesses Chemical Society Reviews 2023 52 8 2790 2832 10.1039/D2CS00757F 37014670

Peng K. Liang B.-B. Liu W. Mao Z.-W. What blocks more anticancer platinum complexes from experiment to clinic: Major problems and potential strategies from drug design perspectives Coord. Chem. Rev. 2021 449 214210 10.1016/j.ccr.2021.214210

Khoury A. Deo K. M. Aldrich-Wright J. R. Recent advances in platinum-based chemotherapeutics that exhibit inhibitory and targeted mechanisms of action Journal of Inorganic Biochemistry 2020 207 111070 10.1016/j.jinorgbio.2020.111070 32299045

Xie , L. ; Guan , R. ; Rees , T. W. ; Chao , H. Organelle-targeting metal anticancer agents . In Advances in Inorganic Chemistry ; Sadler , P. J. , van Eldik , R. Eds.; Academic Press , 2020 ; Vol. 75 , Chapter 9, pp 287 – 337 .

Qiu K. Chen Y. Rees T. W. Ji L. Chao H. Organelle-targeting metal complexes: From molecular design to bio-applications Coord. Chem. Rev. 2019 378 66 86 10.1016/j.ccr.2017.10.022

Huang K.-B. Wang F.-Y. Feng H.-W. Luo H. Long Y. Zou T. Chan A. S. C. Liu R. Zou H. Chen Z.-F. An aminophosphonate ester ligand-containing platinum­(ii) complex induces potent immunogenic cell death in vitro and elicits effective anti-tumour immune responses in vivo Chemical Communications 2019 55 87 13066 13069 10.1039/C9CC06563F 31570904

Widler L. Jaeggi K. A. Glatt M. Müller K. Bachmann R. Bisping M. Born A.-R. Cortesi R. Guiglia G. Jeker H. Highly Potent Geminal Bisphosphonates. From Pamidronate Disodium (Aredia) to Zoledronic Acid (Zometa) J. Med. Chem. 2002 45 17 3721 3738 10.1021/jm020819i 12166945

Deng Z. Li H. Chen S. Wang N. Liu G. Liu D. Ou W. Xu F. Wang X. Lei D. Near-infrared-activated anticancer platinum­(IV) complexes directly photooxidize biomolecules in an oxygen-independent manner Nature Chemistry 2023 15 7 930 939 10.1038/s41557-023-01242-w 37353602

Liang B.-B. Liu Q. Liu B. Yao H.-G. He J. Tang C.-F. Peng K. Su X.-X. Zheng Y. Ding J.-Y. A Golgi-Targeted Platinum Complex Plays a Dual Role in Autophagy Regulation for Highly Efficient Cancer Therapy Angewandte Chemie International Edition 2023 62 44 e202312170 10.1002/anie.202312170 37710398

Ericson N. G. Kulawiec M. Vermulst M. Sheahan K. O’Sullivan J. Salk J. J. Bielas J. H. Decreased mitochondrial DNA mutagenesis in human colorectal cancer PLOS genetics 2012 8 6 e1002689 10.1371/journal.pgen.1002689 22685414 PMC3369930

Su S. Chen Y. Zhang P. Ma R. Zhang W. Liu J. Li T. Niu H. Cao Y. Hu B. The role of Platinum­(IV)-based antitumor drugs and the anticancer immune response in medicinal inorganic chemistry. A systematic review from 2017 to 2022 Eur. J. Med. Chem. 2022 243 114680 10.1016/j.ejmech.2022.114680 36152386

Kamimura K. Matsumoto Y. Zhou Q. Moriyama M. Saijo Y. Myelosuppression by chemotherapy in obese patients with gynecological cancers Cancer Chemotherapy and Pharmacology 2016 78 3 633 641 10.1007/s00280-016-3119-2 27485538

Siddik Z. H. Boxall F. E. Harrap K. R. Haematological toxicity of carboplatin in rats Br. J. Cancer 1987 55 4 375 379 10.1038/bjc.1987.75 3555590 PMC2001698

Onsrud M. Bosnes V. Grahm I. cis-platinum as adjunctive to surgery in early stage ovarian carcinoma: Effects on lymphoid cell subpopulations Gynecologic Oncology 1986 23 3 323 328 10.1016/0090-8258(86)90133-2 3957118

Hato S. V. Khong A. de Vries I. J. M. Lesterhuis W. J. Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics Clin. Cancer Res. 2014 20 11 2831 2837 10.1158/1078-0432.CCR-13-3141 24879823

de Biasi A. R. Villena-Vargas J. Adusumilli P. S. Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence Clin. Cancer Res. 2014 20 21 5384 5391 10.1158/1078-0432.CCR-14-1298 25204552 PMC4216745

Romani A. M. P. Cisplatin in cancer treatment Biochem. Pharmacol. 2022 206 115323 10.1016/j.bcp.2022.115323 36368406

Huang X. Cui S. Shu Y. Cisplatin selectively downregulated the frequency and immunoinhibitory function of myeloid-derived suppressor cells in a murine B16 melanoma model Immunologic Research 2016 64 1 160 170 10.1007/s12026-015-8734-1 26590944

Nio Y. Hirahara N. Minari Y. Iguchi C. Yamasawa K. Toga T. Tamura K. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface Anticancer Research 2000 20 5A 3293 3299 11062756

Hato S. V. Figdor C. G. Takahashi S. Pen A. E. Halilovic A. Bol K. F. Vasaturo A. Inoue Y. de Haas N. Verweij D. Van Herpen C. M.L. Kaanders J. H. van Krieken J. H.J.M. Van Laarhoven H. W.M. Hooijer G. K.J. Punt C. J.A. Asai A. de Vries I. J. M. Lesterhuis W. J. Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity Oncotarget 2017 8 33 54434 10.18632/oncotarget.17661 28903353 PMC5589592

Hato S. V. de Vries I. J. M. Lesterhuis W. J. STATing the importance of immune modulation by platinum chemotherapeutics OncoImmunology 2012 1 2 234 236 10.4161/onci.1.2.18126 22720254 PMC3376994

Tran L. Allen C. T. Xiao R. Moore E. Davis R. Park S.-J. Spielbauer K. Van Waes C. Schmitt N. C. Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma Cancer Immunology Research 2017 5 12 1141 1151 10.1158/2326-6066.CIR-17-0235 29097421 PMC5712281

Ock C.-Y. Kim S. Keam B. Kim S. Ahn Y.-O. Chung E.-J. Kim J.-H. Kim T. M. Kwon S. K. Jeon Y. K. Jung K. C. Kim D.-W. Wu H.-G. Sung M.-W. Heo D. S. Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma Oncotarget 2017 8 58 97920 10.18632/oncotarget.18542 29228662 PMC5716702

Miao X. Zhang Y. Li Z. Huang L. Xin T. Shen R. Wang T. Inhibition of indoleamine 2,3-dioxygenase 1 synergizes with oxaliplatin for efficient colorectal cancer therapy Molecular Therapy - Methods & Clinical Development 2021 20 442 450 10.1016/j.omtm.2020.12.013 33665222 PMC7889448

Stone T. W. Stoy N. Darlington L. G. An expanding range of targets for kynurenine metabolites of tryptophan Trends Pharmacol. Sci. 2013 34 2 136 143 10.1016/j.tips.2012.09.006 23123095

Munn D. H. Mellor A. L. Indoleamine 2,3 dioxygenase and metabolic control of immune responses Trends in Immunology 2013 34 3 137 143 10.1016/j.it.2012.10.001 23103127 PMC3594632

Hao Y. Li R. Pan W. Tian S. Min Y. Platinum Twin and Triplet Drugs Improve Chemoimmunotherapy J. Med. Chem. 2023 66 17 12225 12236 10.1021/acs.jmedchem.3c00792 37665669

Cesario A. Rocca B. Rutella S. The Interplay between Indoleamine 2,3-Dioxygenase 1 (IDO1) and Cyclooxygenase (COX)-2 In Chronic Inflammation and Cancer Current Medicinal Chemistry 2011 18 15 2263 2271 10.2174/092986711795656063 21517752

Shen F. Feng L. Zhu Y. Tao D. Xu J. Peng R. Liu Z. Oxaliplatin-/NLG919 prodrugs-constructed liposomes for effective chemo-immunotherapy of colorectal cancer Biomaterials 2020 255 120190 10.1016/j.biomaterials.2020.120190 32563943

Song L. Hao Y. Wang C. Han Y. Zhu Y. Feng L. Miao L. Liu Z. Liposomal oxaliplatin prodrugs loaded with metformin potentiate immunotherapy for colorectal cancer J. Controlled Release 2022 350 922 932 10.1016/j.jconrel.2022.09.013 36108810

Tian L. Shao M. Gong Y. Wei T. Zhu Y. Chao Y. Liu Z. Epigenetic Platinum Complexes Breaking the “Eat Me/Don’t Eat Me” Balance for Enhanced Cancer Chemoimmunotherapy Bioconjugate Chemistry 2022 33 2 343 352 10.1021/acs.bioconjchem.1c00576 35040313

Oronsky B. Paulmurugan R. Foygel K. Scicinski J. Knox S. J. Peehl D. Zhao H. Ning S. Cabrales P. Summers T. A. RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials Expert Opinion on Investigational Drugs 2017 26 1 109 119 10.1080/13543784.2017.1268600 27935336

Oronsky B. Guo X. Wang X. Cabrales P. Sher D. Cannizzo L. Wardle B. Abrouk N. Lybeck M. Caroen S. Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development J. Med. Chem. 2021 64 11 7261 7271 10.1021/acs.jmedchem.1c00599 34043360

Wang B. Zhou J. Li R. Tang D. Cao Z. Xu C. Xiao H. Activating CD8+ T Cells by Pt­(IV) Prodrug-Based Nanomedicine and aPD-L1 Antibody for Enhanced Cancer Immunotherapy Adv. Mater. 2024 36 2311640 10.1002/adma.202311640 38341667

Guo Y. Pino-Lagos K. Ahonen C. A. Bennett K. A. Wang J. Napoli J. L. Blomhoff R. Sockanathan S. Chandraratna R. A. Dmitrovsky E. A Retinoic AcidRich Tumor Microenvironment Provides Clonal Survival Cues for Tumor-Specific CD8+ T Cells Cancer Res. 2012 72 20 5230 5239 10.1158/0008-5472.CAN-12-1727 22902413 PMC3766319

Li X. Luo X. Chen S. Chen J. Deng X. Zhong J. Wu H. Huang X. Wang C. All-trans-retinoic acid inhibits hepatocellular carcinoma progression by targeting myeloid-derived suppressor cells and inhibiting angiogenesis International Immunopharmacology 2023 121 110413 10.1016/j.intimp.2023.110413 37301119

Wong D. Y. Q. Yeo C. H. F. Ang W. H. Immuno-Chemotherapeutic Platinum­(IV) Prodrugs of Cisplatin as Multimodal Anticancer Agents Angewandte Chemie International Edition 2014 53 26 6752 6756 10.1002/anie.201402879 24844571

Barenholz Y. C. Doxil®The first FDA-approved nano-drug: Lessons learned Journal of controlled release 2012 160 2 117 134 10.1016/j.jconrel.2012.03.020 22484195

Maier-Hauff K. Ulrich F. Nestler D. Niehoff H. Wust P. Thiesen B. Orawa H. Budach V. Jordan A. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme Journal of neuro-oncology 2011 103 317 324 10.1007/s11060-010-0389-0 20845061 PMC3097345

Anselmo A. C. Mitragotri S. Nanoparticles in the clinic: An update Bioeng Transl Med 2019 4 3 e10143 10.1002/btm2.10143 31572799 PMC6764803

Saif M. W. US Food and Drug Administration approves paclitaxel protein-bound particles (Abraxane®) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer JOP. Journal of the Pancreas 2013 14 6 686 688 10.6092/1590-8577/2028 24216565

Passero F. C. Jr Grapsa D. Syrigos K. N. Saif M. W. The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy Expert review of anticancer therapy 2016 16 7 697 703 10.1080/14737140.2016.1192471 27219482

Milano G. Innocenti F. Minami H. Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs Cancer Science 2022 113 7 2224 2231 10.1111/cas.15377 35445479 PMC9277406

Mudry P. Kyr M. Rohleder O. Mahdal M. Staniczkova Zambo I. Jezova M. Tomas T. Sterba J. Improved osteosarcoma survival with addition of mifamurtide to conventional chemotherapy-Observational prospective single institution analysis Journal of Bone Oncology 2021 28 100362 10.1016/j.jbo.2021.100362 33948428 PMC8080518

Silverman J. A. Deitcher S. R. Marqibo®(vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine Cancer chemotherapy and pharmacology 2013 71 3 555 564 10.1007/s00280-012-2042-4 23212117 PMC3579462

Forssen E. A. Ross M. E. Daunoxome® treatment of solid tumors: preclinical and clinical investigations Journal of liposome research 1994 4 1 481 512 10.3109/08982109409037058

Alfayez M. Kantarjian H. Kadia T. Ravandi-Kashani F. Daver N. CPX-351 (vyxeos) in AML Leukemia & lymphoma 2020 61 2 288 297 10.1080/10428194.2019.1660970 31547736

Krauss A. C. Gao X. Li L. Manning M. L. Patel P. Fu W. Janoria K. G. Gieser G. Bateman D. A. Przepiorka D. Shen Y. L. Shord S. S. Sheth C. M. Banerjee A. Liu J. Goldberg K. B. Farrell A. T. Blumenthal G. M. Pazdur R. FDA Approval Summary:(Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid LeukemiaFDA Approval:(Daunorubicin and Cytarabine) Clin. Cancer Res. 2019 25 9 2685 2690 10.1158/1078-0432.CCR-18-2990 30541745

Sartor O. Eligard® 6: a new form of treatment for prostate cancer european urology supplements 2006 5 18 905 910 10.1016/j.eursup.2006.08.006

Berges R. Eligard®: pharmacokinetics, effect on testosterone and PSA levels and tolerability European Urology Supplements 2005 4 5 20 25 10.1016/j.eursup.2005.04.001

Foss F. M. DAB389IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma Clinical lymphoma 2000 1 2 110 116 10.3816/CLM.2000.n.009 11707818

T-Regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors ; Reddys Laboratories , 2022 ; https://ClinicalTrials.gov/show/NCT05200559 .

A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer ; University of Texas Health Science Center at San Antonio , 2007 ; https://ClinicalTrials.gov/show/NCT00880360 .

Bobo D. Robinson K. J. Islam J. Thurecht K. J. Corrie S. R. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date Pharmaceutical research 2016 33 2373 2387 10.1007/s11095-016-1958-5 27299311

Study of Focal Ablation of the Prostate With NanoTherm Therapy System for Intermediate-Risk Prostate Cancer ; MagForce USA , 2021 ; https://ClinicalTrials.gov/show/NCT05010759 .

Liu D. He C. Wang A. Z. Lin W. Application of liposomal technologies for delivery of platinum analogs in oncology International journal of nanomedicine 2013 3309 3319 10.2147/IJN.S38354 24023517 PMC3767488

Boulikas T. Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin Expert opinion on investigational drugs 2009 18 8 1197 1218 10.1517/13543780903114168 19604121

Dragovich T. Mendelson D. Kurtin S. Richardson K. Von Hoff D. Hoos A. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer Cancer Chemotherapy and Pharmacology 2006 58 6 759 764 10.1007/s00280-006-0235-4 16847673

Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours ; Allarity Therapeutics , 2013 ; https://ClinicalTrials.gov/show/NCT01861496 .

NC-6004(Nanoplatin) and Gemcitabine to Treat Pancreatic Cancer in Asia ; NanoCarrier Co., Ltd , 2009 ; https://ClinicalTrials.gov/show/NCT00910741 .

Combination Therapy with NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen ; NanoCarrier Co., Ltd. , 2019 ; https://ClinicalTrials.gov/show/NCT03771820 .

Stathopoulos G. P. Boulikas T. Kourvetaris A. Stathopoulos J. Liposomal Oxaliplatin in the Treatment of Advanced Cancer: A Phase I Study Anticancer Res. 2006 26 2B 1489 16619562

Yang T. Zhang S. Yuan H. Wang Y. Cai L. Chen H. Wang X. Song D. Wang X. Guo Z. Platinum-Based TREM2 Inhibitor Suppresses Tumors by Remodeling the Immunosuppressive Microenvironment Angewandte Chemie International Edition 2023 62 2 e202213337 10.1002/anie.202213337 36259513

Lesterhuis W. J. Punt C. J. A. Hato S. V. Eleveld-Trancikova D. Jansen B. J. H. Nierkens S. Schreibelt G. de Boer A. Van Herpen C. M. L. Kaanders J. H. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice The Journal of Clinical Investigation 2011 121 8 3100 3108 10.1172/JCI43656 21765211 PMC3148725

Fournel L. Wu Z. Stadler N. Damotte D. Lococo F. Boulle G. Ségal-Bendirdjian E. Bobbio A. Icard P. Trédaniel J. Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer Cancer Letters 2019 464 5 14 10.1016/j.canlet.2019.08.005 31404614

Li Z. Li L. Zhao W. Sun B. Liu Z. Liu M. Han J. Wang Z. Li D. Wang Q. Development of a series of flurbiprofen and zaltoprofen platinum­(iv) complexes with anti-metastasis competence targeting COX-2, PD-L1 and DNA Dalton Transactions 2022 51 33 12604 12619 10.1039/D2DT00944G 35924963

Lo Re D. Montagner D. Tolan D. Di Sanza C. Iglesias M. Calon A. Giralt E. Increased immune cell infiltration in patient-derived tumor explants treated with Traniplatin: an original Pt­(iv) pro-drug based on Cisplatin and Tranilast Chemical Communications 2018 54 60 8324 8327 10.1039/C8CC02071J 29796549

Bose R. N. Maurmann L. Mishur R. J. Yasui L. Gupta S. Grayburn W. S. Hofstetter H. Salley T. Non-DNA-binding platinum anticancer agents: Cytotoxic activities of platinum-phosphato complexes towards human ovarian cancer cells Proceedings of the National Academy of Sciences 2008 105 47 18314 18319 10.1073/pnas.0803094105 PMC2587608 19020081

Corte-Rodríguez M. Espina M. Sierra L. M. Blanco E. Ames T. Montes-Bayón M. Sanz-Medel A. Quantitative evaluation of cellular uptake, DNA incorporation and adduct formation in cisplatin sensitive and resistant cell lines: Comparison of different Pt-containing drugs Biochem. Pharmacol. 2015 98 1 69 77 10.1016/j.bcp.2015.08.112 26352094

Soler R. Ames T. Marco-Brualla J. Moreno-Loshuertos R. Price M. Jimeno J. Anel A. PT-112, a first-in-class pyrophosphate-platinum conjugate, selectively targets highly glycolytic tumor cells Eur. J. Cancer 2020 138 S53 S54 10.1016/S0959-8049(20)31219-3

Soler-Agesta R. Marco-Brualla J. Minjárez-Sáenz M. Yim C. Y. Martínez-Júlvez M. Price M. R. Moreno-Loshuertos R. Ames T. D. Jimeno J. Anel A. PT-112 Induces Mitochondrial Stress and Immunogenic Cell Death, Targeting Tumor Cells with Mitochondrial Deficiencies Cancers 2022 14 16 3851 10.3390/cancers14163851 36010843 PMC9405950

Bose R. N. Moghaddas S. Belkacemi L. Tripathi S. Adams N. R. Majmudar P. McCall K. Dezvareh H. Nislow C. Absence of Activation of DNA Repair Genes and Excellent Efficacy of Phosphaplatins against Human Ovarian Cancers: Implications To Treat Resistant Cancers J. Med. Chem. 2015 58 21 8387 8401 10.1021/acs.jmedchem.5b00732 26455832

Jain A. Jain S. K. Ganesh N. Barve J. Beg A. M. Design and development of ligand-appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer Nanomedicine: Nanotechnology, Biology and Medicine 2010 6 1 179 190 10.1016/j.nano.2009.03.002 19447205

Cabral H. Nishiyama N. Kataoka K. Optimization of (1,2-diamino-cyclohexane)­platinum­(II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity J. Controlled Release 2007 121 3 146 155 10.1016/j.jconrel.2007.05.024 17628162

Wang K. Liu L. Zhang T. Zhu Y. J. Qiu F. Wu X. G. Wang X.-L. Hu F. Q. Huang J. Oxaliplatin-incorporated micelles eliminate both cancer stem-like and bulk cell populations in colorectal cancer Int. J. Nanomedicne 2011 6 3027 10.2147/IJN.S26268 PMC3254265 22238509

Li J.-Q. Wang S.-L. Xu F. Liu Z.-Y. Li R. Therapeutic effectiveness of slow-release PLGA-oxaliplatin microsphere on human colorectal tumor-bearing mice Anti-Cancer Drugs 2010 21 6 600 10.1097/CAD.0b013e3283393004 20527722

Wu L. Man C. Wang H. Lu X. Ma Q. Cai Y. Ma W. PEGylated Multi-Walled Carbon Nanotubes for Encapsulation and Sustained Release of Oxaliplatin Pharm. Res. 2013 30 2 412 423 10.1007/s11095-012-0883-5 22992831

Yang C. Liu H.-Z. Lu W.-D. Fu Z.-X. PEG-liposomal oxaliplatin potentialization of antitumor efficiency in a nude mouse tumor-xenograft model of colorectal carcinoma Oncol. Rep. 2011 25 6 1621 1628 10.3892/or.2011.1238 21455585

Yang C. Liu H. Z. Fu Z. X. Lu W. D. Oxaliplatin long-circulating liposomes improved therapeutic index of colorectal carcinoma BMC Biotechnology 2011 11 1 21 10.1186/1472-6750-11-21 21401960 PMC3064655

Abu-Lila A. Suzuki T. Doi Y. Ishida T. Kiwada H. Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model J. Controlled Release 2009 134 1 18 25 10.1016/j.jconrel.2008.10.018 19010364

Abu Lila A. S. Doi Y. Nakamura K. Ishida T. Kiwada H. Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor J. Controlled Release 2010 142 2 167 173 10.1016/j.jconrel.2009.10.020 19861140

Abu Lila A. S. Eldin N. E. Ichihara M. Ishida T. Kiwada H. Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: A possible mechanism and the potential for clinical application Int. J. Pharm. 2012 438 1 176 183 10.1016/j.ijpharm.2012.08.030 22944302

Lee S.-Y. Shieh M.-J. Platinum­(II) Drug-Loaded Gold Nanoshells for Chemo-Photothermal Therapy in Colorectal Cancer ACS Applied Materials & Interfaces 2020 12 4 4254 4264 10.1021/acsami.9b18855 31927943

Guo J. Yu Z. Das M. Huang L. Nano Codelivery of Oxaliplatin and Folinic Acid Achieves Synergistic Chemo-Immunotherapy with 5-Fluorouracil for Colorectal Cancer and Liver Metastasis ACS Nano 2020 14 4 5075 5089 10.1021/acsnano.0c01676 32283007

Guo J. Yu Z. Sun D. Zou Y. Liu Y. Huang L. Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma Molecular Cancer 2021 20 1 10 10.1186/s12943-020-01297-0 33407548 PMC7786897

Charest G. Tippayamontri T. Shi M. Wehbe M. Anantha M. Bally M. Sanche L. Concomitant Chemoradiation Therapy with Gold Nanoparticles and Platinum Drugs Co-Encapsulated in Liposomes International Journal of Molecular Sciences 2020 21 4848 10.3390/ijms21144848 32659905 PMC7402338

Vakili M. R. Mohammed-Saeid W. Aljasser A. Hopwood-Raja J. Ahvazi B. Hrynets Y. Betti M. Lavasanifar A. Development of mucoadhesive hydrogels based on polyacrylic acid grafted cellulose nanocrystals for local cisplatin delivery Carbohydr. Polym. 2021 255 117332 10.1016/j.carbpol.2020.117332 33436175

Shimizu T. Abu Lila A. S. Nishio M. Doi Y. Ando H. Ukawa M. Ishima Y. Ishida T. Modulation of antitumor immunity contributes to the enhanced therapeutic efficacy of liposomal oxaliplatin in mouse model Cancer Science 2017 108 9 1864 1869 10.1111/cas.13305 28643902 PMC5581521

Danışman-Kalındemirtaş F. Kariper İ. A. Erdemir G. Sert E. Erdem-Kuruca S. Evaluation of anticancer effects of carboplatin-gelatin nanoparticles in different sizes synthesized with newly self-assembly method by exposure to IR light Scientific Reports 2022 12 1 10686 10.1038/s41598-022-15051-7 35739313 PMC9226150

Wang Z.-H. Chu M. Yin N. Huang W. Liu W. Zhang Z. Liu J. Shi J. Biological chemotaxis-guided self-thermophoretic nanoplatform augments colorectal cancer therapy through autonomous mucus penetration Science Advances 2022 8 26 eabn3917 10.1126/sciadv.abn3917 35767627 PMC9242589

Cao L. Tian H. Fang M. Xu Z. Tang D. Chen J. Yin J. Xiao H. Shang K. Han H. Activating cGAS-STING pathway with ROS-responsive nanoparticles delivering a hybrid prodrug for enhanced chemo-immunotherapy Biomaterials 2022 290 121856 10.1016/j.biomaterials.2022.121856 36306685

Boztepe T. Scioli-Montoto S. Gambaro R. C. Ruiz M. E. Cabrera S. Alemán J. Islan G. A. Castro G. R. León I. E. Design, Synthesis, Characterization, and Evaluation of the Anti-HT-29 Colorectal Cell Line Activity of Novel 8-Oxyquinolinate-Platinum­(II)-Loaded Nanostructured Lipid Carriers Targeted with Riboflavin Pharmaceutics 2023 15 1021 10.3390/pharmaceutics15031021 36986881 PMC10056074

Go G. Park H. J. Lee J. H. Yun C. W. Lee S. H. Inhibitory Effect of Oxaliplatin-loaded Engineered Milk Extracellular Vesicles on Tumor Progression Anticancer Res. 2022 42 2 857 10.21873/anticanres.15543 35093883

Zhu X. Peng Y. Qiu L. Amino-functionalized nano-vesicles for enhanced anticancer efficacy and reduced myelotoxicity of carboplatin Colloids and Surfaces B: Biointerfaces 2017 157 56 64 10.1016/j.colsurfb.2017.05.041 28575741

Pairoj S. Damrongsak P. Damrongsak B. Jinawath N. Kaewkhaw R. Ruttanasirawit C. Leelawattananon T. Locharoenrat K. Antitumor activities of carboplatin-doxorubicin-ZnO complexes in different human cancer cell lines (breast, cervix uteri, colon, liver and oral) under UV exposition Artificial Cells, Nanomedicine, and Biotechnology 2021 49 1 120 135 10.1080/21691401.2021.1876718 33491496

Tummala S. Gowthamarajan K. Satish Kumar M. N. Wadhwani A. Oxaliplatin immuno hybrid nanoparticles for active targeting: an approach for enhanced apoptotic activity and drug delivery to colorectal tumors Drug Delivery 2016 23 5 1773 1787 10.3109/10717544.2015.1084400 26377238

Wang Y. Zhang X. Zhang W. Dong H. Zhang W. Mao J. Dai Y. Combination of Oxaliplatin and Vit.E-TPGS in Lipid Nanosystem for Enhanced Therapeutic Efficacy in Colon Cancers Pharm. Res. 2018 35 2 27 10.1007/s11095-017-2297-x 29368145

Narmani A. Kamali M. Amini B. Salimi A. Panahi Y. Targeting delivery of oxaliplatin with smart PEG-modified PAMAM G4 to colorectal cell line: In vitro studies Process Biochemistry 2018 69 178 187 10.1016/j.procbio.2018.01.014

Lee P.-C. Lin C.-Y. Peng C.-L. Shieh M.-J. Development of a controlled-release drug delivery system by encapsulating oxaliplatin into SPIO/MWNT nanoparticles for effective colon cancer therapy and magnetic resonance imaging Biomaterials Science 2016 4 12 1742 1753 10.1039/C6BM00444J 27722406

Li M. Mao L. Chen M. Li M. Wang K. Mo J. Characterization of an Amphiphilic Phosphonated Calixarene Carrier Loaded With Carboplatin and Paclitaxel: A Preliminary Study to Treat Colon Cancer in vitro and in vivo Frontiers in Bioengineering and Biotechnology 2019 7 238 10.3389/fbioe.2019.00238 31632958 PMC6779836

Ames T. Slusher B. Wozniak K. Takase Y. Shimizu H. Nishibata-Kobayashi K. Kanada-Sonobe R.M. Kerns W. Fong K.L. Pourquier P. Gongora C. Jimeno J. Chatterjee D. Findings across pre-clinical models in the development of PT-112, a novel investigational platinum-pyrophosphate anti-cancer agent Eur. J. Cancer 2016 69 S153 10.1016/S0959-8049(16)33054-4

Yamazaki T. Buqué A. Ames T. D. Galluzzi L. PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models OncoImmunology 2020 9 1 1721810 10.1080/2162402X.2020.1721810 32117585 PMC7028345

Yamazaki T. Ames T. D. Galluzzi L. Abstract B199: Potent induction of immunogenic cell death by PT-112 Cancer Immunology Research 2019 7 B199 B199 10.1158/2326-6074.CRICIMTEATIAACR18-B199

Yim C. Y. Congenie M. T. Johnson H. L. Mancini M. G. Stossi F. Mancini M. A. Azofeifa J. Price M. R. Baeck J. Ames T. D. Abstract C128: PT-112, a novel immunogenic cell death inducer, causes ribosomal biogenesis inhibition and organelle stress in cancer cells Molecular Cancer Therapeutics 2023 22 C128 C128 10.1158/1535-7163.TARG-23-C128

Karp D. D. Camidge D. R. Bryce A. H. Jimeno J. Infante J. R. A phase I study of PT-112 in advanced solid tumors Journal of Clinical Oncology 2017 35 2519 2519 10.1200/JCO.2017.35.15_suppl.2519

Karp D. D. Camidge D. R. Infante J. R. Ames T. D. Jimeno J. M. Bryce A. H. PT-112: A well-tolerated novel immunogenic cell death (ICD) inducer with activity in advanced solid tumors Annals of Oncology 2018 29 viii143 10.1093/annonc/mdy279.424

Bryce A. H. Dronca R. S. Costello B. A. Infante J. R. Ames T. D. Jimeno J. Karp D. D. PT-112 in advanced metastatic castrate-resistant prostate cancer (mCRPC), as monotherapy or in combination with PD-L1 inhibitor avelumab: Findings from two phase I studies Journal of Clinical Oncology 2020 38 83 83 10.1200/JCO.2020.38.6_suppl.83

Ames T. D. Sharik M. E. Rather G. M. Hochart G. Bonnel D. Linehan S. Stauber J. Wing R. A. Jimeno J. J. Medina D. Translational Research of PT-112, a Clinical Agent in Advanced Phase I Development: Evident Bone Tropism, Synergy In Vitro with Bortezomib and Lenalidomide, and Potent Efficacy in the Vk*MYC Mouse Model of Multiple Myeloma Blood 2017 130 1797 10.1182/blood.V130.Suppl_1.1797.1797

Zou T. Lok C.-N. Fung Y. M. E. Che C.-M. Luminescent organoplatinum­(ii) complexes containing bis­(N-heterocyclic carbene) ligands selectively target the endoplasmic reticulum and induce potent photo-toxicity Chemical Communications 2013 49 47 5423 5425 10.1039/c3cc40953h 23515304

Tham M. J. R. Babak M. V. Ang W. H. PlatinER: A Highly Potent Anticancer Platinum­(II) Complex that Induces Endoplasmic Reticulum Stress Driven Immunogenic Cell Death Angewandte Chemie International Edition 2020 59 43 19070 19078 10.1002/anie.202008604 32716112

Farrer N. J. Woods J. A. Salassa L. Zhao Y. Robinson K. S. Clarkson G. Mackay F. S. Sadler P. J. A Potent Trans-Diimine Platinum Anticancer Complex Photoactivated by Visible Light Angewandte Chemie International Edition 2010 49 47 8905 8908 10.1002/anie.201003399 20677309

Pracharova J. Zerzankova L. Stepankova J. Novakova O. Farrer N. J. Sadler P. J. Brabec V. Kasparkova J. Interactions of DNA with a New Platinum­(IV) Azide Dipyridine Complex Activated by UVA and Visible Light: Relationship to Toxicity in Tumor Cells Chem. Res. Toxicol. 2012 25 5 1099 1111 10.1021/tx300057y 22420335

Zhao Y. Farrer N. J. Li H. Butler J. S. McQuitty R. J. Habtemariam A. Wang F. Sadler P. J. De Novo Generation of Singlet Oxygen and Ammine Ligands by Photoactivation of a Platinum Anticancer Complex Angewandte Chemie International Edition 2013 52 51 13633 13637 10.1002/anie.201307505 24167018 PMC4230391

Shi H. Imberti C. Sadler P. J. Diazido platinum­(iv) complexes for photoactivated anticancer chemotherapy Inorganic Chemistry Frontiers 2019 6 7 1623 1638 10.1039/C9QI00288J PMC7610473 33786191

Acharya S. Sahoo S. K. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect Adv Drug Deliv Rev 2011 63 3 170 183 10.1016/j.addr.2010.10.008 20965219

Iyer A. K. Khaled G. Fang J. Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting Drug Discov Today 2006 11 17–18 812 818 10.1016/j.drudis.2006.07.005 16935749

Takayama R. Inoue Y. Murata I. Kanamoto I. Characterization of Nanoparticles Using DSPE-PEG2000 and Soluplus Colloids and Interfaces 2020 4 3 28 10.3390/colloids4030028

Fritze A. Hens F. Kimpfler A. Schubert R. Peschka-Suss R. Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient Biochim. Biophys. Acta 2006 1758 10 1633 1640 10.1016/j.bbamem.2006.05.028 16887094

Miao L. Guo S. Zhang J. Kim W. Y. Huang L. Nanoparticles with precise ratiometric co-loading and co-delivery of gemcitabine monophosphate and cisplatin for treatment of bladder cancer Advanced functional materials 2014 24 42 6601 6611 10.1002/adfm.201401076 25395922 PMC4225819

Siegal T. Horowitz A. Gabizon A. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy J Neurosurg 1995 83 6 1029 1037 10.3171/jns.1995.83.6.1029 7490617

Bazak R. Houri M. El Achy S. Kamel S. Refaat T. Cancer active targeting by nanoparticles: a comprehensive review of literature J Cancer Res Clin Oncol 2015 141 5 769 784 10.1007/s00432-014-1767-3 25005786 PMC4710367

Suzuki R. Takizawa T. Kuwata Y. Mutoh M. Ishiguro N. Utoguchi N. Shinohara A. Eriguchi M. Yanagie H. Maruyama K. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome Int. J. Pharm. 2008 346 1 143 150 10.1016/j.ijpharm.2007.06.010 17640835

Zalba S. Contreras A. M. Haeri A. ten Hagen T. L. M. Navarro I. Koning G. Garrido M. J. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer J. Controlled Release 2015 210 26 38 10.1016/j.jconrel.2015.05.271 25998052

Li R. He Y. Zhang S. Qin J. Wang J. Cell membrane-based nanoparticles: a new biomimetic platform for tumor diagnosis and treatment Acta Pharm Sin B 2018 8 1 14 22 10.1016/j.apsb.2017.11.009 29872619 PMC5985624

He Z. Zhang Y. Feng N. Cell membrane-coated nanosized active targeted drug delivery systems homing to tumor cells: A review Mater Sci Eng C Mater Biol Appl 2020 106 110298 10.1016/j.msec.2019.110298 31753336

Greening D. W. Xu R. Ji H. Tauro B. J. Simpson R. J. A protocol for exosome isolation and characterization: evaluation of ultracentrifugation, density-gradient separation, and immunoaffinity capture methods Methods Mol. Biol. 2015 1295 179 209 10.1007/978-1-4939-2550-6_15 25820723

Xia Q. Zhang Y. Li Z. Hou X. Feng N. Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application Acta Pharmaceutica Sinica B 2019 9 4 675 689 10.1016/j.apsb.2019.01.011 31384529 PMC6663920

Lees J. G. White D. Keating B. A. Barkl-Luke M. E. Makker P. G. S. Goldstein D. Moalem-Taylor G. Oxaliplatin-induced haematological toxicity and splenomegaly in mice PLOS ONE 2020 15 9 e0238164 10.1371/journal.pone.0238164 32877416 PMC7467301

Wittgen B. P. H. Kunst P. W. A. van der Born K. van Wijk A. W. Perkins W. Pilkiewicz F. G. Perez-Soler R. Nicholson S. Peters G. J. Postmus P. E. Phase I Study of Aerosolized SLIT Cisplatin in the Treatment of Patients with Carcinoma of the Lung Clin. Cancer Res. 2007 13 8 2414 2421 10.1158/1078-0432.CCR-06-1480 17438100

Zarogoulidis P. Darwiche K. Krauss L. Huang H. Zachariadis G. A. Katsavou A. Hohenforst-Schmidt W. Papaiwannou A. Vogl T. J. Freitag L. Inhaled Cisplatin Deposition and Distribution in Lymph Nodes in Stage II Lung Cancer Patients Future Oncology 2013 9 9 1307 1313 10.2217/fon.13.111 23980678

Cheng H. Huang S. Huang G. Design and application of oral colon administration system Journal of Enzyme Inhibition and Medicinal Chemistry 2019 34 1 1590 1596 10.1080/14756366.2019.1655406 31581863 PMC6781185

McCoubrey L. E. Favaron A. Awad A. Orlu M. Gaisford S. Basit A. W. Colonic drug delivery: Formulating the next generation of colon-targeted therapeutics J. Controlled Release 2023 353 1107 1126 10.1016/j.jconrel.2022.12.029 36528195

Van den Mooter G. Samyn C. Kinget R. Azo polymers for colon-specific drug delivery Int. J. Pharm. 1992 87 1 37 46 10.1016/0378-5173(92)90225-Q 9423139

Mi Q. Shu S. Yang C. Gao C. Zhang X. Luo X. Bao C. Zhang X. Niu J. Current status for oral platinum (IV) anticancer drug development International Journal of Medical Physics, Clinical Engineering and Radiation Oncology 2018 7 231 10.4236/ijmpcero.2018.72020

Kelland L. R. An update on satraplatin: the first orally available platinum anticancer drug Expert Opinion on Investigational Drugs 2000 9 6 1373 1382 10.1517/13543784.9.6.1373 11060749

Yap S. Q. Chin C. F. Hong Thng A. H. Pang Y. Y. Ho H. K. Ang W. H. Finely Tuned Asymmetric Platinum­(IV) Anticancer Complexes: Structure-Activity Relationship and Application as Orally Available Prodrugs ChemMedChem 2017 12 4 300 311 10.1002/cmdc.201600577 28028938

Urbanska A. M. Karagiannis E. D. Guajardo G. Langer R. S. Anderson D. G. Therapeutic effect of orally administered microencapsulated oxaliplatin for colorectal cancer Biomaterials 2012 33 18 4752 4761 10.1016/j.biomaterials.2012.03.023 22472433 PMC3586541

Kim Y. H. Lee S. J. Lee S. H. Hahn M. Preclinical efficacy and safety assessment of nano-oxaliplatin oral formulation prepared by novel Fat Employing Supercritical Nano System, the FESNS® Pharmaceutical Development and Technology 2012 17 6 677 686 10.3109/10837450.2011.565349 23216046

Pangeni R. Subedi L. Jha S. K. Kweon S. Kang S.-H. Chang K.-Y. Choi J. U. Byun Y. Park J. W. Improvements in the Oral Absorption and Anticancer Efficacy of an Oxaliplatin-Loaded Solid Formulation: Pharmacokinetic Properties in Rats and Nonhuman Primates and the Effects of Oral Metronomic Dosing on Colorectal Cancer International Journal of Nanomedicine 2020 15 null 7719 7743 10.2147/IJN.S267424 33116497 PMC7555381

Van der Speeten , K. ; Kilian , M. ; Lemione , L. Application of IPC, HIPEC, and PIPAC . In Peritoneal Tumors and Metastases: Surgical, Intraperitoneal and Systemic Therapy ; Rau , B. , Königsrainer , A. , Mohamed , F. , Sugarbaker , P. H. , Eds.; Springer International , 2021 ; pp 111 – 133 .

Lewis K. A. Diggs L. P. Badgwell B. D. Educational Review: Updates on Therapeutic Strategies for Gastric Cancer with Peritoneal Metastasis Annals of Surgical Oncology 2025 32 5 3672 3687 10.1245/s10434-025-17069-3 40016614 PMC12268850

Neuwirth M. G. Alexander H. R. Karakousis G. C. Then and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective Journal of Gastrointestinal Oncology 2015 7 1 18 28 10.3978/j.issn.2078-6891.2015.106 PMC4754315 26941981

Ceelen W. HIPEC with oxaliplatin for colorectal peritoneal metastasis: The end of the road? European Journal of Surgical Oncology 2019 45 3 400 402 10.1016/j.ejso.2018.10.542 30392745

Klempner S. J. Ryan D. P. HIPEC for colorectal peritoneal metastases The Lancet Oncology 2021 22 2 162 164 10.1016/S1470-2045(20)30693-8 33476594

Quénet F. Elias D. Roca L. Goéré D. Ghouti L. Pocard M. Facy O. Arvieux C. Lorimier G. Pezet D. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial The Lancet Oncology 2021 22 2 256 266 10.1016/S1470-2045(20)30599-4 33476595

Daniel S. K. Sun B. J. Lee B. PIPAC for Gastrointestinal Malignancies Journal of Clinical Medicine 2023 12 21 6799 10.3390/jcm12216799 37959264 PMC10650315

Alyami M. Hübner M. Grass F. Bakrin N. Villeneuve L. Laplace N. Passot G. Glehen O. Kepenekian V. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications The Lancet Oncology 2019 20 7 e368 10.1016/S1470-2045(19)30318-3 31267971

Sundar R. Chia D. K. A. Zhao J. J. Lee A. R. Y. B. Kim G. Tan H. L. Pang A. Shabbir A. Willaert W. Ma H. Phase I PIANO trialPIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomes ESMO Open 2024 9 9 103681 10.1016/j.esmoop.2024.103681 39288528 PMC11421236

Lurvink R. J. Rovers K. P. Nienhuijs S. W. Creemers G.-J. Burger J. W. A. de Hingh I. H. J. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-OX) in patients with colorectal peritoneal metastasesa systematic review Journal of Gastrointestinal Oncology 2021 12 S242 S258 10.21037/jgo-20-257 33968441 PMC8100707

Kim G. Tan H. L. Sundar R. Lieske B. Chee C. E. Ho J. Shabbir A. Babak M. V. Ang W. H. Goh B. C. PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases Clin. Cancer Res. 2021 27 7 1875 1881 10.1158/1078-0432.CCR-20-2152 33148667

Peritoneal Cancer Institute . 2025 . https://perito­neal­cancer­institute.com/ (accessed 2025 April 22, 2025).

Bouleftour W. Rowinski E. Louati S. Sotton S. Wozny A.-S. Moreno-Acosta P. Mery B. Rodriguez-Lafrasse C. Magne N. A review of the role of hypoxia in radioresistance in cancer therapy Medical science monitor 2021 27 e934116 10.12659/MSM.934116 34728593 PMC8573967

Beckers C. Pruschy M. Vetrugno I. Tumor hypoxia and radiotherapy: A major driver of resistance even for novel radiotherapy modalities Seminars in Cancer Biology 2024 98 19 30 10.1016/j.semcancer.2023.11.006 38040401

George T. J. Franke A. J. Chakravarthy A. B. Das P. Dasari A. El-Rayes B. F. Hong T. S. Kinsella T. J. Landry J. C. Lee J. J. National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer Cancer 2019 125 16 2732 2746 10.1002/cncr.32150 31017664 PMC6663584

Gill M. R. Vallis K. A. Transition metal compounds as cancer radiosensitizers Chemical Society Reviews 2019 48 2 540 557 10.1039/C8CS00641E 30499573

Li X. Sun H. Lu Y. Xing L. Radiotherapy-triggered prodrug activation: A new era in precise chemotherapy Med 2022 3 9 600 602 10.1016/j.medj.2022.08.004 36087574

Farrer N. J. Higgins G. S. Kunkler I. H. Radiation-induced prodrug activation: extending combined modality therapy for some solid tumours Br. J. Cancer 2022 126 9 1241 1243 10.1038/s41416-022-01746-1 35217798 PMC8873346

Ito T. Tanabe K. Yamada H. Hatta H. Nishimoto S.-i. Radiation- and Photo-induced Activation of 5-Fluorouracil Prodrugs as a Strategy for the Selective Treatment of Solid Tumors Molecules 2008 13 10 2370 2384 10.3390/molecules13102370 18830160 PMC6245186

Tanabe K. Ishizaki J. Ando Y. Ito T. Nishimoto S.-i. Reductive activation of 5-fluorodeoxyuridine prodrug possessing azide methyl group by hypoxic X-irradiation Bioorg. Med. Chem. Lett. 2012 22 4 1682 1685 10.1016/j.bmcl.2011.12.106 22248856

Cividalli A. Ceciarelli F. Livdi E. Altavista P. Cruciani G. Marchetti P. Danesi D. T. Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule International Journal of Radiation Oncology *Biology* Physics 2002 52 4 1092 1098 10.1016/S0360-3016(01)02792-4 11958906

Hermann R. M. Rave-Fränk M. Pradier O. Combining radiation with oxaliplatin: A review of experimental results Cancer/Radiothérapie 2008 12 1 61 67 10.1016/j.canrad.2007.12.006 18243751

Hill E. J. Nicolay N. H. Middleton M. R. Sharma R. A. Oxaliplatin as a radiosensitiser for upper and lower gastrointestinal tract malignancies: What have we learned from a decade of translational research? Critical Reviews in Oncology/Hematology 2012 83 3 353 387 10.1016/j.critrevonc.2011.12.007 22309673

Frerker B. Bock F. Cappel M.-L. Kriesen S. Klautke G. Hildebrandt G. Manda K. Radiosensitizing Effects of Irinotecan versus Oxaliplatin Alone and in Combination with 5-Fluorouracil on Human Colorectal Cancer Cells International Journal of Molecular Sciences 2023 24 12 10385 10.3390/ijms241210385 37373535 PMC10299222

Gerard J.-P. Azria D. Gourgou-Bourgade S. Martel-Laffay I. Hennequin C. Etienne P.-L. Vendrely V. Francois E. de La Roche G. Bouche O. Mirabel X. Denis B. Mineur L. Berdah J.-F. Mahe M. A. Becouarn Y. Dupuis O. Lledo G. Montoto-Grillot C. Conroy T. Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2 Journal of Clinical Oncology 2010 28 10 1638 1644 10.1200/JCO.2009.25.8376 20194850

Aschele C. Cionini L. Lonardi S. Pinto C. Cordio S. Rosati G. Artale S. Tagliagambe A. Ambrosini G. Rosetti P. Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial Journal of Clinical Oncology 2011 29 20 2773 2780 10.1200/JCO.2010.34.4911 21606427

Schmoll H.-J. Haustermans K. Price T. J. Nordlinger B. Hofheinz R. Daisne J.-F. Janssens J. Brenner B. Schmidt P. Reinel H. Hollerbach S. Caca K. Fauth F. W.B. Hannig C. Zalcberg J. R. Tebbutt N. C. Mauer M. E. Messina C. G. M. Lutz M. P. Van Cutsem E. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: First results of the PETACC-6 randomized phase III trial Journal of Clinical Oncology 2013 31 3531 3531 10.1200/jco.2013.31.15_suppl.3531

Rödel C. Liersch T. Becker H. Fietkau R. Hohenberger W. Hothorn T. Graeven U. Arnold D. Lang-Welzenbach M. Raab H.-R. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial The Lancet Oncology 2012 13 7 679 687 10.1016/S1470-2045(12)70187-0 22627104

Yang X.-H. Li K.-G. Wei J.-B. Wu C.-H. Liang S.-X. Mo X.-W. Chen J.-S. Tang W.-Z. Qu S. Retrospective study of preoperative chemoradiotherapy with capecitabine versus capecitabine plus oxaliplatin for locally advanced rectal cancer Scientific Reports 2020 10 1 12539 10.1038/s41598-020-69573-z 32719436 PMC7385078

Fu Q. Zhang S. Shen S. Gu Z. Chen J. Song D. Sun P. Wang C. Guo Z. Xiao Y. Radiotherapy-triggered reduction of platinum-based chemotherapeutic prodrugs in tumours Nature Biomedical Engineering 2024 8 11 1425 1435 10.1038/s41551-024-01239-x 39025943

Ibrahim E. Y. Ehrlich B. E. Prevention of chemotherapy-induced peripheral neuropathy: A review of recent findings Critical Reviews in Oncology/Hematology 2020 145 102831 10.1016/j.critrevonc.2019.102831 31783290 PMC6982645

Finnerup N. B. Sindrup S. H. Jensen T. S. The evidence for pharmacological treatment of neuropathic pain Pain 2010 150 3 573 581 10.1016/j.pain.2010.06.019 20705215

Loprinzi C. L. Lustberg M. B. Hershman D. L. Ruddy K. J. Chemotherapy-induced peripheral neuropathy: ice, compression, both, or neither? Annals of Oncology 2020 31 1 5 6 10.1016/j.annonc.2019.10.009 31912795

Bailey A. G. Brown J. N. Hammond J. M. Cryotherapy for the prevention of chemotherapy-induced peripheral neuropathy: A systematic review Journal of Oncology Pharmacy Practice 2021 27 1 156 164 10.1177/1078155220959431 32955997

Martinez N. W. Sánchez A. Diaz P. Broekhuizen R. Godoy J. Mondaca S. Catenaccio A. Macanas P. Nervi B. Calvo M. Metformin protects from oxaliplatin induced peripheral neuropathy in rats Neurobiology of Pain 2020 8 100048 10.1016/j.ynpai.2020.100048 32490289 PMC7260677

Areti A. Komirishetty P. Kumar A. Carvedilol prevents functional deficits in peripheral nerve mitochondria of rats with oxaliplatin-evoked painful peripheral neuropathy Toxicol. Appl. Pharmacol. 2017 322 97 103 10.1016/j.taap.2017.03.009 28286117

Kim S. T. Chung Y. H. Lee H. S. Chung S. J. Lee J. H. Sohn U. D. Shin Y. K. Park E. S. Kim H.-C. Bang J. S. Protective effects of phosphatidylcholine on oxaliplatin-induced neuropathy in rats Life Sciences 2015 130 81 87 10.1016/j.lfs.2015.03.013 25817232

Ta L. E. Schmelzer J. D. Bieber A. J. Loprinzi C. L. Sieck G. C. Brederson J. D. Low P. A. Windebank A. J. A Novel and Selective Poly (ADP-Ribose) Polymerase Inhibitor Ameliorates Chemotherapy-Induced Painful Neuropathy PLOS ONE 2013 8 1 e54161 10.1371/journal.pone.0054161 23326593 PMC3542321

Waseem M. Parvez S. Neuroprotective activities of curcumin and quercetin with potential relevance to mitochondrial dysfunction induced by oxaliplatin Protoplasma 2016 253 2 417 430 10.1007/s00709-015-0821-6 26022087

Azevedo M. I. Pereira A. F. Nogueira R. B. Rolim F. E. Brito G. A. Wong D. V. T. Lima-Júnior R. C. de Albuquerque Ribeiro R. Vale M. L. The Antioxidant Effects of the Flavonoids Rutin and Quercetin Inhibit Oxaliplatin-Induced Chronic Painful Peripheral Neuropathy Molecular Pain 2013 9 1744 10.1186/1744-8069-9-53 PMC3835704 24152430

Areti A. Komirishetty P. Kalvala A. K. Nellaiappan K. Kumar A. Rosmarinic Acid Mitigates Mitochondrial Dysfunction and Spinal Glial Activation in Oxaliplatin-induced Peripheral Neuropathy Molecular Neurobiology 2018 55 9 7463 7475 10.1007/s12035-018-0920-4 29427084

Di Cesare Mannelli L. Lucarini E. Micheli L. Mosca I. Ambrosino P. Soldovieri M. V. Martelli A. Testai L. Taglialatela M. Calderone V. Effects of natural and synthetic isothiocyanate-based H2S-releasers against chemotherapy-induced neuropathic pain: Role of Kv7 potassium channels Neuropharmacology 2017 121 49 59 10.1016/j.neuropharm.2017.04.029 28431970

Lucarini E. Micheli L. Trallori E. Citi V. Martelli A. Testai L. De Nicola G. R. Iori R. Calderone V. Ghelardini C. Effect of glucoraphanin and sulforaphane against chemotherapy-induced neuropathic pain: Kv7 potassium channels modulation by H2S release in vivo Phytotherapy Research 2018 32 11 2226 2234 10.1002/ptr.6159 30069944

Gierthmuhlen J. Maier C. Baron R. Tolle T. Treede R.-D. Birbaumer N. Huge V. Koroschetz J. Krumova E. K. Lauchart M. Maihofner C. Richter H. Westermann A. Sensory signs in complex regional pain syndrome and peripheral nerve injury PAIN 2012 153 4 765 10.1016/j.pain.2011.11.009 22154921

Di Cesare Mannelli L. Zanardelli M. Landini I. Pacini A. Ghelardini C. Mini E. Bencini A. Valtancoli B. Failli P. Effect of the SOD mimetic MnL4 on in vitro and in vivo oxaliplatin toxicity: Possible aid in chemotherapy induced neuropathy Free Radical Biol. Med. 2016 93 67 76 10.1016/j.freeradbiomed.2016.01.023 26828020

Guillaumot M.-A. Cerles O. Bertrand H. C. Benoit E. Nicco C. Chouzenoux S. Schmitt A. Batteux F. Policar C. Coriat R. Oxaliplatin-induced neuropathy: the preventive effect of a new super-oxide dismutase modulator Oncotarget 2019 10 60 6418 6431 10.18632/oncotarget.27248 31741707 PMC6849645

Prieux-Klotz C. Chédotal H. Zoumpoulaki M. Chouzenoux S. Chêne C. Lopez-Sanchez A. Thomas M. Ranjan Sahoo P. Policar C. Batteux F. A New Manganese Superoxide Dismutase Mimetic Improves Oxaliplatin-Induced Neuropathy and Global Tolerance in Mice International Journal of Molecular Sciences 2022 23 21 12938 10.3390/ijms232112938 36361753 PMC9658974

Tania S. S. Sayedur R. M. Iftekhar Hossain C. Jahan A. Y. Hossni A. M. Shirin A. Effect of Lidocaine Transdermal Patch as Add-On Therapy in Treatment of Oxaliplatin Induced Peripheral Neuropathy in Colorectal Cancer Patients: A Randomized Double-Blind Placebo-Controlled Trial Advances in Cancer Research & Clinical Imaging 2024 4 4 591 10.33552/ACRCI.2024.04.000591

Mine K. Kawashiri T. Inoue M. Kobayashi D. Mori K. Hiromoto S. Kudamatsu H. Uchida M. Egashira N. Koyanagi S. Omeprazole Suppresses Oxaliplatin-Induced Peripheral Neuropathy in a Rodent Model and Clinical Database International Journal of Molecular Sciences 2022 23 16 8859 10.3390/ijms23168859 36012136 PMC9408309

Yazici O. Titiz A. P. Ozdemir N. Aksoy S. Sendur M. A. Arlı B. Zengin N. Role of glutamine for preventing oxaliplatin induced peripheral neuropathy (GELUPO): results of randomized open-label phase II trial Annals of Oncology 2016 27 vi169 10.1093/annonc/mdw370.62

Gu Z. Wei G. Zhu L. Zhu L. Hu J. Li Q. Cai G. Lu H. Liu M. Chen C. Ji Y. Li G. Huo J. Preventive Efficacy and Safety of Yiqi-Wenjing-Fang Granules on Oxaliplatin-Induced Peripheral Neuropathy: A Protocol for a Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Evidence-Based Complementary and Alternative Medicine 2021 2021 1 5551568 10.1155/2021/5551568 34630609 PMC8494586

Yehia R. Saleh S. El Abhar H. Saad A. S. Schaalan M. L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways Toxicol. Appl. Pharmacol. 2019 365 41 50 10.1016/j.taap.2018.12.015 30592963

Attal N. Gaudé V. Brasseur L. Dupuy M. Guirimand F. Parker F. Bouhassira D. Intravenous lidocaine in central pain Neurology 2000 54 3 564 564 10.1212/WNL.54.3.564 10680784

Kerckhove N. Tougeron D. Lepage C. Pezet D. Le Malicot K. Pelkowski M. Pereira B. Balayssac D. Efficacy of donepezil for the treatment of oxaliplatin-induced peripheral neuropathy: DONEPEZOX, a protocol of a proof of concept, randomised, triple-blinded and multicentre trial BMC Cancer 2022 22 1 742 10.1186/s12885-022-09806-8 35799138 PMC9264497

de Andrade D. C. Jacobsen Teixeira M. Galhardoni R. Ferreira K. S. L. Braz Mileno P. Scisci N. Zandonai A. Teixeira W. G. J. Saragiotto D. F. Silva V. Pregabalin for the Prevention of Oxaliplatin-Induced Painful Neuropathy: A Randomized, Double-Blind Trial The Oncologist 2017 22 10 1154 e1105 10.1634/theoncologist.2017-0235 28652279 PMC5634769

Zimmerman C. Atherton P. J. Pachman D. Seisler D. Wagner-Johnston N. Dakhil S. Lafky J. M. Qin R. Grothey A. Loprinzi C. L. MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy Supportive Care in Cancer 2016 24 3 1071 1078 10.1007/s00520-015-2876-5 26248652 PMC4939800

Kotaka M. Saito Y. Kato T. Satake H. Makiyama A. Tsuji Y. Shinozaki K. Fujiwara T. Mizushima T. Harihara Y. A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy Cancer Chemotherapy and Pharmacology 2020 86 5 607 618 10.1007/s00280-020-04135-8 32965539 PMC7561567

Afonseca S. O. d. Cruz F. M. Cubero D. d. I. G. Lera A. T. Schindler F. Okawara M. Souza L. F. d. Rodrigues N. P. Giglio A. d. Vitamin E for prevention of oxaliplatin-induced peripheral neuropathy: a pilot randomized clinical trial Sao Paulo Medical Journal 2013 131 1 35 38 10.1590/S1516-31802013000100006 23538593 PMC10852076

Loprinzi C. L. Qin R. Dakhil S. R. Fehrenbacher L. Flynn K. A. Atherton P. Seisler D. Qamar R. Lewis G. C. Grothey A. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance) Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2014 32 10 997 1005 10.1200/JCO.2013.52.0536 24297951 PMC3965262

Fu X. Wu H. Li J. Wang C. Li M. Ma Q. Yang W. Efficacy of Drug Interventions for Chemotherapy-Induced Chronic Peripheral Neurotoxicity: A Network Meta-analysis Frontiers in Neurology 2017 8 223 10.3389/fneur.2017.00223 28642731 PMC5462987

Wang D.-s. Wang Z.-q. Chen G. Peng J.-w. Wang W. Deng Y.-h. Wang F.-h. Zhang J.-w. Liang H.-l. Feng F. Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer Cancer Medicine 2020 9 1 151 159 10.1002/cam4.2693 31724334 PMC6943144

Pfeiffer P. Lustberg M. Näsström J. Carlsson S. Persson A. Nagahama F. Cavaletti G. Glimelius B. Muro K. Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy: Two Placebo-Controlled, Randomized Phase 3 Studies (POLAR-A/POLAR-M) JNCI Cancer Spectrum 2022 6 pkac075 10.1093/jncics/pkac075 36308441 PMC9678401

Karlsson J. O. G. Jynge P. Ignarro L. J. The Damaging Outcome of the POLAR Phase III Trials Was Due to Avoidable Time-Dependent Redox Interaction between Oxaliplatin and PledOx Antioxidants (Basel, Switzerland) 2021 10 12 1937 10.3390/antiox10121937 34943040 PMC8750726

Cassidy J. Bjarnason G. A. Hickish T. Topham C. Provencio M. Bodoky G. Landherr L. Koralewski P. Lopez-Vivanco G. Said G. Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC) Journal of Clinical Oncology 2006 24 3507 3507 10.1200/jco.2006.24.18_suppl.3507

Kerckhove N. Busserolles J. Stanbury T. Pereira B. Plence V. Bonnetain F. Krakowski I. Eschalier A. Pezet D. Balayssac D. Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup BMJ Open 2019 9 6 e027770 10.1136/bmjopen-2018-027770 PMC6561607 31182448

Chan A. Elsayed A. Ng D. Q. Ruddy K. Loprinzi C. Lustberg M. A global survey on the utilization of cryotherapy and compression therapy for the prevention of chemotherapy-induced peripheral neuropathy Supportive Care in Cancer 2022 30 12 10001 10007 10.1007/s00520-022-07383-x 36214880 PMC9715474

Xu M. Wang F. Zhu X. Hao Z. Efficacy of cryotherapy on chemotherapy-induced peripheral neuropathy in patients with breast cancer: a propensity score-matched study Annals of Medicine and Surgery 2023 85 6 2695 2703 10.1097/MS9.0000000000000906 37363493 PMC10289575

Beijers A. J. M. Bonhof C. S. Mols F. Ophorst J. de Vos-Geelen J. Jacobs E. M. G. van de Poll-Franse L. V. Vreugdenhil G. Multicenter randomized controlled trial to evaluate the efficacy and tolerability of frozen gloves for the prevention of chemotherapy-induced peripheral neuropathy Annals of Oncology 2020 31 131 136 10.1016/j.annonc.2019.09.006 31912787

Authier N. Balayssac D. Marchand F. Ling B. Zangarelli A. Descoeur J. Coudore F. Bourinet E. Eschalier A. Animal Models of Chemotherapy-Evoked Painful Peripheral Neuropathies Neurotherapeutics 2009 6 4 620 629 10.1016/j.nurt.2009.07.003 19789067 PMC5084284

Marmiroli P. Riva B. Pozzi E. Ballarini E. Lim D. Chiorazzi A. Meregalli C. Distasi C. Renn C. L. Semperboni S. Susceptibility of different mouse strains to oxaliplatin peripheral neurotoxicity: Phenotypic and genotypic insights PLOS ONE 2017 12 10 e0186250 10.1371/journal.pone.0186250 29020118 PMC5636145

Warncke U. O. Toma W. Meade J. A. Park A. J. Thompson D. C. Caillaud M. Bigbee J. W. Bryant C. D. Damaj M. I. Impact of Dose, Sex, and Strain on Oxaliplatin-Induced Peripheral Neuropathy in Mice Frontiers in Pain Research 2021 2 683168 10.3389/fpain.2021.683168 35295533 PMC8915759

Deuis J. R. Dvorakova L. S. Vetter I. Methods Used to Evaluate Pain Behaviors in Rodents Frontiers in Molecular Neuroscience 2017 10 284 10.3389/fnmol.2017.00284 28932184 PMC5592204

Christensen S. L. Hansen R. B. Storm M. A. Olesen J. Hansen T. F. Ossipov M. Izarzugaza J. M. G. Porreca F. Kristensen D. M. Von Frey testing revisited: Provision of an online algorithm for improved accuracy of 50% thresholds European Journal of Pain 2020 24 4 783 790 10.1002/ejp.1528 31889375

Ruan Y. Gu L. Yan J. Guo J. Geng X. Shi H. Yu G. Zhu C. Yang Y. Zhou Y. An effective and concise device for detecting cold allodynia in mice Scientific Reports 2018 8 1 14002 10.1038/s41598-018-31741-7 30228362 PMC6143538

Wang X. Yang W. Wang L. Zheng L. Choi W. S. Platinum-based chemotherapy induces demyelination of Schwann cells in oral squamous cell carcinoma treatment Toxicol. Appl. Pharmacol. 2023 481 116751 10.1016/j.taap.2023.116751 37944569

Cerles O. Benoit E. Chéreau C. Chouzenoux S. Morin F. Guillaumot M.-A. Coriat R. Kavian N. Loussier T. Santulli P. Niclosamide Inhibits Oxaliplatin Neurotoxicity while Improving Colorectal Cancer Therapeutic Response Molecular Cancer Therapeutics 2017 16 2 300 311 10.1158/1535-7163.MCT-16-0326 27980107

Poupon L. Kerckhove N. Vein J. Lamoine S. Authier N. Busserolles J. Balayssac D. Minimizing chemotherapy-induced peripheral neuropathy: preclinical and clinical development of new perspectives Expert Opinion on Drug Safety 2015 14 8 1269 1282 10.1517/14740338.2015.1056777 26058312

Kawashiri T. Mine K. Kobayashi D. Inoue M. Ushio S. Uchida M. Egashira N. Shimazoe T. Therapeutic Agents for Oxaliplatin-Induced Peripheral Neuropathy; Experimental and Clinical Evidence International Journal of Molecular Sciences 2021 22 3 1393 10.3390/ijms22031393 33573316 PMC7866815

Poupon L. Lamoine S. Pereira V. Barriere D. A. Lolignier S. Giraudet F. Aissouni Y. Meleine M. Prival L. Richard D. Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin Neuropharmacology 2018 140 43 61 10.1016/j.neuropharm.2018.07.026 30056126

Peppin J. F. Pappagallo M. Capsaicinoids in the treatment of neuropathic pain: a review Therapeutic Advances in Neurological Disorders 2014 7 1 22 32 10.1177/1756285613501576 24409200 PMC3886382

Heuvel S. A. S. v. d. Wal S. E. I. v. d. Smedes L. A. Radema S. A. Alfen N. v. Vissers K. C. P. Steegers M. A. H. Intravenous Lidocaine: Old-School Drug, New PurposeReduction of Intractable Pain in Patients with Chemotherapy Induced Peripheral Neuropathy Pain Research and Management 2017 2017 8053474 10.1155/2017/8053474 28458593 PMC5387833

Cooper T. E. Chen J. Wiffen P. J. Derry S. Carr D. B. Aldington D. Cole P. Moore R. A. Morphine for chronic neuropathic pain in adults Cochrane Database of Systematic Reviews 2019 22 5 CD011669 10.1002/14651858.CD011669.pub2 PMC6481499 28530786

Moore R. A. Derry S. Aldington D. Cole P. Wiffen P. J. Amitriptyline for neuropathic pain in adults Cochrane Database of Systematic Reviews 2015 2015 CD008242 10.1002/14651858.CD008242.pub3 26146793 PMC6447238

Selvy M. Mattévi C. Dalbos C. Aissouni Y. Chapuy E. Martin P.-Y. Collin A. Richard D. Dumontet C. Busserolles J. Analgesic and preventive effects of donepezil in animal models of chemotherapy-induced peripheral neuropathy: Involvement of spinal muscarinic acetylcholine M2 receptors Biomedicine & Pharmacotherapy 2022 149 112915 10.1016/j.biopha.2022.112915 35635358

Bouchenaki H. Danigo A. Bernard A. Bessaguet F. Richard L. Sturtz F. Balayssac D. Magy L. Demiot C. Ramipril Alleviates Oxaliplatin-Induced Acute Pain Syndrome in Mice Frontiers in Pharmacology 2021 12 712442 10.3389/fphar.2021.712442 34349658 PMC8326755

Naegel S. Obermann M. Topiramate in the prevention and treatment of migraine: efficacy, safety and patient preference Neuropsychiatric disease and treatment 2009 17 28 10.2147/NDT.S6459 PMC2951059 20169042

Stankovic J. S. K. Selakovic D. Mihailovic V. Rosic G. Antioxidant Supplementation in the Treatment of Neurotoxicity Induced by Platinum-Based ChemotherapeuticsA Review International Journal of Molecular Sciences 2020 21 20 7753 10.3390/ijms21207753 33092125 PMC7589133

Policar C. Bouvet J. Bertrand H. C. Delsuc N. SOD mimics: From the tool box of the chemists to cellular studies Current Opinion in Chemical Biology 2022 67 102109 10.1016/j.cbpa.2021.102109 35066373

Batinic-Haberle I. Tovmasyan A. Spasojevic I. Mn Porphyrin-Based Redox-Active Drugs: Differential Effects as Cancer Therapeutics and Protectors of Normal Tissue Against Oxidative Injury Antioxidants & Redox Signaling 2018 29 16 1691 1724 10.1089/ars.2017.7453 29926755 PMC6207162

Chu Z. Yang J. Zheng W. Sun J. Wang W. Qian H. Recent advances on modulation of H2O2 in tumor microenvironment for enhanced cancer therapeutic efficacy Coord. Chem. Rev. 2023 481 215049 10.1016/j.ccr.2023.215049

Coriat R. Alexandre J. Nicco C. Quinquis L. Benoit E. Chéreau C. Lemaréchal H. Mir O. Borderie D. Tréluyer J.-M. Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir Journal of Clinical Investigation 2014 124 1 262 272 10.1172/JCI68730 24355920 PMC3871222

Mathieu E. Bernard A.-S. Delsuc N. Quévrain E. Gazzah G. Lai B. Chain F. Langella P. Bachelet M. Masliah J. A Cell-Penetrant Manganese Superoxide Dismutase (MnSOD) Mimic Is Able To Complement MnSOD and Exerts an Antiinflammatory Effect on Cellular and Animal Models of Inflammatory Bowel Diseases Inorganic Chemistry 2017 56 5 2545 2555 10.1021/acs.inorgchem.6b02695 28198622

Schanne G. Zoumpoulaki M. Gazzah G. Vincent A. Preud’homme H. Lobinski R. Demignot S. Seksik P. Delsuc N. Policar C. Inertness of Superoxide Dismutase Mimics Mn­(II) Complexes Based on an Open-Chain Ligand, Bioactivity, and Detection in Intestinal Epithelial Cells Oxidative Medicine and Cellular Longevity 2022 2022 1 3858122 10.1155/2022/3858122 35401918 PMC8993562

Yang Y. Luo L. Cai X. Fang Y. Wang J. Chen G. Yang J. Zhou Q. Sun X. Cheng X. Nrf2 inhibits oxaliplatin-induced peripheral neuropathy via protection of mitochondrial function Free Radical Biol. Med. 2018 120 13 24 10.1016/j.freeradbiomed.2018.03.007 29530794

Miyagi A. Kawashiri T. Shimizu S. Shigematsu N. Kobayashi D. Shimazoe T. Dimethyl Fumarate Attenuates Oxaliplatin-Induced Peripheral Neuropathy without Affecting the Anti-tumor Activity of Oxaliplatin in Rodents Biol. Pharm. Bull. 2019 42 4 638 644 10.1248/bpb.b18-00855 30930422

Kawashiri T. Miyagi A. Shimizu S. Shigematsu N. Kobayashi D. Shimazoe T. Dimethyl fumarate ameliorates chemotherapy agent-induced neurotoxicity in vitro Journal of Pharmacological Sciences 2018 137 2 202 211 10.1016/j.jphs.2018.06.008 30042024

Nishida K. Takeuchi K. Hosoda A. Sugano S. Morisaki E. Ohishi A. Nagasawa K. Ergothioneine ameliorates oxaliplatin-induced peripheral neuropathy in rats Life Sciences 2018 207 516 524 10.1016/j.lfs.2018.07.006 29981320

Smith E. M. L. Pang H. Cirrincione C. Fleishman S. Paskett E. D. Ahles T. Bressler L. R. Fadul C. E. Knox C. Le-Lindqwister N. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial JAMA 2013 309 13 1359 1367 10.1001/jama.2013.2813 23549581 PMC3912515

Grothey A. Nikcevich D. A. Sloan J. A. Kugler J. W. Silberstein P. T. Dentchev T. Wender D. B. Novotny P. J. Chitaley U. Alberts S. R. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7 Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2011 29 4 421 427 10.1200/JCO.2010.31.5911 21189381 PMC3058288

Grothey A. Hart L. L. Rowland K. M. Ansari R. H. Alberts S. R. Chowhan N. M. Shpilsky A. Hochster H. S. Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial Journal of Clinical Oncology 2008 26 4010 4010 10.1200/jco.2008.26.15_suppl.4010

Han C. H. Khwaounjoo P. Kilfoyle D. H. Hill A. McKeage M. J. Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients BMC cancer 2013 13 495 10.1186/1471-2407-13-495 24156389 PMC3870994

Nishioka M. Shimada M. Kurita N. Iwata T. Morimoto S. Yoshikawa K. Higashijima J. Miyatani T. Kono T. The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen International Journal of Clinical Oncology 2011 16 4 322 327 10.1007/s10147-010-0183-1 21258836

Kono T. Hata T. Morita S. Munemoto Y. Matsui T. Kojima H. Takemoto H. Fukunaga M. Nagata N. Shimada M. Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy Cancer Chemotherapy and Pharmacology 2013 72 6 1283 1290 10.1007/s00280-013-2306-7 24121454 PMC3834178

Oki E. Emi Y. Kojima H. Higashijima J. Kato T. Miyake Y. Kon M. Ogata Y. Takahashi K. Ishida H. Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study International Journal of Clinical Oncology 2015 20 4 767 775 10.1007/s10147-015-0784-9 25627820

Stehr J. E. Lundström I. Karlsson J. O. G. Evidence that fodipir (DPDP) binds neurotoxic Pt2+ with a high affinity: An electron paramagnetic resonance study Scientific Reports 2019 9 1 15813 10.1038/s41598-019-52248-9 31676855 PMC6825159

Hines R. B. Schoborg C. Zhu X. Elgin E. Zhang S. Preventives for oxaliplatin-induced peripheral neuropathy in colorectal cancer patients Journal of Clinical Oncology 2022 40 83 83 10.1200/JCO.2022.40.4_suppl.083

Ravera M. Gabano E. Zanellato I. Bonarrigo I. Alessio M. Arnesano F. Galliani A. Natile G. Osella D. Cellular trafficking, accumulation and DNA platination of a series of cisplatin-based dicarboxylato Pt­(IV) prodrugs Journal of Inorganic Biochemistry 2015 150 1 8 10.1016/j.jinorgbio.2015.05.012 26042542

Gabano E. Zanellato I. Pinton G. Moro L. Ravera M. Osella D. The Strange Case: The Unsymmetric Cisplatin-Based Pt­(IV) Prodrug [Pt­(CH3COO)­Cl2­(NH3)­2­(OH)] Exhibits Higher Cytotoxic Activity with respect to Its Symmetric Congeners due to Carrier-Mediated Cellular Uptake Bioinorganic Chemistry and Applications 2022 2022 1 3698391 10.1155/2022/3698391 36620349 PMC9822769

Burger H. Loos W. J. Eechoute K. Verweij J. Mathijssen R. H. J. Wiemer E. A. C. Drug transporters of platinum-based anticancer agents and their clinical significance Drug Resistance Updates 2011 14 1 22 34 10.1016/j.drup.2010.12.002 21251871